2015N227852_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 200911
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A Phase 2a, Multicenter, Randomized, Adaptive, Open -label,  
Dose Ranging Study to Evaluate the Antiviral Effect, Safet y, 
Tolerability  and Pharmacokinetics of Cobicistat -boosted 
[COMPANY_004]2838232 Monotherapy  Over 10 Day s in HIV -1 Infected 
Adults
Compound Number: [COMPANY_004]2838232
Development Phase:IIA
Effective Date: 15-JUN- 2017
Protocol Amendment Number:  03
Author (s):
         PTS, Ware, [LOCATION_006]
         GCSP, Stockley  Park, [LOCATION_006]
         Infectious Diseases, Clinical, Upper Providence, PA, US
         Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
        HIV DPU, Clinical RTP, NC, US
         Virology , HIV DPU, RTP, NC, US
         CPMS, [COMPANY_004], RTP, NC, US
         HIV DPU, RTP, NC, US
        Clinical Phar macology , ViiV Healthcare, RTP, NC, US
         PCPS, [COMPANY_004], Upper Providence, PA, US
        PCPS, [COMPANY_004], Upper Providence, PA, US
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reser ved.  
Unauthorised cop ying or use of this information is prohibited. 2018N360917_00
[COMPANY_003]
2015N227852_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 200911
2Revision Chronology
GlaxoSmithKline 
Document NumberDate Version
2015N227852_00 2016 -NOV-09 Original
2015N227852_01 2017 -APR -26 Amendment No. 1
Amendment 1 includes minor updates to I nclusion- Exclusion (I E) criteria, including 
clarification on use of pre- or post -exposure prophy laxis, and removal of exclusionary  
requirements related to concomitant medications and tobacco and alcohol use during the 
study . Guidance around relevant habits is included in the L ifesty le section of the protocol 
and adjustments were made to reduce restrictions on these requirements. Modifications 
were also made to the pharmacokinetics sampling, allowing for the 12 h PK collection 
timepoint on Day  1 and 10 to be optional. Minor alterations were made regarding the 
order of screening procedures, including the Holter monitoring requirements. 
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. Furthermore, the serial ECG collection (up to 6h post- dose) was removed on 
Day 5. Finall y, the post -study  care guidance was updated to include an option for subjects 
to receive reimbursement for marketed ART for a limited period after completion of 
study  treatment and follow up. Minor c larifications, reformatting of tables, re
-numbering 
of sections and correction of ty pographical errors were also made throughout this 
amendment.
2015N227852_02 [ADDRESS_541159] population to allow treatment 
experienced HIV -1 infected patients, in addition to treatment naive patients. Patients with 
a treatment history  of a prior maturation inhibitor will still be ineligible. Slight 
modifications were made to include flexible language for enrolment into Part B to allow 
prioritization of one dose cohort or to open randomization into Part B cohorts in a parallel 
fashion. Also the upper limit of the BMI inclusion criteria was increased from 31 to 35 
kg/m2.
2015N227852_03 2017 -JUN -15 Amendment No. 3
Amendment 3 includes modification to the protocol Inclusion Criteria (#6) to ensure 
exclusion of treatment -experienced patients with limited remaining treatment options. 2018N360917_00
 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_03 CONFIDENTIA L
200911
4MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager NumberFax Num ber Site Address
Primary 
Medical 
Monitor/SAE 
contact 
[CONTACT_428195] 
([COMPANY_003]) Safety 
Hotline [COMPANY_003], [ADDRESS_541160] 
Collegeville, PA 
[ZIP_CODE]
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_541161]
Middlesex, TW8 9GS
[LOCATION_006]
In some countr ies, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_428196].   
Regulatory  Agency  Identify ing Number(s):  116,[ADDRESS_541162] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 200911 ........................................................ 9
2.INTRODUCTION .................................................................................................... 13
2.1. Study Rationale .......................................................................................... 13
2.2. Brief Background ........................................................................................ 13
2.2.1. Preclinical Summary .................................................................... 14
2.2.2. Clinical Summary of Safety and Pharmacokinetics ...................... 19
[IP_ADDRESS]. Clinical Summary of Safety ......................................... 19
[IP_ADDRESS]. Study 204953 (completed); Pharmacokinetic 
Data ........................................................................... 20
[IP_ADDRESS]. Overall Summary/Conclusions of PK data .................. 23
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 25
4.STUD Y DESIGN .................................................................................................... 26
4.1. Overall Design ............................................................................................ 26
4.2. Type and Number of Subjects ..................................................................... 27
4.3. Design/Dose Justification ............................................................................ 28
4.3.1. [COMPANY_004]2838232 with Ritonavi r......................................................... 28
4.3.2. [COMPANY_004]2838232 with Cobicistat ....................................................... 29
4.3.3. Interim Analysis ........................................................................... 29
4.4. Benefit:Risk Assessment ............................................................................ 30
4.4.1. Risk Assessment ......................................................................... 31
4.4.2. Benefit Assessment ..................................................................... 33
4.4.3. Overall Benefit:Risk Conclusion ................................................... [ADDRESS_541163] AWAL CRITERIA ............. 33
5.1. Inclusion Criteria ......................................................................................... 34
5.2. Exclusion Criteria ........................................................................................ 36
5.3. Screening/Baseline/Run -in Failures ............................................................ 38
5.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 39
5.4.1. Liver Che mistry Stoppi[INVESTIGATOR_2121] ................................................ 39
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_541164] and Other Study Treatment .................................... 41
6.2. Treatment Assignmen t................................................................................ 42
6.3. Planned Dose Adjustments ......................................................................... 42
6.4. Blinding ....................................................................................................... 42
6.5. Preparation/Handling/Storage/Accountability .............................................. 42
6.6. Compliance with Study Tr eatment Administration ....................................... 43
6.7. Treatment of Study Treatment Overdose .................................................... 43
6.8. Treatment after the End of the Study .......................................................... 44
6.9. Lifestyle and/or Dietary Restrictions ............................................................ 44
6.9.1. Meals and Dietary Restrictions .................................................... 44 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
76.9.2. Alcohol, Caffeine and Exercise .................................................... 44
6.10. Contraception ............................................................................................. 44
6.11. Concomitant Medications and Non-Drug Therapi[INVESTIGATOR_014] .................................... 45
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 45
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 45
7.STUDY ASSESSMENTS AN D PROCED URES ..................................................... 45
7.1. Time and Events Table ............................................................................... 47
7.2. Visit W indows ............................................................................................. 49
7.3. Screening and Critical Baseline Assessments ............................................ 49
7.3.1. Holter Monitoring (Screening criteria) ........................................... 49
7.4. Efficacy ....................................................................................................... 50
7.4.1. HIV-1 RNA Sampling ................................................................... 50
7.4.2. Lymphocyte Subsets by [CONTACT_46110] ..................................... 50
7.5. Safety ......................................................................................................... 50
7.5.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 50
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 51
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 51
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 51
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 52
[IP_ADDRESS]. Disease -Related Events and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 52
[IP_ADDRESS]. Regulatory Reporting Requirements for SAE .............. 53
7.5.2. Pregnancy ................................................................................... 53
7.5.3. Physical Exams ........................................................................... 53
7.5.4. Vital Si gns.................................................................................... 54
7.5.5. Electrocardiogram (EGC) ............................................................. 54
7.5.6. Clinical Safety Laboratory Assessments ...................................... 54
7.6. Pharmacokinetics ....................................................................................... 56
7.6.1. Blood Sample C ollection .............................................................. 56
7.6.2. Sample Analysis .......................................................................... 56
7.7. Biomarker(s)/Pharmacodynamic Markers ................................................... 56
7.7.1. Viral Genotypi[INVESTIGATOR_103623] ............................................... 56
7.8. Gene tics..................................................................................................... 56
7.9. Value Evidence and Outcomes ................................................................... 57
8.DATA MANAGEMENT ........................................................................................... 57
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .57
9.1. Hypotheses ................................................................................................ .57
9.2. Sample Size Considerations ....................................................................... 57
9.2.1. Sample Size Assumptions ........................................................... 57
9.2.2. Sample Size Sensitivity ................................................................ 58
9.2.3. Sample Size Re- estimation or Adjustment ................................... 59
9.3. Data Analysis Considerations ..................................................................... 59
9.3.1. Analysis Populations .................................................................... 59
9.3.2. Interim Analysis ........................................................................... 59
9.4. Key Elements of Analysis Plan ................................................................... 60
9.4.1. Primary Analyses ......................................................................... 60
[IP_ADDRESS]. Safety Analyses .......................................................... 60
[IP_ADDRESS]. Efficacy Analyses ....................................................... 60 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
[IP_ADDRESS]. Pharmacokinetic Analyses .......................................... 61
9.4.2. Secondary Analyses .................................................................... 61
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic Analyses ........... 61
[IP_ADDRESS]. Viral Genotypi[INVESTIGATOR_428080] .............. 62
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 62
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 62
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Pr ocess ........................................................................................ 62
10.3. Quality Control (Study Monitoring) .............................................................. 63
10.4. Quality Assurance ....................................................................................... 63
10.5. Study and Site Closure ............................................................................... 63
10.6. Records Retention ...................................................................................... 64
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 65
10.8. Review Committees .................................................................................... 65
11.REFERENCES ....................................................................................................... 66
12.APPENDICES ........................................................................................................ 68
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 68
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 71
12.3. Appendix 3: Liver Safety –Study Treatment Restart or Rechallenge 
Guidelines ................................................................................................... 74
12.4. Appendix 4: Genetic Research ................................................................... 75
12.5. Appendix 5: Definition of and Pr ocedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 78
12.5.1. Definition of Adverse Events ........................................................ 78
12.5.2. Definition of Serious Adverse Events ........................................... 79
12.5.3. Definition of Cardiovascular Events ............................................. 81
12.5.4. Recording of AEs and SAEs ........................................................ 81
12.5.5. Evaluating AEs and SAEs ............................................................ 82
12.5.6. Reporting of SAEs to [COMPANY_004] ........................................................... 83
12.6. Appendix 6: Collection of Pregnancy Information ........................................ 85
12.7. Appendix 7: Country Specific Requirements ............................................... 86
12.8. Appendix 8: Division Of AIDS Table For Grading The Severity Of 
Adult And Pediatric Adverse Events Version 1.0, December 2004; 
Clarification August 2009 ............................................................................ 87
12.9. Appendix 9: Toxicity Management ............................................................ 106
12.10. Appendix 10: Protocol Amendment Changes ............................................ 111
12.10.1. AMENDMENT 1 ......................................................................... 111
12.10.2. AMENDMENT 2 ......................................................................... 129
12.10.3. AMENDMENT 3 ......................................................................... 137 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
91. PROTOCOL SYNOPSIS FOR STUDY 200911
Rationale
[COMPANY_004]2838232 is a novel human immunodeficiency virus (HIV -1) maturation inhibitor 
that is being developed for the treatment of HIV -1 in combination with other 
antiretrovirals.
Three clinical studies of [COMPANY_004]2838232 (n=53 healthy  subjects) have been completed thus 
far. One study  (Study 204953) completed at the end of [ADDRESS_541165] received [COMPANY_004]2838232 or placebo in single or repeated 
dose designs, to a maximum single dose of 250 mg or repeated dose (for 11 days) of 
200mg QD, in combin ation with ritonavir (RTV). 
Study  HMI116787 (completed November 2013) was the First Time in Human study  of 
[COMPANY_004]2838232 and assessed safet y and tolerability  of escalating doses (5 mg to 100 mg), 
food effect, and the impact of stead y-state ritonavir on [COMPANY_004]28 [ZIP_CODE] pharmacokinetics 
(PK). Following successful completion of 3- month toxicology  studies in rat and dog in 
2014, clinical studies 200912 and 200207 were initiated. These were double- blind, 
placebo
-controlled, single (Study  200912) and repeat -dose (Study  200207) escalation 
studies to investigate the safet y, tolerabilit y, and PK of [COMPANY_004]2838232 alone and when co -
administered with ritonavir 100 mg once dail y (QD) for 8 -11 day s. Further assessment of 
an alternative formulation was also an objective in Study  200912.
Both studies were prematurely
 terminated/completed in March/April 2015 because of 
concerns over cardiovascular (CV) toxicity , in particular a clinical CV serious adverse 
event (SAE) whereb y the Food and Drug Administrating (FDA) imposed a clinical hold. 
Following submission of long -term (6 -month rat, 9- month dog) chronic toxicology  data 
and follow up to the clinical SAE in November 2015, the hold was released in January  
2016 and Study  204953 was initiated.
Study  204953 investigated the safet y and PK of [COMPANY_004]2838232 in single and repeat -doses 
as well as the suitability  of a new, capsule formulation. Doses of up to 250 mg 
[COMPANY_004]2838232/100 mg RTV (as single doses) or 200 mg [COMPANY_004]2838232/100 mg RTV (QD 
for 11 day s) were studied. The final cohort of the study  asse ssed unboosted [COMPANY_004]2838232 
(200mg BID) for [ADDRESS_541166] shown [COMPANY_004]2838232 with or without RTV to be well tolerated and, 
together with daily  RTV dosing (“boosting”), demonst rate a PK profile suitable for 
progression to HIV patients in this Phase IIa proof of concept 10 -day, monotherapy  study  
design.  However, potential concerns over protease resistance necessitate a change to a 
pharmacoenhancer without antiviral effects in th is study  of [COMPANY_004]2838232 monotherapy . 
Therefore, for Study  200911, cobicistat (Ty bost,150 mg QD) will be substituted for RTV.  
The objective of Stud y 200911 is to understand the safet y, PK and HIV antiviral profile 
of [COMPANY_004]2838232/cobicistat ([COMPANY_004]2838232/cobi) when given to HIV- infected, treatment 
naive, otherwise health y adults. Approximately  10 HIV -1 infected subjects will be 
enrolled into Part A. If warranted b y an interim safety, virology, and PK data anal ysis,  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
10approximately  8 subjects will be enrolled in e ach of between two and four Cohorts in Part 
B.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected 
patients during 10 days of 
monotherapy.Change from baseline (Day 1) in plasma HIV -1 
RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered 
as monotherapy over 10 days. Safety and tolerability parameters, including 
adverse event, concurrent medication, clinical 
laboratory, electrocardiogram (ECG) and vital 
signs assessments.
To characterize the pharmacokinetics 
of [COMPANY_004]2838232 in HIV -1 infected 
patients following [COMPANY_004]2838232/cobi 
dosing for 10 days. [COMPANY_004]2838232 PK parameters following dose 
administration, as follows:
Day 1 : area under the plasma concentration time 
curve A UC(0 -24), maximum observed 
concentration (Cmax), time to maximum 
observed concentration (tmax), concentration at 
[ADDRESS_541167] dose (C24), absorption lag time 
(tlag); 
Following last repeat administration on Day 10:  
AUC(0 -), pre -dose concentration (C0),
concentration at end of dosing interval (C ), 
Cmax, tmax, t½, and apparent oral clearance 
(CL/F), if data permit
Secondary
 To explore the relationship between 
[COMPANY_004]2838232 exposure and change 
in plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 AUC(0- ), 
Cmax, C with Day 11 HIV -1 RNA change from 
baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when 
administered over 10 days in HIV -1 
infected adults Change from baseline in CD4+ cell count to Day 
11
 To explore the relationship between 
[COMPANY_004]283823 2 exposure and safety or 
immunologic parameters, if 
appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax, C with Day 11 change from 
baseline in CD4+ cell count 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
11Objectives Endpoints
 To assess the development of viral 
resistance (genotypic and 
phenotypic) over 10 days and 
correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, if 
appropriate
 To estimate [COMPANY_004]2838232 
accumulation and to assess 
attainment of steady state following 
administration of [COMPANY_004]2838232/cobi 
for 10 days in HIV inf ected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): Day 
10 AUC(0 -), Cmax, and C compared to Day 1 
AUC(0 -24), Cmax, and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on Days 2 
through 11 
 To examine dose proportio nality of 
[COMPANY_004]2838232 pharmacokinetic 
parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days
in HIV infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and Day 10 
AUC(0 -), Cmax, and C at different dose levels 
for the assessment of dose proportionality
Note: Other exploratory objectives and endpoints will be specified in the RAP
Design, Treatment A rms and Duration
Approximately  34 HIV -1 infected subjects will be enrolled overall. 
This study  is a 10- day monotherapy , open -label, adaptive, dose ranging, repeat -dose 
study  and will be conducted as two parts with an interim (go/no- go) analy sis performed 
after Part A ( Table 1 ). Part A, Cohort 1 will evaluate a safe and well- tolerated dose level 
of [COMPANY_004]2838232 that has been tested (with RTV) in prior Phase I studies and that targets 
a high inhibitory  quotient (IQ) value. Following the completion of an interim analy sis of 
those data and according to criteria defined later in the protocol, further cohorts of 8 
subjects will t hen be studied in Part B in two or more cohorts (depending upon the data 
obtained in Part A). 
The totality  of this data will provide a full dose -response of [COMPANY_004]2838232 over a wide 
dose range to explore the safet y and PK/pharmacodynamics (PD) relationship of 
[COMPANY_004]2838232 in HIV -1 infected subjects and facilitate choice of doses for Phase IIb 
studies. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
12Table 1 Study  Design for 200911
Part A: [COMPANY_004]2838232/cobi 
Once Daily x 10 days1Part B: [COMPANY_004]2838232/cobi 
Once Daily x 10 days1,2
Cohort
N232 Dose
(mg)Cohort
N232 Dose 
(mg)
1 10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B. All 
doses will be given with [ADDRESS_541168] to modification based upon safety, PK and antiviral activity data from Cohort 1 
(Part A). More doses/coho rts (including potential removal of cobi co -dosing) may be added (the maximum dose in 
Part B would likely not exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] was 
lower in HIV infected subjects than in healthy subjects at the same dose level).
The possibility  that an additional, unboosted [COMPANY_004]2838232 monotherapy  cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from Study  204953 where 
unboosted [COMPANY_004]2838232 at a dose of 200 mg twice daily  (BID) was assesse d and Study  
205820, which plans to evaluate [COMPANY_004]2838232 at a dose of 500mg once daily  (QD). 
Subjects in both parts will have a screening visit within [ADDRESS_541169] dose. Maximum duration of study participation 
will be approximately  6 weeks.
HIV Drug Resistance: Following cessation of [COMPANY_004]2838232/cobi dosing for 10 day s, 
there will be prolonged exposure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t½ (i.e., in the “tail” of the PK profile). However, based on in vitro 
resistance passage data with [COMPANY_004]2838232 [and unlike with many  other ARV therapi[INVESTIGATOR_014]], 
there appears to be a limited likelihood of developi[INVESTIGATOR_428081]-infected subjects due to its virologi c profile. 
Analysis
The primary  objectives of this study  are to investigate the safet y, tolerability, PK and 
antiviral activity  of 10 day s repeated doses of [COMPANY_004]2838232/cobi in HIV-1 infected 
otherwise healthy  subjects. Descriptive summaries will be provided for safety , PK, and 
HIV viral load data. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
132. INTRODUCTION
[COMPANY_004]2838232 is a novel human immunodeficiency virus (HIV) -1 maturation inhibitor 
(MI) that is being developed for the treatment of HIV -1 infection in combination with 
other antiretrovirals (ART).
2.1. Study  Rationale
This ‘proof of concept (PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity , pharmacokinetics (PK), the relationship between PK and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg once dail y (QD) cobicistat 
([COMPANY_004]283232/cobi), administered across a range of doses over [ADDRESS_541170] doses for further stud ies in Phase IIb.
2.2. Brief Background
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has demonstrated significant improvement in acquired 
immunodeficiency  syndrome (AIDS) -related morbidity  and mo rtality  over the last 10 -15 
years. Emerging multi -class drug resistant viral strains and long- term toxicities warrant 
development of new classes of antiretroviral therapi[INVESTIGATOR_428082] -
1 viral life cy cle [Wainburg , 2010]. The inhibition of maturation of HIV- [ADDRESS_541171] from viral protease RT or integrase [Saxena , 2012; 
Qian , 2009]. HIV
 maturation is the final cleavage step of the capsidSp1 (transcription 
factor) pol yprotein that generates the functional capsid p24 protein. This mechanism of 
action results in accumulation of the uncleaved p25 protein with subsequent improper 
assembly of the HIV core, resulting in a non -infectious virion. Gel -based mechanism of 
action studies suggest that compound [COMPANY_004]2838232 acts as a maturation inhibitor. 
Western Blot anal ysis shows inhibition of capsid -Sp1 cleavage and accumulation of p25 
in the presence of [COMPANY_004]2838232.
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [ Martin, 2007a; Martin, 2007b; Martin
, 2008; NORVIR , 2013]). 
BVM reached Phase II studies in HIV patients; however, onl y modest reductions in 
plasma HIV -1 ribonucleic acid (RNA) concentrations were observed in Phase IIa 
monoth erapy studies [ Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential) antiviral activity  [Wainburg , 2010] led to termi nation of BVM development. 
The average decrease from baseline to Day  14 plasma HIV -1 ribonucleic acid (RNA) was 
0.54 and 0.70 log10 copi[INVESTIGATOR_014]/mL  for 200 mg and 300 mg twice daily  regimens ( Table 2
); 
all subjects achie ved plasma BVM concentrations above the in vitro EC90. Responders, 
classified based on 5 polymorphisms in HIV -1 gag (at positions 369, 370, and 371), 
achieved an average 1.15 log10 copi[INVESTIGATOR_014]/mL reduction in plasma HIV -1 RNA, while an 
average 0.17 log10 copi[INVESTIGATOR_014] /mL reduction was achieved for non -responders. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
14Table 2 Summary  of Bevirimat A ntiviral Response and PK in a 14 -day 
Monotherapy  Study  in HIV -infected A dults
BVM dosage 
regimenMean (SD) viral load 
change from 
baseline to Day 142IQ Plasma BVM 
1Cmin (g/mL)Plasma BVM 
1Cmax 
(g/mL)Plasma BVM 
1AUC(0 -) 
(g.h/mL)
200mg BID
(N=14)-0.54 (0.64) 1.70 46
(41, 51)58
(53, 64)632
(571, 699)
300mg BID
(N=18)-0.70 (0.77) 2.67 72
(65, 80)91
(84, 99)973
(890, 1064)
1. Cmin, Cmax, and AUC rep orted as geometric mean (95% CI).
2. IQ=geometric mean Cmin/in vitro EC90; reported EC90=27 g/mL; all subjects achieved IQ 1.
        AUC(0 -) = Area under the concentration -time curve over the dosing interval; BVM = Bevirimat; CI = Confidence 
interval; Cm ax = Maximum plasma concentration; Cmin = Minimum plasma concentration; EC90 = 50% protection 
against resistant mutant HIV infection; IQ = Inhibitory quotient; SD = Standard deviation.
Early clinical data for BMS955176, a second generation maturation inh ibitor, have been 
recentl y presented [ Nowicka -Sans , 2015]. In a 10- day monotherapy  trial in HIV - infected 
patients, plasma HIV -[ADDRESS_541172] of 
inhibiting this viral target.
Although BMS955176 is currentl y in Phase II studies in HIV -infected patients, there are 
no maturation inhibitors approved for the treatment of HIV infection.  The uncertainties 
of earl y drug development and continuing need for novel ART, especially for heavil y 
treated/experienced HIV -infected persons, support continued compound development. 
[COMPANY_004]2838232’s low nanomolar in vitro potency  against multiple HI V-1 gag 
polymorphisms and broader spectrum across multiple HIV -1 subt ypes indicates it has 
utility  in this se tting.
2.2.1. Preclinical Summary
Nonclinical pharmacology
Virology
[COMPANY_004]2838232, in vitro, is an inhibitor of HIV maturation by  [CONTACT_428197] p25 to p24. [COMPANY_004]2838232 is a potent antiviral agent with a 
mean 50% maximal inhibitory  concentration (50% maximal inhibitory  concentration 
[IC50]) value of 1.6 nM (range: 0.8 to 4.3 nM) when tested in a panel of 26 HIV -1 
isolates with various polymorphic gag genot ypes in peripheral blood mononuclear cells 
(PBMCs), suggesting that [COMPANY_004] [ADDRESS_541173] spectrum of HIV isolates . In 
another PBMC assay , [COMPANY_004]2838232 showed potent antiviral activity  in 59 of 60 isolates 
with IC50 values ranging from 0.22 to 5.1 nM. [COMPANY_004]2838232 also inhibited HIV- 1 strains 
containing the consensus Sp1 QVT region or the V370A poly morphism in MT4 cells
(IC50 = 0.73 to 0.81 nM).  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
15In an MT2 cell -based assay  utilizing recombinant viruses harboring gag and protease 
from subjects before and after a protease inhibitor (PI) based regimen, [COMPANY_004]2838232 
inhibited 1 2 of 15 viruses with a mean IC50 value of 1.7 nM (range = 0.4 to 3 nM). The 
remaining 3 viruses were not inhibited by  [CONTACT_23983]2838232 up to the top concentrations 
tested at 400 nM. There was no correlation of PI [INVESTIGATOR_428083]2838232. [COMPANY_004]2838232 resistance mutations were selected for b y serial passage of 
virus in a SupT1 cell
-based assay  with increasing concentrations of [COMPANY_004]2838232. I n the 
lab strain NL4- 3 and gag/protease recombinant viruses, the resistance mutation A364V 
arose and resist ance confirmed by  [CONTACT_3725]-directed mutagenesis. This resistance mutation 
maintains susceptibility  to other classes of anti -retrovirals including PIs and non -
nucleoside RT inhibitors.
[COMPANY_004]2838232 was tested in vitro in combination with two marketed PI s, atazana vir and 
darunavir. 
Using a dose -wise additivity  model, [COMPANY_004]2838232A showed additive anti -viral 
activity with both PI s.
Secondary  Pharmacology
In a secondary  pharmacology  study , [COMPANY_004]2838232 was tested against a panel of 
receptors, ion channels and transporter s and demonstrated no significant effect (IC50 of 
1M). It is important to note that the selectivity for antiviral activity  of [COMPANY_004]2828232 
compared to all tested off -target activities was >100 -fold, and the potential for organ 
toxicity  was characterized in the nonclinical toxicology studies (see below).
In safet y pharmacology studies in male rats, there were no hemod ynamic changes or 
neurobehavioral effects following single oral doses up to 300 mg/kg. A single oral dose 
of [COMPANY_004]2838232 at 30 mg/kg or 300 mg/kg produced reversible increases in respi[INVESTIGATOR_428084] (32% and 36%, respectively ) and derived minute volume (17% and 26%, 
respectivel y) at 6hours after dosing. These doses did not produce any  effect on 
respi[INVESTIGATOR_2842], airway  resistance or bod y temperature. There were no respi[INVESTIGATOR_428085] 5 mg/kg (mean maximum plasma concentration [C max] 0.12 g/mL ; AUC 0-24
1.0g.h/mL  based on Day  1 of the 4 -week repeat dose study ). These findings were not 
considered to suggest a safet y concern in humans.
[COMPANY_004]2838232 at the maximum feasible concentration, limited by  [CONTACT_16758] , of 4.09 M 
(3.31 g/mL) caused no inhibition of human ether-a-gogo related gene (hERG) tail 
current in Human Embryonic Kidney 293 cells stably  transfected with hERG cDNA, 
indicating a low probability  for interaction at the hERG channel.
In conscious telemetered male dogs (n=4), a single oral dose of [COMPANY_004]2838232 at 
60mg/kg (C max0.59g/mL; AUC 0-248.7g.h/mL based on Day 1 exposure data from 
the 4- week oral repeat dose toxicit y study ) was associated with one epi[INVESTIGATOR_428086]-sustained ventricular tachy cardia in one dog lasting ~1.2 seconds. There were no 
effects on arterial pressures, heart rate, or 
electrocardiogram (ECG) interval durations. An 
investigative safet y pharmacology cardiovascular study  was conducted in telemetered 
dogs given 60 mg/kg/day for 4 weeks with serial monitoring by  [CONTACT_51541] , 
cardiac biomarkers, qualitative and quantitative electrocardiology , microscopy , and 
transmission electron microscop y (TEM) of the heart.  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
16There were no changes in echocardiograph y endpoints, ECG intervals, ECG waveforms, 
arterial pressures, heart rates, serum cTpn I, N-terminal prohormone of brain natriuretic 
peptide (NTproBNP), or in heart tissue as assessed by  [CONTACT_428198]. With routine microscop y, 
one treated dog had a single focus of degeneration/necrosis of the tunica media 
(moderate) in an extramural artery  and another treated dog had localised, mixed -cell 
inflammation (mild) along the epi[INVESTIGATOR_428087]. Both changes h ave 
been reported in normal beagles and were considered of uncertain relationship to 
treatment in the absence of changes in an y other structural or functional cardiovascular 
endpoints. The 28 -day exposures were similar to the previous 4- week toxicity  study in 
dogs: the C maxrange at 60 mg/kg/day  in this investigative safet y pharmacology stud y was 
0.542 to 2.00 g/mL and range of AUC 0-24was 6.04 to 35.7 g.h/mL. In subsequent 
repeat -dose studies in dogs treated for up to 9 months with up to 70 mg/kg/day , no
changes were evident in cardiac biomarkers (including cTpn I and NTproBNP), functional 
(including ECG waveform) or structural (including microscopic evaluation) 
cardiovascular endpoints at slightly higher exposures than those achieved than in 
previous stud ies. The end of the 9 -month study , gender averaged C maxat 70 mg/kg/day  
was 1.95 g/mL and 
AUC 0-24was 38.8 g.h/mL. These studies support an absence of 
[COMPANY_004]2838232-related functional or structural effects on the heart in preclinical testing. 
The No Observe d Adverse Effect Level (NOAEL) was established at 20 mg/kg/day  (on 
the basis of mild hepatic findings) with an associated area under the curve at 24 hours 
(AUC24) of 16.2 g.hr/mL  and Cmax 0.847 g/mL.
Pharmacokinetics and product metabolism in animals
ThePK of [COMPANY_004]2838232 were investigated in the mouse, rat, and dog. The oral 
bioavailability  of [COMPANY_004]2838232 was low to moderate (~6% to 40%) depending on the 
species and formulation. Plasma and blood clearance were low and the volume of 
distribution at steady  state was high relative to total body  water. The half -life of 
[COMPANY_004]2838232 was short in the mouse and rat, but moderate in the dog. S ystemic exposure 
of [COMPANY_004]2838232 generally increased in a less than dose
-proportional manner.  In rats, 
there were no difference s in sy stemic exposure between single and repeat- dose 
administration, or between males and females.  In a 7 -day study  in dogs, systemic 
exposures were generally similar between males and females and after single and repeat 
dosing; however, in a 4- week stud y, systemic exposures were higher in females than in 
males in the high -dose group (60 mg/kg/day ) and higher after repeat dosing than after a 
single dose. The distribution of radioactivit y in male pi[INVESTIGATOR_428088] a single 
oral administration of [14C] [COMPANY_004]2838232 at a target dose level of 20 mg/kg showed 
radioactivity  was rapi[INVESTIGATOR_428089] y distributed throughout the body with all 
tissues, except the brain and spi[INVESTIGATOR_1831]. There were no tissues that retained detectable 
levels of radioactivity at [ADDRESS_541174] canulated rat study , 30% of the 
administered dose was excreted in the bile as an acy lglucuronide. In the same study , 
unchanged drug and metabolites were eliminated primarily  in the bile and feces, while a 
mean of <1% o f the dose was eliminated in urine.
In vitro, [COMPANY_004]2838232 is highl y protein bound (>99.9%) and has low passive 
permeability . In vivo evidence suggests active uptake of [COMPANY_004]2838232 by  [CONTACT_428199].  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
17After single oral doses of 5, 100, or 300 mg/kg, the average liver to plasma ratio was 51, 
17, and 10, respectivel y. After 7 days of dosing at 30, 100, or 300 mg/kg/day , liver to 
blood ratios ranged from 10 to 16.
In the 13 -week repeat dose studies in dogs given 35 mg/kg BID (70 mg/kg/day ), heart 
tissue collected at necropsy  had [COMPANY_004]2838232 concentrations 2.[ADDRESS_541175] -dose plasma concentrations, similar to the previous 4 -week CV 
investigative findings.  In the 13- week repeat dose studies in rats given 300mg/kg/day , 
heart tissue collected at necrops y had[COMPANY_004]2838232 concentrations approximately  [ADDRESS_541176] -dose plasma concentrations, similar to the previous 7- day 
findings.  Overall [COMPANY_004]2838232 did not appear to be highl y concentrated in heart tissu e 
after repeat dosing and suggests that accumulation upon chronic dosing is unlikely .
Routes of metabolism identified in liver microsomal incubations and rat, dog, and human 
hepatocy tes were N
-dealky lation, oxidation, oxidative deamination, and glucuronida tion, 
alone or in combination , with no human- specific metabolites detected.  N -dealk ylated 
products and glucuronidation were observed in rat plasma and the bile. In general, in 
vitro metabolite profiles of the nonclinical species and human were qualitative ly similar, 
such that all metabolites of [14C] [COMPANY_004]2838232 observed in human hepatocyte 
incubations were observed in rat and/or dog. Minor to trace levels of potential aldeh ydes 
metabolites formed as a result of N- dealk ylation and oxidative deamination were
observed in rat, dog and humans.  
[COMPANY_004]2838232 did not show evidence for glutathione adduct formation in rat or human 
liver microsomes.  Data from pooled human liver microsomes along with recombinant 
cytochrome P450 ( CYP) enzy mes suggest that in vitro the oxidative metabolism of 
[COMPANY_004]2838232 was primarily  mediated b y CYP3A4.  Preliminary  in vitro investigations 
showed [COMPANY_004]2838232 did not inhibit CYP1A2, 2C9, 2C19, 2D6, 3A4 and was not a 
metabolism -dependent inhibitor of CYP3A4. No drug interaction risk was ide ntified for 
co-administrated substrates of UGT1A1, 1A3, 1A6, 1A9, 2B7, and 2B15, OAT1, OAT3, 
OATP1B1, OATP1B3 or OCT2 at a clinical dose of 200 mg [COMPANY_004]2838232/ritonavir 
(predicted Cmax 0.32 µM). Extrapolation of the clinical risk (using FDA and EMA 
regulatory  guidance) did indicate a risk for [COMPANY_004]2838232 -mediated inhibition of 
UGT1A4 and of gut contributions of CYP3A4, P-gp, and BCRP at the same clinical 
exposure; however, the potential for clinicall y significant interactions via these 
mechanisms is predicted to be low (<2 fold change in AUC). [COMPANY_004]2838232 did show 
weak induction of CYP3A4 enzy me activity . However, based on the maximum predicted 
plasma concentrations and high protein binding, the potential for clinicall y significant 
drug interactions through CYP 3A4 induction by  [CONTACT_23983]2838232 appears to be low.
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure); however, there have been no 
preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Toxicology
[COMPANY_004]2838232 administered by  [CONTACT_428200] 6 months duration 
resulted in no adverse treatment- related eff ects in rats given up to 300 mg/kg/day  QD.  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
18In dogs given up to 70 mg/kg/day  (35 mg/kg/day  BID), adverse liver effects were noted 
at this dose in the 9- month repeat dose study .  Though isolated, low grade changes in 
heart rate and cardiac troponin I  (cTnI) had been noted in 4
-week toxicity  studies in rats 
and dogs; however, there were no treatment -related structural or functional 
cardiovascular changes in studies of 3 months and greater duration as assessed by  
[CONTACT_51541], ECG, microscop y, and cardiac biomarkers, indicating an absence of 
[COMPANY_004]2838232-related functional or structural effects on the heart in preclinical testing. 
Only  non- adverse treatment -related changes were noted in the definitive 6-month rat 
study , which included occasional salivation i n animals given 300mg/kg/day and minimal 
clinical pathology  changes without histologic correlates (transient clinical chemistry  
changes at 5mg/kg/day and reversible urine chemistry  changes at 300 mg/kg/day ). The 
NOAEL in this study  was considered to be 3 00mg/kg/day  (mean AUC[0- t] 
21.3g.h/mL , mean Cmax 1.77 g/mL [Week 26 values for males and females 
combined]).  
As noted above, dogs given [COMPANY_004]2838232 at 70 mg/kg/day  for 9 months had minimal to 
moderate pi[INVESTIGATOR_371] (consistent with bile) with minimal t o mild mixed cell infiltration 
in the liver and isolated mild increases in alanine aminotransferase (ALT) activity .  These 
findings were considered adverse, but were reversible after the 6 -week off -dose period.  
The NOAEL for this dog study  was considered to be the mid -dose level of 20 mg/kg/day  
(mean AUC[0- t] 16.2 g.h/mL , mean Cmax 0.847 g/mL [Week 39 values for males and 
females combined]).
Data from genotoxicity  assessments suggest that [COMPANY_004]2838232 does not present a 
genotoxic hazard to humans.
During d iscussions with the FDA regarding the resolution of the clinical hold, the 
Agency  recommended that the sporadic cardiovascular changes observed in the earl y (1-
month) rat GL P study  at the highest dose level (300 mg/kg/day ) should be considered 
when definin g the NOAEL  and establishing a safe dose of GlaxoSmithKline ([COMPANY_004]) for 
the initiation of this study  protocol.  Accordingl y, for the initial PK studies, the reference 
dose level of 30 mg/kg/day  in the 1- month rat study  was initially  used to define the 
NOAEL and therefore the values for fold cover at maximum projected mean exposure 
and Cmax in human subjects were lower, at >2.[ADDRESS_541177] sensi tive species (i.e., 20 mg/kg/day  in the 9- month dog study  
based on liver endpoints) is currentl y used for assessing fold -
cover for projected clinical 
dosing in this study .
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure and toxicity ); however, there 
have been no preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Full details of non -clinical and clinical data may  be found in the current Investigator’s 
Brochure (IB) [[COMPANY_004] Document Number 2012N151889_03]. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
192.2.2. Clinical Summary  of Safety  and Pharmacokinetics
To date, [COMPANY_004]2838232 has been evaluated in three completed clinical studies with or 
without ritonavir (RTV) ([COMPANY_004]2838232/r). A fourth study  (204953) completed late 2016 
and data anal ysis is ongoing. Full details of the clinical results can be found in the 
Investigator’s Brochure.
[IP_ADDRESS]. Clinical Summary  of Safety
As of November 2016 fifty -three subjects had been exposed to [COMPANY_004]2838232 in 3 
completed studies. One study  (204953) completed in late 2016 and the analy sis of results 
are ongoing (63 subjects were exposed to [COMPANY_004]2838232/r or placebo so far in this study ).  
Overall, drug -
related adverse events have been few and mild, and included headache, 
dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428090] .  Similarly , treatment- emergent 
laboratory  abnormalities have also been few and mostly  grade 1.  There have been no 
discernible patterns, thus far, in terms of AEs or laboratory  abnormalities.
One subject in study  200912 discontinued treatment with RTV due to an AE.  A 47- year-
old female who developed right upper quadrant abdominal pain, nausea and flatulence 
associated with grade 4 elevations in AL T and aspartate aminotransferase, and grade 2 
elevations in total bilirubin (BIL). She was diagnosed with a common bile duct 
obstruction due to gallstones that spontaneously  resolved. The Investigator assessed this 
AE as unrelated to study treatment.
Due to sporadic CV -related safet y signals in the early animal studies (see Section 2.2.2), 
intense CV monitoring was in place for all four studies.  
One AE oc curred in HMI116787 that was initially  considered a CV AE but after further 
evaluation was considered not to be of cardiac etiology .  Two CV AEs occurred in 
[ADDRESS_541178] been a small number of CV -related events of any  sort: 
There 
have  been n o serious adverse drug reactions, and no clinically  significant drug -related 
abnormal findings for 12 -lead ECGs, vital signs, safet y laboratory results (including 
cardiac troponin I), or telemetry .  The following cardiovascular AEs were observed 
during the course of the study  but were not considered to be caused b y [COMPANY_004]2838232 
exposure:
In Part 1A (Cohort 1), Period 2, a subject was withdrawn due to an AE (low 
hemoglobin) prior to [COMPANY_004]2838232 exposure Day -2.  A replacement subject 
was brought in, but was not dosed with [COMPANY_004]2838232 or placebo because during 
the 2- day RTV run -in, on Day  -1, the replacement subject met the stoppi[INVESTIGATOR_428091], NSVT prior to 
the first dose of [COMPANY_004]2838232 or placebo.  Because the subje ct was excluded 
from the study  prior to the first dose of investigational drug, the NSVT was not 
considered to be a serious and unexpected adverse drug reaction that would 
qualify  for IND safety  reporting.   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
20In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject was 
discontinued prior to the first dose of study  drug due to a series of 
cardiovascular findings (pre -ventricular contractions on telemetry ).  None of the 
findings were abnormal or aty pi[INVESTIGATOR_2855], but the investigator determined that this 
would not be a good etiology  to have in a subject about to receive 
investigational drug.  Because the event occurred prior to first dose of 
investigational drug, the finding was no t considered to be due to [COMPANY_004]2838232 
exposure.  
In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject who 
had alread y been dosed on 2 previous occasions (with either [COMPANY_004]2838232 or 
placebo) was dosed for 2 day s with RTV, and then on 05 May  2016 was dosed 
with either [COMPANY_004]2838232/r or placebo/r as scheduled. On the following day (06 
May 2016), the subject experienced an as ymptomatic, [ADDRESS_541179] had received placebo prior to experien cing the 
NSVT, the event was not considered to be due to [COMPANY_004]2838232 exposure or a 
serious and unexpected suspected adverse reaction that would qualify  for IND 
safet y reporting.
In Part 2 (Cohort 6, 200mg/r), a 40 y ear old male enrolled in the study  with no
significant medical history experienced an as ymptomatic ventricular triplet 
(NSVT) while asleep at 5:33am on Day  8 (of 11 day s worth of dosing) 
approximately  21 hours after receiving 200 mg [COMPANY_004]2838232/r on the previous 
day at 8.25am. This event was noted by [CONTACT_428201]. The 
[COMPANY_004] medical monitor was notified.   Because the subject was not s ymptomatic 
and this did not meet protocol -defined stoppi[INVESTIGATOR_3418], the study  was not 
unblinded at the time, and the subject was allowed to continue dosing. Dosing 
in the study  is now complete and no further events have been noted. It was the 
assessment of the site PI [INVESTIGATOR_428092] /monitoring team that a ventricular 
triplet can be seen in healthy  volunteers on continuous Holter monitoring.
Therefore neither the PI [INVESTIGATOR_428093] a serious and 
unexpected suspected adverse reaction.
[IP_ADDRESS]. Study  204953 (completed); Pharmacokinetic Data
Study  [ADDRESS_541180] of a normal fat meal on the bioavailability  of a single 
dose of [COMPANY_004]2838232 in the capsule formulation with RTV.  I t will evaluate 
[COMPANY_004]2838232 exposure after repeated doses of unboosted [COMPANY_004]2838232 in the capsule 
formulation. Noncompartmental PK anal ysis was performed using scheduled sample 
times.  The anay lsis of data from this study  is ongoing; preliminary  results are presented.
Pharmac okinetic anal ysis was performed on [COMPANY_004]2838232 plasma concentration -time 
data using nominal time following single doses of 50, 100, and 250 mg in combination 
with RTV in Part 1A of Study  204953 ( Table 3 ).  On averag e, [COMPANY_004]2838232 Cmax 
values were reached [ADDRESS_541181] dose proportionalit y was observed 
for Cmax and AUC(0- ) values with ascending single doses of [COMPANY_004]2838232 (50, 100, 
and 250 mg with 100 mg RTV).
Table 3 Summary  of Preliminary  Pharmacokinetic Parameter Values after 
Single Doses of [COMPANY_004]2838232 in Combination with 100 mg Ritonavir 
(Study  204953, Part 1A )
Dose (mg) n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)
50 8 22.7
(17%)
(17.2- 28.5)0.188
(138%)
(0-0.5)3.63
(41%)
(2.5-6.0)17.2
(43%)
(8.7-27.9)458.6
(33%)
(210.6- 662.0)
100 6 18.0
(14%)
(15.8- 22.3)0.167
(155%)
(0-0.5)6.00
(59%)
(2.5-12.0)25.2
(20%)
(17.5-31.5)890.5
(20%)
(619.1- 1053)
250 5 17.3
(6.4%)
(15.5- 18.6)0
(-)
(0-0)5.50
(71%)
(2.0-12.0)60.7
(23%)
(40.8- 73.1)1731
(29%)
(1222- 2505)
Data are presented as mean (CV) (minimum -maximum).
Study  204953 Part 1B was an open label, 2x2+[ADDRESS_541182] on the capsule formulation in Per iod 3.  
The relative bioavailability  of the micronized powder blend in 50 mg hand- filled capsules 
compared to the micronized API  [INVESTIGATOR_428094] 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre-doses (48 h) in the fa sted state 
in a randomized crossover design in [ADDRESS_541183] two periods of Part 1B of 
Study  204953. Preliminary  geometric mean AUC(0 -) and Cmax values were 
approximately  45% and 60% higher, respectivel y, after administration in the capsule 
formulation compared to oral suspension from PiB ( Table 4). 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
22Table 4 Preliminary  Assessment of Relative Bioavailability  of Capsule 
Formulation vs. Po wder -in-Bottle Formulation of [COMPANY_004]2838232 (Stu dy 
204953, Part 1B)
Parameter Test Reference n Ratio of Geometric 
Least Square Means90% CI of Ratio
AUC(0 -) Capsule PiB 12 1.43 (1.194,1.702)
Cmax Capsule PiB 12 1.58 (1.312,1.900)
PiB = powder -in-bottle.
The potential food effect with the capsule formulation was assessed as 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
and with a normal fat meal in a non-randomized crossover design (fasted in either Period 
1 or 2, fed in Period 3).  Eleven subjects pr ovided data for both dietary  conditions.   
Preliminary  geometric mean AUC(0 -) and Cmax values were approximately  60% 
higher after administration in the capsule formulation with a normal fat meal compared to 
the fasted state ( Table 
5).
Table [ADDRESS_541184] of a Normal Fat Meal on 
[COMPANY_004]2838232 Exposure when Administered as a Capsule 
Formulation with Ritonavir (Study  204953, Part 1B)
Parameter n Capsule –food
Geometric me anCapsule –
fasted
Geometric 
meanRatio of geometric 
means 
(food/fasted)
AUC(0 -) (ng.h/mL) 11 2414 1539 1.57
Cmax (ng/mL) 11 76.9 47.2 1.63
Repeat dose PK parameter values in Study  204953 Part 2 were determined on Day  1 and 
Day 11 using nominal time in Part 2 of Study  204953 ( Table 6). After the Day  11 dose of 
[COMPANY_004]2838232 with RTV, exposure (Cmax, AUC[0 -]) appeared to increase 
proportionally  with the increase in dose level with the PiB and capsule formulations .  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
23Table 6 Summary  of Preliminary  Pharmacokinetic Parameter Values on 
Day 1 and Day  11 during Repeated Dosing of [COMPANY_004]2838232 in 
Combination with 100 mg Ritonavir (Study  204953, Part 2)
Dose 
(mg)n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)C
(ng/mL)
Study Day 1
20
(PiB)6 - 0.417
(49%)
(0-0.5)3.67
(11%)
(3.0-4.0)12.2
(47%)
(5.8-20.8)189.4
(40%)
(83.7- 284.4)6.1
(39%)
(2.5-8.9)
50
(PiB)6 - 0.167
(155%)
(0-0.5)3.00
(51%)
(2.0-6.0)18.7
(40%)
(9.0-25.9)288.7
(39%)
(138.6- 380.2)9.5
(35%)
(5.1-12.6)
100
(capsules)6 - 0.167
(155%)
(0-0.5)2.25
(23%)
(1.5-3.0)48.4
(32%)
(28.1- 69.6)664.1
(31%)
(422.5- 932.7)21.6
(33%)
(12.8- 29.3)
200
(capsules)6 - 0.083
(245%)
(0-0.5)2.50
(25%)
(2.0-3.5)79.4
(38%)
(50.8-125)1124
(39%)
(636.7- 1794)38.9
(36%)
(21.7- 58.6)
Study Day 11
20
(PiB)6 19.2
(16%)
(15.1-
24.2)- 5.00
(32%)
(2.5-6.0)27.4
(38%)
(11.3- 40.4)474.3
(31%)
(214.3- 613.2)15.3
(30%)
(7.1-19.2)
50
(PiB)6 27.3
(52%)
(15.2-
50.4)- 3.50
(46%)
(1.5-6.0)58.0
(24%)
(40.9- 78.0)1113
(23%)
(762.6- 1459)38.8
(29%)
(24.5- 51.7)
100
(capsules)6 17.9
(18%)
(15.2-
23.7)- 4.00
(40%)
(2.5-6.0)133
(23%)
(94.7- 164)2492
(27%)
(1624- 3301)81.7
(30%)
(45.9- 113)
200
(capsules)6 -1 - 3.33
(45%)
(1.5-6.0)240
(38%)
(127-368)4389
(45%)
(2095- 7161)151
(46%)
(67.8- 250)
Data are presented as mean (CV) (minimum -maximum).
1. Concentration data were available up to 24 h after the Day 11 dose, and t½ values were not 
calculated.
[IP_ADDRESS]. Overall Summary /Conclusions of PK data
The origina l formulation used in the first three studies with [COMPANY_004]2838232 (HMI 116787, 
200207, and 200912) was SDD.  Data from Stud y 200912 demonstrated that a change to 
the API  [INVESTIGATOR_428095]2838232 was feasible for future clinical studies. Study  
204953 utilized m icronized API [INVESTIGATOR_428096] a bottle as well as in a capsule. The capsule 
was shown to be a viable solid dosage form for subsequent studies.  A more detailed 
summary  of the data from Study  204953 is in Section [IP_ADDRESS]. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
24[COMPANY_004]2838232 SDD did not overall demonstrate significant escalation in exposure 
from an increase in dose from 100 mg to 200 mg in a cross -study  comparison.  The 
API [INVESTIGATOR_428097] a proportional increase in AUC and Cmax for a 2 -fold 
dose escalati on from 100 mg to 200 mg.
The observed tmax of the API  [INVESTIGATOR_428098] (the API [INVESTIGATOR_428099]).
The bioavailability  of the [COMPANY_004]2838232 API  [INVESTIGATOR_428100] 30 -50% of 
the bioavailability  of SDD formulation, but there was a large observed range of 
relative intra -subject exposures (11- 150%).
Both 10 mg SDD and 20 mg API [INVESTIGATOR_428101] a 10 -fold or greater increase in AUC with 
steady -state RTV (100 mg QD for 10 day s)with a smaller ( ≤4-fold) increase in 
observed Cmax.  The t½ of [COMPANY_004]2838232 increased from 15-18 hours to 34-42 
hours in the presence of stead y-state RTV, regardless of formulation.
After single doses of 50 to 250 mg [COMPANY_004]2838232 with RTV, increases in Cmax and 
AUC(0 -) values were broadly  proportional to the increase in dose.  On Day  11 
after repeated dail y 20 to 200 mg doses of [COMPANY_004]2838232 with RTV, increases in 
Cmax and AUC(0 -) values appeared to be proportional to the increase in dose with 
the PiB and caps ule formulations.  
The relative bioavailability  of the micronized API  [INVESTIGATOR_428102]  45% -60% higher than the bioavailability of the micronized 
API [INVESTIGATOR_428103].
Co-administration of the micronized API  [INVESTIGATOR_428104] a 
normal fat meal resulted in an approximately  60% increase in geometric mean 
Cmax and AUC(0 -) values compared to the fasted state with RTV (Study  
204953).
Variability  remains fairly constant acros s formulations and boosted versus 
unboosted at around 30% -40% (moderate -high).
Projections of potential future efficacious boosted [COMPANY_004]2838232 API  [INVESTIGATOR_428105] [ADDRESS_541185] 3 -fold above the derived 90% maximal 
inhibitory  concentration (IC90) target value (5 ng/mL ). Even if protein binding has 
more impact than envisaged and causes a 5 -
fold increase in IC90 as seen in some 
preclinical virology  studies, the predicted troughs will still be significantly  higher 
than the 5 -fold shifted IC90 (25 ng/mL) at doses of 50 mg or higher with RTV. 
The average and maximum AUC/Cmax values observed at the maximum dose 
studied to date are below NOAEL values in preclinical ch ronic toxicology  studies 
(6-
month rat, 9- month dog). 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
253. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected patients 
during 10 -days of monotherapy.Maximum decline from baseline (Day 1) in 
plasma HIV -1 RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered as 
monotherapy over 10 days. Safety and tolerability parameters, 
including adverse event, concurrent 
medication, clinical laboratory, 
electrocardiogram (ECG) a nd vital signs 
assessments.
To characterize pharmacokinetics (PK) of 
[COMPANY_004]2838232 in HIV -1 infected patients 
following [COMPANY_004]2838232/cobi dosing for 10 
days [COMPANY_004]2838232 PK parameters following 
dose administration, as follows:
Day 1 :  area under the plasma 
conc entration time curve AUC(0 -24), 
maximum observed concentration 
(Cmax), time to maximum observed 
concentration (tmax), concentration at [ADDRESS_541186] dose (C24), absorption lag 
time (tlag); 
Following last repeat administration on 
Day 10 :  AUC(0 -), pre -dose 
concentration (C0), concentration at end 
of dosing interval (C ), Cmax, tmax, t½, 
and apparent oral clearance (CL/F), if 
data permit
Secondary
 To explore the relationship between 
[COMPANY_004]2838232 exposure and change in 
plasma HIV -1 RNA [COMPANY_004]2838232 PK paramet ers Day 10 
AUC(0 -), Cmax, C with Day 11 HIV -1 
RNA change from baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when administered over 
10 days in HIV -1 infected adults Change from baseline in CD4+ cell count 
to Day 11
 To explore the relation ship between 
[COMPANY_004]2838232 exposure and safety or 
immunologic parameters, if appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax, C   with Day 11 change 
from baseline in CD4+ cell count
 To assess the development of viral 
resistance (genotypic and phenotypic) over 
10 days and correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, 
if appropriate 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
26Objectives Endpoints
 To estimate [COMPANY_004]2838232 accumulation and 
to assess attainment of steady state 
following administration of 
[COMPANY_004]2838232/cobi fo r 10 days in HIV 
infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): 
Day 10 AUC(0- ), Cmax, and C 
compared to Day 1 AUC(0- 24), Cmax, 
and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on 
Day 2 through 11 
 To exa mine dose proportionality of 
[COMPANY_004]2838232 PK parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days in HIV 
infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and 
Day 10 AUC(0- ), Cmax and C   at 
different doses levels for the assessment 
of dose proportional ity
Note: Other exploratory objectives and endpoints will be specified in the RAP
4. STUDY DESIGN
4.1. Overall Design
This is a Phase IIa, multicenter, open -label, adaptive dose ranging, study  to evaluate the 
antiviral effect, safet y, tolerability, and PK of [COMPANY_004] 2838232/cobi monotherap y over [ADDRESS_541187] dose 
of study  drug.  Eligible HIV -1 infected subjects will receive study  treatments for 10 day s.
Table 7 Study  Design for 200911
[COMPANY_004]2838232/cobi Once Daily for 10 days1,2
Part A Part B 
Cohort 1 Dose
(mg)Interim Analysis Cohort
N(mg)
N=10 100
2 8 200
3 8 50
4 8 20 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
271. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B.  All 
doses will be given with [ADDRESS_541188] to 
modification based upon safety, PK and antiviral activity data from Cohort 1 (Part A). More doses/cohorts 
(including potential remova l of cobicistat co -dosing) may be added. (The maximum dose in Cohort B will likely not  
exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] is lower in HIV -infected 
subjects than in healthy subjects at the same dose level).
After successfull y completing screening evaluations, the first cohort will enroll 10 
subjects to receive the 100 mg [COMPANY_004]2838232/cobi dose.  Following interim anal ysis of 
Cohort 1, if warranted, Cohorts 2 -4 will each enroll 8 subjects to receive a range of 
[COMPANY_004]2 838232/cobi doses.
Day 1 – Day 10: Dosing 
Subjects will report to the clinic for outpatient visits in the morning on Day s 1 through 10 
during the treatment period, except for the weekend (Day s 6 and 7).  Subjects will arrive 
each day  prior to administration of the morning dose for safety and lab assessments, 
including HIV -
1 RNA blood draws, as described in the Time and Events Table (Section 
7.1).  Subjects will begin receiving stud y drug in the morning of Day 1.   
Serial, intensive blood PK samples will be collected on Day  1 (up to [ADDRESS_541189] -
morning dose) and Day  10 (up to [ADDRESS_541190] -morning dose), and limited, single blood 
PK samples pre -morning doses on Day s [ADDRESS_541191] for 10 hours [overnight] prior to the morning check in on the 
intensive PK sampling day s (Day s 1 and 10).  All dosing day s will require co -
administration of treatment with a light snack/meal per cobicistat labeling guidelines. All 
doses of study  medication will be taken with 240 mL  of water.  Subjects will be required 
to stay  in the clinic on Day s 1 and 10 until all specified assessments are completed (8-[ADDRESS_541192] -dose). Following Day  10, subjects will be required to attend the clinic for 
follow up assessments including virological and PK blood sampling for up to 3 weeks.
Subjects will be given morning doses on Day s 1 through 10 (except for the weekend) in 
the clinic.  Weekend morning doses (Day s 6 and 7) will be packaged and sen t home for 
self-administration.  After Day  11, the subjects will return frequentl y for assessments 
including blood draws for PK and HIV viral load. A diary  card will be used to monitor 
dosing adherence.
Follow -up Visits:
Subjects will return to the clinic on Day s 11, 12, 14 ( 1 day ), and 21 ( 1 day ) for PK and 
measurement of HIV -1 RNA levels, viral genot ype/phenoty pe and safet y assessments as 
shown in the Time and Events Table (Section 7.1). 
4.2. Type and Number of S ubjects
At least 34 subjects will be enrolled such that approximately  6
-10 evaluable subjects 
complete a number of cohorts.  Additional subjects/cohorts may be enrolled to allow for 
evaluation of additional dose levels as appropriate.  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
28If subjects prematur ely discontinue the study, additional subjects may be randomized and 
assigned to the same treatment cohort at the discretion of the Sponsor in consultation with 
the Investigator.
4.3. Design/Dose Justification
The fastest track to establishing antiviral potenti al of any  novel HIV drug is to study  a 
short course of monotherapy  in HIV infected subjects. There is precedent for this across a 
number of classes of ART drugs. 
Uncertainties over the impact of protein binding on the activity  of [COMPANY_004]2838232 and the 
inhere nt potency  of inhibiting the HIV maturation process as a target remain key  
objectives for the [COMPANY_004]2838232 program. This two -part adaptive design will allow an 
early understanding of the potential of [COMPANY_004]2838232 in combination with cobicistat (and 
by [CONTACT_118414], RTV), while not exposing HIV -infected subjects to longer courses of 
what may  be suboptimal doses and possible development of resistance. 
Early clinical studies have indicated that in order to achieve reasonable IQ values likely 
to be associated with antiviral efficacy , [COMPANY_004]2838232 will need to be boosted with a 
pharmacoenhancer, such as RTV or cobicistat (in common with many  CYP3A4 
substrates). 
There is no a priori intention to study  [COMPANY_004]2838232 unboosted, unless: i) following the 
preliminary  anal ysis of Part A Cohort 1, there is such pronounced antiviral activity  that it 
would seem the estimates of projected IQ are low, in which case [COMPANY_004]2838232 may be 
evaluated in a subsequent cohort unboosted, or ii) the data from ongoing and planned 
healthy  volunteer trials,Study  204953 ([COMPANY_004]2838232 200 mg BID unboosted) and Study  
205820 ([COMPANY_004]2838232 500mg QD unboosted) support it.
4.3.1. [COMPANY_004]2838232 with Ritonavir
In Stud y HMI116787, a single dose of 10 mg [COMPANY_004]2838232 (SDD) given after 10 day s of 
RTV 100 mg dail y dosing (to ste ady state) demonstrated an increase in overall exposure 
(AUC) and Cmax by  [CONTACT_5554] 10.[ADDRESS_541193] . Studies 200912 and 200207 also indicated the utility  of RTV in 
boosting [COMPANY_004]2838232 concentrations.
These data indicate the viability  of study ing a number of [COMPANY_004]2838232+RTV regimens in 
thisPoC study . Predicted exposures following different [COMPANY_004]2838232 doses with steady -
state RTV are presented in Table 8, based on the results of linear regression anal yses of 
the preliminary  Day  11 data in Study  204953 (dose levels of 20 to 200 mg) and assuming 
no significant differences in PK (ADME) between HIV -infected subjects and healthy  
subjects.  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
29Table 8 Predicted Mean Steady -State [COMPANY_004]2838232 A UC(0 -24), Cmax, and IQ, 
Follo wing Repeated Dose Administration + RTV with Fold Cover to 
NOA EL
Dose 
(mg)Projected AUC24 
(ng.h/mL)1Fold cover to 
NOAEL Dog2Projected 
Cmax 
(ng/mL)1Fold cover to 
NOAEL Dog2IQ3
20+RTV 451 36 24 35 3.1
50+ RTV 1127 14 61 14 7.7
100+ RTV 2253 7.2 122 6.9 15
150+RTV 3380 4.8 183 4.6 23
200+RTV [ADDRESS_541194] NOAEL, 20 mg/kg/day obtained from 9 -month study in dogs ( AUC24 [ZIP_CODE] ng.h/mL and Cmax 847 
ng/mL)
3. Mean IQs derived from predicted C /IC90 (with target of 5 ng/mL).
C= Pre-dose (trough) concentration at the end of the dosing interval , IQ= inhibitory quotient.
The IQ following 20 mg to 200 mg [COMPANY_004]2838232/r QD is predicted to be >3 to >30 -fold 
above the m inimal target value (5 ng/mL) which was derived from preclinical virological 
assessment as 4 ×EC50. No p rotein binding adjustment has been made because there was 
a minimal ( ≤5 fold) shift in assays where the effect of protein was assessed. If protein 
binding has more impact than anticipated, it is possible that the target Cmin value is 
approximately  25ng/mL . In that scenario, projected IQ values at 200 mg/r QD would still 
be >5.
4.3.2. [COMPANY_004]2838232 with Cobicistat
There have been no preclinical or clinical studies with [COMPANY_004]2838232 and cobicistat to 
date; however, a review of the literature indicates that pharmacoenhan cement of drugs 
that are known to have dominant CYP3A metabolic pathway s is similar with either RTV 
or cobicistat [ Kakuda , 2009; Elion , 2011; Gallant , 2013].  Thus, the use of cobicistat as 
the CYP3A4 inhibitor pharmacoenhancer in this Phase IIa study  in place of ritonavir is 
expected to produce a similar profile of [COMPANY_004]2838232 ADME (and therefore s ystemic 
exposure).  The pharmacokinetic data available after Part A Cohort 1 will confirm this 
assumption.  
4.3.3. Interim A nalysis
An evaluation of [COMPANY_004]2838232 safet y, efficacy  and PK data will be done after Part A 
Cohort 1, if the exposure level of [COMPANY_004]2838232 is in the range of the maximum 
[COMPANY_004]2838232 expo sure seen previousl y in healthy subjects and the Bay esian probability  
from Cohort 1 is less than 70%, the study will not move forward into Part B, otherwise 
doses will be selected for evaluation in Part B. If pharmacokinetic exposure after the 100 
mg [COMPANY_004]28 [ZIP_CODE]/cobi dose is in the range of values observed after 100 mg 
[COMPANY_004]2838232/r in prior studies, the doses for Part B will be extended to both lower 
(20mg and/or 50 mg) and higher (200 mg) doses. The highest dose tested in Part B will 
be selected to result in exposures similar to those seen with 200 mg/r in Study  204953.   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
304.4. Benefit:Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
[COMPANY_004]2838232 can be found in the I nvestigator’s Brochure.   The following section 
outlines the risk assessment and mitigation strategy for this protocol:   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
314.4.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [COMPANY_004]2838232 
Cardiovascular Pre-clinical s tudies have shown the following findings:  elevated heart rates, an 
isolated epi[INVESTIGATOR_43180] -sustained ventricular tachycardia and minimal to mild, 
sporadic troponin I elevations in dogs.  A subsequent investigative cardiovascular 
study in telemetered dogs treated for 4 weeks did not replicate these effects. 
Isolated microscopic cardiovascular changes were noted (focal extramural 
arteritis and localized epi[INVESTIGATOR_428106]), however these changes were 
considered of uncertain relationship to [COMPANY_004]2838232 because similar findings 
occur at low incidence in normal beagles and there were no [COMPANY_004]2838232 -related 
functional changes by [CONTACT_428202], or changes in cTpnI and 
NTproBNP.  In addition there was no correlation between histologic changes an d 
plasma exposure or heart tissue concentrations of [COMPANY_004]2838232. 
3, [ADDRESS_541195], other than a 30% incidence of 
gastrointestinal symptoms (including diarrhea). There were no significant 
cardiovascular AEs reported in published clinical studies.Subject s will be clinically monitored for any signs 
of myocardial injury (chest pain, shortness of 
breath, pain with inspi[INVESTIGATOR_1516]), elevated heart rate 
or arrhythmias. Samples for the assessment of 
troponin will be taken. Baseline EKG and Holter 
(to use for screen ing and for later comparisons if 
needed)
Exposures of [COMPANY_004]2838232 will be closely 
monitored in the clinical study so as to not 
exceed pharmacokinetic stoppi[INVESTIGATOR_3418].   
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
32Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigati on Strategy
Cobicistat (Tybost)
General The cobicistat label includes the following information: 
TYBOST decreases estimated creatinine clearance due to inhibition of tubular 
secretion of creatinine without affecting actual renal glomerular function. Thi s 
effect should be considered when interpreting changes in estimated creatinine 
clearance in patients initiating TYBOST
In one study investigating cobi+( atazanavir and tenofovir DF/emtricitabine) vs 
RTV+( atazanavir and tenofovir DF/emtricitabine), a high er frequency of reports 
of jaundice (6% and 3%) and ocular icterus (4% and 2%) were reported in the 
cobi group compared to the RTV group.  
Changes from baseline in total cholesterol, HDL -cholesterol, LDL -cholesterol, and 
triglycerides have been observed. The implications of these findings are 
unknown.
The vast majority of available safety data has been obtained in combination 
studies with other ART. There are no warnings of obvious cobicistat -related 
adverse events or safety concerns. Subjects will be clo sely monitored for any signs 
or symptoms potentially associated with 
cobicistat administration, in particularchanges in 
serum creatinine and liver chemistry.
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible Drug -Drug
Interactions (DDIs)HIV Drug Resistance to unique mechanism
Recognize HIV patients have a higher chance of comorbidities/diseases and a 
risk of taking a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resista nce
Strict adherence to protocol criteria around 
concurrent meds  
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
334.4.2. Benefit A ssessment
This study  in HIV -1 infected but otherwise healthy  subjects is a 10 -day monotherapy  
design. It is anticipated that all subjects receiving [COMPANY_004]2838232 will experience ant i-HIV 
effects whereb y their (blood) HIV viral titres are reduced, until administration stops and 
the viral load returns to baseline levels. There is no expected longer term anti- HIV 
benefit to administration of [COMPANY_004]2838232.  Participation in this study  cont ributes to the 
process of developi[INVESTIGATOR_428107]2838232 and other new therapi[INVESTIGATOR_428108].
4.4.3. Overall Benefit:Risk Conclusion
To date, [ADDRESS_541196] received single do ses up to 200 mg SDD alone (studies HMI116787 and 
200912), 250 mg API [INVESTIGATOR_428109] (204953), and then in repeated dail y 
doses of up to 50 mg SDD alone (200207) for 5 day s or 200 mg in combination with 
RTV (204953) for [ADDRESS_541197] was receiving [COMPANY_004]2838232 to date (one in 200207, one in 204953). Neither is 
thought likely  to be due to [COMPANY_004]2838232.
There have been no other withdrawals due to drug -related AEs and no t rends relative to 
laboratory  toxicity .  One subject was withdrawn in Part 1A of [ADDRESS_541198] been no cli nically  
significant changes in troponin, heart rate, blood pressure, ECG, or telemetry monitoring.
Subjects will also be at risk for AEs from cobicistat use and will be monitored closel y for 
such events.
Given the preclinical profile and the clinical profi le to date, the overall risk to HIV -1 
infected but otherwise healthy  subjects at the proposed [COMPANY_004]2838232 doses (with or 
without cobicistat) for [ADDRESS_541199] eligibility  is provided in the Investigator’s Brochure.
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize the scientific integrity of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
34Approximately  10-12 HIV -1 infected subjects will be enrolled into Part A. If warranted 
by [CONTACT_428203] y, virology and PK data anal ysis, approximately  8 subjects will be 
enrolled in each of Cohorts 2 -4 in Part B. Eligible patients are those who are maturation 
inhibitor -naïve and who are not currentl y receiving ART therap y.
Additional subjects/cohorts may  be enrolled t o allow for evaluation of additional dose 
levels or configurations (e.g., [COMPANY_004]2838232 alone).
If subjects prematurel y discontinue the study, additional subjects may be enrolled .
5.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl yif all of the following criteria 
apply :
AGE
1.Between [ADDRESS_541200] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Health y (other than HIV infection) male or female as determine d by [CONTACT_428204] y qualified designee based on a medical evaluation including medical 
history , phy sical examination, laboratory  tests and cardiac monitoring. Defined as no 
other chronic medical conditions and taking no chronic medications.
3.A subject with a clinical abnormality  or laboratory  parameter(s) which is/are not 
specificall y listed in the inclusion or exclusion criteria, outside the reference range 
for the population being studied may  be included only  if the investigator in 
consultat ion with the Medical Monitor agree and document that the finding is 
unlikely  to introduce additional risk factors and will not interfere with the study  
procedures. 
4.A creatinine clearance >80 mL/min as determined by  [CONTACT_3158]- Gault equation 
[Cockcroft , 1976] CLcr (mL /min) = (140 – age) * Wt / (72 * Scr) (times 0.85 if 
female) where age is in years, weight (Wt) is in kg, and serum creatinine (Scr) is in 
units of mg/dL .
5.Confirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. 
6.Antiretroviral treatment naive or ART -experienced (maturation inhibitor naive) . No 
current ART (last dose completed at least [ADDRESS_541201] dose of study  
drug). A previous course of pre -or post -exposure prophy laxis is allowed provided 
that it was completed at least [ADDRESS_541202] dose of study  drug. NOTE: 
Subjects with limited therapeutic options, including but not limited to t hose who 
have failed ≥[ADDRESS_541203] documented resistance 
to >[ADDRESS_541204] interrupted their treatment due to resistance, 
will not be eligible. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
35WEI GHT
7.Body weight 50kg (110 lbs.) for men and 45kg (99 lbs) for women and body  
mass index (BMI) within the range 18.5 -35.0 kg/m2(inclusive)
SEX
8.Male or Female
A female subject of reproductive or non -reproductive potential is eligible to 
participate if she is not pregnant (as confirmed b y a negat ive serum or urine human 
chorionic gonadotrophin (hCG) test at screening and prior to first dose), not 
lactating, and at least one of the following conditions applies:
Reproductive potential:
Females of reproductive potential may  only be enrolled if they a re using two forms 
of complementary  contraception, which must include one barrier method. They  will 
be counselled on safer sex practices
There is no definitive DDI information with [COMPANY_004]2838232 and an interaction with 
oral contraceptives is possible, so othe r (barrier, inter- uterine device etc.) methods of 
contraception will be required.
Fertile females, who have an established, long -term lifesty le of sexual abstinence, or 
only same sex partners, require no other means of birth control.  
Non-reproductive pot ential:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause (refer to 
laboratory  reference ranges for confirmatory  levels).  Females on hormone 
replacement therap y (HRT) must discontinue HRT to allow confirmation of 
post-menopausal status prior to study  enrolment.
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first dose of study  medication 
until one week after the last dose of study  medication.
a.Vasectom y with documentation of azoospermia.  
b.
Male condom plus partner use of one of the contraceptive options below:
Contraceptive subdermal implant that meets the SOP effectiveness criteria  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
36including a <1% rate of failure per year, as stated in the product label
Intrauterine device or intrauterine s ystem that meets the SOP effectiveness 
criteria including a <1% rate of failure per year, as stated in the pr oduct 
label
Oral contraceptive, either combined or progestogen alone or Injectable 
progestogen 
Contraceptive vaginal ring 
Percutaneous contraceptive patches
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label.  The investigator is responsible 
for ensuring that subjects understand how to properly  use these methods of 
contraception.
INFORMED CONSENT
9. Capable of giving signed informed consent as described in Section 10.2, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if any of the follow ing criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1. Alanine aminotransferase (ALT) and BIL >1.5xupper limit of normal (ULN; isolated 
BIL >1.5xUL N is acceptable if BIL is fractionated and direct BIL <35%). 
2.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones); HBV and/or 
HCV positive.
3.Subjects who have an y other chronic medical condition, including CV, res pi[INVESTIGATOR_696] , 
neurologic, ps ychiatric, renal, gastrointestinal (GI), oncologic, rheumatologic, or 
dermatologic
4.Medical history  of cardiac arrhy thmias or cardiac disease or a famil y or personal 
history  of long QT s yndrome. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
37CONTRAINDICATIONS 
5.History  of sens itivity  to any  of the stud y medications, or components thereof or a 
history  of drug or other allergy  that, in the opi[INVESTIGATOR_427175], contraindicates their participation.
REL EVANT HABITS 
6.Chronic marijuana or use of other elic it medications (cocaine, heroin) is an exclusion 
criteria.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
7.Presence of hepatitis B surface antigen (HBsAg), positive (confirmed b y 
Recombinant I mmuno -Blot Assay  [RIBA]) hepatitis C antibody  test result at 
screen ing or within [ADDRESS_541205] dose of study  treatment.
8. Screening or baseline cardiac troponin I greater than the 99% cutoff (>0.045 ng/mL 
by [CONTACT_428205] ).
9.A positive pre -study  drug/alcohol screen.  
10.Prior history  of receiving an HIV maturation inhibitor
11.Where participation in the study would result in donation of blood or blood products 
in excess of [ADDRESS_541206] dosing day  in the current 
study : [ADDRESS_541207] (whichever is longer).
13.Exposure to more than four new chemical entities within [ADDRESS_541208] 
dosing day .
14.Treatment with radiation therap y or cy totoxic chemotherapeutic agents within 
30days of study  drug administration or anticipated need for such treatment within 
the study .
15.Treatment with immunomodulating agents (such as sy stemic corticosteroids, 
interleukins, interferons) or an y agent with known anti -HIV activity  (such as 
hydroxyurea or foscarnet) within 30 day s of study  drug administration.
16.An active Center for Disease Control and Prevention (CDC) Category  C disease 
except cu taneous Kaposi’s sarcoma not requiring sy stemic therapy  during the trial.
17.Treatment with an y vaccine within 30 days prior to receiving stud y medication.
18. Exclusion Criteria for 24- Hour Screening Holter:
Any symptomatic arrhy thmia (except isolated extra s ystoles).
Sustained cardiac arrh ythmias (such as atrial fibrillation,flutter or 
supraventricular tach ycardia ( 10 seconds)
Non-sustained or sustained ventricular tach ycardia (defined as 3 consecutive  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
38ventricular ectopic beats).
Any conduction abnormality  including but not specific to left or complete 
bundle branch block, atrioventricular [AV] block, high grade or complete heart 
block Wolff -Parkinson- White [WPW] sy ndrome etc.).
Sinus Pauses >3 seconds.
19.
Exclusion criteria for screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according t o Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual participant in 200911 will be Friderici a’s formula. 
Note: A heart rate from 100 to 110 beats per minute (bpm) can be rechecked by 
[CONTACT_428206] 30 minutes to verify eligibility.
Evidence of previous myocardial infarction (Does not include ST segment 
changes associated with repolarization).
Any conduction abnormality  (including but not specific to left or right complete 
bundle branch block, AV block [2nd degree or higher], WPW syndrome).
Sinus Pauses >3 seconds.
Any significant arrh ythmia which, in the opi[INVESTIGATOR_428110], will interfere with the safet y for the individual 
subject. 
Non-sustained or sustained ventricular tach ycardia ( 3 consecutive ventricular 
ectopic beats).
5.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjec ts who consent to participate in the clinical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and resp ond to queries from Regulatory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure 
details, Eligibility  Criteria, and an y SAEs. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
395.4. Withdrawal/Stoppi[INVESTIGATOR_428111] a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_541209]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreach able, only  then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
A subject may  withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of t
he investigator for safet y, behavioural or 
administrative reasons. If a subject withdraws from the study , he/she may  request 
destruction of an y samples taken, and the investigator must document this request has 
occurred in the site study records. 
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/d ownloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
40Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 , Section 12.2 and Section 12.3. 
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_007] c riteria are met by  
[CONTACT_428207].
5.4.2. QTc Stoppi[INVESTIGATOR_2121]
The same QT correction formula 
must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the subject has been enrolled.
For example, if a subject is eligible for the protocol based on QTcB , then QTcB 
must be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chose n for a subject’s eligibility , the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis .  Safety  ECGs and other non -protocol specified 
ECGs are an exception.  
The QTc should be based on single or averag ed QTc values of triplicate ECGs 
obtained over a brief (e.g., 5- 10 minutes) recording period.  
A subject who meets either of the bulleted criteria below will be withdrawn from the 
study : 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
41QTc >500 msec OR Uncorrected QT >600 msec
Change from baseline of QT c >60 msec
5.5. Stoppi[INVESTIGATOR_428112] A dverse Events
Any grade 3 or higher treatment -related adverse events that occur in ≥[ADDRESS_541210]’s last visit.
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products r eceived b y the subject as per the protocol design. Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Treatment
Product name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Formulation 
description:[COMPANY_004]2838232 powder blend in a 
capsuleTablet
Dosage form: Swedish orange, unmarked 
capsules (50 mg), and white, 
unmarked capsules (10 mg)Orange, round, biconvex, film -coated 
tablets debossed with “GSI” on one side 
and plain faced o n the other side 
providing 150 mg of cobicistat.
Unit dose strength(s)/
Dosage level(s):50 mg capsule for 200 mg, 100 mg, 
50 mg doses and 10 mg capsule for 
20 mg doses 150 mg for 150 mg doses
Route/
Administration/
Duration:Administered orally QD fo r [ADDRESS_541211] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Dosing instructions: Administer with light meal and 240 
mL of water . Administer with light meal and 240 mL 
water.
Manufacturer/
source of 
procurement:[COMPANY_004] [COMPANY_009]
Method for 
individualizing dosage:Capsules s upplied in high -density 
polyethylene bottles for 
individualized dosing by [CONTACT_428208]
6.2. Treatment A ssignment
Subjects will be assigned to treatment (active) groups in accordance wit h the 
randomization schedule generated by  [CONTACT_278814], prior to the start of the study , 
using validated internal software.
6.3. Planned Dose A djustments
Following the interim analy sis of safet y, virology  and PK data from the first cohort of 
subjects in Part A, the option to adjust dose levels from those described exists. No dose 
will be administered that has an associated projected mean AUC or Cmax value higher 
than the most conservative NOAEL obtained from the chronic toxicity  studies (i.e., from 
the 9
-month dog toxicity  study  described in Section 2.2.1).
6.4. Blinding
This will be an open -label study . Treatment allocation and [COMPANY_004]2838232 dose levels in 
Part B will be determined after the anal ysis of Part A data.
Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.5. Preparation/Handling/Storage/A ccountability
A description of the methods and materials required for capsule/tablet storage and 
dispensing wil l be detailed in a Study  Specific Technical Agreement/Memo or Pharmacy  
Manual, which will be accompanied b y a Quality Agreement.
No special preparation of study  treatment is required.
Only  subjects enrolled in the study  may  receive study  treatment and onl
y
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
43(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e., receipt, reconciliation and final disposition records).
Further guidance and information for final disposition of unused study  treatment 
are provided in the study  reference manual (SRM). 
Under normal conditions of handling and administration, study  treatment is not 
expected to po se significant safet y risks to site staff .  
A Material Safety  Data Sheet/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is avai lable upon request from 
[COMPANY_004].
6.6. Compliance with Study  Treatment A dministration
When subjects are dosed at the site, they  will receive study  treatment directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
admini stered in the clinic will be recorded in the source documents.  The dose of study  
treatment and study subject identification will be confirmed at the time of dosing b y a 
member of the stud y site staff other than the person administering the stud y treatment .  
When subjects self- administer study  treatment(s) at home , compliance with study  
treatment(s) will be assessed through querying the subject during the site visits and 
documented in the source documents and case report form (CRF).  A record of the 
number of study  treatment(s) dispensed to and taken by  [CONTACT_428209].  Treatment start and stop 
dates, including dates for treatment delay s and/or dose reductions will also be recorded in 
the CRF.
6.7. Treatment of Study  Treatment Overdose
For this study , any  dose of [COMPANY_004]2838232 >200 mg+cobicistat within a 28 -hour time 
period will be considered an overdose.
[COMPANY_004] does not recommend specific treatment for an overdose; however, in the event of an 
overdose, the investigator or treating ph ysician should:
Contact [CONTACT_27465]
Closely  monitor the subject for AEs/SAEs and laboratory  abnormalities until 
[COMPANY_004]2838232 can no longer be detected s ystemically  (at least 10 day s for 
[COMPANY_004]2838232)
Obtain a plasma sample for PK anal ysis within [ADDRESS_541212] dose 
of study  treatment if requested by  [CONTACT_1689] (determined on a case -by-case 
basis) 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
44Document the quantit y of the excess dose as well as the duration of the overdos ing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_424359].
6.8. Treatment after the End of the Study
Subjects receiving [COMPANY_004]28 [ZIP_CODE] may  opt to receive marketed antiretrovirals after the 
completion of 10 day s of [COMPANY_004]2838232 dosing and study  follow -up visits (through 
Day 21) eligible for sponsor compan y reimbursement up to a maximum of [ADDRESS_541213]’s medical condition, whether or not [COMPANY_004] is providing 
reimbursement for post -study  treatment.
6.9. Lifest yle and/or Diet ary Restrictions
6.9.1. Meals and Dietary  Restrictions
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice 
from [ADDRESS_541214] dose of study medication until after the final dose.
Doses will be given in the fed state ( light breakfast), following overnight fasting 
(>10 hours). 
6.9.2. Alcohol, Caffeine and Exercise
During  the study   alcohol consumption should be limited to the following:
An average weekl y intake of <14 drinks for males or <7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL ) of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
Subjects should abstain from strenuous exercise during the treatment period.
6.10. Contraception
Female subjects can be of ch ildbearing or non -child bearing potential.  
Females of reproductive potential may  only be enrolled if they are using two forms of 
complementary  contraception, which must include one barrier method.  Although use of 
oral contraceptives is permitted, there is no definitive DDI information with 
[COMPANY_004]2838232 and an interaction with oral contraceptives is possible, so other (barrier, 
inter-uterine device etc.) methods of contraception will be required.
Females of reproductive potential, who have an established, long- term lifesty le of sexual 
abstinence, or onl y same sex partners, require no other means of birth control.  
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first do se of stud y medication 
until one week after the last dose of study medication: 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
451. Vasectom y with documentation of azoospermia. The documentation on male 
sterility  can come from the site personnel’s review of subject’s medical records, 
medical examination a nd/or semen anal ysis, or medical history  interview.
OR
2. Male condom plus partner use of one of the contraceptive options below that 
meets the SOP effectiveness criteria including a <1% rate of failure per year, as 
stated in the product label:
-Contracep tive subdermal implant
-Intrauterine device or intrauterine s ystem
- Combined estrogen and progestogen oral contraceptive 
-Injectable progestogen
-Contraceptive vaginal ring 
-Percutaneous contraceptive patches 
These allowed methods of contraception a re only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
6.11. Concomitant Medications and Non -Drug The rapi[INVESTIGATOR_014]
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
Acetaminophen at doses of 2grams/day  or NSAIDs are permitted for use any  time 
during the stud y and their use documented in the CRF.  Other concomitant 
medication may  be considered on a case by  [CONTACT_276944] s by [CONTACT_428210].
Concomitant medications (prescription and non- prescription) should be administered 
only as medically  necessary  during the study . Subjects must notify  their Investigator 
of an y current or proposed concomitant medication, whether prescribed or over -the-
counter, because of the potential for interactions between such treatments and the 
study  medications.
6.11.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_014]
Subjects must refrain from all illici
t drugs throughout the study  (from Screening until 
discharge from the study).  Drug screening will occur at Screening and Day -1 and at 
additional timepoints throughout the stud y.  A positive result will lead to exclusion 
from the remainder of the study .
7. STUDY A SSESSMENTS A NDPROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table (Section 7.1), are essential and required for stud y 
conduct. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541215] be noted: 
If assessments are schedu led for the same nominal time, THEN the assessments 
should occur in the following order:
1. 12 -lead ECG
2.vital signs
3.blood draws.  
Note: The timing of the assessments should allow the blood draw to occur at the 
exact nominal time. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
477.1. Time and Events Table
Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/exclusion X X
Demography including height, weight 
and BMIX
Brief physical X
Medical/medic ation/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therapy X
12-lead ECG3 X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and 
hepatitis C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X X14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X 
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
48Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Telephone call to IVRS13 X X X
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within [ADDRESS_541216] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 and 6, perform all “Day 5” assessments on Day 7.
3. On Day 1, ECGs will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541217] -dose. To accommodate scheduling, serial ECGs collected on 
Days 4 and 8 may be performed [ADDRESS_541218] dose.  On Day 11, an ECG will be obtained 
prior to the 24 -hour PK sample. ECGs will be performed in triplicate at all timepoints. 
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained on Day [ADDRESS_541219] -morning dose, and at day 12 and Follow -up (Day 21).
5. Only SAEs related to study part icipation will be collected between screening and Day 1. An AE enquiry will be made at each visit, subjects will be asked if they have 
experienced any neuropsychiatric adverse events, including psychosis or altered mental status.
6. On Days [ADDRESS_541220] es for HIV -1 RNA PCR collected before morning dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart.  HIV -1 RNA PCR samples will also be collected on days 12, 14 & Follow -up (Day 21).
7. Lymphocyte subsets by [CONTACT_304910] (total lymphocyte counts, percentage, and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determin ation of [COMPANY_004]2838232 will be collected on Day 1 and Day 10 at pre dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3 , 4, 6, 
8, 12 (optional), and 24 hours (to occur on morning of Day [ADDRESS_541221] -am dose and in the morning on Day 11) .  Pre -dose PK samp les (within 15 minutes prior to dose) will be 
taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be taken on Days 12 and 14.
10. Samples (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541222] 10 hours .On Days 6 a nd 7, doses will be self administered but confirmed by [CONTACT_648] 
12. PGx sample should be collected on Day 1.
13. A screening/registration call should be made to the IVRS to register the subject at screening.   An additional call will be m ade to document a screen failure.   A randomization 
call should be made to the IVRS system approximately one week prior to scheduled Day 1.  Note: The randomization call must be made in order to have study drug on site for 
Day 1. Additional calls will be made every day that the subje ct has a scheduled study visit to the clinic.  If a subject terminates the study prematurely a call should be made to 
the IVRS
14. Only if early termination visits occur during the treatment period.
15. Plasma samples for storage will be collected at each visit st arting at Day 1, including unscheduled visits (e.g. for HIV -1 RNA levels and immunological parameters).  
Additionally these samples will be used when needed, such as when samples are lost or arrive at the laboratory unevaluable.
AE = Adverse event; CDC= C enter for Disease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Human chorionic gonadotrophi n; HIV = Human 
immunodeficiency virus;  IVRS= Interactive Voice Response System; PCR = Polymerase chain reaction; PK=Pharmacokineti c. 
 
 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
497.2. Visit Windows
Screening (baseline to pre -dose ): All screening assessments should take place within 
14-[ADDRESS_541223] dose. The screening visit window may  be extended to 30 
days upon discussion with the Medical Monitor (i.e.; subject has sc heduling conflicts or 
any screening assessment needs to be repeated).
Days 4 and 8: 
Based on subject and clinic schedule, Day  4 and Day  8 serial (up to 6h 
post-dose) ECG assessments may  be conducted 1 day . 
Weekend(s): The T&E table is set up for study  start (Day  1) to occur on a Monday  and 
Days 6 and 7 to fall on the weekend. If the weekend occurs instead on Day s 5 and 6, Day  
5 assessments should be performed on Day  7. The study  start (Day  1) may  also be 
adjusted to allow visits with assessments to be c onducted over the weekend based on 
subject and clinic schedule.  
Assessments: The following applies to timing of procedures:
-Window for assessments [ADDRESS_541224] -dose = 5 minutes 
-Window for assessments >4 and < [ADDRESS_541225] -dose = 15 minutes
-Window for assessments > [ADDRESS_541226] -dose = 30 minutes
End of Treatment visit : should be within [ADDRESS_541227] for assessment of advers e events.
7.3. Screening and Critical Baseline A ssessments
Cardiovascular medical history /risk factors (as detailed in the CRF) will be assessed at 
screening.
The following demographic parameters will be captured: year of birth, sex, race, and 
ethnicity .
Medic al/medication/family  history  will be assessed as related to the inclusion/exclusion 
criteria.
Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count) and obtained prior to signing of informed consent may  be utilized fo r Screening or 
baseline purposes provided the procedure meets the protocol- defined criteria and has 
been performed in the timeframe of the stud y.
7.3.1. Holter Monitoring (Screening criteria)
The 24-hour Holter monitoring will be performed during the Screening pe riod using a 
Holter monitoring device supplied by  [CONTACT_1034]. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
50Analy sis of the Holter tapes will consider the following:
Heart rate (brad ycardia and tachy cardia)
Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractio ns, premature 
ventricular contractions, couplets, triplets, and ventricular tach ycardias
Atrio- ventricular conduction defects
Atrial fibrillation and flutter
7.4. Efficacy
7.4.1. HIV-1 RNA  Sampling
Plasma for quantitative HIV- 1 RNA will be collected at timepoints listed in the Time and 
Events Table in Section 7.1. To reduce sample variability , two plasma HIV -1 RNA 
samples will be collected on Day s 1, 10, and 11.
An HIV -1 RNA PCR assay  with a lower limit of detection (LLOD) o
f 50 copi[INVESTIGATOR_014]/mL  
(ultrasensitive assay ) will be used for post- baseline assessments. An HIV -1 RNA PCR 
assay  with a LLOD of 400 copi[INVESTIGATOR_014]/mL  (standard assay ) will be used for screening and 
baseline assessments and will include a re -test with and ultrasensitive assay for all 
baseline values below the LLOD. An HIV -1 RNA PCR assay  with a LLOD of 2 
copi[INVESTIGATOR_014]/mL (supersensitive assay ) may  be used for exploratory  anal ysis.
7.4.2. Lymphocyte Subsets by  [CONTACT_428211] r the analy sis of 
lymphocy te subsets b y flow cy tometry  at the timepoints listed in the Time and Events 
Table in Section 7.1.
Details concerning the handling, labeling and shippi[INVESTIGATOR_428113] .
7.5. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1).  Additional time points for safety tests (such as vital signs, physical exams 
and labor atory  safet y tests) may be added during the course of the stud y based on newl y 
available data to ensure appropriate safet y monitoring.
7.5.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 5 , Section 12.5 .
The investigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE.  2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
[IP_ADDRESS]. Time period and Freque ncy for collecting A E and SA E information
AEs and SAEs will be collected from the start of Study  Treatment until the 
follow -up contact (see Section [IP_ADDRESS]), at the timepoints specified in the Time 
and Events Ta ble (Section 7.1). An AE enquiry  will be made at each visit, where 
subjects will be specifically  asked if they  have experienced an y neurops ychiatric 
adverse events, including psy chosis or altered mental status  
Medical occurrences that begin prior to the start of study
 treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
Any SAEs assessed as related to study  participation (e.g., prot ocol-mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
All SAEs will be recorded and rep orted to Sponsor within 24 hours, as indicated 
in Appendix 5 , Section 12.5.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, i f the investigator learns of any SAE, including a death, at any  
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 5
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non
-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had any (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
“Have you experienced any  alteration in personality , behaviour, mood or any  
altered mental status?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 12.5) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until th
e subject is lost to follow-up  2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
52(as defined in Section 5.4). Further information on follow -up procedures is given in 
Appendix 5 .
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in Appendix 5 (Section 12.5.3) and all deaths, 
whether or not they  are considered SAEs, specific CV and Death sections of the CRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non -cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Even t data query  prompting its completion. 
The Death CRF is provided immediately
 after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed 
within oneweek of when the death is reported.
[IP_ADDRESS]. Disease- Rela ted Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease -related events (DREs) are common in subjects with HIV-1 
infection and can be serious/life threatening:
events or outcomes listed in the CDC Classification Sy stem for HI V-1 Infections 
(see Appendix 9 ; Section 12.8)
sign, s ymptom, diagnosis, illness, and/or clinical laboratory  abnormality  that can 
be linked to an y of these events or outcomes
Because these events are ty pi[INVESTIGATOR_1306] y associated with the disease under study, they will not 
be reported according to the standard process for expedited reporting of SAEs to [COMPANY_004] 
(even though the event may
 meet the definition of a serious adverse event). 
These events will be recorded on the DRE page in the subject’s CRF using the HIV 
Associated Conditions eCRF. These DREs will be monitored by [CONTACT_428212].
However, if an y of the following conditions apply, then the event should be reported as 
an SAE using the standard process:
The event is, in the Investigator’s opi[INVESTIGATOR_1649], of greater intensity , frequency , or 
duration than expected for the individual subject, 
or
The Investigator considers that there is a reasonable possibil ity that the event was 
related to treatment with the investigational product.
or 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
53Death occurring for an y reason during a stud y, including death due to a disease 
related event, will alway s be reported promptly . 
If either of the above conditions is met the n record the DRE on the SAE page rather than 
the HIV Associated Conditions eCRF page and report promptly to [COMPANY_004].
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA E
Prompt notification by  [CONTACT_428213]- serious AEs 
related to stu dy treatment (even for non -interventional post -marketing studies) is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and the safety of a product under clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are fo rwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
7.5.2. Pregnancy
Details of all pregnancies in female subjects and if indicated female partners of 
male subjects will be collected after the start of dosing and until one week post 
study
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 24hrs 
of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 7 , Section 12.6 .
7.5.3. Physical Exams
A comple te ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , GI and Neurological sy stems. Height and weight will 
also be measured and recorded. 
A brief ph ysical examination will include, at a minimum assessments of th e skin, 
lungs, cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
547.5.4. Vital Signs
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_541228] a nd will 
include temperature, s ystolic and diastolic blood pressure and pulse rate 
Three readings of blood pressure and pulse rate will be taken
First reading should be rejected
Second and third readings should be averaged to give the measurement to be 
recorded in the CRF. 
7.5.5. Electrocardiogram (EGC)
Triplicate [ADDRESS_541229] be 
conducted in accordance with the SRM and Protocol Time and Events Schedule (Section 
7.1). Laboratory  requisition forms must be completed and samples must be clearl y 
labelled with the subject number, protocol number, site
/centre number, and visit date.
Details for the preparation and shipment of samples will be provided b y the laboratory 
and are detailed in the SRM. Reference ranges for all safet y parameters will be provided 
to the site by  [CONTACT_428214] t he assessments.
If additional non -protocol -specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or do se 
modification) the results must be recorded in the CRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
All study -required laboratory  assessments will be performed b y a central lab oratory :
NOTE:  Local laboratory results are onl y required in the event that the central laboratory 
results are not available in time for either a treatment and/or response evaluation to be 
performed. If a local sample is required it is important that the sample for central 
analysis is obtained at the same time. Additionally  if the local laboratory  results are used 
to make either a treatment or response evaluation, the results must be entered in the CRF. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
55Haematology , clinical chemistry , urinal ysis, and ad ditional parameters to be tested are 
listed below. 
Table 9 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neut rophils
Hemoglobin MCH Lymphocytes with T -cell 
subsets
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Bicarbonates Alkali ne phosphatise Albumin
Troponin I
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsHIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C ant ibody )
FSH and estradiol (as needed in women of non -child bearing 
potential only )
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (as needed for women of child bearing 
potential) 2
NOTES:
1. Details of Liver Chemistry Stoppi[INVESTIGATOR_131963] -Up Assessments after liver 
stoppi[INVESTIGATOR_31777] 12.[ADDRESS_541230] dose of study  treatment 
should be repeated until the values return to normal or baseline.  If such values do not 
return to normal within a period judged reasonable by  [CONTACT_1188], the etiology
should be identified and the sponsor notified. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
567.6. Pharmacokinetics
7.6.1. Blood Sample Collection
Blood samples for anal ysis of [COMPANY_004]2838232 concentrations will be collected at the time 
points indicated in Time and Events Tables (Section 7.1).  
The actual date and time of each blood sample collection will be recorded.  The timing of 
PK samples may  be altered and/or PK samples may  be obtained at additional time points 
to ensure thorough PK monitoring.  
Deta ils of PK blood sample collection (including volume to be collected), processing, 
storage and shippi[INVESTIGATOR_428114] (SRM).
7.6.2. Sample A nalysis
Plasma analy sis will be performed by  [CONTACT_55412], Madison under the control of 
Bioanal ysis, Immunogenicity  and Biomarkers (BIB), PTS, GlaxoSmithKline.
Concentrations of [COMPANY_004]2838232 will be determined in plasma using the currentl y 
approved bioanaly tical methodology . 
Once the plasma has been anal yzed for [COMPANY_004]2838232 any  remaining plasma may be 
analyzed qualitatively  for other circulating metabolites and these results would be 
reported under a separate PTS protocol.
Raw data will be archived at the Covance, Madison facility .
7.7. Biomarker(s)/Pharmacody namic Markers
7.7.1. Viral Genoty pi[INVESTIGATOR_428115], at the times listed in the Time and Events Table in 
Section 7.1. Details concernin g the handling, labeling and shippi[INVESTIGATOR_428116] y.
Genoty pic and phenot ypic anal yses will be carried out by  [CONTACT_428215]/PR and PR/RT formats, in which PCR amplification is used to generate HIV 
cDNA products including the Gag and the PR and RT coding regions, respectivel y. 
Phenoty pic anal yses of the GAG/PR region will include susceptibility  to [COMPANY_004]2838232 . 
Analy sis will be done on Day  1 and Day  11 samples.  In the case of rebound HIV -1 viral 
load, ana lysis will be completed on samples corresponding to time point of rebound 
occurrence. 
7.8. Genetics
Information regarding genetic research is included in Appendix 4 , Section 12.4 . 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
577.9. Value Evidence and Outcomes
Not required.
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data system, 
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data 
(e.g., removing errors and inconsistencies in the data).
Adverse events and concomitant medications ter ms will be coded using MedDRA 
and an internal validated medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials
will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  objectives of this study  are to investigate the safet y, tolerability, and 
antiviral activity  of [COMPANY_004]2838232 administer ed as monotherap y in combination with 
cobicistat in HIV -[ADDRESS_541231] e Size A ssumptions
The sample size for this study  is based primarily  on feasibility  to provide adequate 
precision for the estimations.
Based on data from the short term monotherap y study  of BMS -955176 PoC (AI468002) 
study  and assuming viral load values for individual subjects follow a log -normal 
distribution, 1000 trial simulations in Fixed and Adaptive Clinical Trial Simulation 
(FACTS ) software were conducted from the distribution with mean of change from 
baseline viral load drop on log scale at 1.0 to 1.5 copi[INVESTIGATOR_428117]=0.4 and sample sizes=10 
for Part A.  Using Bay esian calculation with non -informative priors for the mean and 
weakl y informative priors for the error parameters, Normal (0, 100) for mean and Inverse 
Gamma (0.35, 0.0875) for error parameters, the posterior probability  to achieve a 
cutpoint 1.2 log was calculated for each simulated trial, and percentage of the trials with  2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
58posterior probability  of viral load< -1.2log drop given true mean) ≥70% were calculated 
and are shown below in Table 10.
Table 10 Percentage of the trials with posterior probability >=70% for Part A
True Mean Cutpoint Posterior Prob>=70%
1.0 1.2 1.4%
1.1 1.2 9%
1.2 1.2 29%
1.3 1.2 59%
1.4 1.2 83%
1.5 1.2 96%
An Emax model with functional uniform priors [ Bornkamp , 2014] was conducted using 
simulated data combining Part A and Part B with all doses. Success is defined as a 
posterior probability  of the highest dose to achi eve a cutpoint 1.2 log reduction in viral 
load.   This was calculated for each simulated trial and the percentage of the trials with 
posterior probability  greater or equal to 70% were also calculated and are shown below 
(Table 11). The table lists different viral load drop scenarios. The last scenario assumes 
the flat drop for all doses are 0.5.  This scenario reflects the null hy pothesis of no 
treatment effect. In this scenario 0% of the trials achieve the pre -specified decision rule 
for success.
Table 11 Percentage of the trials with posterior probability  ≥70%
Cutpoint Posterior Prob ≥ Part A+ Part B 
mean VL drop for doses 200, 
100, 50, 20Part A+ Part B
1.2 70% 1.5, 1.4, 1.2, 0 99%
1.5, 1.4, 1.2, 0.5 96%
1.5, 1.4, 1.0, 0.5 93%
1.5, 1.3, 1.2, 0.5 86%
0.5, 0.5, 0.5, 0.5 0%
9.2.2. Sample Size Sensitivity
Similar simulations in FACTS were conducted from the distribution with mean of change 
from baseline viral load drop on log scale at 1 .5 copi[INVESTIGATOR_428117]=0.4 or 0.6 and sample 
sizes of 6- 8 or 10 for Part A.  Using Bay esian calculation, t he posterior probability  to 
achieve a cutpoint 1.2 log (in Table 12) was calculated for each simulated trial, and 
percentage of the trials with posterior probability  greater than or equal to 70% was 
calculated and are shown below. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
59Table 12 Percentage of the trials with posterior probability  ≥70% for Part A
True 
MeanCutpoint Posterior 
Prob ≥Std for log10 
VLN=6 N=8 N=10
1.5 1.2 70% 0.4 90% 94% 96%
0.6 75% 81% 84%
9.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation will be performed.
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Intent to Treat Exposed Population (IT T)
The ITT- Exposed Population is defined as all subjects who meet study  criteria and are 
enrolled into the study  with documented evidence of having received at least [ADDRESS_541232]- baseline HIV -1 RNA measurement. This will be the
primary  population for the final efficacy  anal ysis for all active treatment groups.
Per Protocol Population (PP)
The Per Protocol Population is defined as all subjects who meet study  criteria and are 
enrolled into the study  with documented evidence of having received all doses and all 
post-baseline HIV -[ADDRESS_541233] dose based on this review (e.g., the exposure level of 
[COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838232 exposure seen previously  in 
healthy  subjects), the Bayesian posterior probability  that the log10 viral load decline from 
baseline is greater than a cut- point will be calculated. If the Bay esian probability  from 
Cohort 1 is less than 70%, this will provide evidence to not move forward into Part B. 
Otherwise, the stud y team will review the data in order to make a dose selection decision 
for the subsequent Part B Cohorts.  I f the pharmacokinetic exposures after the 100 mg 
[COMPANY_004]2838232/cobi dose look similar to those obtained with 100 mg [COMPANY_004]2838232/r in  2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
60prior studies, the doses for Part B will be extended to both lower (20 mg, 50 mg) and 
higher (200 mg) [COMPANY_004]2838232 doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be su mmarized 
by [CONTACT_428216] . The proportion of subjects with plasma HIV -1 RNA 
<400 and <50 copi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if the two populations are 
not the same. 
9.4. Key Elements of A nalysis Plan
9.4.1. Primary  Analyses
The final analy sis will be performed after the completion of the study  and final datasets 
authorization. Data will be listed and summarized according to GlaxoSmithKline 
reporting standards, where applicable. Listings will be sorted b y subject, period, day, and 
time, noting treatment; summaries will be presented by  [CONTACT_3148], day , and time. Unless 
stated otherwise, descriptive summaries will include n, mean, standard deviation (SD), 
coefficien t of variation (%CV), median, minimum, and maximum, geometric mean with 
associated 95% confidence interval (CI), and %CVb for continuous variables, whereas n 
and percent will be used as summary  statistics for categorical variables. Baseline or pre -
dose ass essment is the last available assessment prior to time of the first dose unless it is 
specified otherwise. If there are multiple assessments collected on the same scheduled 
time, the average of these assessments will be used. For tabulated safet y summaries , only  
the scheduled assessments will be included in the summary tables. Version 9.1 or higher 
of the SAS sy stem will be used to anal yze the data as well as to generate tables, figures, 
and listings. Complete details will be documented in the Reporting and Analy sis Plan 
(RAP).
[IP_ADDRESS]. Safety  Analyses
Safety  data will be presented in tabular format and summarized descriptively  according to 
[COMPANY_004]’s Integrated Data Standards Library  standards and data will be in CDISC format. 
No formal statistical analysis of the safet ydata will be conducted. 
[IP_ADDRESS]. Efficacy  Analyses
Both the PP and ITT Populations will be used for all efficacy  analy ses if there are 
dropouts.  Plasma HIV -[ADDRESS_541234], and assessment day  and 
summarized by  [CONTACT_428218].
Plots of mean and median plasma HIV -1 RNA actual and change from baseline data will 
be ge nerated b y treatment and assessment day.
Plasma HIV -1 RNA change from baseline to the on- treatment nadir (maximum 
change) will be calculated for each subject and summarized by  [CONTACT_3148]. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
[ADDRESS_541235] of lower doses on potential development of resistance. A dose -response 
curve will be fit to the data from Parts A & B using functional uniform priors.  
[IP_ADDRESS]. Pharmacokinetic A nalyses
Pharmacokinetic anal ysis will be the responsibility of the Clinical Pharmacokinetics 
Modeling and Simulation Department, GlaxoSmithKline. Plasma [COMPANY_004]2838232 
concentration -time data will be anal yzed by [CONTACT_105] -compartmental methods with 
WinNonlin Version 6.1 or higher. Calculations will be based on the ac tual sampling 
times recorded during the study. From the plasma concentration- time data, the following 
pharmacokinetic parameters will be determined, as data permit:
Plasma [COMPANY_004]2838232 Pharmacokinetic Parameters to be Estimated:
Study Day Parameters
1 AUC(0 -24), Cmax, tmax, tlag, C24
10 AUC(0 -), Cmax, tmax, t½, C0, C , CL/F, R_AUC, R_Cmax, R_C 
Results based on samples collected from a subject with emesis within 4 hours of the dose 
will not be considered as evaluable.
All PK data will be stored in the R& D archives, GlaxoSmithKline.
Statistical analyses of the pharmacokinetic parameter data will be the responsibility  of 
Clinical Statistics, GlaxoSmithKline. Details of the statistical anal yses will be provided in 
the RAP. An outline is provided below:
Pharm acokinetic data will be presented in graphical and tabular form and will be 
summarized descriptively. Plasma [COMPANY_004]2838232 PK parameters, with the exception of 
tmax and tlag, will be log- transformed prior to analy sis.
Dose proportionality  of plasma [COMPANY_004]2838232 PK parameters from Day  1 [AUC(0 -24) 
and Cmax] and Day  10 [AUC(0-τ) and Cmax] will be assessed using a power model if 
multiple dose levels are assessed. The power model will be fitted by  [CONTACT_428219] (REML ) using SAS Proc Mixed. A fixed ef fects power model will be used. 
The mean slope will be estimated from the power model with the corresponding 90% CI. 
The accumulation ratio (R) and stead y-state assessments will be performed, if quality  of 
the data permits. Comparisons of Day  10 with Day  1PK for each dose will be used for 
the accumulation ratio (R) evaluation. Pre -dose concentrations between Day s 7-10 will be 
used for stead y-state assessment. 
9.4.2. Secondary  Analyses
[IP_ADDRESS]. Pharmacokinetic/Pharmacody namic A nalyses
Relationships between various PK para meters (e.g., AUC, Cmax, Cτ, etc.) and PD 
measures (e.g., log10 reduction from baseline in plasma HIV -1 RNA on Day  11 or safet y  2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
62parameters) will be explored using various models including Emax. The relationship 
between dose and PD measures will also be exp lored. Details of the PK/PD exploratory  
analyses will be provided in the RAP.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_428118]/phenot ypic data will be listed and descriptive summaries will be 
provided. Details of the analy ses will be provided in t he clinical virology  report.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subje cts begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Cli nical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority
, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optiona l assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.   2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
63Approval of the optional assessments may occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors or designee will contact [CONTACT_428220] w with the site staff the protocol, study  requirements, and their 
responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentati on of data items for which the CRF will 
serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in acco rdance with the currently approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all releva nt documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any time during or 
after completion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate t heir time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or prematu re discontinuation of the study , the [COMPANY_004] monitor or 
designee will conduct site closure activities with the investigator or site staff, as 
appropriate, in accordance with applicable regulations including GCP, and [COMPANY_004] 
Standard Operating Procedures.
[COMPANY_004] reser ves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.   2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
64If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the he ad of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or inst itution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or th e head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true a nd 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable quali ty control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard ap plicable to that site for the study , as dictated by  
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off -site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
[PHONE_8893].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to stati stical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
10.8. Review  Committees
The Safet y Review Team (SRT) is a [COMPANY_004] cross -functional team reviewing all available 
safet y data related to the project, including in -stream data from this study , in an ongoing 
manner. The SRT is an internal [COMPANY_004] requirement put in place to ensure holistic 
evaluation of the safet y profile of an investigational product with systematic, periodic and 
documented reviews of available safety  data, with the appropriate communication and 
escalation of new findings that have the potential to impact pa tient safet y 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
[PHONE_8894]. REFERENCES
Bloch M, Bodsworth N, Fidler M, Workman C, Balach A, By [CONTACT_428221] H, et al. Efficacy , 
safet y and pharmacokinetics of MPC -4326 (bevirimat dimeglumine) 200mg BID and 
300mg BID monotherapy  administered for 14 day s in subjects with HIV -1 infection. 
ICAAC . 2009; Abstract H - 1230.
Bornkamp B, Practical considerations for using functional uniform prior distributions for 
dose-response estimation in clinical trials. Biometrical Journal 56 (2014) 6, 947 -962
Cockcroft DW, Gault MH. Prediction of cre atinine clearance form serum creatinine. 
Nephron. 1976;16:31-41.
Dang Z, Huang L, Chen C. HI V
-1 maturation inhibitors:  An update. Drugs of the Future. 
2009;34 (10):797 -802.
Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, et al.  Phase 2 study  of 
cobicistat versus ritonavir each with once- daily  atazanavir and fixed -dose 
emtricitabine.tenofovir df in the initial treatment of HIV infection.  AIDS .  2011; 
25:1881-1886.
Food and Drug Administration (FDA). Guidance for industry : Estimating the maximum 
safe starting dose in initial clinical trials for therapeutics in adult healthy  subjects. CDER, 
Rockville, MD; 2005. UCM078932.
Food and Drug Administration (FDA). Guidance for Industry : Human Immunodeficiency  
Virus -1 Infection: Developi[INVESTIGATOR_428119]. CDER, Rockville, 
MD; 2015. UCM355128.
Gallant JE, Koenig E, Andrade -Villaneuva J, Chetchotisakd P, deJesus E, Antunes F, 
Arastéh K,  et al.  Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus 
emtricitabine/tenofovir disoproxil fumarate in treatment- naïve HIV t ype 1-infected 
patients:  week [ADDRESS_541236]. Dis.  2013; 208 -:32- 39.
GlaxoSmithKline Document Number 2012N151889_03 Compound [COMPANY_004]2838232. 
Investigator’s Brochure.  Effective November 2016.
GlaxoSmithKline Non-Clinical Research report. Document Number 2013N163221_00.
Hatcher RA, Trussel J, Nelson AL , Cates W, Stewart F, Kowal D, editors. Contraceptive 
Technology . 19th ed. [LOCATION_001]:Ardent Media; 2007. 
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteel e T, Hillewaert V, et 
al.  Pharmacokinetics of darunavir in fixed -dose combination with cobicistat compared 
with coadministration of darunavir and ritonavir as single agents in healthy volunteers.  J. 
Clin. Pharmacol.  2009; 54:949-957. 2018N360917_00
2015N2278 52_03 CONFIDENTIA L
200911
67Lalezari J, McCalli ster S, Gigliotti M, Cohen C, Elion R, Brinson C, et al. Safet y and 
efficacy  study  of bevirimat (BVM) in heavil y treatment experienced HIV+ patients 
identifies the target phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Mahmood I . Prediction of human drug clearance from animal data. Application of the 
rule of exponent and fu corrected intercept method (FCIM). J Pharm Sci. 
2006;95:1810-21. 
Martin D, Galbraith H, Ellis C, Schettler J and Doto J. Minimal effect of ritonavir (RTV) 
on the pharmacokinetics of bevirimat in health y volunteers [abstract]. IAS Conference on 
HIV Pathogenesis, Treatment and Prevention. 2007; Abstract no. WEPEB015:Poster 
discussion.
Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple -dose pharmacokinetics and 
safet y of beviri mat, a novel inhibitor of HIV maturation, in healthy  volunteers. Clin 
Pharmacokinet. 2007(a);46(7):589-98.
Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, et al. Safety and 
pharmacokinetics of bevirimat (PA -457), a novel inhibitor of human im munodeficiency  
virus maturation, in healthy  volunteers. Antimicrobial Agents and Chemotherapy. 
2007(b);Sep:3063 -6.
Martin DE, Galbraith H, Schettier J, Ellis C, Doto J. Pharmacokinetic properties and 
tolerability  of bevirimat and atazanavir in healthy volu nteers:  An open- label, parallel -
group stud y. Clinical Therapeutics. 2008;30(10):1794 -1805.
NORVI R (ritonavir) Product I nformation. January , 2013.
Nowicka -Sans B, Protack T, L in Z, Li Z, Zhang S, Meanwell N, et al. BMS -955176: 
Characterization of a second- generation HIV -1 maturation inhibitor. 8th IAS Conference 
on HIV Pathogenesis, Treatment and Prevention, July  19-22, 2015, Vancouver, Canada.
Qian K, Morris -Natschke SL , Lee KH. HIV entry  inhibitors and their potential in HIV 
therap y. Medicinal Research Re views. 
2009;29(2):369-93.
Saxena SK, Gupta A, Bhagy ashree K, Saxena R, Arora N, Banerjee AK, et al. Targeti ng 
strategies for human immunodeficiency  virus: A combinatorial approach. Min Rev Med 
Chem. 2012;12(3):236- 54.
TYBOST (cobicistat) Product I nformatio n. 2012
Wainburg MA, Albert J. Can the further clinical development of bevirimat be justified?. 
AIDS. 2010;24:773 -4. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8895]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
g/mL Microgram per millilitre
ABC Abacavir
AE Adverse Event
AIDS Acquired immunodeficiency  syndrome
ALT Alanine aminotransferase
API [INVESTIGATOR_428120] y
AST Aspartate aminotransferase
AUC Area under the plasma concentration time curve
AUC(0 -) Area under the concentration- time curve from time zero 
(pre-dose) extrapolated to infinite time
AUC(0 -) Area under the concentration- time curve over the dosing 
interval 
AUC(0 -24) Area under the concentration- time curve from zero (pre -
dose) to 24 h
AUC(0 -48) Area under the concentrati on-time curve from zero (pre -
dose) to 48 h
AUC(0 -t) Area under the concentration- time curve from zero (pre -
dose) to time of last quantifiable concentration
BCRP Breast cancer resistance protein
BID Twice dail y
Bpm beats per minute
BVM Bevirimat
BIL Bilirubin
C Pre-dose (trough) concentration at the end of the dosing 
interval
C24 24hour trough concentration
CDC Center for Disease Control and Prevention
CI Confidence interval
CL/F Oral Clearance
Cmax Maximum plasma concentration
Cmin Minimum p lasma concentration
CPK Creatine Phosphokinase
CRF Case report form
cTnI Cardiac troponin I
CV Coefficient of variation
CVb Between -subject variability
CYP Cytochrome P450
DDI Drug Drug Interaction
DNA Deox yribonucleic acid
EC50 50% protection aga inst resistant mutant HI V infection  2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541237] time in Human Study
g Gram
GI Gastrointestinal
[COMPANY_004] GlaxoSmithKline
h Hour(s)
HBsAg Hepatitis B surface antigen
hcG Human chorionic gonadotrophin
HDPE High densit y pol yethylene
hERG Human Ether -a-gogo Related Gene
HIV Human Immunodeficiency  Virus
IC50/90 50% or 90% maximal inhibitory  concentration
IEC International Ethics Committee
IQ Inhibit ory quotient
IRB Institutional Review Board
ISR Injection site reaction
IV Intravenous
IVRS Interactive voice response sy stem
kg Kilogram
L Litre
LLOD Lower limit of detection
MC Melanocortin
MedDRA Medical Dictionary  for Regulatory  Activities
mg/mL Milligram per millilitre
MI Maturation inhibitor
mL Milliliter
mRNA messenger Ribonucleic Acid
ND Not done
ng/mL Nanogram per millilitre 
nm Nanometer
NO Not observed
NOAEL No Observed Adverse Effect Level
NTproBNP N-terminal prohormone of bra in natriuretic peptide
NSVT Non-sustained ventricular tachy cardia
OAT Organic anion transporter
OATP Organic anion transporting pol ypeptide
OCT Organic cation transporter
PBL Peripheral Blood Ly mphocy tes
PBMC Peripheral Blood Mononuclear Cells
PD Pharmacod ynamics
[COMPANY_003] Pharmaceutical Product Development
P-gp P-glycoprotein
PHIV Pseudo- HIV 2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541238] quantifiable concentration
tmax Time of occurrence of Cmax
U Units
UGT Uridine 5' -diphospho- glucuronos yltransferase
Vz/F Mean apparent oral volume of distribution
WPW Wolff -Parkinson -White
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_428222], [COMPANY_002] HIV kit
Chiron RIBA 
Inform
Monogram
Phoenix WinNonlin 
SAS
Tybost (cobicistat) 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8896].2. Appendix 2: Liver Safety  Required A ctions and Follow up 
Assessments
Phase II liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma tion/Guid
ances/UCM174090.pdf.
Phase II liver chemistry stoppi[INVESTIGATOR_420682] – Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2 ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2 ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3 ALT   3xULN associated with symptoms (new or worsening) believed t o be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the l iver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with study 
treatment unless allowed per protocol and [COMPANY_004] 
Medical Governance approval is granted 
If restart/rechallenge not allowed per protocol 
or not granted, permanently discontinue study 
treatment and may con tinue subject in the study Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtained within 24hrs after 
last dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
72for any protocol specified follow up assessments 
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within 
24hours
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72hours 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineform including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on t he liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum aceta minophen adduct high-
performance liquid chromatography
assay (quantifies potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week 
Liver imaging (ultrasound, magnetic 
resonance, or com puterised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, na usea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); H epatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
73Phase II liver c hemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_541239] safety. 
Subject can continue study treatment  
Subject must return weekly for repeat liver 
chemi stries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8897].3. Appendix 3: Liver Safety  –Stud y Treatment Restart or 
Rechallenge Guidelines
Study  treatment restart or re -challenge after liver chemistry  stoppi[INVESTIGATOR_3418] a re met by  
[CONTACT_428207]. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8898].4. Appendix 4: Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to me dicine, including [COMPANY_004]2838232/RTV or an y concomitant 
medicines;
HIV susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives hi ghlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, a s appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variabilit y in disease and medicine response.  
A 6 ml blood or 2 ml saliva sample will be taken for Deox yribonucleic acid 
(DNA) extraction. A sample is collected at the baseline visit, after the subject has 
been randomized and provided informed consent for genetic research. Instructions 
for collection and shippi[INVESTIGATOR_428121]. The DNA from the blood/saliva sample may  undergo quality  control 
analyses to confirm the integrit y of the sample. If there are concerns regardi ng the 
quality  of the sample, then the sample may  be destroy ed. The blood/saliva sample 
is taken on a single occasion unless a duplicate sample is required due to an 
inability  to utilize the original sample.  
The genetic sample is labelled (or “coded”) wi th the same stud y specific number used to 
label other samples and data in the study.   This number can be traced or linked back to  2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541240] by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_541241] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only  use samples collect ed from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed atany time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood/saliva being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample des truction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the s tudy or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet t he entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample  2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541242]’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is gener ally preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8899].5. Appendix 5: Definitio n of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporall y 
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measure ments), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  T his should be reported regardless of sequelae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will b e reported if they  fulfil the definition 
of an AE or SAE.
The signs and symptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of efficacy " or 
"failure of expected phar macological action" also constitutes an AE or SAE. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
79Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judg ed by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
c.Results in death
d.Is life -threat ening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more seve re.
e.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is ser ious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
80f.Results in d isability/incapacity
NOTE:
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated head ache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
g. Is a congenital anomaly/birth defect
h.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
i.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total b ilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin 2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
Refer to Appendix 2 for the required liver chemistry  follow -up instructions 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8900].5.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specif ic CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial throm boembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.5.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], labor atory , and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu o f completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_1309] t he medical records prior to 
submission of to [COMPANY_004].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the in dividual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in acco rdance with standard scoring and statistical procedures detailed b y  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
82the scale’s developer.
The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
12.5.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomf ort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the defini tion of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to sugge st a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk fac tors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/he r assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004]. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
83The investigator may  change his/her opi[INVESTIGATOR_1101] c ausality  in light of follow -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
By [CONTACT_428223], the investigator is oblig ated to report an y grade 2 or higher 
“alteration in personality -behavior or in mood” or “altered mental status” adverse 
events that occur in subjects taking this drug, to [COMPANY_004] within 3 day s.
The investigator is obligated to assist.  This may  include addit ional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology . 
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.5.6. Reporting of SAEs to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or change s to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
84on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE fo rm or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] via paper CRF
Facsim0ile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of the SAE data collection tool sent by 
[CONTACT_9338]
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medica l Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] via PI[INVESTIGATOR_46427]
Facsimile transmission of the following PI[INVESTIGATOR_428122]:
SAE listing
Demographic listing
Study  treatment listing
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of all required information sent by [CONTACT_428224].
If the PI[INVESTIGATOR_428123] n the SAE occurs, the site will use the paper 
SAE form and fax that to the Medical Monitor or protocol contact. The site will enter 
the SAE data into PI [INVESTIGATOR_428124] s ystem becomes available. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8901].6. Appendix 6: Collection of Pregnancy  Information
Investigat or will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24hrs of learning of a subject's pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated deli
very date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_541243] who becomes pregnant while participating 
will discontinue study  medication andbe withdrawn from the study
This will only  be included if either of the following appl y:
Investigator will attempt to collect preg nancy  information on any  female partner of a 
male study  subject who becomes pregnant while participating in this study .  This 
applies only  to subjects who are randomized to receive study  medication. 
After obtaining the necessary  signed informed consent fr om the female partner 
directly , the investigator will record pregnancy  information on the appropriate form 
report the event and submit it to [COMPANY_004] within 24hrs of learning of the partner’s 
pregnancy
Partner will also be followed to determine the outcome of t he pregnancy .  
Information on the status of the mother and child will be forwarded to [COMPANY_004]. 
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date.  An y termination of the pregnancy  will be reported regardless of fet al 
status (presence or absence of anomalies) or indication for procedure. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8902].7. Appendix 7: Country  Specific Requirements
No country -specific requirements exist. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[PHONE_8903].8. Appendix 8: Division Of A IDS Table For Grading The 
Severit y Of A dult And Pediatric A dverse Events Ve rsion 1.0, 
December 2004; Clarification A ugust 2009
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
ESTIMATING SEVERITY GRADE
Clinical adverse 
event NOT identified 
elsewhere in the 
grading tableMild symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicatedModerate 
symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention not 
indicatedSevere sympto ms 
causing inability to 
perform usual social 
& functional activities 
with intervention or 
hospi[INVESTIGATOR_428125] -
threatening symptoms 
causing inability to 
perform basic self -care 
functions OR Medical or 
operative intervention 
indicated to prevent 
permanent impairment, 
persistent disability, or 
death 
CARDIOVASCULAR
Arrhythmia
(by[CONTACT_223081])
Specify type, if
applicableNo symptoms 
AND No 
intervention 
indicatedNo symptoms AND
non-urgent 
intervention 
indicatedNon-life-threatening 
symptoms AND Non -
urgent intervention 
indicatedLife-threatening 
arrhythmia OR Urgent 
intervention indicated
Blood Pressure 
Abnormalities1 
Hypertension (with 
the lowest reading 
taken after repeat 
testing during a visit) 
≥ 18 years of age 140 to < 160 
mmHg systolic 
OR 90 to < 100 
mmHg diastolic ≥ 160 to < 180 
mmHg systolic OR 
≥ 100 to < 110 
mmHg diastolic ≥ 180 mmHg systolic 
OR ≥ 110 mmHg 
diastolic Life-threatening 
consequences in a 
participant not 
previously diagnosed
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_373] 
< 18 years of age > 120/80 mmHg ≥ 95th to < 99th 
percentile + 5 
mmHg adjusted for 
age, height, and 
gender (systolic 
and/or diastolic) ≥ 99th percentile + 5 
mmHg adjusted fo r 
age, height, and 
gender (systolic 
and/or diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_428126] (stable 
angina) OR New 
testing consistent 
with ischemia Unstable angina OR 
Acute myocardial 
infarction  2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541244] or 
with minimal activity 
orexertion (e.g., 
hypoxemia) OR 
Intervention indicated 
(e.g., oxygen) Life-threatening 
consequences OR 
Urgent intervention 
indicated (e.g., 
vasoactive medications, 
ventricular assist device, 
heart transplant) 
Hemorrhage (with 
significant acute 
blood loss) NA Symptoms AND No 
transfusion 
indicated Symptoms AND 
Transfusion of ≤ 2 
units packed RBCs 
indicated Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs (for 
children, packed RBCs 
> 10 cc/kg) indicated 
Prolonged PR 
Interval or AV B lock 
Report only one 
> 16 years of age PR interval 0.21 
to < 0.25 seconds PR interval ≥ 0.25 
seconds OR Type I 
2nd degree AV 
block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
≤ [ADDRESS_541245] degree AV 
block (PR interval 
> normal for age 
and rate) Type I 2nd degree 
AV block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
Prolonged QTc 
Interval2 0.45 to 0.47 
seconds > 0.47 to 0.50 
seconds > 0.50 seconds OR ≥ 
0.06 seco nds above 
baseline Life-threatening 
consequences (e.g., 
Torsade de pointes, 
other associated serious 
ventricular dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention 
indicated Symptoms AND 
Intervention indicated Life-threatening embolic 
event (e.g., pulmonary 
embolism, thrombus) 
DERMATOLOGIC
Alopecia (scalp only) Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visu al 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities NA NA 
Bruising Localized to one 
area Localized to more 
than one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment indicated 
(e.g., or al 
antibiotics, 
antifungals, 
antivirals) IV treatment 
indicated (e.g., IV 
antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (e.g., 
sepsis, tissue necrosis)  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
89PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperpi[INVESTIGATOR_428127] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Hypopi[INVESTIGATOR_428128] & 
function al 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Petechiae Localized to one 
area Localized to more 
than one area Generalized NA 
Pruritus3(without 
skin lesions) Itchin g causing no 
or minimal 
interference with 
usual social & 
functional 
activities Itching causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Itching causing 
inability to perform 
usual social & 
functional activities NA 
Rash 
Specify type, if 
applicable Localized rash Diffuse rash OR 
Target lesions Diffuse rash AND 
Vesicles or limited 
number of bullae or 
superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized 
bullous lesions OR 
Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Stevens-
Johnson syndrome OR 
Toxic epi[INVESTIGATOR_428129]-threatening 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non -
ketotic coma, end organ 
failure) 
Gynecomastia Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing pain with 
greater than 
minimal 
interference with 
usual social & 
functional activities Disfigu ring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social 
& functional activities NA  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
90PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperthyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
suppression 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
thyroid storm) 
Hypothyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
replacement 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
myxedema coma) 
Lipoatrophy4 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy5 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
GASTROINTESTINAL
Anorexia Loss of appetite 
without decreased 
oral intake Loss of appetite 
associated with 
decreased oral 
intake without 
significant weight 
loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
Ascites No symptoms Symptoms AND 
Intervention 
indicated (e.g., 
diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despi[INVESTIGATOR_144482]-threatening 
consequences  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
91PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Bloating or 
Distension 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cholecystitis NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (e.g., 
sepsis, perforation) 
Constipation NA Persistent 
constipation 
requiring regular 
use of dietary 
modificat ions, 
laxatives, or 
enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (e.g., 
obstruction) 
Diarrhea ≥ 1 year of 
age Transient or 
intermittent 
epi[INVESTIGATOR_428130] ≤ 
3 stools over 
baseline per 24 -
hour period Persistent epi[INVESTIGATOR_428131] 4 to 6 
stools over baseline 
per 24- hour period Increase of ≥7 stools 
per 24- hour period 
OR IV fluid 
replacement 
indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one 
and specify 
location Symptoms but 
able to eat usual 
diet Symptoms causing 
altered dietary 
intake with no 
intervention 
indicated Symptoms causing 
severely altered 
dietary intake with 
intervention indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other 
than iron 
supplement Endoscopic 
intervention 
indicated Transfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Mucositis or 
Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes 
or ulcerations Confluent 
pseudomembranes 
or ulce rations OR 
Mucosal bleeding 
with minor trauma Life-threatening 
consequences (e.g., 
aspi[INVESTIGATOR_1516], choking) OR 
Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
Nausea Transient (< 24 
hours) or 
intermittent AND 
No or minimal 
interference with 
oral intake Persistent nausea 
resulting in 
decreased oral 
intake for 24 to 48 
hours Persistent nausea 
resulting in minimal 
oral intake for > 48 
hours OR 
Rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pancreati tis NA Symptoms with 
hospi[INVESTIGATOR_184842]-threatening 
consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis)  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
92PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort 
with no 
intervention 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Medical 
intervention 
indicated Symptoms causing 
inability to perform 
usual social &
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (e.g., 
perforation) 
Rectal Discharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND 
No or minimal 
interfe rence with 
oral intake Frequent epi[INVESTIGATOR_428132] 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
MUSCULOSKELETAL
Arthralgia Joint pain causing 
no or minimal 
interference with 
usual social & 
functional 
activities Joint pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self -care 
functions 
Arthritis Stiffness or joint 
swelling causing 
no or minimal 
interference with 
usual social & 
functional 
activities Stiffness or joint 
swelling causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions 
Myalgia 
(generalized) Muscle pain 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Muscle pain 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
inability to perfor m 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self -care 
functions 
Osteonecrosis NA No symptoms but 
with radiographic 
findings AND No 
operative 
intervention 
indicated Bone pain with 
radiographic findin gs 
OR Operative 
intervention indicated Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self -care 
functions 
Osteopenia6
≥ 30 years of age BMD t -score -2.5 
to -1 NA NA NA  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
93PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
< 30 years of age BMD z -score -2 to 
-1 NA NA NA 
Osteoporosis6
≥ 30 years of age NA BMD t -score < -2.5 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
< 30 years of age NA BMD z -score < -2 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
NEUROLOGIC
Acute Central 
nervous system 
(CNS) Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accide nt (e.g., stroke 
with neurological deficit) 
Altered Mental 
Status (for 
Dementia, see 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance below) Changes causing 
no or minimal 
interference with 
usual social & 
functional 
activities Mild lethargy or 
somnolen ce 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Confusion, memory 
impairment, lethargy, 
or somnolence 
causing inability to 
perform usual social 
& functional activities Delirium OR 
Obtundation OR Coma 
Ataxia Sympt oms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
ataxia detected on 
examination Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self -care 
functions 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance 
(includes dementia 
and attention deficit 
disorder) 
Specify type, if 
applicable Disability causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR 
Specialized 
resources not 
indicated Disability causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part -
time basis indicated Disability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full-
time basis indicated Disability causing 
inability to perform basic 
self-care functions OR 
Institutionalization 
indicated  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
94PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Developmental 
Delay < 18 years of 
age 
Specify type, if 
applicable Mild 
developmental 
delay, either 
motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental 
delay, either motor
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Severe 
developmental delay, 
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting 
Headache Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms cau sing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428133] (includes 
myopathy and 
neuropathy) 
Specify type, if 
applicable Minimal muscle 
weakness causing 
no or minimal 
interference with 
usual social & 
functional
activities OR No 
symptoms with 
decreased 
strength on 
examination Muscle weakness 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle weakness 
causing inability to 
perform usual social 
& functional activities Disab ling muscle 
weakness causing 
inability to perform basic 
self-care functions OR 
Respi[INVESTIGATOR_428134] (includes 
paresthesia and 
painful neuropathy) 
Specify type, if 
applicable Minimal 
paresthesia 
causi ng no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
sensory alteration 
on examination Sensory alteration 
or paresthesia 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Sensory al teration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self -care 
functions 
Seizures New Onset 
Seizure 
≥ 18 years of age NA NA 1 to 3 seizures Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
< 18 years of age 
(includes new or pre -
existing febrile 
seizures) Seizure lasting < 
5 minutes w ith < 
24 hours postictal 
state Seizure lasting 5 to 
< 20 minutes with < 
24 hours postictal 
state Seizure lasting ≥ 20 
minutes OR > 24 
hours postictal state Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002])  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
95PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Pre-existing Seizure NA Increased 
frequency from 
previous level of 
control without 
change in seizure 
character Change in seizure 
character either in 
duration or quality 
(e.g., severity or 
focality) Prolonged and repetitive 
seizures (e .g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Syncope Near syncope 
without loss of 
consciousness 
(e.g., pre-
syncope) Loss of 
consciousness with 
no intervention 
indicated Loss of 
consciousness AND 
Hospi[INVESTIGATOR_428135], PUERPERIUM, AND PERINATAL
Fetal Death or 
Stillbirth (report 
using mother’s 
participant ID) 
Report only one NA NA Fetal loss occurring 
at ≥ 20 weeks 
gestation NA 
Preterm Delivery7
(report using 
mother’s participant 
ID) Delivery at 34 to < 
37 weeks 
gestational age Delivery at 28 to < 
34 weeks 
gestational age Delivery at 24 to < 28 
weeks gestational 
age Delivery at < 24 weeks 
gestational age 
Spontaneous 
Abortion or 
Miscarriage8(report 
using mother’s 
participant ID) 
Report only one Chemical 
pregnancy Uncomplicated 
spontaneous 
abortion or 
miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
PSYCHIATRIC
Insomnia Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early Moderate difficul ty 
falling asleep, 
staying asleep, or 
waking up early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric 
Disorders 
(includes anxiety, 
depression, mania, 
and 
psychosis) 
Specify disorder Symptoms with 
intervention no t 
indicated OR 
Behavior causing 
no or minimal 
interference with 
usual social & 
functional 
activities Symptoms with 
intervention 
indicated OR 
Behavior causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms with 
hospit alization 
indicated OR 
Behavior causing 
inability to perform 
usual social & 
functional activities Threatens harm to self 
or others OR Acute 
psychosis OR Behavior 
causing inability to 
perform basic self -care 
functions  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
96PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Suicidal Ideation or 
Attempt 
Report only one Preoccupi[INVESTIGATOR_428136] 1 
second or peak 
flow reduced to ≥ 
70 to < 80% OR 
Mild symptoms 
with intervention 
not indicated Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 50 to < 
70% OR Symptoms 
with intervention 
indicated OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 25 to < 
50% OR Symptoms 
causing inability to 
perform usual social 
& functional activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow < 25% OR 
Life-threatening 
respi[INVESTIGATOR_428137] & 
functional 
activities OR 
Wheezing OR 
Minimal increase 
in respi[INVESTIGATOR_428138] & 
functional activities 
OR Nasal flaring 
OR Intercostal 
retraction s OR 
Pulse oximetry 90 
to < 95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional activities 
OR Pulse oximetry < 
90% Respi[INVESTIGATOR_184852] (e.g., 
Continuous positive 
airway pressure [CPAP], 
Bilevel positive airway 
pressure [BPAP], 
intubation) 
SENSORY
Hearing Loss 
≥ 12 years of age NA Hearing aid or 
intervention not 
indicated Hearing aid or 
intervention indicated Profound bilateral 
hearing loss (> 80 dB at 
2 kHz and above) OR 
Non-serviceable hear ing 
(i.e., >50 dB audiogram 
and <50% speech 
discrimination) 
< 12 years of age 
(based on a 1, 2, 3, 
4, 6 and 8 kHz 
audiogram) > 20 dB hearing 
loss at ≤ 4 kHz > 20 dB hearing 
loss at > 4 kHz > 20 dB hearing loss 
at ≥ 3 kHz in one ear 
with additional 
speech language 
related services 
indicated (where 
available) OR 
Hearing loss 
sufficient to indicate 
therapeutic 
intervention, including 
hearing aids Audiologic indication for 
cochlear implant and 
additional speech -
language related 
services indicated 
(where available)  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
97PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Tinnitus Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Uveitis No symptoms 
AND Detectable 
on examination Anterior uveitis with 
symptoms OR 
Medicamylasal 
intervention 
indicated Posterior or pan -
uveitis OR Operative 
interv ention indicated Disabling visual loss in 
affected eye(s) 
Vertigo Vertigo causing 
no or minimal 
interference with 
usual social & 
functional 
activities Vertigo causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self -care 
functions 
Visual Changes 
(assessed from 
baseline) Visual changes 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Visual changes 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Visual changes 
causing inability to 
perform usual social 
& functional activities Disabling visual loss in 
affected eye(s) 
SYSTEMIC
Acute Allergic 
Reaction Localized urticaria 
(wheals) with no 
medical 
intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with 
no intervention 
indicated Generalized urticaria 
OR Angioedema with 
intervention indicated
OR Symptoms of 
mild bronchospasm Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference wit h 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9Mild signs and 
symptoms AND 
Therapy (i.e., 
antibody infusion) 
interruption not 
indicated Therapy (i.e., 
antibody infusion) 
interruption 
indicated AND 
Responds promptly 
to symptomatic 
treatment OR 
Prophylactic 
medications 
indicated for ≤ 24 
hours Prolonged severe 
signs and symptoms 
OR Recurrence of 
symptoms following 
initial improvement Life-threatening 
conse quences (e.g., 
requiring pressor or 
ventilator support)  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
98PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Fatigue or Malaise 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating 
symptoms of fatigue or 
malaise causing inability 
to perform basic self -
care functions 
Fever (non-axillary 
temperatures only) 38.0 to < 38.6°C 
or 100.4 to < 
101.5°F ≥ 38.6 to < 39.3°C 
or ≥ 101.5 to < 
102.7°F ≥ 39.3 to < 40.0°C or 
≥ 102.7 to < 104.0°F ≥ 40.0°C or ≥ 104.0°F 
Pain10(not 
associated with study 
agent injections and 
not specified 
elsewhere) 
Specify location Pain causing no 
or minimal 
interference with 
usual social & 
functional 
activities Pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Pain causing inability 
to perform usual 
social & functional 
activities Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428139]11 Mild signs and 
symptoms Moderate signs and 
symptoms AND 
Intervention 
indicated (e.g., 
antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(e.g., steroids or IV 
fluids) Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Underweight12
> 5 to 19 years of 
age NA World Health 
Organization 
(WHO) BMI z- score 
< -2 to ≤ -3 WHO BMI z -score < -
3 WHO BMI z -score < -3 
with life- threatening 
consequences 
2 to 5 years of age NA WHO Weight -for-
height z -score 
< -2 to ≤ -3 WHO Weight -for-
height z -score < -3 WHO Weight -for-height 
z-score < -3 with life -
threatening 
consequences 
< 2 years of age NA WHO Weight -for-
lengt h z-score 
< -2 to ≤ -3 WHO Weight -for-
length z -score < -3 WHO Weight -for-length 
z-score < -3 with life -
threatening 
consequences 
Weight Loss 
(excludes postpartum 
weight loss) NA 5 to < 9% loss in 
body weight from 
baseline ≥ 9 to < 20%  loss in 
body w eight from 
baseline ≥ 20% loss in body 
weight from baseline OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
URINARY
Urinary Tract 
Obstruction NA Signs or symptoms 
of urinary tract 
obstruction without 
hydronephros is or 
renal dysfunction Signs or symptoms of 
urinary tract 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing life -
threatening 
consequences  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
99PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
SITE REACTIONS TO INJECTIONS AND INFUSIONS
Injection Site Pain 
or Tenderness 
Report only one Pain or 
tenderness 
causing no or 
minimal limitation 
of use of limb Pain or tenderness 
causing greater 
than minimal 
limitation of use of 
limb Pain or tenderness 
causing inability to 
perform usual social 
& functional activities Pain or tenderness 
causing inability to 
perform basic self -care 
function OR 
Hospi[INVESTIGATOR_428140]13 
Report only one 
> 15 years of age 2.5 to < 5 cm in 
diameter OR 6.25 
to < 25 cm2 
surface area AND 
Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities ≥ 5 to < 10 cm in 
diameter OR ≥ 25 
to < 100 cm2 
surface area OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities ≥ 10 cm in diameter 
OR ≥ 100 cm2 
surface area OR 
Ulceration OR 
Secondary infection 
OR Phlebitis OR
Sterile abscess OR 
Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
≤ 15 years of age ≤2.5 cm in 
diameter > 2.5 cm in 
diameter with < 
50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) ≥ 50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) OR Ulceration 
OR Secondary 
infection OR Phlebitis 
OR Sterile abscess 
OR Drainage Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or 
Swelling 
Report only one 
> 15 years of age Same as for 
Injecti on Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, > 15 years of 
age 
≤ 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
age 
Injection Site 
Pruritus Itching localized 
to the injection 
site that is 
relieved 
spontaneously or 
in < 48 hours of 
treatment Itching beyond the 
injection site that is 
not generalized OR 
Itching localized to 
the injection s ite 
requiring ≥ 48 
hours treatment Generalized itching 
causing inability to 
perform usual social 
& functional activities NA 
LABORATORY VALUES Chemistries
Acidosis NA pH ≥ 7.3 to < Lower 
limit of normal 
(LLN) pH < 7.3 without life -
threatening 
conseq uences pH < 7.3 with life -
threatening 
consequences 
Albumin, Low (g/dL; 
g/L) 3.0 to < LLN 
30 to < LLN ≥ 2.0 to < 3.0
≥ 20 to < 30 < 2.0 
< 20 NA  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
100PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Alkaline 
Phosphatase, High 1.25 to < 2.[ADDRESS_541246] 2.5 to < 5.[ADDRESS_541247] 5.0 to < 10.[ADDRESS_541248] ≥ 10.0 x UL N 
Alkalosis NA pH > ULN to ≤ 7.5 pH > 7.5 without life -
threatening 
consequences pH > 7.5 with life -
threatening 
consequences 
ALT or SGPT, High 
Report only one 1.25 to < 2.[ADDRESS_541249] 2.5 to < 5.[ADDRESS_541250] 5.0 to < 10.[ADDRESS_541251] ≥ 10.[ADDRESS_541252] 
Amylase 
(Pancreatic) or 
Amylase (Total), 
High 
Report only one 1.1 to < 1.[ADDRESS_541253] 1.5 to < 3.[ADDRESS_541254] 3.0 to < 5.[ADDRESS_541255] ≥ 5.[ADDRESS_541256] or SGOT, High 
Report only one 1.25 to < 2.[ADDRESS_541257] 2.5 to < 5.[ADDRESS_541258] 5.0 to < 10.[ADDRESS_541259] ≥ 10.[ADDRESS_541260] 
Bicarbonate, Low
(mEq/L; mmol/L ) 16.0 to < LLN 
16.0 to < LLN 11.0 to < 16.0 
11.0 to < 16.0 8.0 to < 11.0 
8.0 to < 11.0 < 8.0 
< 8.[ADDRESS_541261] 
Bilirubin14, High 
> 28 days of age NA NA > ULN > ULN with life -
threatening 
consequences (e.g., 
signs and sympt oms of 
liver failure) 
≤ [ADDRESS_541262] to ≤ 1 mg/dL > 1 to ≤ 1.5 mg/dL > 1.5 to ≤ 2 mg/dL > 2 mg/dL 
Total Bilirubin, High 
> 28 days of age 1.1 to < 1.[ADDRESS_541263] 1.6 to < 2.[ADDRESS_541264] 2.6 to < 5.[ADDRESS_541265] ≥ 5.[ADDRESS_541266] 
≤ 28 days of age Total Bilirubin for 
Term and Preter m 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for Term 
and Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L ) 
≥ 7 days of age 10.6 to < 11.5 
2.65 to < 2.88 11.5 to < 12.5 
2.88 to < 3.13 12.5 to < 13.5 
3.13 to < 3.38 ≥ 13.5 
≥ 3.38 
< 7 days of age 11.5 to < 12.4 
2.88 to < 3.10 12.4 to < 12.9 
3.10 to < 3.23 12.9 to < 13.5 
3.23 to < 3.38 ≥ 13.5 
≥ 3.38 
Calcium (Ionized), 
High (mg/dL; 
mmol/L ) > ULN to < 6.0
> ULN to < 1 .5 6.0 to < 6.4 
1.5 to < 1.6 6.4 to < 7.2 
1.6 to < 1.8 ≥ 7.2 
≥ 1.8  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
101PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Calcium, Low 
(mg/dL; mmol/L ) 
≥ 7 days of age 7.8 to < 8.4 
1.95 to < 2.10 7.0 to < 7.8 
1.75 to < 1.95 6.1 to < 7.0 
1.53 to < 1.75 < 6.1 
< 1.53 
< 7 days of age 6.5 to < 7. 5 
1.63 to < 1.88 6.0 to < 6.5 
1.50 to < 1.63 5.50 to < 6.0 
1.38 to < 1.50 < 5.50 
< 1.38 
Calcium (Ionized), 
Low (mg/dL; mmol/L ) < LLN to 4.0 
< LLN to 1.0 3.6 to < 4.0 
0.9 to < 1.0 3.2 to < 3.6 
0.8 to < 0.9 < 3.2 
< 0.8 
Cardiac Troponin I, 
High NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as 
defined by [CONTACT_428225], 
High 3 to < [ADDRESS_541267] 6 to < [ADDRESS_541268] 10 to < [ADDRESS_541269] ≥ [ADDRESS_541270] > 1.[ADDRESS_541271] 
OR Increase of > 
0.3 mg/dL above 
baseline > 1.8 to < 3.[ADDRESS_541272] 
OR Increase of 1.5 to 
< 2.0 x above 
baseline ≥ 3.[ADDRESS_541273] OR 
Increase of ≥ 2.0 x 
above baseline 
Creatinine 
Clearance15or
Estimated 
glomerular filtration 
rate (eGFR), Low 
Report only one NA < 90 to 60 mL/min 
or mL/min/1.73 m2 
OR 10 to < 30% 
decrease from 
baseline < 60 to 30 mL/min or 
mL/min/1.73 m2 OR 
≥ 30 to < 50%  
decrease from 
baseline < 30 mL/min or 
mL/min/1.73 m2 OR ≥ 
50% decrease from 
baseline or dialysis 
needed 
Glucose 
(mg/dL; mmol/L ) 
Fasting, High 110 to 125 
6.11 to < 6.95 > 125 to 250 
6.95 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Nonfasting, High 116 to 160 
6.44 to < 8.89 > 160 to 2 50 
8.89 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Glucose, Low 
(mg/dL; mmol/L ) 
≥ 1 month of age 55 to 64 
3.05 to 3.55 40 to < 55 
2.22 to < 3.05 30 to < 40 
1.67 to < 2.22 < 30 
< 1.[ADDRESS_541274] to < 2.[ADDRESS_541275] without 
acidosis ≥ 2.[ADDRESS_541276] without 
acidosis Increased lactate with 
pH < 7.3 without life -
threatening 
consequences Increased lactate with 
pH < 7.3 with life -
threatening 
consequences 
Lipase, High 1.1 to < 1.[ADDRESS_541277] 1.5 to < 3.[ADDRESS_541278] 3.0 to < 5.[ADDRESS_541279] ≥ 5.[ADDRESS_541280]  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
102PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Lipid Disorders 
(mg/dL; mmol/L ) 
Cholesterol, 
Fasting, High 
≥ 18 years of age 200 to < 240 
5.18 to < 6.19 240 to < 300 
6.19 to < 7.77 ≥ 300 
≥ 7.77 NA 
< 18 years of age 170 to < 200 4.40 
to < 5.15 200 to < 300 5.15 to 
< 7.77 ≥ 300 ≥ 7.77 NA 
Low Density 
Lipoprotein (LDL),
Fasting, High 
≥ 18 years of age 130 to < 160 3.37 
to < 4.12 160 to < 190 4.12 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
> 2 to < 18 years of 
age 110 to < 130 2.85 
to < 3.34 130 to < 190 3.34 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
Triglycerides, 
Fasting, High 150 to 300 
1.71 to 3.42 >300 to 500 
>3.42 to 5.7 >500 to < 1,000 
>5.7 to 11.4 > 1,000 
> 11.4 
Magnesium16, Low 
(mEq/L; mmol/L ) 1.2 to < 1.4 
0.60 to < 0.70 0.9 to < 1.2 
0.45 to < 0.60 0.6 to < 0.9 
0.30 to < 0.45 < 0.6 
< 0.30 
Phosphate, Low 
(mg/dL; mmol/L ) 
> 14 years of age 2.0 to < LLN 
0.81 to < LLN 1.4 to < 2.0 
0.65 to < 0.81 1.0 to < 1.4 
0.32 to < 0.65 < 1.0 
< 0.32 
1 to 14 years of age 3.0 to < 3.5 
0.97 to < 1.13 2.5 to < 3.0 
0.81 to < 0.97 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
< 1 year of age 3.5 to < 4.5 
1.13 to < 1.45 2.5 to < 3.5 
0.81 to < 1.13 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
Potassium, High 
(mEq/L; mmol/L ) 5.6 to < 6.0 
5.6 to < 6.0 6.0 to < 6.5 
6.0 to < 6.5 6.5 to < 7.0 
6.5 to < 7.0 ≥ 7.0 
≥ 7.0 
Potassium, Low 
(mEq/L; mmol/L ) 3.0 to < 3.4 
3.0 to < 3.4 2.5 to < 3.0 
2.5 to < 3.0 2.0 to < 2.5 
2.0 to < 2.5 < 2.0 
< 2.0 
Sodium, High 
(mEq/L; mmol/L ) 146 to < 150 
146 to < 150 150 to < 154 
150 to < 154 154 to < 160 
154 to < 1 60 ≥ 160 
≥ 160 
Sodium, Low 
(mEq/L; mmol/L ) 130 to < 135 
130 to < 135 125 to < 130 
125 to < 135 121 to < 125 
121 to < 125 ≤ 120 
≤ 120 
Uric Acid, High 
(mg/dL; mmol/L ) 7.5 to < 10.0 
0.45 to < 0.59 10.0 to < 12.0 
0.59 to < 0.71 12.0 to < 15. 0 
0.71 to < 0.89 ≥ 15.0 
≥ 0.89  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
103PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
HEMATOLOGY
Absolute cluster of 
differentiation 4 
(CD4+) Count, Low 
(cell/mm3; cells/L ) 
> 5 years of age (not 
HIV infected) 300 to < 400 
300 to < 400 200 to < 300 
200 to < 300 100 to < 200 
100 to < 200 < 100 
< 100 
Absolute 
Lymphocyte Count, 
Low 
(cell/mm3; cells/L ) 
> 5 years of age 
(not HIV infected) 600 to < 650 
0.600 x 109to < 
0.650 x 109500 to < 600 
0.500 x 109to < 
0.600 x 109350 to < 500 
0.350 x 109to < 
0.500 x 109< 350 
< 0.350 x 109
Absolu te Neutrophil 
Count (ANC), Low 
(cells/mm3; cells/L ) 
> 7 days of age 800 to 1,000 
0.800 x 109to 
1.000 x 109600 to 799 
0.600 x 109to 0.799 
x 109400 to 599 
0.400 x 109to 0.599 
x 109< 400 
< 0.400 x 109
2 to 7 days of age 1,250 to 1,500 
1.250 x 109to 
1.500 x 1091,000 to 1,249 
1.000 x 109to 1.249 
x 109750 to 999 
0.750 x 109to 0.999 
x 109< 750 
< 0.750 x 109
≤ 1 day of age 4,000 to 5,000 
4.000 x 109to 
5.000 x 109 3,000 to 3,999 
3.000 x 109to 3.999 
x 1091,500 to 2,999 
1.500 x 109to 2.999 
x 109< 1,500 
< 1.500 x 109
Fibrinogen, 
Decreased (mg/dL; 
g/L) 100 to < 200 
1.00 to < 2.00 OR 
0.75 to < 1.[ADDRESS_541281] 75 to < 100 
0.75 to < 1.00 OR ≥ 
0.50 to < 0.[ADDRESS_541282] 50 to < 75 
0.50 to < 0.75 OR 
0.25 to < 0.[ADDRESS_541283] < 50 
< 0.50 OR < 0.[ADDRESS_541284] 
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L )18 
≥ 13 years of age 
(male only) 10.0 to 10.9 
6.19 to 6.76 9.0 to < 10.0 
5.57 to < 6.19 7.0 to < 9.0 
4.34 to < 5.57 < 7.0 
< 4.34 
≥ 13 years of age 
(female only ) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
57 days of age to < 
13 years of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
<4.03  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
104PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
36 to 56 days of age 
(male and female) 8.5 to 9.6 
5.26 to 5.99 7.0 to < 8.5 
4.32 to < 5.26 6.0 to < 7.0 
3.72 to < 4.32 < 6.0 
< 3.72 
22 to 35 days of age 
(male and female) 9.5 to 11.0 
5.88 to 6.86 8.0 to < 9.5 
4.94 to < 5.88 6.7 to < 8.0 
4.15 to < 4.94 < 6.7 
< 4.15 
8 to ≤ 21 days of age 
(male and female) 11.0 to 13.0 
6.81 to 8.10 9.0 to < 11.0 
5.57 to < 6.81 8.0 to < 9.0 
4.96 to < 5.57 < 8.0 
< 4.96 
≤ 7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to < 13.0 
6.19 to < 8.05 9.0 to < 10.0 
5.59 to < 6.19 < 9.0 
< 5.59 
INR, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541285] 1.5 to < 2.[ADDRESS_541286] 2.0 to < 3.[ADDRESS_541287] ≥ 3.[ADDRESS_541288] 
Methemoglobin (% 
hemoglobin) 5.0 to < 10.0% 10.0 to < 15.0% 15.0 to < 20.0% ≥ 20.0% 
PTT, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541289] 1.66 to < 2.[ADDRESS_541290] 2.33 to < 3.[ADDRESS_541291] ≥ 3.[ADDRESS_541292] 
Platelets, 
Decreased 
(cells/mm3; cells/L ) 100,000 to < 
124,999 100.000 
x 109to < 124.999 
x [ZIP_CODE],000 to < 100,000 
50.000 x 109to < 
100.000 x 109 25,000 to < 50,000 
25.000 x 109to < 
50.000 x 109< 25,000 < 25.000 x 109
PT, High 
(not on 
anticoagulation 
therapy 1.1 to < 1.[ADDRESS_541293] 1.25 to < 1.[ADDRESS_541294] 1.50 to < 3.[ADDRESS_541295] ≥ 3.[ADDRESS_541296] 
WBC, Decreased
(cells/mm3; cells/L ) 
> 7 days of age 2,000 to 2,499 
2.000 x 109to 
2.499 x 1091,500 to 1,999 
1.500 x 109to 1.999 
x 1091,000 to 1,499 
1.000 x 109 to 1.499 
x 109< 1,000 
< 1.000 x 109
≤ 7 days of age 5,500 to 6,999 
5.500 x 109to 
6.999 x 109 4,000 to 5,499 
4.000 x 109to 5.499 
x 1092,500 to 3,999 
2.500 x 109to 3.999 
x 109< 2,500 
< 2.500 x 109
URINALYSIS
Glycosuria ( random 
collection tested by 
[CONTACT_5230]) Trace to 1+ or 
≤ 250 mg 2+ or ˃  250 to 
≤ 500 mg > 2+ or > 500 mg NA  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
105PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hematuria (not to be 
reported based on 
dipstick findings or 
on blood believed to 
be of menstrual 
origin) 6 to < 10 RBCs 
per high power 
field ≥ 10 RBCs per high 
power field Gross, with or without 
clots OR With RBC 
casts OR Intervention 
indicated Life-threatening 
consequences 
Proteinuria (random 
collection tested by 
[CONTACT_5230]) 1+ 2+ 3+ or higher NA 
1. Blood pressure norms for children <18 years of age can be found in: Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and Adolescents. Pediatrics 2011;128;S213; originally 
published online November 14, 2011; DOI: 10.1542/peds.2009 -2107C.  
2. As per Bazett’s formula.  
3. For pruritus associated with injections or infusions, see the Site Reactions to Injections and In fusions section.  
4. Definition: A disorder characterized by [CONTACT_184941], extremities, and buttocks. 
5. Definition: A disorder characterized by [CONTACT_184942], breasts, and abdomen.  
6. Bone mineral density (BMD) t an d z scores can be found in: Kanis JA on behalf of the World Health Organization 
Scientific Group (2007). Assessment of osteoporosis at the primary health -care level. Technical Report. World 
Health Organization Collaborating Centre for Metabolic Bone Diseas es, University of Sheffield, [LOCATION_006]. 2007: Printed 
by [CONTACT_184943].  
7. Definition: A delivery of a live -born neonate occurring at ≥20 to <37 weeks gestational age. 
8. Definition: A clinically recognized pregnancy occurring at <20 weeks gestational age.  
9. Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of 
breath. 
10. For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section.
11. Definition: A disord er characterized by [CONTACT_411], arthralgia, myalgia, skin eruptions, lymphadenopathy, marked 
discomfort, and/or dyspnea.
12. WHO reference tables may be accesed by [CONTACT_184944]: 
http://www.who.int/growthref/who20 07_bmi_for_age/en/ for participants >5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤ [ADDRESS_541297] bilirubin >1.5 mg/dL in a participant <28 days of age should be graded as Grade 2, if <10% of the total 
bilirubin.  
15. Use the applicable formula (i.e., Cockroft -Gault in mL/min or Schwatrz in mL/min/1.73m2).  
16. To convert a ma gnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.  
17. Male and female sexes are defined as sex at birth. 
18. The conversion factor used to convert g/dL to mmol/L is 0.[ADDRESS_541298] be converted to g/dL using the appropriate conversion factor for the particular laboratory.   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
[ZIP_CODE].9. Appendix 9: Toxicity  Management
ANEMIA
Grade 1 (mild) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541299] be repeated with the 
following additional tests:
20.peripheral blood smear
21. indirect bilirubin (abnormal if increased >50% from baseline)
22.haptoglobin (abnormal if  25 mg/dL)
23.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will per manently  discontinue study  medication and 
be withdrawn from the trial.  Subjects should be followed up until resolution of anemia.
Grade 2 (moderate) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541300] be repeated with the 
following additional tests:
1.peripheral blood smear
2. indirect bilirubin (abnormal if increased > 50% from baseline)
3.haptoglobin (abnormal if  25 mg/dL)
4.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will permanently  discontinue study  medication and 
be withdrawn from the trial.  Consultation with a Hematologist s hould be considered.  
Subjects should be followed up until resolution of anemia.
Grade 3 (severe) or Grade 4 (potentially life threatening) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541301] be repeated with 
the follow ing additional tests:
5.peripheral blood smear
6. indirect bilirubin
7.haptoglobin
8.reticulocy te count  2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541302] should be considered.  Subjects should be followed up 
until resolution of anemia.
TOTA L BILIRUBIN ELEVA TION
Grade 1 (mild) bilirubin elevation (1.[ADDRESS_541303]) or Grade 2 (moderate 
-1.6-2.[ADDRESS_541304]):
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects may  continue study  medication.  Subjects should 
be followed up until resolution (return to baseline) of elevation.
Grade 3 (severe –2.6-5.[ADDRESS_541305]) or 4 (life- threatening -> 5.[ADDRESS_541306]) 
bilirubin elevation :
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects will permanently  discontinue study medication 
and be withdrawn from the trial.  Subjects should be followed up until resoluti on (return 
to baseline) of bilirubin elevation.
AST AND ALT ELEVA TION
See Appendix 9 .
RASH
Grade 1 rash (Localized macular rash):
Subjects with Grade [ADDRESS_541307].  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
9.Temperature > 38.5°C
10.Lym phadenopathy
11.Phary ngitis
12.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541308] should remain on the study  to be 
followed for safet y and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
108Grade 2 rash (Diffuse macular, maculopapular, or morbilliform rash OR Target
lesions):
Subjects with Grade [ADDRESS_541309].  The study  drug should b e permanentl y 
discontinued if the following signs or s ymptoms are noted at an y time:
13.Temperature > 38.5°C
14.Lym phadenopathy
15.Phary ngitis
16.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subject s with Grade [ADDRESS_541310] should remain on the study to be followed for safety and PK as 
outlined in Section 10.5.
Grade 3 rash (Diffuse macular, mac ulopapular, or morbilliform rash with vesicles 
or limited number of bullae OR Superficial ulcerations of mucous membrane 
limited to one site):
Subjects with a Grade [ADDRESS_541311] should be evaluated in the phy sician’s office immediatel y and should be seen in 
the phy sician’s office or contact[CONTACT_428226]  [ADDRESS_541312] should remain on the 
study  to be followed for safet y and PK as outlined in Section 10.5.
Grade 4 rash (Extensive or generalized bullous lesions OR Stevens -Johnson 
syndrome OR Ulceration of mucous membrane involving two or more distinct 
mucosal sites OR Toxic epi[INVESTIGATOR_194] (TEN)):
Subjects with a Grade [ADDRESS_541313] sh
ould remain on the stud y to be followed 
for safety  and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
109ALLERGIC RE ACTION
Grade 1 allergic reaction (Pruritis without rash):
Subjects with Grade 1 allergic reaction should be evalu ated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
17.Temperature > 38.5°C
18.Eosinophilia
19.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
20.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541314] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428142].  The subject should remain on the study  to be 
followed for safety and PK as outlined.
Grade 2 allergic reaction (Localized urticaria):
Subjects with Grade 2 allergic reaction should be evaluated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
21.Temperature > 38.5°C
22.Eosinophilia
23.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
24.Any indicatio n of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541315] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard 
management, i ncluding discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428143].  The subject should remain on the study  to be 
followed for safet y and PK as outlined in Section 7. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
110Grade 3 allergic reaction (Generalized urticaria or angioedema):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Grad e 4 allergic reaction (Anaphylaxis):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Revised ACTG Toxicity Grade Definitions Investigator Action
Grade 1 Pruritus without rash May continue therapy
Grade 2 Localized urticaria May continue therapy
Grade 3 Generalized urticaria
AngioedemaDiscontinu e Therapy
Grade 4 Anaphylaxis Discontinue Therapy 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
[ZIP_CODE].10. Appendix 10: Protocol A mendment Changes
12.10.1. AMENDMENT 1
Protocol Amendment 1 (26- Apr-2017) from the original protocol (09 -Nov-2016)
Where the A mendment A pplies
This amendment applies to all subjects who will participate in this study  in all countries.
List of Specific Changes: (bold indicates text added and strikethrough indicates text 
removed)
Summary  of Protocol A mendment Changes with Rationale
Amendment 1 includes minor updates to I nclusion criteria (IE) c riteria, including 
clarification on use of pre- or post -exposure prophy laxis, and removal of exclusionary  
requirements related to concomitant medications and tobacco and alcohol use during the 
study . Guidance around relevant habits is included in the L ifestyle section of the protocol 
and adjustments were made to reduce restrictions on these requirements. Modifications 
were also made to the pharmacokinetics sampling, allowing for the 12 h PK collection 
timepoint on Day  1 and 10 to be optional. Minor alterati ons were made regarding the 
order of screening procedures, including the Holter monitoring requirements. 
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. Furthermore, the serial ECG collection (up to 6h post -dose) was removed on 
Day 5. Finall y, the post -study  care guidance was updated to include an option for subjects 
to receive reimbursement for marketed ART for a limited period after completion of 
study  treatment and follow up. Minor clarifications, reformatt ing of tables, re -numbering 
of sections and correction of ty pographical errors were also made throughout this 
amendment.
List of A uthors
Rationale for change
The list of authors was updated based on internal [COMPANY_004] team personnel changes.
Revised Text
PTS, Ware, [LOCATION_006]
GCSP, Stockley  Park, [LOCATION_006]
Infectious Diseases, Clinical, Upper Providence, PA, US
Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
HIV DPU, RTP, NC, US
Virology ,HIV DPU, RTP, NC, US 2018N360917_00
[COMPANY_003]
2015N227852_03 CONFIDENTIA L
200911
112CPMS, [COMPANY_004], RTP, NC, US
HIV DPU, RTP, NC, US
Clinical Pharmacology , ViiV Healthcare, RTP, NC, US
PCPS, [COMPANY_004], Upper Providence, PA, US
PCPS, [COMPANY_004], Collegeville, PA, US 
Clinical Statistics, PAREXEL , RTP, NC, US
Infectious Diseases, Clinical, Cambridge, MA, US
Medical Monitor/SA E Contact [CONTACT_428227] t the current 
contact [CONTACT_428228] y and medical monitoring. 
Revised Text
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor/SAE 
contact 
[CONTACT_428229]
([COMPANY_003]) Safety 
Hotline [LOCATION_011], 
MA[COMPANY_003], [ADDRESS_541316] 
information MD[LOCATION_011], MA
Synopsis: Design, Treatment A rms and Duration
Rationale for change
Minor clarifications were made to this section to reflect current status of studies being 
referenced. As s ynopsis being a standalone document, cross -referenced has been 
removed. 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_03 CONFIDENTIA L
200911
113Revised Text
Fourth paragraph
The possibility  that an additional, unboo sted [COMPANY_004]2838232 monotherap y cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from ongoing Study  204953 
where unboosted [COMPANY_004]2838232 at a dose of 200 mg twice dail y (BID) is being was
assessed.
Sixth paragraph
HIV Drug Resistance: Following cessation of [COMPANY_004]2838232/cobi dosing for 10 day s, 
there will be prolonged exposure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t½ (i.e., in the “tail” of the PK profile). However, based on in vitro 
resistance passage data with [COMPANY_004]2838232 [and unlike with many  other ARV therapi[INVESTIGATOR_014]], 
there appears to be a limited likelihood of developi[INVESTIGATOR_428081]-infected subjects due to its virologic profile [[COMPANY_004] Document Number 
2013N163221_00] . 
Section [ADDRESS_541317] instance has been defined.
Revised Text
[COMPANY_004]2838232 is a novel human immunodeficiency virus ( HIV)-1 maturation inhibitor 
(MI) that is being developed for the treatment of HIV -1 infection in combination with 
other antiretrovirals (ART).
Section 2.[ADDRESS_541318] instance has been defined.
Revised Text
This ‘proof of concept (PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity , pharmacokinetics (PK), the relationship between PK and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg once daily (QD) cobicistat 
([COMPANY_004]283232/cobi), administered across a range of doses over [ADDRESS_541319] paragraph
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has demonstrated significant improvement in acquired 
immunodeficiency syndrome (AIDS)-related morbidity  and mortalit y over the last 10-
15 years.
Addition of abbreviation for RNA  in second paragraph
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [Martin, 2007a; Martin, 2007b; Martin, 2008; NORVIR, 2013]). 
BVM reached Phase II studies in HIV patients; however, onl y modest reductions in 
plasma HIV -1 ribonucleic acid (RNA) concentrations were observed in Phase IIa 
monotherap y studies [Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential) antiviral activity  [Wainburg, 2010] led to termination of BVM development. 
The average decrease from baseline to Day  14 plasma HIV -1 ribonucleic acid (RNA) 
was 0.54 and 0.70 log10 copi[INVESTIGATOR_014]/mL  for 200 mg and 300 mg twice daily  regimens (Table 
2); all subjects achieved plasma BVM concentrations above the in vitro EC90. 
Responders, classified based on 5 poly morphisms in HIV -1 gag (at positions 369, 370, 
and 371), achieved an average 1.15 log10 copi[INVESTIGATOR_014]/mL reduction in plasma HIV -1 RNA, 
while an avera ge 0.17 log10 copi[INVESTIGATOR_014]/mL  reduction was achieved for non- responders.
Section 2.2.[ADDRESS_541320] current status of studies being 
referenced.
Revised Text
To date, [COMPANY_004]2838232 has been evaluated in three completed clinical studies with or 
without ritonavir (RTV) ([COMPANY_004]2838232/r). A fourth study  (204953) is on- going as of 1st
November completed late 2016 and data analysis is ongoing . Full details of the clinical 
results can be found in the Investigator’s Brochure.
Section [IP_ADDRESS] Clinical Summary  of Safety
Rationale for change
Minor clarifications were made to this section to reflect current status of studies being 
referenced. 2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541321] hadbeen exposed to [COMPANY_004]2838232 
in 3 completed studies. One study  (204953) is completed in late 2016 and the analysis 
of results are ongoing ( [ADDRESS_541322] been 63 subjects were exposed to 
[COMPANY_004]2838232/r or placebo so far in this study). Overall, drug -related adverse events have 
been few and mild, and included headache, dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428144] .  Similarly , treatment -emergent laboratory  abnormalities have also been few 
and mostly  grade 1.  There have been no discernible patterns, thus far, in terms of AEs or 
laboratory  abnormalities.
Section [IP_ADDRESS] Study 204953 (completed); Pharmacokinetic Data
Rationale for change
Minor clarifications were made to this section to reflect current stat us of studies being 
referenced.
Change in Heading
Section [IP_ADDRESS] Study 204953 ( on-going completed ); Pharmacokinetic Data
Section 4.4.[ADDRESS_541323] instance has been defined.
Revised Text 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
116Potential Ris k of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible Drug -Drug 
Interactions (DDIs )HIV Drug Resistance to unique mechanism
Recognize HIV p atients have a higher chance of comorbidities/diseases and a 
risk of taking a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resistance
Strict adherence to protocol criteria around 
concurrent meds  
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541324] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
5 . Confirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. No current and no prior ART. (A previous course of 
pre- or post -exposure prophylaxis is allowed provided that it was completed at least 
[ADDRESS_541325] dose of study drug).
Section 5.2 Exclusion Criteria
Rationale for change
This exclusion criteria was removed and the guidance for use of concomitant medications 
was further addressed in Section 6.12, Concomitant Medications and Non -Drug 
Therapi[INVESTIGATOR_014]. The Relevant Habits section of the Exclusionary  criteria was also removed 
and addressed in Section 6.10, L ifesty le and/or Dietary  Restrictions, with the exception 
of illicit drug use. Smoking and limited alcohol use are no longer exclusionary . 
Additional clarification added to note that positive Hepatitis C result would need to be 
confirmed b y RIBA. Abbreviation used on first instance has been defined.  Additional 
minor ty pographical errors were corrected.
Revised Text
CONCOMI TANT MEDICATIONS
5.Unable to refrain from the use of prescription or non- prescription drugs, including 
vitamins, herbal and dietary  supplements (including St John’s Wort) within 7 day s 
(or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is 
longer) prior to the first dose of study medication, unless in the opi[INVESTIGATOR_428145] y. 
REL EVANT HABITS
6.History  of regular alcohol consump tion within 6 months of the study  defined as: 
An average weekl y intake of >14 drinks for males or >7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL ) of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof d istilled spi[INVESTIGATOR_2120].
7.Smoking is an exclusion criteria for this study . Urinary  cotinine levels indicative of  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
118smoking at screening.
6.Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion 
criteria.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
7 . Presence of hepatitis B surface antigen (HBsAg), positive (confirmed by 
[CONTACT_428230]- Blot Assay [RIBA]) hepatitis C antibody  test result at screening 
or within [ADDRESS_541326] dose of study  treatment.
19 . Exclusion criteria f or screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual participant in 204953200911 will be Fridericia’s 
formula. 
Section 6.[ADDRESS_541327] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Method for 
individualizing dosage:Capsules supplied in high -density 
polyethylene bottles for 
individualized dosing by [CONTACT_428231] 6.9 Treatment after the End of the Study
Rationale for change 
Additional language was included in this section to allow subjects to opt to receive 
reimbursement from [COMPANY_004] for up to 3 months for marketed antiretroviral therap y (as  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
119directed and pr escribed by  [CONTACT_5936]) based on the CDC guideline recommendations that 
patients be put on ARTs when diagnosed with HIV (test and treat guidelines). 
Revised Text
Subjects will not receive any  additional treatment from [COMPANY_004].
Subjects receiving [COMPANY_004]2838232 may opt to receive marketed antiretrovirals after 
the completion of 10 days of [COMPANY_004]2838232 dosing and study follow-up visits 
(through Day 21) eligible for sponsor company reimbursement up to a maximum of 
[ADDRESS_541328]’s medical condition, whether or not [COMPANY_004] is providing specific 
reimbursement for post-study  treatment.
Section 6.10.1 Meals and Dietary  Restrictions
Previous section number 6.12
Rationale for change
This section was updated to remove language around meal provisions (language 
consistent for an in -patient trial). As this is an out -patient trial, it will be up to trial site to 
arrange when/how meals are provided during a subject’s participation in the trial. The 
section ‘L ifestyle and/or Dietary  Restrictions’ had no content described under it. The 
sections ‘Meals and Dietary  Restrictions’ and ‘Alcohol, Caffeine and Exercise’ has b een 
moved as sub- sections under the section ‘L ifestyle and/or Dietary  Restrictions’, as the 
sub-sections are related to this section.   
Revised Text
Second Bullet
Doses will be given in the fed state (light breakfast), following overnight fasting (>10 
hours). Lunch will provided 4 hours after the dose; water will be allowed ad libitum 
throughout.
Section 6.10.2 Alcohol, Caffeine and Exercise
Previous section number 6.13
Rationale for change 
Adjustments were made to these lifesty le habits to eliminate re strictions on use of 
tobacco products, reduce restrictions on alcohol use and to allow occasional and light 
exercise during study  treatment.   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
120Revised Text
Alcohol, Caffeine , Tobacco and Exercise
Subjects should refrain from alcohol for 48 hours before scr eening and then for 48 
hours prior to admission and baseline assessments (on Day  1). Alcohol is then not 
permitted for the duration of the treatment period (through Day  10) and until the 
final follow -up visit.  
Use of tobacco products is not allowed from screening until after the final follow -up 
visit
Subjects will During  the study  alcohol consumption should be limited to the 
following:
An average weekly intake of <14 drinks for males or <7 drinks for females.  
One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 
ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
Subjects willshould abstain from strenuous exercise for 72 hours prior to each blood 
collection for clinical laboratory  tests.  Subjects may  partic ipate in light recreational 
activities during studies (e.g., watch television, read). the treatment period.
Section 6.[ADDRESS_541329] include one barrier method.  There Although 
use of oral contraceptives is permitted, tThere is no d efinitive DDI information with 
[COMPANY_004]2838232 and an interaction with oral contraceptives is possible, so other (barrier, 
inter-uterine device etc.) methods of contraception will be required.
Section 6.12 Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_428146] 6.14
Rationale for change
Adjustments were made to the concomitant medication section to clarify  that certain 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (Section 6.10), the section has been 
re-numbered. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
121Deleted Text
Subjects mu st refrain from all illicit drugs throughout the study (from Screening until 
discharge from the study).  Drug screening will occur at Screening and Day -1 for 
each treatment period.  A positive result will lead to exclusion from the remainder of 
the study .
The Principal Investigator [INVESTIGATOR_428147] y 
medications taken from the time of screening until the subject is discharged from the 
study .  Over -the-counter medications will not be permitted during the treatment 
period except a s needed to treat an AE. If medication is needed, use should be 
restricted to 4 hours after dosing if possible. 
Section 6.12.1 Permitted Medications and Non -Drug Therapi[INVESTIGATOR_428146] 6.14.1
Rationale for change
Adjustments were made to the concomitant medication section to clarify  that certain 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
Section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous Section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (Section 10), the section has been re -
numbered.
Revised Text
Addition of Second bullet
Concomitant medications (prescription and non- prescription) should be 
administered only as medically necessary during the study. Subjects must 
notify their Investigator of any current or proposed concomitant medication, 
whether prescribed or over- the-counter, because of the potential for 
interactions between such t reatments and the study medications.
Section 6.12.2 Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_428148] 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
Section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous Section 6.13) has been 
moved under Lifest yle and/or Dietary  Restriction s’ (Section 10), the section has been re -
numbered. 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
122Previous section number 6.14.2
Revised Text
Subjects must abstain from taking prescription or non- prescription drugs (including 
vitamins and dietary  or herbal supplements), within 7 day s (or 14 day s if the drug is 
a potential enzy me inducer) or 5 half -lives (whichever is longer) prior to the first 
dose of study medication until completion of the follow -up visit, unless in the 
opi[INVESTIGATOR_2511] I nvestigator and sponsor the medication will not interfere with the
study . 
Subjects must refrain from all illicit drugs throughout the study (from 
Screening until discharge from the study).  Drug screening will occur at 
Screening and Day -[ADDRESS_541330]- dose 12- lead ECG on Day  5, 
which remains in line with the FDA’s guidance regarding day s on which to perform post -
dose (2 & 6 hours to capture near Tmax) ECGs. Modifications were also made to the 
pharmacokinetics sampling, allowing for the 12 h PK collection timepoint on Day  1 and 
10 to be optional. Visit/procedure windows were included to allow more flexibility  with 
scheduling of assessments. Also minor clarifications were made and t ypographical errors 
were corrected.
Revised Text 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
123Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/ exclusion X X
Demography including height, weight and 
BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therap y X
12-lead ECG3 X X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and hepatitis 
C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X XX14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X
AE enquiry13 X X X X X X X X X X X X X
Telephone call to IVRS1314 X X X X X X X X X X X X X X X 
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
124Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within 14-[ADDRESS_541331] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 and 6, perform al l “Day 5” assessments on Day 7.
3. On Day 1, ECGs (x2)will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541332] -dose. To accommodate scheduling, 
serial ECGs collected on Days 4 and 8 may be performed 1 day.   On Day 10, ECGs (x2)will be performed pre -dose, and then 1, 1.5, 2, 3, [ADDRESS_541333] dose.  On 
Day 11, an ECG will be obtained prior to the 24 -hour PK sample. ECGs will be performed in triplicate at all timepoints.
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained o n Day [ADDRESS_541334] -morning dose, and at day 12 and Follow -up (Day 21) .
5. Only SAEs related to study participation will be collected between screening and Day 1. An AE enquiry will be made at each visit, subjects will be asked if they have 
experienced any neuropsychiatric adverse events, including psychosis or altered mental status.
6. On Days 1 -5 and 8 -10 samples for HIV -1 RNA PCR collected before morning dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart. HIV -1 RNA PCR samples will also be collected on days 12, 14 & Follow -up (Day 21).
7. Lymphocyte subsets by [CONTACT_4133] (total lymphocyte counts, perce ntage, and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determination of [COMPANY_004]2838232 will be collected on Day 1 and Day 10 at pre dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12 (optional), and 24 hours (to occur on morning of Day [ADDRESS_541335]- am dose and in the morning on Day 11) .  Pre -dose PK samples (within 15 minutes prior to dose) will be 
taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be taken on Days 12 and 14.
10. Samples (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541336] experienced any neuropsychiatric adverse events , including psychosis or altered mental status
13. A screening/regist ration call should be made to the IVRS to register the subject at screening.   An additional call will be made to document a screen failure.   A randomization 
call should be made to the IVRS system approximately one week prior to scheduled Day 1.  Note: Th e randomization call must be made in order to have study drug on site for 
Day 1. Additional calls will be made every day that the subject has a scheduled study visit to the clinic.  If a subject term inates the study prematurely a call should be made to 
theIVRS
14. Only if early termination visits occur during the treatment period.
15. Plasma samples for storage will be collected at each visit starting at Day 1, including unscheduled visits (e.g. for HIV -1 RNA levels and immunological 
parameters).  Additionally the se samples will be used when needed, such as when samples are lost or arrive at the laboratory unevaluable.
AE = Adverse event; CDC= Center for Disease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Hu man chorionic gonadotr ophin; HIV = Human 
immunodeficiency virus;  IVRS= Interactive Voice Response System; PCR = Polymerase chain reaction; PK=Pharmacokinetic. 
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
125Section 7.2 Visit Windows
Rationale for Addition
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. 
New Section
Screening (baseline to pre -dose): All screening assessments should take place within 
14-[ADDRESS_541337] dose. The screening visit window may be extended to 30 
days upon discussion with the Medical Monit or (i.e.; subject has scheduling conflicts 
or any screening assessment needs to be repeated).
Days 4 and 8: Based on subject and clinic schedule, Day 4 and Day 8 serial (up to 6h 
post-
dose) ECG assessments may be conducted 1 day.  
Weekend(s): The T&E ta ble is set up for study start (Day 1) to occur on a Monday 
and Days 6 and 7 to fall on the weekend. If the weekend occurs instead on Days 5 
and 6, Day 5 assessments should be performed on Day 7. The study start (Day 1) 
may also be adjusted to allow visits with assessments to be conducted over the 
weekend based on subject and clinic schedule.  
Assessments: The following applies to timing of procedures:
-Window for assessments [ADDRESS_541338] -dose = 5 minutes 
-Window for assessments >4 and < [ADDRESS_541339] -dose =  15 minutes
-Window for assessments > [ADDRESS_541340] -dose =  30 minutes
End of Treatment visit: should be within [ADDRESS_541341] for assessment of adverse events.
Section 7.3.1 Holter Monitoring (Screening criteria)
After addition of new section before this section, the section numbers from this section 
until Sections under 7.[ADDRESS_541342] has met all other inclusion criteria. period using a Holter monitoring 
device supplied by [CONTACT_1034].
Analy sis of the Holter tapes will consider the following:
Heart rate (brad ycardia and tach ycardia) 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
126Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractions, premature 
ventricular contractions, couplets, triplets, and ventricular tach ycardias
Atrio- ventricular conduction defects
Atrial fibrillation and flut ter
Section [IP_ADDRESS] Time period and Frequency  for collecting A E and      
SAE information
Rationale for Change 
Minor clarifications made regarding Sponsor (to include [COMPANY_003]). 
Revised Text
Bullet 4
All SAEs will be recorded and reported to [COMPANY_004] Sponsor within [ADDRESS_541343] dose based on this review (e.g., the 
exposure level of [COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838232 exposure 
seen previousl y in healthy subjects), the Bay esian posterior probability  that the log10 
viral load decline from baseline is greater than a cut
-point will be calculated. If the 
Bayesian probability from Cohort 1 is less than 70% ,this wi ll provide evidenceto 
evidence to not move forward into Part B. Otherwise, the study  team will review the data 
in order to make a dose selection decision for the subsequent Part B Cohorts.  I f the 
pharmacokinetic exposures after the 100 mg [COMPANY_004]2838232/cobi dose look similar to 
those obtained with 100 mg [COMPANY_004]2838232/r in prior studies, the doses for Part B will be 
extended to both lower (20 mg, 50 mg) and higher (200 mg) [COMPANY_004]2838232 doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be summ arized 
by [CONTACT_428216] . The proportion of subjects with plasma HIV -1 RNA 
<400 and <50 copi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if the two populations ar e 
not the same.
Section 10.3 Quality  Control (Study Monitoring)
Rationale for Change
Minor clarifications made regarding Sponsor (to include [COMPANY_003]).  2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541344] the site prior to the start of the study  to review with the 
site staff the protocol, study  requirements, and their responsibilities to satisfy  regulatory , 
ethical, and [COMPANY_004] requirements.
Section 10.5 Study and Site Closure
Rationale for Change 
Minor clarifications made regarding Sponsor (to include [COMPANY_003]). 
Revised Text
First Bullet
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor or 
designee will conduct site closure activities with the investigat or or site staff, as 
appropriate, in accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
Section [ADDRESS_541345].  Phase 2 study  of cobicistat versus ritonavir each with once -
daily  atazanavir and fixed -dose emtricitabine.tenofovir df in the initial treatment of HI V 
infection.  AIDS .  2011; 25:1881 -1886.
Gallant JE, Koenig E, Andrade -Villaneuva J, Chetchotisakd P, deJesus E, Antunes F, 
Arastéh K, et al. Moy le G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, 
Scwarcberg J, Rhee MS, Cheng AK.   Cobicistat versus r itonavir as a pharmacoenhancer 
of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment -naïve HIV 
type 1-infected patients:  week [ADDRESS_541346]. Dis.  2013; 208- :32- 39.
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteel e T, Hillewaert V, et 
al.Petrovic R, Hoetelmans RMW.  Pharmacokinetics of darunavir in fixed -dose 
combination with cobicistat compared with coadministration of darunavir and ritonavir as 
single agents in health y volunteers.  J. Clin. Pharmacol.   2009; 54: 949-957.
Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, et al. Safety  and 
efficacy  study  of bevirimat (BVM) in heavil y treatment experienced HIV+ patients 
identifies the target phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Mart in DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL , et al. Safety  and 
pharmacokinetics of bevirimat (PA -457), a novel inhibitor of human immunodeficiency   2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
128virus maturation, in healthy  volunteers. Antimicrobial Agents and Chemotherapy. 
2007(b);Sep:[ADDRESS_541347] Develop ment
QD Once daily
RIBA Recombinant Immuno- Blot Assay
t1/2t½ Terminal elimination half- life 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
[ZIP_CODE].10.2. AMENDMENT 2
Protocol Amendment 2 (24- MAY -2017) from the Protocol Amendment 1 (26 -Apr-2017)
Where the A mendment A pplies
This amendment applies to all subjects wh o will participate in this study  in all countries.
List of Specific Changes: (bold indicates text added and strikethrough indicates text 
removed)
Summary  of Protocol A mendment Changes with Rationale
Amendment [ADDRESS_541348] population to allow treatment 
experienced HIV -1 infected patients, in addition to treatment naive patients. Patients with 
a treatment history  of a prior maturation inhibitor will still be ineligible. Slight 
modifications were made to include flexible languag e for enrolment into Part B to allow 
prioritization of one dose cohort or to open randomization into Part B cohorts in a parallel 
fashion. Also the upper limit of the BMI inclusion criteria was increased from 31 to 35 
kg/m2. 
Minor clarifications, re -numbering of sections and correction of ty pographical errors 
were also made throughout this amendment.
Author (s)
Rationale for change A minor correction was made to this section.
A minor correction was made to this section.
Revise d Text
                PCPS, [COMPANY_004], Collegeville Upper Providence , PA, US
Title Page
Rationale for change
The protocol title was updated to reflect the new subject population, which is no longer 
limited to treatment naive patients.
Revised Te xt
A Phase 2a, Multicenter, Randomized, Adaptive, Open -label,  Dose Ranging Study to 
Evaluate the Antiviral Effect, Safety , Tolerability  and Pharmacokinetics of Cobicistat -
boosted [COMPANY_004]2838232 Monotherap y Over 10 Days in HI V-1 Infected Treatment- Naive
Adults 2018N360917_00
[COMPANY_003]
2015N227852_03 CONFIDENTIA L
200911
130Synopsis
Rationale
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which is now completed). The reference to a parallel enrolment design for Part 
B was also removed to allow for prioritizing enrolment into any  one dose cohort based on 
emerging data from Part A.
Revised Text
Second paragraph
Three clinical studies of [COMPANY_004]2838232 (n=53 healthy  subjects) have been completed thus 
far. One study  (Study  204953) is on- going completed at the end of [ADDRESS_541349] received [COMPANY_004]2838232 or placebo in single or 
repeated dose designs, to a maximum single dose of 250 mg or repeated dose (for 
11days) of 200 mg QD, in combination with ritonavir (RTV).
Fifth paragraph
Study  204953 is an on -going stud y and continues the investigated the safety and PK of 
[COMPANY_004]2838232 in single and repeat -dosesexploration of safet y and PK of [COMPANY_004]2838232 as 
well as the suitability  of a new, capsule formulation. Doses of up to 250 mg
[COMPANY_004]2838232/100 mg RTV (as single doses) or 200 mg [COMPANY_004]2838232/100 mg RTV (QD 
for 11 day s) were studied. As of 26 October 2016, the study  is ongoing with a cohort of 
subjects due to receive The final cohort of the study assessed unboosted [COMPANY_004]2838232 
(200mg B ID) for 11 days. The study completed at the end of 2016 and the data 
analysis is ongoing.
Seventh paragraph
The objective of Stud y 200911 is to understand the safet y, PK and HIV antiviral profile 
of [COMPANY_004]2838232/cobicistat ([COMPANY_004]2838232/cobi) when given to HIV- infected, treatment 
naive, otherwise health y adults. Approximately  [ADDRESS_541350] paragraph
Approximately  34 HIV -1 infected treatment -naive subjects will be enrolled overall.
Second paragraph
This study  is a 10- day monotherapy , open -label, adaptive, dose ranging, repeat- dose 
study  and will be conducted as two parts with an interim (go/no- go) analy sis performed 
after Part A (Table 1). Part A, Cohort 1 will evaluate a safe and well -tolerated dose level 
of [COMPANY_004]2838232 that has been tested (with RTV) in prior Phase I studies and th at targets 
a high inhibitory  quotient (IQ) value. Following the completion of an interim analy sis of 
those data and according to criteria defined later in the protocol, further cohorts of 8 
subjects will then be studied in Part B in a parallel design in two or more cohorts 
(depending upon the data obtained in Part A).
Table 1 Study  Design for 200911
Part A: [COMPANY_004]2838232/cobi 
Once Daily x10 days1Part B: [COMPANY_004]2838232/cobi 
Once Daily x10 days1,2
Cohort
N232 Dose
(mg)Cohort
N232 Dose 
(mg)
1 10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B , which 
are planned to run in a parallel, randomized fashion . All doses will be given with [ADDRESS_541351] to modification based upon safety, PK and antiviral activity data from Cohort 
1 (Part A). More doses /cohorts (including potential removal of cobi co -dosing) may be added (the maximum dose 
in Part B would likely not exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] was 
lower in HIV infected subjects than in healthy subjects at the same dose level).
Fourth paragraph
The possibility  that an additional, unboosted [COMPANY_004]2838232 monotherapy  cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from Study  204953 where 
unboosted [COMPANY_004]2838232 at a dose of 200 mg twice d aily (BID) was assessed and Study 
205820, which plans to evaluate [COMPANY_004]2838232 at a dose of 500mg once daily (QD) . 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
132Section [IP_ADDRESS] Clinical Summary  of Safety
Rationale for change
Minor clarifications were made to this section to provide clarification reg arding Study  
204953 (which is now completed).
Revised Text
Fifth paragraph
In ongoing Study  204953, there have been a small number of CV -related events of an y 
sort: There have  been n o serious adverse drug reactions, and no clinically  significant 
drug-related abnormal findings for 12 -lead ECGs, vital signs, safet y laboratory  results 
(including cardiac troponin I ), or telemetry .  The following cardiovascular AEs were 
observed during the course of the stud y but were not considered to be caused by 
[CONTACT_23983]2838232 ex posure
Section [IP_ADDRESS] Study 204953 (completed); Pharmacokinetic Data
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which is now completed and anal ysis is ongoing).
Revised Text
Second paragraph
In addition, it evaluated the relative bioavailability of a single fasted dose of micronized 
API [INVESTIGATOR_428149] -in-bottle for oral 
suspension with RTV and the effect of a normal fat meal on the bioavailability  of a single 
dose of [COMPANY_004]2838232 in the capsule formulation with RTV.  I t will evaluate 
[COMPANY_004]2838232 exposure after repeated doses of unboosted [COMPANY_004]2838232 in the capsule 
formulation. Noncompartmental PK anal ysis was performed using scheduled sample 
times.  This
The study  isanaylsis of data from this study is ongoing; preliminary results 
are presented.
Section 4.[ADDRESS_541352], safet y, tolerability, and PK of [COMPANY_004]2838232/cobi monotherap y over [ADDRESS_541353] received an y ART (including prior MI) prior maturation ihibitor
therap y will not be eligible for this study. To minimize the number of subjects exposed to 
suboptimal doses, an adaptive and dose ranging design is applied in this study .
Study  Design for 200911
[COMPANY_004]2838232/cobi Once Daily for 10 days1,2
Part A Part B 
Cohort 1 Dose
(mg)Interim Analysis Cohort
N(mg)
N=10 100
2 8 200
3 8 50
4 8 20
Day 1 –Day 10: Dosing
Second paragraph
Serial, intensive blood PK samples will be collected on Day  1 (up to [ADDRESS_541354] -
morning dose) and Day  10 (up to [ADDRESS_541355]- morning dose), and limited, single blood 
PK samples pre -morning doses on Day s [ADDRESS_541356] for 10 hours [overnight] prior to the morning check in on the 
intensive PK sampling day s (Days 1 and 10).  All dosing day s will require co -
administration of treatment with a light snack/meal per cobicistat labeling guidelines. All 
doses of study  medication will be taken with 240 mL  of water.  Subjects will be required 
to stay  in the clinic on D ays 1 and 10 until all specified assessments are completed ( 8-[ADDRESS_541357] -dose). Following Day  10, subjects will be required to attend the clinic for 
follow up assessments including virological and PK blood sampling for up to 3 weeks.1 . Part A Cohort 1 safety /PK/virology  data will be evaluated at interim, prior to initiating 
other cohorts in Part B
, which are planned to run in a parallel, randomized fashion .  All 
doses will be given with [ADDRESS_541358] to modification based upon safet y, PK and antiviral activity data 
from Cohort 1 (Part A). More doses/cohorts (including potential removal of cobicistat co -
dosing) may  be added. (The maximum dose in Cohort B will likely not exceed 200 mg 
with cobicistat unless overall plasma exposure [as AUC and Cmax] is lower in HIV-
infected subjects than in healthy  subjects at the same dose level). 2018N360917_00
2015N227852_03 CONFIDENTIA L
[ADDRESS_541359] 34 subjects will be enrolled such that approximately  6-10 evaluable subjects 
complete a number of cohorts.  Additional subjects/cohorts may  beenrolled to allow for 
evaluation of additional dose levels as appropriate. 
If subjects prematurel y discontinue the study, additional replacement subjects may  be 
randomisedrandomized and assigned to the same treatment cohort at the discretion of the 
Sponso r in consultation with the I nvestigator.
Section 4.3 Design/Dose Justification
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which is now completed).
Revised Text
Last paragraph
There is no a priori intention to study  [COMPANY_004]2838232 unboosted, unless: i) following the 
preliminary  anal ysis of Part A Cohort 1, there is such pronounced antiviral activity  that it 
would seem the estimates of projected IQ are low, in which case [COMPANY_004]2838232 may be 
evaluated in a subsequent cohort unboosted, or ii) the data from ongoing and planned 
healthy volunteer trial s,Cohort 7 in Study  204953 ( planned, [COMPANY_004]2838232 200 mg BID 
unboosted ) and Study 205820 ([COMPANY_004]2838232 500mg QD unboosted )support it.
Section 4.3.3 Interim A nalysis
Rationale for change 
Minor clarifications were made to this section to allow for flexibility  around selecting 
dose cohorts for Part B based on emerging data from Part A.
Revised Text
An evaluation of [COMPANY_004]2838232 safet y, efficacy  and PK data w ill be done after Part A 
Cohort 1, if the exposure level of [COMPANY_004]2838232 is in the range of the maximum 
[COMPANY_004]2838232 exposure seen previousl y in healthy subjects and the Bay esian probability  
from Cohort 1 is less than 70%, the study  will not move forward into Part B, otherwise 
doses will be selected for evaluation in Part B. If pharmacokinetic exposure after the 100 
mg [COMPANY_004]2838232/cobi dose is in the range of values observed after 100 mg 
[COMPANY_004]2838232/r in prior studies, the doses for Part B will be extended to bot h lower  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
135(20mg and/or , 50 mg) and higher (200 mg) doses. The highest dose tested in Part B will 
be selected to result in exposures similar to those seen with 200 mg/r in Study  204953.
Section 4.4.3 Overall Benefit:Risk Conclusion
Rationale for change 
Mino r clarifications were made to this section to provide clarification regarding Study  
204953 (which is now completed).
Revised Text
To date, [ADDRESS_541360] received [COMPANY_004]2838232 in fourthree completed 
studies. One study  (204953) is ongoing ([ADDRESS_541361] completed this study  so 
far).
Section [ADDRESS_541362] population, which is no 
longer limited to treatment naive patients. Also the upper limit of the BMI inclusion 
criteria was increased from 31 to 35 k g/m2.  2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
136Revised Text
5.Confirmed HI V positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. No current and no prior ART. (A previous course of pre -
or post -exposure proph ylaxis is allowed provided that it was completed at least [ADDRESS_541363] dose of study  drug).
5 .6.Antiretroviral treatment naive or ART -experienced (maturation inhibitor 
naive) . No current ART (last dose completed at least [ADDRESS_541364] dose 
of study drug). (A previous course of pre -or post -exposure proph ylaxis is allowed 
provided that it was completed at least [ADDRESS_541365] dose of study  drug ).
6 .7. Bod y weight 50kg (110 lbs.) for men and 45kg (99 lbs) for women and bod y 
mass index (BMI) within the range 18 .5-351.0 kg/m2(inclusive)
Section 6.2 Treatment A ssignment
Rationale for change
A minor clarification was made to this section.
Revised Text
Subjects will be assigned to treatment (active) groups in accordance with the 
randomization schedule generated by [CONTACT_278814], prior to the start of the study , 
using validated internal software.
Section 6.4 Blinding
Rationale for change 
Minor clarifications were made to this section.
Revised Text
This will be an open -label study . Treatment allocation and GS K2838232 dose levels in 
Part B will be determined after the analysis of Part A data. randomised (to 
[COMPANY_004]2838232 dose level). 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
[ZIP_CODE].10.3. AMENDMENT 3
Protocol Amendment 3 ( 15-JUN- 2017) from the Protocol Amendment 2 (24 -MAY - 2017)
Where the A mendment A pplies
This amendme nt applies to all subjects who will participate in this study in all countries.
List of Specific Changes: (bold indicates text added and strikethrough indicates text 
removed)
Summary  of Protocol A mendment Changes with Rationale
Amendment 3 includes modific ation to the protocol I nclusion Criteria (#6) to ensure 
exclusion of treatment -experienced patients with limited remaining treatment options.
Section 5.1Inclusion Criteria
Rationale for change
Additional language was added to the protocol Inclusion Crit eria (#6) to clarify that with 
the patient population being expanded to include treatment -experienced patients for 
enrolment, patients with limited or no treatment options would remain ineligible. 
Revised Text
6. Antiretroviral treatment naive or ART- expe rienced (maturation inhibitor naive). No 
current ART (last dose completed at least [ADDRESS_541366] dose of study  drug). A 
previous course of pre -or post -exposure proph ylaxis is allowed provided that it was 
completed at least [ADDRESS_541367] dose of study  drug. NOTE: Subjects with 
limited therapeutic options, including but not limited to those who have failed ≥[ADDRESS_541368] documented resistance to >[ADDRESS_541369] interrupted their treatment due to resista nce, will not be 
eligible.
Section 7 Time and Events Table
Rationale for change
A modification was made to this section to clarify the day s where site calls to I VRS 
would
bemade (Screen, Randomization, Early  Termination and/or unscheduled visits 
only). 
Revised Text 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
138Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/exclusion X X
Demography including height, weight and 
BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therapy X
12-lead ECG3 X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and hepatitis 
C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fastin g lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X X14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X
Telephone call to IVRS13 X XX X X X X X X X X X X XX 
 
 2018N360917_00
2015N227852_03 CONFIDENTIA L
200911
139Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X 
 
 2018N360917_00
2015N227852_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200911
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A Phase 2a, Multicenter, Randomized, Adaptive, Open -label,  
Dose Ranging Study to Evaluate the Antiviral Effect, Safet y, 
Tolerability  and Pharmacokinetics of Cobicistat -boosted 
[COMPANY_004]2838232 Monotherapy  Over 10 Day s in HIV -1 Infected 
Adults
Compound Number: [COMPANY_004]2838232
Development Phase:IIA
Effective Date: 24-MAY - 2017
Protocol Amendment Number:  02
Author (s):
           PTS, Ware, [LOCATION_006]
           GCSP, Stockley  Park, [LOCATION_006]
           Infectious Diseases, Clinical, Upper Providence, PA, US
           Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
           HIV DPU, Clinical RTP, NC, US
           Virology , HIV DPU, RTP, NC, US
           CPMS, [COMPANY_004], RTP, NC, US
           HIV DPU, RTP, NC, US
          Clinical Pharm acology , ViiV Healthcare, RTP, NC, US
           PCPS, [COMPANY_004], Upper Providence, PA, US
          PCPS, [COMPANY_004], Upper Providence , PA, US
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2018N360917_00
[COMPANY_003]
2015N227852_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200911
2Revision Chronology
GlaxoSmithKline 
Document NumberDate Version
2015N227852_00 2016 -NOV-09 Original
2015N227852_01 2017 -APR -26 Amendment No. 1
Amendment 1 includes minor updates to I nclusion -Exclusion (I E) criteria, including 
clarification on use of pre- or post -exposure prophy laxis, and removal of exclusionary  
requirements related to concomitant medications and tobacco and alcohol use during the 
study . Guidance around relevant habits i s included in the L ifesty le section of the protocol 
and adjustments were made to reduce restrictions on these requirements. Modifications 
were also made to the pharmacokinetics sampling, allowing for the 12 h PK collection 
timepoint on Day  1 and 10 to be optional. Minor alterations were made regarding the 
order of screening procedures, including the Holter monitoring requirements. 
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. Furthermore, the serial ECG collection (up to 6h post -dose) was removed on 
Day 5. Finall y, the post -study  care guidance was updated to include an option for subjects 
to receive reimbursement for marketed ART for a limited period after completion of 
study  treatment and follow up. Minor cl arifications, reformatting of tables, re -numbering 
of sections and correction of ty pographical errors were also made throughout this 
amendment.
2015N227852_02 [ADDRESS_541370] population t oallow treatment 
experienced HIV -1 infected patients, in addition to treatment naive patients. Patients with 
a treatment history  of a prior maturation inhibitor will still be ineligible. Slight 
modifications were made to include flexible lan
guage for enrolment into Part B to allow 
prioritization of one dose cohort or to open randomization into Part B cohorts in a parallel 
fashion. Also the upper limit of the BMI inclusion criteria was increased from 31to 35
kg/m2. 2018N360917_00
 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_02 CONFIDENTIA L
200911
4MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_428260]-hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor/SAE 
contact 
[CONTACT_428195] 
([COMPANY_003]) Safety 
Hotline [COMPANY_003], [ADDRESS_541371] 
Collegeville, PA 
[ZIP_CODE]
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_541372]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_428232].   
Regulatory  Agency  Identify ing Number(s):  116,[ADDRESS_541373] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator S ignature Date 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 200911 ........................................................ 9
2.INTRODUCTION .................................................................................................... 13
2.1. Study Rationale .......................................................................................... 13
2.2. Brief Background ........................................................................................ 13
2.2.1. Preclinical Summary .................................................................... 14
2.2.2. Clinical Summary of Safety and Pharmacokinetics ...................... 19
[IP_ADDRESS]. Clinica l Summary of Safety ......................................... 19
[IP_ADDRESS]. Study 204953 (completed); Pharmacokinetic 
Data ........................................................................... 20
[IP_ADDRESS]. Overall Summary/Conclusions of PK data .................. 23
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 25
4.STUDY DESIGN .................................................................................................... 26
4.1. Overall Design ............................................................................................ 26
4.2. Type and Number of Subjects ..................................................................... 27
4.3. Design/Dose Justification ............................................................................ 28
4.3.1. [COMPANY_004]2838232 with Ritonavir ......................................................... 28
4.3.2. [COMPANY_004]2838232 with Cobicistat ....................................................... 29
4.3.3. Interim Analysis ........................................................................... 29
4.4. Benefit:Risk Assessment ............................................................................ 30
4.4.1. Risk Assessment ......................................................................... 31
4.4.2. Benefit Assessment ..................................................................... 33
4.4.3. Overall Benefit:Risk Conclusion ................................................... [ADDRESS_541374] AWAL CRITERIA ............. 33
5.1. Inclusion Criteria ......................................................................................... 34
5.2. Exclusion Criteria ........................................................................................ 36
5.3. Screening/Baseline/Run -in Failures ............................................................ 38
5.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 39
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 39
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_541375] and Other Study Treatment .................................... 41
6.2. Treatment Assignment ................................................................................ 42
6.3. Planned Dose Adjustments ......................................................................... 42
6.4. Blinding ....................................................................................................... 42
6.5. Preparation/Handling/Storage/Accountability .............................................. 42
6.6. Compliance with Study Treatment Administration ....................................... 43
6.7. Treatment of Study Treatment Overdose .................................................... 43
6.8. Treatment after the End of the Study .......................................................... 44
6.9. Lifes tyle and/or Dietary Restrictions ............................................................ 44
6.9.1. Meals and Dietary Restrictions .................................................... 44 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
76.9.2. Alcohol, Caffeine and Exercise .................................................... 44
6.10. Contraception ............................................................................................. 44
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 45
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 45
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 45
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 45
7.1. Time and Events Table ............................................................................... 47
7.2. Visit W indows ............................................................................................. 49
7.3. Screening and Critical Baseline Assessments ............................................ 49
7.3.1. Holter Monitoring (Screening criteria) ........................................... 49
7.4. Efficacy ....................................................................................................... 50
7.4.1. HIV-1 RNA Sampling ................................................................... 50
7.4.2. Lymphocyte Subsets by [CONTACT_46110] ..................................... 50
7.5. Safety ......................................................................................................... 50
7.5.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 50
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 51
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 51
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 51
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 52
[IP_ADDRESS]. Disease -Related Even ts and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 52
[IP_ADDRESS]. Regulatory Reporting Requirements for SAE .............. 53
7.5.2. Pregnancy ................................................................................... 53
7.5.3. Physical Exams ........................................................................... 53
7.5.4. Vital Signs .................................................................................... 54
7.5.5. Electrocardiogram (EGC) ............................................................. 54
7.5.6. Clinical Safety Laboratory Assessments ...................................... 54
7.6. Pharmacokinetics ....................................................................................... 56
7.6.1. Blood Sample Collection .............................................................. 56
7.6.2. Sample Analysis .......................................................................... 56
7.7. Biomarker(s)/Pharmacodynamic Markers ................................................... 56
7.7.1. Viral Genotypi[INVESTIGATOR_103623] ............................................... 56
7.8. Genetics ..................................................................................................... 56
7.9. Value Evidence and Outcomes ................................................................... 57
8.DATA MANAGEMENT ........................................................................................... 57
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .57
9.1. Hypotheses ................................................................................................ .57
9.2. Sample Size Considerations ....................................................................... 57
9.2.1. Sample Size Assumptions ........................................................... 57
9.2.2. Sample Size Sensitivity ................................................................ 58
9.2.3. Sample Size Re- estimation or Adjustment ................................... 59
9.3. Data Analysis Considerations ..................................................................... 59
9.3.1. Analysis Populations .................................................................... 59
9.3.2. Interim Analysis ........................................................................... 59
9.4. Key Elements of Analysis Plan ................................................................... 60
9.4.1. Primary Analyses ......................................................................... 60
[IP_ADDRESS]. Safety Analyses .......................................................... 60
[IP_ADDRESS]. Efficacy Analyses ....................................................... 60 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
[IP_ADDRESS]. Pharmacokinetic Analyses .......................................... 61
9.4.2. Secondary Analyses .................................................................... 61
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic Analyses ........... 61
[IP_ADDRESS]. Viral Genotypi[INVESTIGATOR_428150] .............. 62
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 62
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 62
10.2. Regulatory and Ethical Considerat ions, Including the Informed 
Consent Process ........................................................................................ 62
10.3. Quality Control (Study Monitoring) .............................................................. 63
10.4. Quality Assurance ....................................................................................... 63
10.5. Study and Site Closure ............................................................................... 63
10.6. Records Retention ...................................................................................... 64
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 65
10.8. Revie w Committees .................................................................................... 65
11.REFERENCES ....................................................................................................... 66
12.APPENDICES ........................................................................................................ 68
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 68
12.2. Appendix 2: Liver Safety Req uired Actions and Follow up 
Assessments .............................................................................................. 71
12.3. Appendix 3: Liver Safety –Study Treatment Restart or Rechallenge 
Guidelines ................................................................................................... 74
12.4. Appendix 4: Genetic Research ................................................................... 75
12.5. Appendix 5: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 78
12.5.1. Definition of Adverse Events ........................................................ 78
12.5.2. Definition of Serious Advers e Events ........................................... 79
12.5.3. Definition of Cardiovascular Events ............................................. 81
12.5.4. Recording of AEs and SAEs ........................................................ 81
12.5.5. Evaluating AEs and SAEs ............................................................ 82
12.5. 6.Reporting of SAEs to [COMPANY_004] ........................................................... 83
12.6. Appendix 6: Collection of Pregnancy Information ........................................ 85
12.7. Appendix 7: Country Specific Requirements ............................................... 86
12.8. Appendix 8: Division Of AIDS Table For Grading The Severity Of 
Adult And Pediatric Adverse Events Version 1.0, December 2004; 
Clarification August 2009 ............................................................................ 87
12.9. Appendix 9: Toxicity Management ............................................................ 106
12.10. Appendix 10: Protocol Amendment Changes ............................................ 111
12.10.1. AMENDMENT 1 ......................................................................... 111
12.10.2. AMENDMENT 2 ......................................................................... 129 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
91. PROTOCOL SYNOPSIS FOR STUDY 200911
Rationale
[COMPANY_004]2838232 is a novel human immunodefi ciency  virus (HIV -1) maturation inhibitor 
that is being developed for the treatment of HIV -1 in combination with other 
antiretrovirals.
Three clinical studies of [COMPANY_004]2838232 (n=53 healthy  subjects) have been completed thus 
far. One study  (Study  204953) completed at the end of [ADDRESS_541376] received [COMPANY_004]2838232 or placebo in single or repeated 
dose designs, to a maximum single dose of 250 mg or repeated dose (for 11 days) of 
200mg QD, in combination with ritonavir (RTV). 
Study  HMI116787 (completed November 2013) was the First Time in Human study  of 
[COMPANY_004]2838232 and assessed safet y and tolerability  of escalating doses (5 mg to 100 mg), 
food effect, and the impact of stead y-state ritonavir on [COMPANY_004]2838232 pharmacoki netics 
(PK). Following successful completion of 3- month toxicology  studies in rat and dog in 
2014, clinical studies 200912 and 200207 were initiated. These were double- blind, 
placebo
-controlled, single (Study  200912) and repeat -dose (Study  200207) escalati on 
studies to investigate the safet y, tolerabilit y, and PK of [COMPANY_004]2838232 alone and when co -
administered with ritonavir 100 mg once dail y (QD) for 8 -11 day s. Further assessment of 
an alternative formulation was also an objective in Study  200912.
Both studie s were prematurely  terminated/completed in March/April 2015 because of 
concerns over cardiovascular (CV) toxicity , in particular a clinical CV serious adverse 
event (SAE) whereb y the Food and Drug Administrating (FDA) imposed a clinical hold. 
Following sub mission of long -term (6 -month rat, 9- month dog) chronic toxicology  data 
and follow up to the clinical SAE in November 2015, the hold was released in January  
2016 and Study  204953 was initiated.
Study  204953 investigated the safet y and PK of [COMPANY_004]2838232 in single and repeat -doses
as well as the suitability  of a new, capsule formulation. Doses of up to 250 mg 
[COMPANY_004]2838232/100 mg RTV (as single doses) or 200 mg [COMPANY_004]2838232/100 mg RTV (QD 
for 11 day s) were studied. The final cohort of the study  assessed unboosted G SK2838232 
(200mg BID) for [ADDRESS_541377] shown [COMPANY_004]2838232 with or without RTV to be well tolerated and, 
together with daily  RTV dosing (“boosting”), demonstrate a PK profile suitable for 
progression to HIV patients in this Phase IIa proof of concept 10 -day, monotherapy  study  
design.  However, potential concerns over protease resistance necessitate a change to a 
pharmacoenhancer without antiviral effects in this study  of [COMPANY_004]2 838232 monotherapy . 
Therefore, for Study  200911, cobicistat (Ty bost,150 mg QD) will be substituted for RTV.  
The objective of Stud y 200911 is to understand the safet y, PK and HIV antiviral profile 
of [COMPANY_004]2838232/cobicistat ([COMPANY_004]2838232/cobi) when given to H IV-infected, treatment 
naive, otherwise health y adults. Approximately  10 HIV -1 infected subjects will be 
enrolled into Part A. If warranted b y an interim safety, virology, and PK data anal ysis,  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
10approximately  8 subjects will be enrolled in each of between t wo and four Cohorts in Part 
B.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected 
patients during 10 days of 
monotherapy.Change from baseline (Day 1) in plasma HIV -1 
RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered 
as monotherapy over 10 days. Safety and tolerability parameters, including 
adverse event, concurrent medication, clinical 
laboratory, electrocardiogram (ECG) and vital 
signs assessments.
To char acterize the pharmacokinetics 
of [COMPANY_004]2838232 in HIV -1 infected 
patients following [COMPANY_004]2838232/cobi 
dosing for 10 days. [COMPANY_004]2838232 PK parameters following dose 
administration, as follows:
Day 1 : area under the plasma concentration time 
curve AUC(0 -24), maximu m observed 
concentration (Cmax), time to maximum 
observed concentration (tmax), concentration at 
[ADDRESS_541378] dose (C24), absorption lag time 
(tlag); 
Following last repeat administration on Day 10:  
AUC(0 -), pre -dose concentration (C0), 
concentration a t end of dosing interval (C ), 
Cmax, tmax, t½, and apparent oral clearance 
(CL/F), if data permit
Secondary
 To explore the relationship between 
[COMPANY_004]2838232 exposure and change 
in plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 AUC(0- ), 
Cmax, C with Day 11 HIV -1 RNA change from 
baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when 
administered over 10 days in HIV -1 
infected adults Change from baseline in CD4+ cell count to Day 
11
 To explore the relationship between 
[COMPANY_004]2838232 exposure and s afety or 
immunologic parameters, if 
appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax, C with Day 11 change from 
baseline in CD4+ cell count 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
11Objectives Endpoints
 To assess the development of viral 
resistance (genotypic and 
phenotypic) over 10 days and 
correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, if 
appropriate
 To estimate [COMPANY_004]2838232 
accumulation and to assess 
attainment of steady state following 
administration of [COMPANY_004]2838232/cobi 
for 10 days in HIV infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): Day 
10 AUC(0 -), Cmax, and C compared to Day 1 
AUC(0 -24), Cmax, and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on Days 2 
through 11 
 To examine dose proportionality of 
[COMPANY_004]283 8232 pharmacokinetic 
parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days
in HIV infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and Day 10 
AUC(0 -), Cmax, and C at different dose levels 
for the assessment of dose proportionality
Note: Other explor atory objectives and endpoints will be specified in the RAP
Design, Treatment A rms and Duration
Approximately  34 HIV -1 infected subjects will be enrolled overall. 
This study  is a 10- day monotherapy , open -label, adaptive, dose ranging, repeat- dose 
study  and will be conducted as two parts with an interim (go/no- go) analy sis performed 
after Part A ( Table 1 ). Part A, Cohort 1 will evaluate a safe and well- tolerated dose level 
of [COMPANY_004]2838232 that has been tested (with R TV) in prior Phase I studies and that targets 
a high inhibitory  quotient (IQ) value. Following the completion of an interim analy sis of 
those data and according to criteria defined later in the protocol, further cohorts of 8 
subjects will then be studied in Part B in two or more cohorts (depending upon the data 
obtained in Part A). 
The totality  of this data will provide a full dose -response of [COMPANY_004]2838232 over a wide 
dose range to explore the safet y and PK/pharmacodynamics (PD) relationship of 
[COMPANY_004]2838232 in HIV-1 infected subjects and facilitate choice of doses for Phase IIb 
studies. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
12Table 1 Study  Design for 200911
Part A: [COMPANY_004]2838232/cobi 
Once Daily x 10 days1Part B: [COMPANY_004]2838232/cobi 
Once Daily x 10 days1,2
Cohort
N232 Dose
(mg)Cohort
N232 Dose 
(mg)
1 10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B. All 
doses will be given with [ADDRESS_541379] to modification based upon safety, PK and antiviral activity data from Cohort 1 
(Part A). More doses/cohorts (including p otential removal of cobi co -dosing) may be added (the maximum dose in 
Part B would likely not exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] was 
lower in HIV infected subjects than in healthy subjects at the same dose level) .
The possibility  that an additional, unboosted [COMPANY_004]2838232 monotherapy  cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from Study  204953 where 
unboosted [COMPANY_004]2838232 at a dose of 200 mg twice daily  (BID) was assessed and Study  
205820, which plans to evaluate [COMPANY_004]2838232 at a dose of 500mg once daily  (QD) . 
Subjects in both parts will have a screening visit within [ADDRESS_541380] dose. Maximum duration of study  participation 
will be approximately  6 weeks.
HIV Drug Resistance: Following cessation of [COMPANY_004]2838232/cobi dosing for 10 day s, 
there will be prolonged exposure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t½ (i.e., in the “tail” of the PK profile). Ho wever, based on in vitro 
resistance passage data with [COMPANY_004]2838232 [and unlike with many  other ARV therapi[INVESTIGATOR_014]], 
there appears to be a limited likelihood of developi[INVESTIGATOR_428081]
-infected subjects due to its virologic profile. 
Analysis
The primary  objectives of this study  are to investigate the safet y, tolerability, PK and 
antiviral activity  of 10 day s repeated doses of [COMPANY_004]2838232/cobi in HIV-1 infected 
otherwise healthy  subjects. Descriptive summaries will be provided for safety , PK, and 
HIV viral load data. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
132. INTRODUCTION
[COMPANY_004]2838232 is a novel human immunodeficiency virus (HIV) -1 maturation inhibitor 
(MI) that is being developed for the treatment of HIV -1 infection in combination with 
other antiretrovirals (ART).
2.1. Stud y Rationale
This ‘proof of concept (PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity , pharmacokinetics (PK), the relationship between PK and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg once dail y (QD) cobicistat 
([COMPANY_004]283232/cobi), administered across a range of doses over [ADDRESS_541381] doses for further studies in Phase IIb .
2.2. Brief Background
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has demonstrated significant improvement in acquired 
immunodeficiency  syndrome (AIDS) -related morbidity and mortality  over the last 10-15 
years. Emerging multi -class drug resistant viral strains and long- term toxicities warrant 
development of new classes of antiretroviral therapi[INVESTIGATOR_428082] -
1 viral life cy cle [Wainburg , 2010]. The inhibition of maturation of HIV- [ADDRESS_541382] from viral protease RT or integrase [Saxena , 2012; 
Qian , 2009]. HI V maturation is the final cleavage step of the capsidSp1 (transcription 
factor) pol yprotein that generates the functional capsid p24 protein. This mechanism of 
action results in accumulation of the uncleaved p25 protein with subsequent improper 
assembly  of the HIV core , resulting in a non
-infectious virion. Gel -based mechanism of 
action studies suggest that compound [COMPANY_004]2838232 acts as a maturation inhibitor. 
Western Blot anal ysis shows inhibition of capsid -Sp1 cleavage and accumulation of p25 
in the presence of [COMPANY_004]2838232.
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [ Martin, 2007a; Martin, 2007b; Martin, 2008; NORVIR , 2013]). 
BVM reached Phase II studies in HIV patients; however, onl y modest reductions in 
plasma HIV -1 ribonucleic acid (RNA) concentrations were observed in Phase IIa 
monotherap y studies [ Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential) antiviral activity  [Wainburg , 2010] led to termination of BVM de velopment. 
The average decrease from baseline to Day  14 plasma HIV -1 ribonucleic acid (RNA) was 
0.54 and 0.70 log10 copi[INVESTIGATOR_014]/mL  for 200 mg and 300 mg twice daily  regimens ( Table 2); 
all subjects achieved plasma BVM c oncentrations above the in vitro EC90. Responders, 
classified based on 5 polymorphisms in HIV -1 gag (at positions 369, 370, and 371), 
achieved an average 1.15 log10 copi[INVESTIGATOR_014]/mL reduction in plasma HIV -1 RNA, while an 
average 0.17 log10 copi[INVESTIGATOR_014]/mL  reduction wa s achieved for non -responders. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
14Table 2 Summary  of Bevirimat A ntiviral Response and PK in a 14 -day 
Monotherapy  Study  in HIV -infected A dults
BVM dosage 
regimenMean (SD) viral load 
change from 
baseline to Day 142IQ Plasma BVM 
1Cmin (g/mL)Plasma BVM 
1Cmax 
(g/mL)Plasma BVM 
1AUC(0 -) 
(g.h/mL)
200mg BID
(N=14)-0.54 (0.64) 1.70 46
(41, 51)58
(53, 64)632
(571, 699)
300mg BID
(N=18)-0.70 (0.77) 2.67 72
(65, 80)91
(84, 99)973
(890, 1064)
1. Cmin, Cmax, and AUC reported as geometr ic mean (95% CI).
2. IQ=geometric mean Cmin/in vitro EC90; reported EC90=27 g/mL; all subjects achieved IQ 1.
        AUC(0 -) = Area under the concentration -time curve over the dosing interval; BVM = Bevirimat; CI = Confidence 
interval; Cmax = Maximum pla sma concentration; Cmin = Minimum plasma concentration; EC90 = 50% protection 
against resistant mutant HIV infection; IQ = Inhibitory quotient; SD = Standard deviation.
Early clinical data for BMS955176, a second generation maturation inhibitor, have bee n 
recentl y presented [ Nowicka -Sans , 2015]. In a 10- day monotherapy  trial in HIV - infected 
patients, plasma HIV -[ADDRESS_541383] of 
inhibiting this viral target.
Although BMS955176 is currentl y in Phase II studies in HIV - infected patients, there are 
no maturation inhibitors approved for the treatment of HIV infection.  The uncertainties 
of earl y drug development and continuing need for novel ART, especially for heavil y 
treated/experi enced HIV -infected persons, support continued compound development. 
[COMPANY_004]2838232’s low nanomolar in vitro potency  against multiple HI V-1 gag 
polymorphisms and broader spectrum across multiple HIV -1 subt ypes indicates it has 
utility  in this setting.
2.2.1. Preclinic al Summary
Nonclinical pharmacology
Virology
[COMPANY_004]2838232, in vitro, is an inhibitor of HIV maturation by  [CONTACT_428197] p25 to p24. [COMPANY_004]2838232 is a potent antiviral agent with a 
mean 50% maximal inhibitory  concentr ation (50% maximal inhibitory  concentration 
[IC50]) value of 1.6 nM (range: 0.8 to 4.3 nM) when tested in a panel of 26 HIV -1 
isolates with various polymorphic gag genot ypes in peripheral blood mononuclear cells 
(PBMCs), suggesting that [COMPANY_004]2838232 can inhi bit a broad spectrum of HIV isolates. In 
another PBMC assay , [COMPANY_004]2838232 showed potent antiviral activity  in 59 of 60 isolates 
with IC50 values ranging from 0.22 to 5.1 nM. [COMPANY_004]2838232 also inhibited HIV- 1 strains 
containing the consensus Sp1 QVT region or t he V370A poly morphism in MT4 cells
(IC50 = 0.73 to 0.81 nM).  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
15In an MT2 cell -based assay  utilizing recombinant viruses harboring gag and protease 
from subjects before and after a protease inhibitor (PI) based regimen, [COMPANY_004]2838232 
inhibited 12 of 15 viruses with a mean IC50 value of 1.7 nM (range = 0.4 to 3 nM). The 
remaining 3 viruses were not inhibited by  [CONTACT_23983]2838232 up to the top concentrations 
tested at 400 nM. There was no correlation of PI [INVESTIGATOR_428083]2838232. [COMPANY_004]2838232 resistance mutations were selected for b y serial passage of 
virus in a SupT1 cell- based assay  with increasing concentrations of [COMPANY_004]2838232. I n the 
lab strain NL4- 3 and gag/protease recombinant viruses, the resistance mutation A364V 
arose and resistance confirmed b y site -directed mutagenesis. This resistance mutation 
maintains susceptibility  to other classes of anti -retrovirals including PIs and non-
nucleoside RT inhibitors.
[COMPANY_004]2838232 was tested in vitro in combination with two marketed PI s, atazanavir and 
darunavi
r. Using a dose -wise additivity  model, [COMPANY_004]2838232A showed additive anti -viral 
activity with both PI s.
Secondary  Pharmacology
In a secondary  pharmacology  study , [COMPANY_004]2838232 was tested against a panel of 
receptors, ion channels and transporters and demonstrated no significant effect (IC50 of 
1M). It is important to note that the selectivity for antiviral activity  of [COMPANY_004]2828232 
compared to all tested off -target activities was >100 -fold, and the potential for organ 
toxicity  was characterized in the nonclinica l toxicology  studies (see below).
In safet y pharmacology studies in male rats, there were no hemod ynamic changes or 
neurobehavioral effects following single oral doses up to 300 mg/kg. A single oral dose 
of [COMPANY_004]2838232 at 30 mg/kg or 300 mg/kg produced reve rsible increases in respi[INVESTIGATOR_428084] (32% and 36%, respectively ) and derived minute volume (17% and 26%, 
respectivel y) at 6hours after dosing. These doses did not produce any  effect on 
respi[INVESTIGATOR_2842], airway  resistance or bod y temperature. There were no respi[INVESTIGATOR_428085] 5 mg/kg (mean maximum plasma concentration [C max] 0.12 g/mL ; AUC 0-24
1.0g.h/mL  based on Day  1 of the 4 -week repeat dose study ). These findings were not 
considered to suggest a safet y concern in humans.
[COMPANY_004]2838232 at the maximum feasible concentration, limited by  [CONTACT_16758] , of 4.09 M 
(3.31 g/mL) caused no inhibition of human ether
-a-gogo related gene (hERG) tail 
current in Human Embryonic Kidney 293 cells stably  transfected with hERG cDNA, 
indicating a low pro bability  for interaction at the hERG channel.
In conscious telemetered male dogs (n=4), a single oral dose of [COMPANY_004]2838232 at 
60mg/kg (C max0.59g/mL; AUC 0-248.7g.h/mL based on Day 1 exposure data from 
the 4- week oral repeat dose toxicity  study ) was ass ociated with one epi[INVESTIGATOR_428086]-sustained ventricular tachy cardia in one dog lasting ~1.2 seconds. There were no 
effects on arterial pressures, heart rate, or 
electrocardiogram (ECG) interval durations. An 
investigative safet y pharmacology cardiovascular s tudy was conducted in telemetered 
dogs given 60 mg/kg/day for 4 weeks with serial monitoring by  [CONTACT_51541] , 
cardiac biomarkers, qualitative and quantitative electrocardiology , microscopy , and 
transmission electron microscop y (TEM) of the heart.  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
16Ther e were no changes in echocardiograph y endpoints, ECG intervals, ECG waveforms, 
arterial pressures, heart rates, serum cTpn I, N-terminal prohormone of brain natriuretic 
peptide (NTproBNP), or in heart tissue as assessed by  [CONTACT_428198]. With routine microscopy , 
one treated dog had a single focus of degeneration/necrosis of the tunica media 
(moderate) in an extramural artery  and another treated dog had localised, mixed -cell 
inflammation (mild) along the epi[INVESTIGATOR_428087]. Both changes have 
been reporte d in normal beagles and were considered of uncertain relationship to 
treatment in the absence of changes in an y other structural or functional cardiovascular 
endpoints. The 28 -day exposures were similar to the previous 4- week toxicity  study  in 
dogs: the C maxrange at 60 mg/kg/day  in this investigative safet y pharmacology stud y was 
0.542 to 2.00 g/mL and range of AUC 0-24was 6.04 to 35.7 g.h/mL. In subsequent 
repeat -dose studies in dogs treated for up to 9 months with up to 70 mg/kg/day , no 
changes were ev ident in cardiac biomarkers (including cTpnI and NTproBNP), functional 
(including ECG waveform) or structural (including microscopic evaluation) 
cardiovascular endpoints at slightly higher exposures than those achieved than in 
previous studies. The end of the 9- month study , gender averaged C maxat 70 mg/kg/day  
was 1.95 g/mL and 
AUC 0-24was 38.8 g.h/mL. These studies support an absence of 
[COMPANY_004]2838232-related functional or structural effects on the heart in preclinical testing. 
The No Observed Adverse Effect Level (NOAEL) was established at 20 mg/kg/day  (on 
the basis of mild hepatic findings) with an associated area under the curve at 24 hours 
(AUC24) of 16.2 g.hr/mL  and Cmax 0.847 g/mL.
Pharmacokinetics and product metabolism in animals
The PK of [COMPANY_004]283823
2 were investigated in the mouse, rat, and dog. The oral 
bioavailability  of [COMPANY_004]2838232 was low to moderate (~6% to 40%) depending on the 
species and formulation. Plasma and blood clearance were low and the volume of 
distribution at steady  state was high re lative to total body  water. The half -life of 
[COMPANY_004]2838232 was short in the mouse and rat, but moderate in the dog. S ystemic exposure 
of [COMPANY_004]2838232 generally increased in a less than dose-proportional manner.  In rats, 
there were no differences in sy stemic ex posure between single and repeat -dose 
administration, or between males and females.  In a 7 -day study  in dogs, systemic 
exposures were generally similar between males and females and after single and repeat 
dosing; however, in a 4- week stud y, systemic expo sures were higher in females than in 
males in the high -dose group (60 mg/kg/day ) and higher after repeat dosing than after a 
single dose. The distribution of radioactivit y in male pi[INVESTIGATOR_428088] a single 
oral administration of [14C] [COMPANY_004]2838232 at a target dose level of 20 mg/kg showed 
radioactivity  was rapi[INVESTIGATOR_428089] y distributed throughout the body with all 
tissues, except the brain and spi[INVESTIGATOR_1831]. There were no tissues that retained detectable 
levels of radioactivity  at [ADDRESS_541384] canulated rat study, 30% of the 
administered dose was excreted in the bile as an acy lglucuronide. In the same study , 
unchanged drug and metabolites were eliminated primarily  in the bile and feces, while a 
mean of <1% of the dose was e liminated in urine.
In vitro, [COMPANY_004]2838232 is highl y protein bound (>99.9%) and has low passive 
permeability . In vivo evidence suggests active uptake of [COMPANY_004]2838232 by  [CONTACT_428199].  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
17After single oral doses of 5, 100, or 300 mg/kg, the averag e liver to plasma ratio was 51, 
17, and 10, respectivel y. After 7 days of dosing at 30, 100, or 300 mg/kg/day , liver to 
blood ratios ranged from 10 to 16.
In the 13 -week repeat dose studies in dogs given 35 mg/kg BID (70 mg/kg/day ), heart 
tissue collected at necropsy  had [COMPANY_004]2838232 concentrations 2.[ADDRESS_541385] -dose plasma concentrations, similar to the previous 4 -week CV 
investigative findings.  In the 13- week repeat dose studies in rats given 300mg/kg/day , 
heart tissue collec ted at necrops y had[COMPANY_004]2838232 concentrations approximately  [ADDRESS_541386] -dose plasma concentrations, similar to the previous 7- day 
findings.  Overall [COMPANY_004]2838232 did not appear to be highl y concentrated in heart tissue 
after repeat d osing and suggests that accumulation upon chronic dosing is unlikely .
Routes of metabolism identified in liver microsomal incubations and rat, dog, and human 
hepatocy tes were N
-dealky lation, oxidation, oxidative deamination, and glucuronidation, 
alone or i n combination, with no human- specific metabolites detected.  N -dealk ylated 
products and glucuronidation were observed in rat plasma and the bile. In general, in 
vitro metabolite profiles of the nonclinical species and human were qualitatively  similar, 
such that all metabolites of [14C] [COMPANY_004]2838232 observed in human hepatocyte 
incubations were observed in rat and/or dog. Minor to trace levels of potential aldeh ydes 
metabolites formed as a result of N
-dealk ylation and oxidative deamination were 
observed in rat , dog and humans.  
[COMPANY_004]2838232 did not show evidence for glutathione adduct formation in rat or human 
liver microsomes.  Data from pooled human liver microsomes along with recombinant 
cytochrome P450 ( CYP) enzy mes suggest that in vitro the oxidative metabo lism of 
[COMPANY_004]2838232 was primarily  mediated b y CYP3A4.  Preliminary  in vitro investigations 
showed [COMPANY_004]2838232 did not inhibit CYP1A2, 2C9, 2C19, 2D6, 3A4 and was not a 
metabolism -dependent inhibitor of CYP3A4. No drug interaction risk was identified for 
co-administrated substrates of UGT1A1, 1A3, 1A6, 1A9, 2B7, and 2B15, OAT1, OAT3, 
OATP1B1, OATP1B3 or OCT2 at a clinical dose of 200 mg [COMPANY_004]2838232/ritonavir 
(predicted Cmax 0.32 µM). Extrapolation of the clinical risk (using FDA and EMA 
regulatory  guidance) did indicate a risk for [COMPANY_004]2838232 -mediated inhibition of 
UGT1A4 and of gut contributions of CYP3A4, P-gp, and BCRP at the same clinical 
exposure; however, the potential for clinicall y significant interactions via these 
mechanisms is predicted to be low (<2 f old change in AUC). [COMPANY_004]2838232 did show 
weak induction of CYP3A4 enzy me activity . However, based on the maximum predicted 
plasma concentrations and high protein binding, the potential for clinicall y significant 
drug interactions through CYP3A4 induction by [CONTACT_23983]2838232 appears to be low.
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure); h owever, there have been no 
preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Toxicology
[COMPANY_004]2838232 administered by  [CONTACT_428200] 6 months duration 
resulted in no adverse treatment- related effects in rats giv en up to 300 mg/kg/day  QD.  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
18In dogs given up to 70 mg/kg/day  (35 mg/kg/day  BID), adverse liver effects were noted 
at this dose in the 9- month repeat dose study .  Though isolated, low grade changes in 
heart rate and cardiac troponin I  (cTnI) had been noted in 4-week toxicity  studies in rats 
and dogs; however, there were no treatment -related structural or functional 
cardiovascular changes in studies of 3 months and greater duration as assessed by  
[CONTACT_422878]
y, ECG, microscop y, and cardiac biomarkers, indi cating an absence of 
[COMPANY_004]2838232-related functional or structural effects on the heart in preclinical testing. 
Only  non- adverse treatment -related changes were noted in the definitive 6-month rat 
study , which included occasional salivation in animals given 300mg/kg/day and minimal 
clinical pathology  changes without histologic correlates (transient clinical chemistry  
changes at 5mg/kg/day and reversible urine chemistry  changes at 300 mg/kg/day ). The 
NOAEL in this study  was considered to be 300 mg/kg/day  (mean AUC[0- t] 
21.3g.h/mL , mean Cmax 1.77 g/mL [Week 26 values for males and females 
combined]).  
As noted above, dogs given [COMPANY_004]2838232 at 70 mg/kg/day  for 9 months had minimal to 
moderate pi[INVESTIGATOR_371] (consistent with bile) with minimal to mild mixed cel l infiltration 
in the liver and isolated mild increases in alanine aminotransferase (ALT) activity .  These 
findings were considered adverse, but were reversible after the 6 -week off -dose period.  
The NOAEL for this dog study  was considered to be the mid -dose level of 20 mg/kg/day  
(mean AUC[0
-t] 16.2 g.h/mL , mean Cmax 0.847 g/mL [Week 39 values for males and 
females combined]).
Data from genotoxicity  assessments suggest that [COMPANY_004]2838232 does not present a 
genotoxic hazard to humans.
During discussions with the FDA regarding the resolution of the clinical hold, the 
Agency  recommended that the sporadic cardiovascular changes observed in the earl y (1-
month) rat GL P study  at the highest dose level (300 mg/kg/day ) should be considered 
when defining the NOAEL  and establishing a safe dose of GlaxoSmithKline ([COMPANY_004]) for 
the initiation of this study  protocol.  Accordingl y, for the initial PK studies, the reference 
dose level of 30 mg/kg/day  in the 1- month rat study  was initially  used to define the 
NOAEL and therefore th e values for fold cover at maximum projected mean exposure 
and Cmax in human subjects were lower, at >2.[ADDRESS_541387] sensitive species (i. e., 20 mg/kg/day  in the 9- month dog study  
based on liver endpoints) is currentl y used for assessing fold -
cover for projected clinical 
dosing in this study .
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure and toxicity ); however, there 
have been no preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Full details of non -clinical and clinical data may  be found in the current Investigator’s 
Brochure (IB) [[COMPANY_004] Document Number 2012N151889_03]. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
192.2.2. Clinical Summary  of Safety  and Pharmacokinetics
To date, [COMPANY_004]2838232 has been evaluated i n three completed clinical studies with or 
without ritonavir (RTV) ([COMPANY_004]2838232/r). A fourth study  (204953) completed late 2016 
and data anal ysis is ongoing. Full details of the clinical results can be found in the 
Investigator’s Brochure.
[IP_ADDRESS]. Clinical Summary  of Safety
As of November 2016 fifty -three subjects had been exposed to [COMPANY_004]2838232 in 3 
completed studies. One study  (204953) completed in late 2016 and the analy sis of results 
are ongoing (63 subjects were exposed to [COMPANY_004]2838232/r or placebo so far in this study ).  
Overall, drug -related adverse events have been few and mild, and included headache, 
dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428090] .  Similarly , treatment- emergent 
laboratory  abnormalities have also been few and mostly  grade 1.  There have been no 
discernible patterns, thus far, in terms of AEs or laboratory  abnormalities.
One subject in study  200912 discontinued treatment with RTV due to an AE.  A 47- year-
old female who developed right upper quadrant abdominal pain, nausea and flatulence 
associated with grade 4 elevations in AL T and aspartate aminotransferase, and grade 2 
elevations in total bilirubin (BIL). She was diagnosed with a common bile duct 
obstruction due to gallstones that spontaneously  resolved. The Investigator assessed this 
AE as unrelated to study treatment.
Due to sporadic CV -related safet y signals in the early animal studies (see Section 2.2.2), 
intense CV monitoring was in place for all four studies.  
One AE occurred in HMI116 [ADDRESS_541388] been a small number of CV -related events of any  sort: 
There 
have  been no serious adverse drug reactions, and no clinically  significant drug -related 
abnormal findings for 12 -lead ECGs, vital signs, safet y laboratory results (including 
cardiac troponin I), or telemetry .  The following cardiovascular AEs were observed 
during the course of the study  but were not considered to be caused b y [COMPANY_004]2838232 
exposure:
In Part 1A (Cohort 1), Period 2, a subject was withdrawn due to an AE (low 
hemoglobin) prior to [COMPANY_004]2838232 exposure Day 
-2.  A replacement subject 
was brought in, but was not dosed with [COMPANY_004]2838232 or placebo because during 
the 2- day RTV run -in, on Day  -1, the replacement subject met the stoppi[INVESTIGATOR_428091], NSVT prior to 
the first dose of [COMPANY_004]2838232 or placebo.  Because the subject was excluded 
from the study  prior to the first dose of investigational drug, the NSVT was not 
considered to be a serious and unexpected adverse drug reaction that would 
qualify  for IND safety  reporting.   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
20In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject was 
discontinued prior to the first dose of study  drug due to a series of 
cardiovascular findings (pre -ventricular contractions on telemetry ).  None of the 
findings were abnormal or aty pi[INVESTIGATOR_2855], but the investigator determined that this 
would not be a good etiology  to have in a subject about to receive 
investigational drug.  Because the event occurred prior to first dose of 
investigational drug, the finding was not considered to be due to [COMPANY_004]2838232 
exposure.  
In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject who 
had alread y been dosed on 2 previous occasions (with either [COMPANY_004]2838232 or
placebo) was dosed for 2 day s with RTV, and then on 05 May  2016 was dosed 
with either [COMPANY_004]2838232/r or placebo/r as scheduled. On the following day (06 
May 2016), the subject experienced an as ymptomatic, [ADDRESS_541389] had received placebo prior to experiencing the 
NSVT, t he event was not considered to be due to [COMPANY_004]2838232 exposure or a 
serious and unexpected suspected adverse reaction that would qualify  for IND 
safet y reporting.
In Part 2 (Cohort 6, 200mg/r), a 40 y ear old male enrolled in the study  with no 
significant medical history  experienced an as ymptomatic ventricular triplet 
(NSVT) while asleep at 5:33am on Day  8 (of 11 day s worth of dosing) 
approximately  21 hours after receiving 200 mg [COMPANY_004]2838232/r on the previous 
day at 8.25am. This event was noted by  [CONTACT_428233]. The 
[COMPANY_004] medical monitor was notified.   Because the subject was not s ymptomatic 
and this did not meet protocol -defined stoppi[INVESTIGATOR_3418], the study  was not 
unblinded at the time, and the subject was allowed to continue dosing. Dosing 
in the study  is now complete and no further events have been noted. It was the 
assessment of the site PI [INVESTIGATOR_428092] /monitoring team that a ventricular 
triplet can be seen in healthy  volunteers on continuous Holter monitoring.
Therefore neither the PI [INVESTIGATOR_428093] a serious and 
unexpected suspected adverse reaction.
[IP_ADDRESS]. Study  204953 (completed); Pharmacokinetic Data
Study  [ADDRESS_541390] of a normal fat meal on the bioavailability  of a single 
dose of [COMPANY_004]2838232 in the capsule formulation with RTV.  I t will evaluate 
[COMPANY_004]2838232 exposur e after repeated doses of unboosted [COMPANY_004]2838232 in the capsule 
formulation. Noncompartmental PK anal ysis was performed using scheduled sample 
times.  The anay lsis of data from this study  is ongoing; preliminary  results are presented.
Pharmacokinetic anal ysis was performed on [COMPANY_004]2838232 plasma concentration -time 
data using nominal time following single doses of 50, 100, and 250 mg in combination 
with RTV in Part 1A of Study  204953 ( Table 3 ).  On average, [COMPANY_004]2838232 Cm ax 
values were reached [ADDRESS_541391] dose proportionalit y was observed 
for Cmax and AUC(0- ) values with ascending single doses of [COMPANY_004]2838232 (50, 100, 
and 250 mg with 100 mg RTV).
Table 3 Summary  of Preliminary  Pharmacokinetic Parameter Values after 
Single Doses of [COMPANY_004]2838232 in Combination with 100 mg Ritonavir 
(Study  204953, Part 1A )
Dose (mg) n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)
50 8 22.7
(17%)
(17.2- 28.5)0.188
(138%)
(0-0.5)3.63
(41%)
(2.5-6.0)17.2
(43%)
(8.7-27.9)458.6
(33%)
(210.6- 662.0)
100 6 18.0
(14%)
(15.8- 22.3)0.167
(155%)
(0-0.5)6.00
(59%)
(2.5-12.0)25.2
(20%)
(17.5- 31.5)890.5
(20%)
(619.1- 1053)
250 5 17.3
(6.4%)
(15.5- 18.6)0
(-)
(0-0)5.50
(71%)
(2.0-12.0)60.7
(23%)
(40.8- 73.1)1731
(29%)
(1222- 2505)
Data are presented as mean (CV) (minimum -maximum).
Study  204953 Part 1B was an open label, 2x2+[ADDRESS_541392] on the capsule formulation in Period 3.  
The rel ative bioavailability  of the micronized powder blend in 50 mg hand- filled capsules 
compared to the micronized API  [INVESTIGATOR_428094] 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
in a randomized crossover design in [ADDRESS_541393] two periods of Part 1B of 
Study  204953. Preliminary  geometric mean AUC(0 -) and Cmax values were 
approximately  45% and 60% higher, respectivel y, after administration in the capsule 
formulation compare d to oral suspension from PiB ( Table 4). 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
22Table 4 Preliminary  Assessment of Relative Bioavailability  of Capsule 
Formulation vs. Po wder -in-Bottle Formulation of [COMPANY_004]2838232 (Study 
204953, Part 1B)
Parameter Test Reference n Ratio of Geometric 
Least Square Means90% CI of Ratio
AUC(0 -) Capsule PiB 12 1.43 (1.194,1.702)
Cmax Capsule PiB 12 1.58 (1.312,1.900)
PiB = powder -in-bottle.
The potential food effect with the capsule formulation was assessed as 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
and with a normal fat meal in a non-randomized crossover design (fasted in either Period 
1 or 2, fed in Period 3).  Eleven subjects provided data for both dietary  conditions.   
Preliminary  geometric mean AUC(0 -) and Cmax values were approximately  60% 
higher after administration in the capsule formulation with a normal fat meal compared to 
the fasted state ( Table 
5).
Table [ADDRESS_541394] of a Normal Fat Meal on 
[COMPANY_004]2838232 Exposure when Administered as a Capsule 
Formulation with Ritonavir (Study  204953, Part 1B)
Parameter n Capsule –food
Geometric meanCapsule –
fasted
Geometric 
meanRatio of geometric 
means 
(food/fasted)
AUC(0 -) (ng.h/mL) 11 2414 1539 1.57
Cmax (ng/mL) 11 76.9 47.2 1.63
Repeat dose PK parameter values in Study  204953 Part 2 were determined on Day  1 and 
Day 11 using nominal time in Part 2 of Stu dy 204953 ( Table 6). After the Day  11 dose of 
[COMPANY_004]2838232 with RTV, exposure (Cmax, AUC[0 -]) appeared to increase 
proportionally  with the increase in dose level with the PiB and capsule formulations.  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
23Table 6 Summary  of Preliminary  Pharmacokinetic Parameter Values on 
Day 1 and Day  11 during Repeated Dosing of [COMPANY_004]2838232 in 
Combination with 100 mg Ritonavir (Study  204953, Part 2)
Dose 
(mg)n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)C
(ng/mL)
Study Day 1
20
(PiB)6 - 0.417
(49%)
(0-0.5)3.67
(11%)
(3.0-4.0)12.2
(47%)
(5.8-20.8)189.4
(40%)
(83.7- 284.4)6.1
(39%)
(2.5-8.9)
50
(PiB)6 - 0.167
(155%)
(0-0.5)3.00
(51%)
(2.0-6.0)18.7
(40%)
(9.0-25.9)288.7
(39%)
(138.6- 380.2)9.5
(35%)
(5.1-12.6)
100
(capsules)6 - 0.167
(155%)
(0-0.5)2.25
(23%)
(1.5-3.0)48.4
(32%)
(28.1- 69.6)664.1
(31%)
(422.5- 932.7)21.6
(33%)
(12.8- 29.3)
200
(capsules)6 - 0.083
(245%)
(0-0.5)2.50
(25%)
(2.0-3.5)79.4
(38%)
(50.8- 125)1124
(39%)
(636.7 -1794)38.9
(36%)
(21.7- 58.6)
Study Day 11
20
(PiB)6 19.2
(16%)
(15.1-
24.2)- 5.00
(32%)
(2.5-6.0)27.4
(38%)
(11.3- 40.4)474.3
(31%)
(214.3- 613.2)15.3
(30%)
(7.1-19.2)
50
(PiB)6 27.3
(52%)
(15.2-
50.4)- 3.50
(46%)
(1.5-6.0)58.0
(24%)
(40.9- 78.0)1113
(23%)
(762.6- 1459)38.8
(29%)
(24.5- 51.7)
100
(capsules)6 17.9
(18%)
(15.2-
23.7)- 4.00
(40%)
(2.5-6.0)133
(23%)
(94.7- 164)2492
(27%)
(1624- 3301)81.7
(30%)
(45.9- 113)
200
(capsules)6 -1 - 3.33
(45%)
(1.5-6.0)240
(38%)
(127-368)4389
(45%)
(2095- 7161)151
(46%)
(67.8- 250)
Data are presented as mean (CV) (minimum -maximum).
1. Concentration data were available up to 24 h after the Day 11 dose, and t½ values were not 
calculated.
[IP_ADDRESS]. Overall Summary /Conclusions of PK data
The original formulation used in the first three studies with [COMPANY_004]2838232 (HMI 116787, 
200207, and 200912) was SDD.  Data from Stud y 200912 demonstrated that a change to 
the API  [INVESTIGATOR_428095]2838232 was feasible for future clinical studies. Study  
204953 utilized micronized API [INVESTIGATOR_428151] a bottle as well as in a capsule. The capsule 
was shown to be a viable solid dosage form for subsequent studies.  A more detailed 
summary  of the data from Study  204953 is in Section [IP_ADDRESS]. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
24[COMPANY_004]2838232 S DD did not overall demonstrate significant escalation in exposure 
from an increase in dose from 100 mg to 200 mg in a cross -study  comparison.  The 
API [INVESTIGATOR_428097] a proportional increase in AUC and Cmax for a 2 -fold 
dose escalation from 100 mg to 200 mg.
The observed tmax of the API  [INVESTIGATOR_428098] (the API [INVESTIGATOR_428099]).
The bioavailability  of the [COMPANY_004]2838232 API  [INVESTIGATOR_428100] 30 -50% of 
the bioavailability  of SDD formulation, but there was a large observed range of 
relative intra -subject exposures (11
-150%).
Both 10 mg SDD and 20 mg API [INVESTIGATOR_428101] a 10 -fold or greater increase in AUC with 
steady -state RTV (100 mg QD for 10 day s) with a smaller ( ≤4-fold) increase in 
observed Cmax.  The t½ of [COMPANY_004]2838232 increased from 15
-18 hours to 34-42 
hours in the presence of stead y-state RTV, regardless of formulation.
After single doses of 50 to 250 mg [COMPANY_004]2838232 with RTV, increases in Cmax and 
AUC(0 -) values were broadly  proportional to the increase in dose.  On Day  11 
after repeated dail y 20 to 200 mg doses of [COMPANY_004]2838232 with RTV, increases in 
Cmax and AUC(0 -) values appeared to be proportional to the increase in dose with 
the PiB and capsule formulations.  
The relative bi oavailability  of the micronized API  [INVESTIGATOR_428102]  45% -60% higher than the bioavailability of the micronized 
API [INVESTIGATOR_428103].
Co-administration of the micronized API  [INVESTIGATOR_428104] a 
normal fat meal resulted in an approximately  60% increase in geometric mean 
Cmax and AUC(0 -) values compared to the fasted state with RTV (Study  
204953).
Variability  remains fairly constant across formulations and boosted versus 
unboosted at around 30% -40% (moderate -high).
Projections of potential future efficacious boosted [COMPANY_004]2838232 API  [INVESTIGATOR_428105] [ADDRESS_541395] 3 -fold above th
e derived 90% maximal 
inhibitory  concentration (IC90) target value (5 ng/mL ). Even if protein binding has 
more impact than envisaged and causes a 5 -fold increase in IC90 as seen in some 
preclinical virology  studies, the predicted troughs will still be sign ificantly  higher 
than the 5 -fold shifted IC90 (25 ng/mL) at doses of 50 mg or higher with RTV. 
The average and maximum AUC/Cmax values observed at the maximum dose 
studied to date are below NOAEL values in preclinical chronic toxicology  studies 
(6-month r at, 9- month dog). 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
253. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected patients 
during 10 -days of monotherapy.Maximum decline from baseline (Day 1) in 
plasma HIV -1 RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered as 
monotherapy over 10 days. Safety and tolerability parameters, 
including adverse event, concurrent 
medication, clinical laboratory, 
electrocardiogram (ECG) and vital signs 
assessments.
To cha racterize pharmacokinetics (PK) of 
[COMPANY_004]2838232 in HIV -1 infected patients 
following [COMPANY_004]2838232/cobi dosing for 10 
days [COMPANY_004]2838232 PK parameters following 
dose administration, as follows:
Day 1 :  area under the plasma 
concentration time curve AUC(0 -24), 
maximum observed concentration 
(Cmax), time to maximum observed 
concentration (tmax), concentration at [ADDRESS_541396] dose (C24), absorption lag 
time (tlag); 
Following last repeat administration on 
Day 10 :  AUC(0 -), pre -dose 
concentration (C0), concentratio n at end 
of dosing interval (C ), Cmax, tmax, t½, 
and apparent oral clearance (CL/F), if 
data permit
Secondary
 To explore the relationship between 
[COMPANY_004]2838232 exposure and change in 
plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 
AUC(0 -), Cmax, C with Day 11 HIV -1 
RNA change from baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when administered over 
10 days in HIV -1 infected adults Change from baseline in CD4+ cell count 
to Day 11
 To explore the relationship between 
[COMPANY_004]2838232 exposure an d safety or 
immunologic parameters, if appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax, C   with Day 11 change 
from baseline in CD4+ cell count
 To assess the development of viral 
resistance (genotypic and phenotypic) over 
10 days and correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, 
if appropriate 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
26Objectives Endpoints
 To estimate [COMPANY_004]2838232 accumulation and 
to assess attainment of steady state 
following administration of 
[COMPANY_004]2838232/cobi for 10 days in HIV 
infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): 
Day 10 AUC(0- ), Cmax, and C 
compared to Day 1 AUC(0- 24), Cmax, 
and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on 
Day 2 through 11 
 To examine dose proportionality of 
[COMPANY_004]283 8232 PK parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days in HIV 
infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and 
Day 10 AUC(0- ), Cmax and C   at 
different doses levels for the assessment 
of dose proportionality
Note: Other exploratory object ives and endpoints will be specified in the RAP
4. STUDY DESIGN
4.1. Overall Design
This is a Phase IIa, multicenter, open -label, adaptive dose ranging, study  to evaluate the 
antiviral effect, safet y, tolerability, and PK of [COMPANY_004]2838232/cobi monotherap y over [ADDRESS_541397] dose 
of study  drug.  Eligible HIV -1 infected subjects will receive study  treatments for 10 day s.
Table 7 Study  Design for 200911
[COMPANY_004]2838232/cobi Once Daily for 10 days1,2
Part A Part B 
Cohort 1 Dose
(mg)Interim Analysis Cohort
N(mg)
N=10 100
2 8 200
3 8 50
4 8 20 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
271. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B.  All 
doses will be given with [ADDRESS_541398] to 
modification based upon safety, PK and antiviral activity data from Cohort 1 (Part A). More doses/cohorts 
(including potential removal of cobicistat co -dosing) may be a dded. (The maximum dose in Cohort B will likely not  
exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] is lower in HIV -infected 
subjects than in healthy subjects at the same dose level).
After successfull y completing screenin g evaluations, the first cohort will enroll 10 
subjects to receive the 100 mg [COMPANY_004]2838232/cobi dose.  Following interim anal ysis of 
Cohort 1, if warranted, Cohorts 2 -4 will each enroll 8 subjects to receive a range of 
[COMPANY_004]2838232/cobi doses.
Day 1 – Day 10: Dosing 
Subjects will report to the clinic for outpatient visits in the morning on Day s 1 through 10 
during the treatment period, except for the weekend (Day s 6 and 7).  Subjects will arrive 
each day  prior to administration of the morning dose for safet y and lab assessments, 
including HIV -1 RNA blood draws, as described in the Time and Events Table (Section 
7.1).  Subjects will begin receiving stud y drug in the morning of Day 1.  
Serial, intensive blood PK sampl es will be collected on Day  1 (up to [ADDRESS_541399] -
morning dose) and Day  10 (up to [ADDRESS_541400] -morning dose), and limited, single blood 
PK samples pre -morning doses on Day s [ADDRESS_541401] for 10 hours [overnight] prior to the morning check in on the 
intensive PK sampling day s (Day s 1 and 10).  All dosing day s will require co -
administration of treatment with a light snack/meal per cobicistat labeling guidelines. All 
doses of study  medication will be t aken with 240 mL  of water.  Subjects will be required 
to stay  in the clinic on Day s 1 and 10 until all specified assessments are completed ( 8-[ADDRESS_541402] -dose). Following Day  10, subjects will be required to attend the clinic for 
follow up assessments in
cluding virological and PK blood sampling for up to 3 weeks.
Subjects will be given morning doses on Day s 1 through 10 (except for the weekend) in 
the clinic.  Weekend morning doses (Day s 6 and 7) will be packaged and sent home for 
self-administration.  Af ter Day  11, the subjects will return frequentl y for assessments 
including blood draws for PK and HIV viral load. A diary  card will be used to monitor 
dosing adherence.
Follow -up Visits:
Subjects will return to the clinic on Day s 11, 12, 14 ( 1 day ), and 21 (1 day ) for PK and 
measurement of HIV -1 RNA levels, viral genot ype/phenoty pe and safet y assessments as 
shown in the Time and Events Table (Section 7.1). 
4.2. Type and Number of Subjects
At least 34 subjects will b e enrolled such that approximately  6
-10 evaluable subjects 
complete a number of cohorts.  Additional subjects/cohorts may be enrolled to allow for 
evaluation of additional dose levels as appropriate.  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
28If subjects prematurel y discontinue the study, addition al subjects may  be randomi zed and 
assigned to the same treatment cohort at the discretion of the Sponsor in consultation with 
the Investigator.
4.3. Design/Dose Justification
The fastest track to establishing antiviral potential of any  novel HIV drug is to stud y a 
short course of monotherapy  in HIV infected subjects. There is precedent for this across a 
number of classes of ART drugs. 
Uncertainties over the impact of protein binding on the activity  of [COMPANY_004]2838232 and the 
inherent potency  of inhibiting the HIV ma turation process as a target remain key  
objectives for the [COMPANY_004]2838232 program. This two -part adaptive design will allow an 
early understanding of the potential of [COMPANY_004]2838232 in combination with cobicistat (and 
by [CONTACT_118414], RTV), while not exposing HIV -infected subjects to longer courses of 
what may  be suboptimal doses and possible development of resistance. 
Early clinical studies have indicated that in order to achieve reasonable IQ values likely 
to be associated with antiviral efficacy , [COMPANY_004]2838232 will need to be boosted with a 
pharmacoenhancer, such as RTV or cobicistat (in common with many  CYP3A4 
substrates). 
There is no a priori intention to study  [COMPANY_004]2838232 unboosted, unless: i) following the 
preliminary  anal ysis of Part A Cohort 1, there is such pronounced antiviral activity that it 
would seem the estimates of projected IQ are low, in which case [COMPANY_004]2838232 may be 
evaluated in a subsequent cohort unboosted, or ii) the data from ongoing and planned
healthy  volunteer trials,Study  204953 ([COMPANY_004]2838232 20 0 mg BID unboosted) and Study  
205820 ([COMPANY_004]2838232 500mg QD unboosted) support it.
4.3.1. [COMPANY_004]2838232 with Ritonavir
In Stud y HMI116787, a single dose of 10 mg [COMPANY_004]2838232 (SDD) given after 10 day s of 
RTV 100 mg dail y dosing (to stead y state) demonstrated an increase in overall exposure 
(AUC) and Cmax by  [CONTACT_5554] 10.[ADDRESS_541403] . Studies 200912 and 200207 also indicated the utility  of RTV in 
boosting [COMPANY_004]2838232 concentrations.
These data indicate the viability  of study ing a number of [COMPANY_004]2838232+RTV regimens in 
this PoC study . Predicted exposures fol lowing different [COMPANY_004]2838232 doses with steady -
state RTV are presented in Table 
8, based on the results of linear regression anal yses of 
the preliminary  Day  11 data in Study  204953 (dose levels of 20 to 200 mg) and assuming 
no significant differences in PK (ADME) between HIV -infected subjects and healthy  
subjects.  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
29Table 8 Predicted Mean Steady -State [COMPANY_004]2838232 A UC(0 -24), Cmax, and IQ, 
Follo wing Repeated Dose A dministration + RTV with Fold Cov er to 
NOA EL
Dose 
(mg)Projected AUC24 
(ng.h/mL)1Fold cover to 
NOAEL Dog2Projected 
Cmax 
(ng/mL)1Fold cover to 
NOAEL Dog2IQ3
20+RTV 451 36 24 35 3.1
50+ RTV 1127 14 61 14 7.7
100+ RTV 2253 7.2 122 6.9 15
150+RTV 3380 4.8 183 4.6 23
200+RTV [ADDRESS_541404] NOAEL, 20 mg/kg/day obtained from 9 -month study in dogs ( AUC24 [ZIP_CODE] ng.h/mL and Cmax 847 
ng/mL)
3. Mean IQs derived from predicted C /IC90 (with target of 5 ng/mL).
C= Pre-dose (trough) concentration at the end of the dosing interval , IQ= inhibitory quotient.
The IQ following 20 mg to 200 mg [COMPANY_004]2838232/r QD is predicted to be >3 to >30 -fold 
above the minimal target value (5 ng/mL) which was derived from preclinical virological 
assessment as 4 × EC50. No protein binding adjustment has been made because there was 
a minimal ( ≤5 fold) shift in assays where the effect of protein was assessed. If protein 
binding has more impact than anticipated, it is possible that the target Cmin value is 
approximately  25ng/mL . In that scenario, projected IQ values at 200 mg/r QD would still 
be>5.
4.3.2. [COMPANY_004]2838232 with Cobicistat
There have been no preclinical or clinical studies with [COMPANY_004]2838232 and cobicistat to 
date; however, a review of the literature indicates that pharmacoenhancement of drugs 
that are known to have dominant CYP3A metabolic pathw ays is similar with either RTV 
or cobicistat [ Kakuda , 2009; Elion , 2011; Galla nt, 2013].  Thus, the use of cobicistat as 
the CYP3A4 inhibit or pharmacoenhancer in this Phase IIa study in place of ritonavir is 
expected to produce a similar profile of [COMPANY_004]2838232 ADME (and therefore s ystemic 
exposure).  The pharmacokinetic data available after Part A Cohort 1 will confirm this 
assumption.  
4.3.3. Interim Analy sis
An evaluation of [COMPANY_004]2838232 safet y, efficacy  and PK data will be done after Part A 
Cohort 1, if the exposure level of [COMPANY_004]2838232 is in the range of the maximum 
[COMPANY_004]2838232 exposure seen previousl y in healthy subjects and the Bay esian probability
from Cohort 1 is less than 70%, the study will not move forward into Part B, otherwise 
doses will be selected for evaluation in Part B. If pharmacokinetic exposure after the 100 
mg [COMPANY_004]2838232/cobi dose is in the range of values observed after 100 mg 
[COMPANY_004]2838232/r in prior studies, the doses for Part B will be extended to both lower 
(20mgand/or 50 mg) and higher (200 mg) doses. The highest dose tested in Part B will 
be selected to result in exposures similar to those seen with 200 mg/r in Study  204953.   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
304.4. Benefit:Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
[COMPANY_004]2838232 can be found in the I nvestigator’s Brochure.   The following section 
outlines the risk assessment and mitigation strategy for this protocol:   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
314.4.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [COMPANY_004]2838232 
Cardiovascular Pre-clinical studies have shown the following findings:  elevated heart rates, an 
isolated epi[INVESTIGATOR_43180] -sustained ventricular tachycardia and minimal to mild, 
sporadic troponin I elevations in dogs.  A subsequent investigative cardiovascular 
study in telemetered dogs treated for 4 weeks did not replicate these effects. 
Isolated microsc opic cardiovascular changes were noted (focal extramural 
arteritis and localized epi[INVESTIGATOR_428106]), however these changes were 
considered of uncertain relationship to [COMPANY_004]2838232 because similar findings 
occur at low incidence in normal beagles and t here were no [COMPANY_004]2838232 -related 
functional changes by [CONTACT_428202], or changes in cTpnI and 
NTproBNP.  In addition there was no correlation between histologic changes and 
plasma exposure or heart tissue concentrations of [COMPANY_004]2838232. 
3, 6and [ADDRESS_541405], other than a 30% incidence of 
gastrointestinal symptoms (including diarrhea). There were no significant 
cardiovascular AEs reported in published clinical studies.Subjects will be clinically monitored for any signs 
of myocardial injury (ch est pain, shortness of 
breath, pain with inspi[INVESTIGATOR_1516]), elevated heart rate 
or arrhythmias. Samples for the assessment of 
troponin will be taken. Baseline EKG and Holter 
(to use for screening and for later comparisons if 
needed)
Exposures of [COMPANY_004]2838232 will be closely 
monitored in the clinical study so as to not 
exceed pharmacokinetic stoppi[INVESTIGATOR_3418].   
 
 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
32Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Cobicistat (Tybost)
General The cobicistat label includ es the following information: 
TYBOST decreases estimated creatinine clearance due to inhibition of tubular 
secretion of creatinine without affecting actual renal glomerular function. This 
effect should be considered when interpreting changes in estimated creatinine 
clearance in patients initiating TYBOST
In one study investigating cobi+( atazanavir and tenofovir DF/emtricitabine) vs 
RTV+( atazanavir and tenofovir DF/emtricitabine), a higher frequency of reports 
of jaundice (6% and 3%) and ocular icterus (4% and 2%) were reported in the 
cobi group compared to the RTV group.  
Changes from baseline in total cholesterol, HDL -cholesterol, LDL -cholesterol, and 
triglycerides have been observed. The implications of these findings are 
unknown.
The vast majority of available safety data has been obtained in combination 
studies with other ART. There are no warnings of obvious cobicistat -related 
adverse events or safety concerns. Subjects will be closely monitored for any signs 
or symptoms potentially associated with 
cobicistat administration, in particularchanges in 
serum creatinine and liver chemistry.
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible Drug -Drug 
Interactions (DDIs)HIV Drug Resistance to unique mechanism
Recogni ze HIV patients have a higher chance of comorbidities/diseases and a 
risk of taking a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resistance
Strict adherence to protocol criteria around 
concurrent meds  
 
 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
334.4.2. Benefit A ssessment
This study  in HIV -1 infected but otherwise healthy  subjects is a 10 -day monotherapy  
design. It is anticipated that all subjects receiving [COMPANY_004]2838232 will experience anti -HIV 
effects whereb y their (blood) HIV viral titres are reduced, unt il administration stops and 
the viral load returns to baseline levels. There is no expected longer term anti- HIV 
benefit to administration of [COMPANY_004]2838232.  Participation in this study  contributes to the 
process of developi[INVESTIGATOR_428107]2838232 and other new therapi [INVESTIGATOR_428108].
4.4.3. Overall Benefit:Risk Conclusion
To date, [ADDRESS_541406] received single doses up to 200 mg SDD alone (studies HMI116787 and 
200912), 250 mg API [INVESTIGATOR_428109] (204953), and then in repeated dail y 
doses of up to 50 mg SDD alone (200207) for 5 day s or 200 mg in combination with 
RTV (204953) for [ADDRESS_541407] been two cardiovascular SAEs reported from clinical studies where the 
subjec t was receiving [COMPANY_004]2838232 to date (one in 200207, one in 204953). Neither is 
thought likely  to be due to [COMPANY_004]2838232.
There have been no other withdrawals due to drug -related AEs and no trends relative to 
laboratory  toxicity .  One subject was withdrawn in Part 1A of [ADDRESS_541408] been no clinically  
significant changes in troponin, heart rate, blood pressure, ECG, or telemetry  monitoring.
Subjects will also be at risk for AEs from cobicistat use and will be monitored closel y for 
such events.
Given the preclinical profile and the clinical profile to date, the overall risk to HIV -1 
infected but otherwise healthy  subjects at the proposed [COMPANY_004]2838232 doses (with or 
without cobicistat) for [ADDRESS_541409] subjec t eligibility  is provided in the Investigator’s Brochure.
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
34Approximately  10-12 HIV -1 infected subjects will be enrolled into Part A. If warranted 
by [CONTACT_428203] y, virology  and PK data anal ysis, approximately  8 subjects will be 
enrolled in e ach of Cohorts 2- 4 in Part B. Eligible patients are those who are maturation 
inhibitor -naïve and who are not currentl y receiving ART therap y.
Additional subjects/cohorts may be enrolled to allow for evaluation of additional dose 
levels or configurations (e .g., [COMPANY_004]2838232 alone).
If subjects prematurel y discontinue the study, additional subjects may be enrolled .
5.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
AGE
1.Between [ADDRESS_541410] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Health y (other than HIV infection) male or female as determined b y the investigator 
or medicall y qualified designee based on a medi cal evaluation including medical 
history , phy sical examination, laboratory  tests and cardiac monitoring. Defined as no 
other chronic medical conditions and taking no chronic medications.
3.A subject with a clinical abnormality  or laboratory  parameter(s) whic h is/are not 
specificall y listed in the inclusion or exclusion criteria, outside the reference range 
for the population being studied may  be included only  if the investigator in 
consultation with the Medical Monitor agree and document that the finding is 
unlikely  to introduce additional risk factors and will not interfere with the study  
procedures. 
4.A creatinine clearance >80 mL/min as determined by  [CONTACT_3158]
-Gault equation 
[Cockcroft , 1976] CLcr (mL /min) = (140 – age) * Wt / (72 * Scr) (times 0.85 if 
female) where age is in years, weight (Wt) is in kg, and serum creatinine (Scr) is in 
units of mg/dL .
5.Confirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. 
6.Antiretrovira l treatment naive or ART -experienced (maturation inhibitor naive) . No 
current ART (last dose completed at least [ADDRESS_541411] dose of study  
drug). A previous course of pre -or post -exposure prophy laxis is allowed provided 
that it was completed at least [ADDRESS_541412] dose of study  drug. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
35WEI GHT
7.Body weight 50kg (110 lbs.) for men and 45kg (99 lbs) for women and body  
mass index (BMI) within the range 18.5 -35.0 kg/m2(inclusive)
SEX
8.Male or Female
A female subject of reproductive or non -reproductive potential is eligible to 
participate if she is not pregnant (as confirmed b y a negative serum or urine human 
chorionic gonadotrophin (hCG) test at screening and prior to first dose), not 
lactating, and at least one of the following conditions applies:
Reproductive potential:
Females of reproductive potential may  only be enrolled if they are using two forms 
of com plementary  contraception, which must include one barrier method. They  will 
be counselled on safer sex practices
There is no definitive DDI information with [COMPANY_004]2838232 and an interaction with 
oral contraceptives is possible, so other (barrier, inter- uterine device etc.) methods of 
contraception will be required.
Fertile females, who have an established, long -term lifesty le of sexual abstinence, or 
only same sex partners, require no other means of birth control.  
Non-reproductive potential:
Pre-menopausal fe males with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of sp ontaneous amenorrhea in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause (refer to 
laboratory  reference ranges for confirmatory  levels).  Females on hormone 
replacement th erapy (HRT) must discontinue HRT to allow confirmation of 
post-menopausal status prior to study  enrolment.
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first dose o f study  medication 
until one week after the last dose of study  medication.
a.Vasectom y with documentation of azoospermia.  
b. Male condom plus partner use of one of the contraceptive options below:
Contraceptive subdermal implant that meets the SOP effectiveness criteria  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
36including a <1% rate of failure per year, as stated in the product label
Intrauterine device or intrauterine s ystem that meets the SOP effectiveness 
criteria including a <1% rate of failure per year, as stated in the product 
label
Oral contrace ptive, either combined or progestogen alone or Injectable 
progestogen 
Contraceptive vaginal ring 
Percutaneous contraceptive patches
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the pr oduct label.  The investigator is responsible 
for ensuring that subjects understand how to properly  use these methods of 
contraception.
INFORMED CONSENT
9. Capable of giving signed informed consent as described in Section 10.2, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCU RRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1. Alanine aminotransferase (ALT) and BIL >1.5xupper limit of normal (ULN; isolated 
BIL >1.5xUL N is acceptable if BIL is fractionated and direct BIL <35%). 
2. Current or chronic histo ry of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones); HBV and/or 
HCV positive.
3.Subjects who have an y other chronic medical condition, including CV, respi[INVESTIGATOR_696] , 
neurologic, ps ychiatric, renal, gastrointestinal (GI), oncologic, rheumatologic, or 
dermatologic
4.Medical history  of cardiac arrhy thmias or cardiac disease or a famil y or personal 
history  of long QT s yndrome. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
37CONTRAINDICATIONS 
5.History  of sensitivity  to any  of the study  medications, or components thereof or a 
history  of drug or other allergy  that, in the opi[INVESTIGATOR_427175], contraindicates their participation.
REL EVANT HABITS 
6. Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion 
criteria.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
7.Presence of hepatitis B surface antigen (HBsAg), positive (confirmed b y 
Recombinant I mmuno -Blot Assay  [RIBA]) hepatitis C antibody  test result at 
screening or within [ADDRESS_541413] dose of study  treatment.
8. Screening or baseline cardiac troponin I greater than the 99% cutoff (>0.045 ng/mL 
by [CONTACT_428205] ).
9.A positive pre -study  drug/alcohol screen.  
10.Prior history  of receiving an HIV maturation inhibitor
11.Where participation in the study would result in donation of blood or blood products 
in excess of [ADDRESS_541414] dosing day  in the current 
study : [ADDRESS_541415] (whichever is longer).
13.Exposure to more than four new chemical entities within [ADDRESS_541416] 
dosing day .
14.Treatment with radiation therap y or cy totoxic chemotherapeutic agents within 
30days of study  drug administration or anticipated need for such treatment within 
the study .
15.Treatment with immunomodulating agents (such as sy stemic corticosteroids, 
interleukins, interferons) or an y agent with known anti -HIV activity  (such as 
hydroxyurea or foscarnet) within 30 day s of study  drug administration.
16.An active Center for Disease Control and Prevention (CDC) Category  C disease 
except cutaneous Kaposi’s sarcoma not requiring sy stemic therapy  during the trial.
17.Treatment with an y vaccine within 30 days prior to receiving stud y medication.
18. Exclusion Criteria for 24- Hour Screening Holter:
Any symptomatic arrhy thmia (except isolated extra s ystoles).
Sustained cardiac arrhy thmias (such as atrial fibrillation,flutter or 
supraventricular tach ycardia ( 10 seconds)
Non-sustained or sustained ventricular tach ycardia (defined as 3 consecutive  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
38ventricular ectopic beats).
Any conduction abnormality  including but not specific t o left or complete 
bundle branch block, atrioventricular [AV] block, high grade or complete heart 
block Wolff -Parkinson- White [WPW] sy ndrome etc.).
Sinus Pauses >3 seconds.
19.Exclusion criteria for screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB) , Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual participant in 200911 will be Fridericia’s formula. 
Note: A he art rate from 100 to 110 beats per minute (bpm) can be rechecked by 
[CONTACT_428206] 30 minutes to verify eligibility.
Evidence of previous myocardial infarction (Does not include ST segment 
changes associated with repolarization).
Any conduction abnor mality  (including but not specific to left or right complete 
bundle branch block, AV block [2nd degree or higher], WPW syndrome).
Sinus Pauses >3 seconds.
Any significant arrh ythmia which, in the opi[INVESTIGATOR_428152] , will interfere with the safet y for the individual 
subject. 
Non-sustained or sustained ventricular tach ycardia ( 3 consecutive ventricular 
ectopic beats).
5.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjects who consent to partici pate in the clinical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from Regul atory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure 
details, Eligibility  Criteria, and an y SAEs. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
395.4. Withdrawal/Stoppi[INVESTIGATOR_428111] a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascerta in whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_541417]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only then will he/s he be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
A subject may  withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioural or 
administrative reasons. If a subject withdraws from the study , he/she may  request 
destruction of an y samples taken, and the investigator must document this request has 
occurred in the site study records. 
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceCo mplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
40Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 , Section 12.2 and Section 12.3. 
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_428153].
5.4.2. QTc Stoppi[INVESTIGATOR_2121]
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the subject has been enrolled.
For example, if a subject is eligible for the protocol based on QTcB , then QTcB 
must be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibi lity, the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis .  Safety  ECGs and other non -protocol specified 
ECGs are an exception.  
The QTc should be based on single or averaged QTc values of triplica te ECGs 
obtained over a brief (e.g., 5- 10 minutes) recording period.  
A subject who meets either of the bulleted criteria below will be withdrawn from the 
study : 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
41QTc >500 msec OR Uncorrected QT >600 msec
Change from baseline of QTc >60 msec
5.5. Stoppi[INVESTIGATOR_428154] A dverse Events
Any grade 3 or higher treatment -related adverse events that occur in ≥[ADDRESS_541418]’s last visit.
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design. Stu dy treatment may  
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Treatment
Product name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Formulation 
description:[COMPANY_004]2838232 powder blend in a 
capsuleTablet
Dosage form: Swedish orange, unmarked 
capsules (50 mg), and white, 
unmarked capsules (10 mg)Orange, round, biconvex, film -coated 
tablets debossed with “GSI” on one side 
and plain faced on the other side 
providing 150 mg of cobicistat.
Unit dose strength(s)/
Dosage level(s):50 mg capsule for 200 mg, 100 mg, 
50 mg doses and 10 mg capsule for 
20 mg doses 150 mg for 150 mg doses
Route/
Administration/
Duration:Administered orally QD for [ADDRESS_541419] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Dosing i nstructions: Administer with light meal and 240 
mL of water . Administer with light meal and 240 mL 
water.
Manufacturer/
source of 
procurement:[COMPANY_004] [COMPANY_009]
Method for 
individualizing dosage:Capsules supplied in high -density 
polyethylene bottles for 
individualized dosing by [CONTACT_428208]
6.2. Treatment A ssignment
Subjects will be assigned to treatment (active) groups in accordance with the 
randomization schedule generated by  [CONTACT_428234], prior to the start of the study , 
using validated internal software.
6.3. Planned Dose A djustments
Following the interim analy sis of safet y, virology  and PK data from the first cohort of 
subjects in Part A, the option to adjust dose levels from those de scribed exists. No dose 
will be administered that has an associated projected mean AUC or Cmax value higher 
than the most conservative NOAEL obtained from the chronic toxicity  studies (i.e., from 
the 9- month dog toxicity  study  described in Section 2.2.1).
6.4. Blinding
This will be an open -label study . Treatment allocation and [COMPANY_004]2838232 dose levels in 
Part B will be determined after the anal ysis of Part A data.
Packaging and Labeling
The contents of the label will b e in accordance with all applicable regulatory 
requirements.
6.5. Preparation/Handling/Storage/A ccountability
A description of the methods and materials required for capsule/tablet storage and 
dispensing will be detailed in a Study  Specific Technical Agreement/ Memo or Pharmacy  
Manual, which will be accompanied b y a Quality Agreement.
No special preparation of study  treatment is required.
Only  subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
43(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The inves tigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e., receipt, reconciliation and final disposition records).
Further guidance and in formation for final disposition of unused study  treatment 
are provided in the study  reference manual (SRM). 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  
A Materia l Safety  Data Sheet/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
6.6. Compliance with Study  Treatment A dministration
When subjects are dosed at the site, they  will receive study  treatment directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source do cuments.  The dose of study  
treatment and study subject identification will be confirmed at the time of dosing b y a 
member of the stud y site staff other than the person administering the stud y treatment.  
When subjects self- administer study  treatment(s) a t home , compliance with study  
treatment(s) will be assessed through querying the subject during the site visits and 
documented in the source documents and case report form (CRF).  A record of the 
number of stud y treatment(s) dispensed to and taken by [CONTACT_428209].  Treatment start and stop 
dates, including dates for treatment delay s and/or dose reductions will also be recorded in 
the CRF.
6.7. Treatment of Study  Treatment Overdose
For this study , any  dose of [COMPANY_004]2838232 >200 mg+cobicistat within a 28 -hour time 
period will be considered an overdose.
[COMPANY_004] does not recommend specific treatment for an overdose; however, in the event of an 
overdose, the investigator or treating ph ysician should:
Contact [CONTACT_27465]
Closely  monitor the subject for AEs/SAEs and laboratory  abnormalities until 
[COMPANY_004]2838232 can no longer be detected s ystemically  (at least 10 day s for 
[COMPANY_004]2838232)
Obtain a plasma sample for PK anal ysis within [ADDRESS_541420] dose 
of study  treatment if requested by  [CONTACT_1689] (determined on a case -by-case 
basis) 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
44Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_424359].
6.8. Treatment after the End of the Study
Subjects receiving [COMPANY_004]2838232 may  opt to receive marketed antiretrovirals afte r the 
completion of 10 day s of [COMPANY_004]2838232 dosing and study  follow -up visits (through 
Day 21) eligible for sponsor compan y reimbursement up to a maximum of [ADDRESS_541421]’s medical condition, whether or not [COMPANY_004] is providing 
reimbursement for post -study  treatment.
6.9. Lifest yle and/or Dietary  Restrictions
6.9.1. Meals and Dietary  Restrictions
Refrai n from consumption of red wine, Seville oranges, grapefruit or grapefruit juice 
from [ADDRESS_541422] dose of study medication until after the final dose.
Doses will be given in the fed state (light breakfast), following overnight fasting 
(>10 hours). 
6.9.2. Alcohol, Caffeine and Exercise
During  the study   alcohol consumption should be limited to the following:
An average weekl y intake of <14 drinks for males or <7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL ) of be er, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
Subjects should abstain from strenuous exercise during the treatment period.
6.10. Contraception
Female subjects can be of childbearing or non -child bearing potential.  
Females o f reproductive potential may  only be enrolled if they are using two forms of 
complementary  contraception, which must include one barrier method.  Although use of 
oral contraceptives is permitted, there is no definitive DDI information with 
[COMPANY_004]2838232 and a n interaction with oral contraceptives is possible, so other (barrier, 
inter-uterine device etc.) methods of contraception will be required.
Females of reproductive potential, who have an established, long -term lifesty le of sexual 
abstinence, or onl y same sex partners, require no other means of birth control.  
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first dose of stud y medication 
until one week after the last d ose of study  medication: 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
451. Vasectom y with documentation of azoospermia. The documentation on male 
sterility  can come from the site personnel’s review of subject’s medical records, 
medical examination and/or semen anal ysis, or medical history  interview.
OR
2. Male condom plus partner use of one of the contraceptive options below that 
meets the SOP effectiveness criteria including a <1% rate of failure per year, as 
stated in the product label:
-Contraceptive subdermal implant
-Intrauterine device or intrau terine s ystem
- Combined estrogen and progestogen oral contraceptive 
-Injectable progestogen
-Contraceptive vaginal ring 
-Percutaneous contraceptive patches 
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014]
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
Acetaminophen at doses of 2grams/day  or NSAIDs are permitted for use any  time 
during the stud y and their use documented in the CRF.  Other concomitant 
medication may  be considered on a case by  [CONTACT_428235].
Concomitant medications (prescription and non- prescription) should be administered 
only as medically  necessary  during the study . Subjects must notify  their Investigator 
of an y current or proposed concomitant medication, whether prescr ibed or over -the-
counter, because of the potential for interactions between such treatments and the 
study  medications.
6.11.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_014]
Subjects must refrain from all illicit drugs throughout the study  (from Screening until 
dis
charge from the study).  Drug screening will occur at Screening and Day -1 and at 
additional timepoints throughout the stud y.  A positive result will lead to exclusion 
from the remainder of the study .
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or ex emptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table (Section 7.1), are essentia l and required for study  
conduct. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541423] be noted: 
If assessments are scheduled for the same nominal time, THEN the assessments 
should occur in the following order:
1.
12-lead ECG
2.vital signs
3.blood draws.  
Note: The timing of the assessments should allow the blood draw to occur at the 
exact nominal time. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
477.1. Time and Events Table
Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/exclusion X X
Demography including height, weight 
and BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Cl assification X X X X
Prior antiretroviral therapy X
12-lead ECG3 X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface anti gen and 
hepatitis C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X X14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X 
 
 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
48Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Telephone call to IVRS13 X X X X X X X X X X X X X X X
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within [ADDRESS_541424] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 a nd 6, perform all “Day 5” assessments on Day 7.
3. On Day 1, ECGs will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541425] -dose. To accommodate scheduling, serial ECGs collected on 
Days 4 and 8 may be performed [ADDRESS_541426] dose.  On Day 11, an ECG will be obtained 
prior to the 24 -hour PK sample. ECGs will be performed in triplicate at all timepoints. 
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained on Day [ADDRESS_541427] -morning dose, and at day 12 and Follow -up (Day 21).
5. Only SAEs related to study participation will be collected between screen ing and Day 1. An AE enquiry will be made at each visit, subjects will be asked if they have 
experienced any neuropsychiatric adverse events, including psychosis or altered mental status.
6. On Days 1 -5 and 8 -10 samples for HIV -1 RNA PCR collected before morn ing dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart.  HIV -1 RNA PCR samples will also be collected on days 12, 14 & Follow -up (Day 21).
7. Lymphocyte subsets by [CONTACT_4133] (total lymphocyte counts, percentage , and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determination of [COMPANY_004]2838232 will be collected on D ay 1 and Day 10 at pre dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12 (optional), and 24 hours (to occur on morning of Day [ADDRESS_541428] -am dose and in the morning on Day 11) .  Pre -dose PK samples (within 15 minutes prior to dose) will be 
taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be taken on Days 12 and 14.
10. Samples (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541429] 10 hours .On Days 6 and 7, doses will be self administered bu t confirmed by [CONTACT_648] 
12. PGx sample should be collected on Day 1.
13. A screening/registration call should be made to the IVRS to register the subject at screening.   An additional call will be m ade to document a screen failure.   A randomization 
call should be mad e to the IVRS system approximately one week prior to scheduled Day 1.  Note: The randomization call must be made in order to have study drug on site for 
Day 1. Additional calls will be made every day that the subject has a scheduled study visit to the clin ic.  If a subject terminates the study prematurely a call should be made to 
the IVRS
14. Only if early termination visits occur during the treatment period.
15. Plasma samples for storage will be collected at each visit starting at Day 1, including unscheduled vis its (e.g. for HIV -1 RNA levels and immunological parameters).  
Additionally these samples will be used when needed, such as when samples are lost or arrive at the laboratory unevaluable.
AE = Adverse event; CDC= Center for Disease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Human chorionic gonadotrophin; HIV = Human 
immunodeficiency virus;  IVRS= Interactive Voice Response System; PCR = Polymerase chain reaction; PK=Pharmacokinetic. 
 
 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
497.2. Visit Windows
Screening (baseline to pre-dose ): All screening assessments should take place within 
14-[ADDRESS_541430] dose. The screening visit window may  be extended to 30 
days upon discussion with the Medical Monitor (i.e.; subject has scheduling conflicts or 
any screening assess ment needs to be repeated).
Days 4 and 8: 
Based on subject and clinic schedule, Day  4 and Day  8 serial (up to 6h 
post-dose) ECG assessments may  be conducted 1 day . 
Weekend(s): The T&E table is set up for study  start (Day 1) to occur on a Monday  and 
Days 6 and 7 to fall on the weekend. If the weekend occurs instead on Day s 5 and 6, Day  
5 assessments should be performed on Day  7. The study  start (Day  1) may  also be 
adjusted to allow visits with assessments to be conducted over the weekend based on 
subject and clinic schedule.  
Assessments: The following applies to timing of procedures:
-Window for assessments [ADDRESS_541431] -dose = 5 minutes 
-Window for assessments >4 and < [ADDRESS_541432] -dose = 15 minutes
-Window for assessments > [ADDRESS_541433] -dose = 30 minutes
End of Treatment visit : should be within [ADDRESS_541434] for assessment of adverse events.
7.3. Screening and Critical Baseline Assessments
Cardiovascular medical history /risk factors (as detailed in the CRF) will be assessed at 
screening.
The following demographic parameters will be captured: year of birth, sex, race, and 
ethnicity .
Medical/medication/family  history  will be asses sed as related to the inclusion/exclusion 
criteria.
Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count) and obtained prior to signing of informed consent may be utilized for Screening or 
baseline purposes provided the procedure meets the protocol- defined criteria and has 
been performed in the timeframe of the stud y.
7.3.1. Holter Monitoring (Screening criteria)
The 24-hour Holter monitoring will be performed during the Screening period using a 
Holter monitoring device supp lied by  [CONTACT_1034]. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
50Analy sis of the Holter tapes will consider the following:
Heart rate (brad ycardia and tachy cardia)
Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractions, premature 
ventricular contractions, co uplets, triplets, and ventricular tach ycardias
Atrio- ventricular conduction defects
Atrial fibrillation and flutter
7.4. Efficacy
7.4.1. HIV-1 RNA  Sampling
Plasma for quantitative HIV- 1 RNA will be collected at timepoints listed in the Time and 
Events Table in Section 7.1. To reduce sample variability , two plasma HIV -1 RNA 
samples will be collected on Day s 1, 10, and 11.
An HIV -1 RNA PCR assay  with a lower limit of detection (LLOD) of 50 copi[INVESTIGATOR_014]/mL  
(ultrasensitive assay ) will be used for post -baseline assessments. An HIV -1 RNA PCR 
assay  with a LLOD of 400 copi[INVESTIGATOR_014]/mL  (standard assay ) will be used for screening and 
baseline assessments and will include a re -test with and ultrasensitive assay for all 
baseline values below the LLOD . An HIV -1 RNA PCR assay  with a LLOD of 2 
copi[INVESTIGATOR_014]/mL
 (supersensitive assay ) may  be used for exploratory  anal ysis.
7.4.2. Lymphocyte Subsets by  [CONTACT_428236] b y flow cy tometry  at the timepoints listed in the Time and Events 
Table in Section 7.1.
Details concerning the handling, labeling and shippi[INVESTIGATOR_339181] .
7.5. Safet y
Planned time points 
for all safety assessments are listed in the Time and Events Table 
(Section 7.1).  Additional time points for safety tests (such as vital signs, physical exams 
and laboratory  safet y tests) may be added during th e course of the stud y based on newl y 
available data to ensure appropriate safet y monitoring.
7.5.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 5 , Section 12.5 .
The investigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE.  2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
AEs and SAEs will be collected from the start of Study  Treatment until the 
follow -up contact (see Section [IP_ADDRESS]), at the timepoints specified in the Time 
and Events Table (Section 7.1). An AE enquiry  will be made at each visit, where 
subjects will be specifically  asked if they  have experienced an y neurops ychiatric 
adverse events, including psy chosis or altered mental status  
Medical occurrences that begin prior to t he start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
All SAEs will be recorded and reported to Sponsor within 24 hours, as indic ated 
in Appendix 5 , Section 12.5 .
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, incl uding a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evalua ting and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 5
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open
-ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our la st visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
“Have you experienced any  alteration in personality , behaviour, mood or any  
altered mental status?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 12.5) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until th
e subject is lost to follow-up  2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
52(as defined in Section 5.4). Further information on follow -up procedures is given in 
Appendix 5 .
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in Appendix 5 (Section 12.5.3) and all deaths, 
whether or not they  are considered SAEs, specific CV and Death sections of the CRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non
-cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed 
within oneweek of when the death is reported.
[IP_ADDRESS]. Disease- Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease -related events (DREs) are common in subjects with HIV-1 
infection and can be serious/life threatening:
events or outcomes listed in the CDC Classification Sy stem for HIV- 1 Infections 
(see Appendix 9 ; Section 12.8)
sign, s ymptom, diagnosis, illness, and/or clinical laboratory  abnormality  that can 
be linked to an y of these events or outcomes
Because these events are ty pi[INVESTIGATOR_1306] y associ ated with the disease under study , they  will not 
be reported according to the standard process for expedited reporting of SAEs to [COMPANY_004] 
(even though the event may
 meet the definition of a serious adverse event). 
These events will be recorded on the DRE page in the subject’s CRF using the HIV 
Associated Conditions eCRF. These DREs will be monitored by [CONTACT_428212].
However, if an y of the following conditions apply, then the event should be reported as 
an SAE using the st andard process:
The event is, in the Investigator’s opi[INVESTIGATOR_1649], of greater intensity , frequency , or 
duration than expected for the individual subject, 
or
The Investigator considers that there is a reasonable possibility  that the event was 
related to treatmen t with the investigational product.
or 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
53Death occurring for an y reason during a stud y, including death due to a disease 
related event, will alway s be reported promptly . 
If either of the above conditions is met then record the DRE on the SAE page rather th an 
the HIV Associated Conditions eCRF page and report promptly to [COMPANY_004].
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA E
Prompt notification by  [CONTACT_428213]- serious AEs 
related to stud y treatment (even for non -interventional post -marketing studies) is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and the safety of a product under clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulator y authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/ Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirement s.
7.5.2. Pregnancy
Details of all pregnancies in female subjects and if indicated female partners of 
male subjects will be collected after the start of dosing and until one week post 
study
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 24hrs 
of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 7 , Section 12.6 .
7.5.3. Physical Exams
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , GI and Neurological sy stems. Height and weight will 
also be measured and recorded. 
A brief ph ysical examination will include, at a minimum assessments of the skin, 
lungs, cardiovascular s ystem, and 
abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
547.5.4. Vital Signs
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_541435] and will 
include temperature, s ystolic and diastolic blood pressure and pulse rate 
Three readings of blood pressure and pulse rate will be taken
First reading should be rejected
Second and third readings should be averaged to give the measurement to be 
recorded in the CRF. 
7.5.5. Electrocardiogram (EGC)
Triplicate [ADDRESS_541436] be 
conducted in accordance with the SRM and Protocol Ti me and Events Schedule (Section 
7.1). Laboratory  requisition forms must be completed and samples must be clearl y 
labelled with the subject number, protocol number, site/centre 
number, and visit date.
Details f or the preparation and shipment of samples will be provided b y the laboratory 
and are detailed in the SRM. Reference ranges for all safet y parameters will be provided 
to the site by  [CONTACT_90633].
If additional non -protocol -specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recor ded in the CRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
All study -required laboratory  assessments will be performed b y a central laboratory :
NOTE:  Local laboratory results a re onl y required in the event that the central laboratory 
results are not available in time for either a treatment and/or response evaluation to be 
performed. If a local sample is required it is important that the sample for central 
analysis is obtained a t the same time. Additionally  if the local laboratory  results are used 
to make either a treatment or response evaluation, the results must be entered in the CRF. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
55Haematology , clinical chemistry , urinal ysis, and additional parameters to be tested are 
listed below. 
Table 9 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes with T -cell 
subsets
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Bicarbonates Alkaline phosphatise Albumin
Troponin I
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsHIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody )
FSH and estradiol (as needed in wom en of non -child bearing 
potential only )
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (as needed for women of child bearing 
potential) 2
NOTES:
1. Deta ils of Liver Chemistry Stoppi[INVESTIGATOR_131963] -Up Assessments after liver 
stoppi[INVESTIGATOR_31777] 12.[ADDRESS_541437] dose of study  treatment 
should be repeated until the values return to normal or baseline.  If such values do not 
return to normal within a period judged reasonable by  [CONTACT_093], the etiology
should be identified and the sponsor notified. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
567.6. Pharmacokinetics
7.6.1. Blood Sample Collection
Blood samples for anal ysis of [COMPANY_004]2838232 concentrations will be collected at the time 
points indicated in Time and Events Tables (Section 7.1).  
The actual date and time of each blood sample collection will be recorded.  The timing of 
PK samples may  be altered and/or PK samples may  be obtained at additional time points 
to ensure thorough PK monitoring.  
Details of PK blood sample collection (includi ng volume to be collected), processing, 
storage and shippi[INVESTIGATOR_428114] (SRM).
7.6.2. Sample A nalysis
Plasma analy sis will be performed by  [CONTACT_55412], Madison under the control of 
Bioanal ysis, Immunogenicity  and Biomarkers (BIB), PTS, GlaxoSmithKline.
Concentrations of [COMPANY_004]2838232 will be determined in plasma using the currentl y 
approved bioanaly tical methodology . 
Once the plasma has been anal yzed for [COMPANY_004]2838232 any  remaining plasma may  be 
analyzed qualitatively  for other c irculating metabolites and these results would be 
reported under a separate PTS protocol.
Raw data will be archived at the Covance, Madison facility .
7.7. Biomarker(s)/Pharmacody namic Markers
7.7.1. Viral Genoty pi[INVESTIGATOR_428155] o btained from each subject to provide plasma for 
viral genoty pe and phenoty pe anal ysis, at the times listed in the Time and Events Table in 
Section 7.1. Details concerning the handling, labeling and shippi[INVESTIGATOR_31081] t hese samples will 
be supplied separatel y.
Genoty pic and phenot ypic anal yses will be carried out by  [CONTACT_428215]/PR and PR/RT formats, in which PCR amplification is used to generate HIV 
cDNA products including the Gag and the PR and RT coding regions, respectivel y. 
Phenoty pic anal yses of the GAG/PR region will include susceptibility  to [COMPANY_004]2838232 . 
Analy sis will be done on Day  1 and Day  11 samples.  In the case of rebound HIV -1 viral 
load, anal ysis will be completed on samples corresp onding to time point of rebound 
occurrence. 
7.8. Genetics
Information regarding genetic research is included in Appendix 4 , Section 12.4 . 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
577.9. Value Evidence and Outcomes
Not require d.
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data system, 
Management of clinical data will be performe d in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data 
(e.g., removing errors and inconsistencies in the data).
Adverse events and concomitant medications terms will be coded using MedDRA 
and an inter nal validated medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
will not be collected or transmitted to G SK according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  objectives of this study  are to investigate the safet y, tolerability, and 
antiviral activity  of [COMPANY_004]2838232 administered as monotherapy  in combination with 
cobicistat in HIV -1 infected subjects, over a 10 day  treatment period. The antiviral 
activity  will be assessed by  [CONTACT_428237] -1 RNA max change from baseline 
during the stud y. 
9.2. Sample Size Considerations
9.2.1. Sample Size A ssumptions
The sample size for thi s study  is based primarily  on feasibility  to provide adequate 
precision for the estimations.
Based on data from the short term monotherap y study  of BMS -955176 PoC (AI468002) 
study  and assuming viral load values for individual subjects follow a log -normal 
distribution, 1000 trial simulations in Fixed and Adaptive Clinical Trial Simulation 
(FACTS ) software were conducted from the distribution with mean of change from 
baseline viral load drop on log scale at 1.0 to 1.5 copi[INVESTIGATOR_428117]=0.4 and sample sizes=10 
forPart A.  Using Bay esian calculation with non -informative priors for the mean and 
weakl y informative priors for the error parameters, Normal (0, 100) for mean and Inverse 
Gamma (0.35, 0.0875) for error parameters, the posterior probability  to achieve a 
cutpoint 1.2 log was c alculated for each simulated trial, and percentage of the trials with  2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
58posterior probability  of viral load< -1.2log drop given true mean) ≥70% were calculated 
and are shown below in Table 10.
Table 10 Percentage of the trials with posterior probability >=70% for Part A
True Mean Cutpoint Posterior Prob>=70%
1.0 1.2 1.4%
1.1 1.2 9%
1.2 1.2 29%
1.3 1.2 59%
1.4 1.2 83%
1.5 1.2 96%
An Emax model with functional uniform priors [ Bornkamp , 2014] was conducted using 
simulated data combining Part A and Part B with all doses. Success is defined as a 
posterior probability  of the highest dose to achieve a cutpoint 1.2 log reduction in viral 
load.   This was ca lculated for each simulated trial and the percentage of the trials with 
posterior probability  greater or equal to 70% were also calculated and are shown below 
(Table 11). The table lists different viral load drop s cenarios. The last scenario assumes 
the flat drop for all doses are 0.5.  This scenario reflects the null hy pothesis of no 
treatment effect. In this scenario 0% of the trials achieve the pre -specified decision rule 
for success.
Table 11 Percentage of the trials with posterior probability  ≥70%
Cutpoint Posterior Prob ≥ Part A+ Part B 
mean VL drop for doses 200, 
100, 50, 20Part A+ Part B
1.2 70% 1.5, 1.4, 1.2, 0 99%
1.5, 1.4, 1.2, 0.5 96%
1.5, 1.4, 1.0, 0.5 93%
1.5, 1.3, 1. 2, 0.5 86%
0.5, 0.5, 0.5, 0.5 0%
9.2.2. Sample Size Sensitivity
Similar simulations in FACTS were conducted from the distribution with mean of change 
from baseline viral load drop on log scale at 1.5 copi[INVESTIGATOR_428117]=0.4 or 0.6 and sample 
sizes of 6- 8 or 10 for Part A.  Using Bayesian calculation, t he posterior probability  to 
achieve a cutpoint 1.2 log (in Table 12) was calculated for each simulated trial, and 
percentage of the trials with posterior probability  greater t han or equal to 70% was 
calculated and are shown below. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
59Table 12 Percentage of the trials with posterior probability  ≥70% for Part A
True 
MeanCutpoint Posterior 
Prob ≥Std for log10 
VLN=6 N=8 N=10
1.5 1.2 70% 0.4 90% 94% 96%
0.6 75% 81% 84%
9.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation will be performed.
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Intent to Treat Exposed Population (ITT)
The ITT-Exposed Population is defined as all subjects who meet stud y criteria and are 
enrolled into the study  with documented evidence of having received at least [ADDRESS_541438]- baseline HIV -1 RNA measurement. This will be the 
primary  population for the final efficacy  anal ysis for all a ctive treatment groups.
Per Protocol Population (PP)
The Per Protocol Population is defined as all subjects who meet study  criteria and are 
enrolled into the study  with documented evidence of having received all doses and all 
post-baseline HIV -[ADDRESS_541439] dose based on this review (e.g., the exposure level of 
[COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838232 exposure seen previously  in 
healthy  subjects), the Bayesian posterior probability  that the log10 viral load decline from 
baseline is greater than a cut- point will be calculated. If the Bay esian probability  from 
Cohort 1 is less than 70%, this will provide evidence to not move forward into Par t B. 
Otherwise, the stud y team will review the data in order to make a dose selection decision 
for the subsequent Part B Cohorts.  I f the pharmacokinetic exposures after the 100 mg 
[COMPANY_004]2838232/cobi dose look similar to those obtained with 100 mg [COMPANY_004]2838232/ r in  2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
60prior studies, the doses for Part B will be extended to both lower (20 mg, 50 mg) and 
higher (200 mg) [COMPANY_004]2838232 doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be summarized 
by [CONTACT_428216] . The proportion of subjects with plasma HIV -1 RNA 
<400 and <50 copi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if the two populations are 
not the same. 
9.4. Key Elements of A nalysis Plan
9.4.1. Primary  Analyses
The final analy sis will be performed after the completion of the study  and final datasets 
authorization. Data will be listed and summarized according to GlaxoSmithKline 
reporting standards, where applicable. Listings will be sorted b y subject, period, day, and 
time, noting treatment; summaries will be presented by  [CONTACT_3148], day , and time. Unless 
stated otherwise, descriptive summaries will include n, mean, standard deviation (SD), 
coefficient of variation (%CV), median, minimum, and maximum, geometric mean with 
associated 95% confidence interval (CI), and %CVb for continuous variables, whereas n 
and percent will be used as summary  statistics for categorical variables. Baseline or pre -
dose assessment is the last available assessment prior to time of the first dose unless it is 
specified otherwise. If there are multiple assessments collected on the same scheduled 
time, the average of these assessments will be used. For tabulated safet y summaries, only 
the scheduled assessments will be included in the summ ary tables. Version 9.1 or higher 
of the SAS sy stem will be used to anal yze the data as well as to generate tables, figures, 
and listings. Complete details will be documented in the Reporting and Analy sis Plan 
(RAP).
[IP_ADDRESS]. Safety  Analyses
Safety  data will be pre sented in tabular format and summarized descriptively  according to 
[COMPANY_004]’s Integrated Data Standards Library  standards and data will be in CDISC format. 
No formal statistical analysis of the safet y data will be conducted. 
[IP_ADDRESS]. Efficacy  Analyses
Both the PP and ITT Populations will be used for all efficacy  analy ses if there are 
dropouts.  Plasma HIV -[ADDRESS_541440], and assessment day  and 
summarized by  [CONTACT_428218].
Plots of mean and median plasma HIV -1 RNA actual and change from baseline data will 
be generated b y treatment and assessment day.
Plasma HIV -1 RNA cha nge from baseline to the on -treatment nadir (maximum 
change) will be calculated for each subject and summarized by  [CONTACT_3148]. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
[ADDRESS_541441] of lower doses on potential development of resistance. A dose -response 
curve will be fit to the data from Parts A & B using functional uniform priors.  
[IP_ADDRESS]. Pharmacokinetic A nalyses
Pharmacokinetic anal ysis will be the responsibility of the Clinical Pharmacokinetics 
Modeling and Simulation Department, GlaxoSmithKline. Plasma [COMPANY_004]2838232 
concentration -time data will be anal yzed by [CONTACT_105] -compartmental methods with 
WinNonlin Version 6.1 or higher. Calculations will be based on the actual sampling 
times recorded during the study . From the plasm a concentration -time data, the following 
pharmacokinetic parameters will be determined, as data permit:
Plasma [COMPANY_004]2838232 Pharmacokinetic Parameters to be Estimated:
Study Day Parameters
1 AUC(0 -24), Cmax, tmax, tlag, C24
10 AUC(0 -), Cmax, tmax, t½, C0, C, CL/F, R_AUC, R_Cmax, R_C 
Results based on samples collected from a subject with emesis within 4 hours of the dose 
will not be considered as evaluable.
All PK data will be stored in the R&D archives, GlaxoSmithKline.
Statistical analyses of the pharmacokinetic parameter data will be the responsibility  of 
Clinical Statistics, GlaxoSmithKline. Details of the statistical anal yses will be provided in 
the RAP. An outline is provided below:
Pharmacokinetic data will be presented in graphical and tabular fo rm and will be 
summarized descriptively. Plasma [COMPANY_004]2838232 PK parameters, with the exception of 
tmax and tlag, will be log- transformed prior to analy sis.
Dose proportionality  of plasma [COMPANY_004]2838232 PK parameters from Day  1 [AUC(0 -24) 
and Cmax] and Day  10 [AU C(0-τ) and Cmax] will be assessed using a power model if 
multiple dose levels are assessed. The power model will be fitted by  [CONTACT_428219] (REML ) using SAS Proc Mixed. A fixed effects power model will be used. 
The mean slope will be estima ted from the power model with the corresponding 90% CI. 
The accumulation ratio (R) and stead y
-state assessments will be performed, if quality  of 
the data permits. Comparisons of Day  10 with Day  1 PK for each dose will be used for 
the accumulation ratio (R) evaluation. Pre -dose concentrations between Day s 7-10 will be 
used for stead y-state assessment. 
9.4.2. Secondary  Analyses
[IP_ADDRESS]. Pharmacokinetic/Pharmacody namic A nalyses
Relationships between various PK parameters (e.g., AUC, Cmax, Cτ, etc.) and PD 
measures (e.g., log 10 reduction from baseline in plasma HIV- 1 RNA on Day  11 or safet y  2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
62parameters) will be explored using various models including Emax. The relationship 
between dose and PD measures will also be explored. Details of the PK/PD exploratory  
analyses will be prov ided in the RAP.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_428118]/phenot ypic data will be listed and descriptive summaries will be 
provided. Details of the analy ses will be provided in the clinical virology  report.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulato ry requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed inform ed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subjec t prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.   2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
63Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol wh ere required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors or designee will contact [CONTACT_395117], study requirements, and t heir 
responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the CRF will 
serve as the source d ocument.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other stu dy agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor or 
designee will conduct site closure activities with the investigator or site staff, as 
appropriate, in accordance with applicable regulations including GCP, and [COMPANY_004] 
Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.   2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
64If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
infor m the relevant regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inf orm the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  recor ds (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be ava ilable for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard c opy (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and r etrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_428238], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
[PHONE_8893].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where requir ed by [CONTACT_428239], an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have th e 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
10.8. Review  Committees
The Safet y Review Team (SRT) is a [COMPANY_004] cross -functional team reviewing all available 
safet y data related to the project, including in -stream data from this study , in an ongoing 
manner. The SRT is an internal [COMPANY_004] requirement put in place to ensure holistic 
evaluation of the safet y profile of an invest igational product with sy stematic, periodic and 
documented reviews of available safety  data, with the appropriate communication and 
escalation of new findings that have the potential to impact patient safet y 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
[PHONE_8894]. REFERENCES
Bloch M, Bodsworth N, Fidler M, Workm an C, Balach A, By [CONTACT_428221] H, et al. Efficacy , 
safet y and pharmacokinetics of MPC -4326 (bevirimat dimeglumine) 200mg BID and 
300mg BID monotherapy  administered for 14 day s in subjects with HIV -1 infection. 
ICAAC . 2009; Abstract H - 1230.
Bornkamp B, Practical considerations for using functional uniform prior distributions for 
dose-response estimation in clinical trials. Biometrical Journal 56 (2014) 6, 947 -962
Cockcroft DW, Gault MH. Prediction of creatinine clearance form serum creatinine. 
Nephron. 1976;16:31-41.
Dang Z, Huang L, Chen C. HI V
-1 maturation inhibitors:  An update. Drugs of the Future. 
2009;34 (10):797 -802.
Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, et al.  Phase 2 study  of 
cobicistat versus ritonavir each with once -daily  atazanavir an d fixed -dose 
emtricitabine.tenofovir df in the initial treatment of HIV infection.  AIDS .  2011; 
25:1881-1886.
Food and Drug Administration (FDA). Guidance for industry : Estimating the maximum 
safe starting dose in initial clinical trials for therapeutics in adult healthy  subjects. CDER, 
Rockville, MD; 2005. UCM078932.
Food and Drug Administration (FDA). Guidance for Industry : Human Immunodeficiency  
Virus -1 Infection: Developi[INVESTIGATOR_184804]. CDER, Rockville, 
MD; 2015. UCM355128.
Galla nt JE, Koenig E, Andrade-Villaneuva J, Chetchotisakd P, deJesus E, Antunes F, 
Arastéh K,  et al.  Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus 
emtricitabine/tenofovir disoproxil fumarate in treatment -naïve HIV t ype 1-infected 
patients:  week [ADDRESS_541442]. Dis.  2013; 208 -:32-39.
GlaxoSmithKline Document Number 2012N151889_03 Compound [COMPANY_004]2838232. 
Investigator’s Brochure.  Effective November 2016.
GlaxoSmithKline Non-Clinical Research report. Document Number 2013N163221_00.
Hatcher RA, Trussel J, Nelson AL , Cates W, Stewart F, Kowal D, editors. Contraceptive 
Technology . 19th ed. [LOCATION_001]:Ardent Media; 2007. 
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteele T, Hillewaert V, et 
al.  Pharmacokinetics of darunavir in f ixed-dose combination with cobicistat compared 
with coadministration of darunavir and ritonavir as single agents in healthy volunteers.  J. 
Clin. Pharmacol.  2009; 54:949-957. 2018N360917_00
2015N2278 52_02 CONFIDENTIA L
200911
67Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, et al. Safety and 
efficacy  study  of bevirimat (BVM) in heavil y treatment experienced HIV+ patients 
identifies the target phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Mahmood I . Prediction of human drug clearance from animal data. Application of the 
rule of ex ponent and fu corrected intercept method (FCIM). J Pharm Sci. 
2006;95:1810-21. 
Martin D, Galbraith H, Ellis C, Schettler J and Doto J. Minimal effect of ritonavir (RTV) 
on the pharmacokinetics of bevirimat in healthy  volunteers [abstract]. IAS Conference on 
HIV Pathogenesis, Treatment and Prevention. 2007; Abstract no. WEPEB015:Poster 
discussion.
Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple -dose pharmacokinetics and 
safet y of bevirimat, a novel inhibitor of HIV maturation, in healthy voluntee rs. Clin 
Pharmacokinet. 2007(a);46(7):589-98.
Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, et al. Safety and 
pharmacokinetics of bevirimat (PA -457), a novel inhibitor of human immunodeficiency  
virus maturation, in healthy  volunteers. Antim icrobial Agents and Chemotherapy. 
2007(b);Sep:3063 -6.
Martin DE, Galbraith H, Schettier J, Ellis C, Doto J. Pharmacokinetic properties and 
tolerability  of bevirimat and atazanavir in healthy volunteers:  An open -label, parallel -
group stud y. Clinical Therap eutics. 2008;30(10):1794 -1805.
NORVI R (ritonavir) Product I nformation. January , 2013.
Nowicka -Sans B, Protack T, L in Z, Li Z, Zhang S, Meanwell N, et al. BMS -955176: 
Characterization of a second- generation HIV -1 maturation inhibitor. 8th IAS Conference 
on HI V Pathogenesis, Treatment and Prevention, July  19-22, 2015, Vancouver, Canada.
Qian K, Morris -Natschke SL , Lee KH. HIV entry  inhibitors and their potential in HIV 
therap y. Medicinal Research Reviews. 2009;29(2):369
-93.
Saxena SK, Gupta A, Bhagy ashree K, Saxena R, Arora N, Banerjee AK, et al. Targeti ng 
strategies for human immunodeficiency  virus: A combinatorial approach. Min Rev Med 
Chem. 2012;12(3):236- 54.
TYBOST (cobicistat) Product I nformation. 2012
Wainburg MA, Albert J. Can the further clinical devel opment of bevirimat be justified?. 
AIDS. 2010;24:773 -4. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8895]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
g/mL Microgram per millilitre
ABC Abacavir
AE Adverse Event
AIDS Acquired immunodeficiency  syndrome
ALT Alanine aminotransferas e
API [INVESTIGATOR_428120] y
AST Aspartate aminotransferase
AUC Area under the plasma concentration time curve
AUC(0 -) Area under the concentration- time curve from time zero 
(pre-dose) extrapolated to infinite time
AUC(0 -) Area under the concentration- time curve over the dosing 
interval 
AUC(0 -24) Area under the concentration- time curve from zero (pre -
dose) to 24 h
AUC(0 -48) Area under the concentration- time curve from zero (pre -
dose) to 48 h
AUC(0 -t) Area und er the concentration- time curve from zero (pre -
dose) to time of last quantifiable concentration
BCRP Breast cancer resistance protein
BID Twice dail y
Bpm beats per minute
BVM Bevirimat
BIL Bilirubin
C Pre-dose (trough) concentration at the end of t he dosing 
interval
C24 24hour trough concentration
CDC Center for Disease Control and Prevention
CI Confidence interval
CL/F Oral Clearance
Cmax Maximum plasma concentration
Cmin Minimum plasma concentration
CPK Creatine Phosphokinase
CRF Case rep ort form
cTnI Cardiac troponin I
CV Coefficient of variation
CVb Between -subject variability
CYP Cytochrome P450
DDI Drug Drug Interaction
DNA Deox yribonucleic acid
EC50 50% protection against resistant mutant HI V infection  2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541443] time in Human Study
g Gram
GI Gastrointestinal
[COMPANY_004] GlaxoSmithKline
h Hour(s)
HBsAg Hepatitis B surface antigen
hcG Human chorionic gonadotrophin
HDPE High densit y pol yethylene
hERG Human Ether -a-gogo Related Gene
HIV Human Immunodeficiency  Virus
IC50/90 50% or 90% maximal inhibitory  concentration
IEC International Ethics Committee
IQ Inhibitory  quotient
IRB Institutional Review Board
ISR Injection s ite reaction
IV Intravenous
IVRS Interactive voice response sy stem
kg Kilogram
L Litre
LLOD Lower limit of detection
MC Melanocortin
MedDRA Medical Dictionary  for Regulatory  Activities
mg/mL Milligram per millilitre
MI Maturation inhibitor
mL Milliliter
mRNA messenger Ribonucleic Acid
ND Not done
ng/mL Nanogram per millilitre 
nm Nanometer
NO Not observed
NOAEL No Observed Adverse Effect Level
NTproBNP N-terminal prohormone of brain natriuretic peptide
NSVT Non-sustained ventricular tachy cardia
OAT Organic anion transporter
OATP Organic anion transporting pol ypeptide
OCT Organic cation transporter
PBL Peripheral Blood Ly mphocy tes
PBMC Peripheral Blood Mononuclear Cells
PD Pharmacod ynamics
[COMPANY_003] Pharmaceutical Product Development
P-gp P-glycoprotein
PHIV Pseudo- HIV 2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541444] quantifiable concentration
tmax Time of occurrence of Cmax
U Units
UGT Uridine 5' -diphospho- glucuronos yltransferase
Vz/F Mean apparent oral volume of distribution
WPW Wolff -Parkinson -White
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_428222], [COMPANY_002] HIV kit
Chiron RIBA 
Inform
Monogram
Phoenix WinNonlin 
SAS
Tybost (cobicistat) 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8896].2. Appendix 2: Liver Safety  Required A ctions and Follow up 
Assessments
Phase II liver chemistry stoppi[INVESTIGATOR_428156] e subject safet y and evaluate liver event etiology (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Phase II liver chemistry stoppi [INVESTIGATOR_420682] – Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2 ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2 ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3 ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Ac tions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if th e event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with study 
treatm ent unless allowed per protocol and [COMPANY_004] 
Medical Governance approval is granted 
If restart/rechallenge not allowed per protocol 
or not granted, permanently discontinue study 
treatment and may continue subject in the study Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtained within 24hrs after 
last dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
72for any protocol specified follow up assessments 
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within 
24hours
Monitor subjects twice weekly until liver 
chemistries re solve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within   24-
72hours 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineform including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct high-
performance liquid chromatography
assay (quantifies potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week 
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that su bject if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR m easurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or j aundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr v iral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
73Phase II liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_541445] safety. 
Subject can continue study treatment  
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver ch emistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. D rug Metab Dispos 2009; 37:1779-1784. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8897].3. Appendix 3: Liver Safety  –Stud y Treatment Restart or 
Rechallenge Guidelines
Study  treatment restart or re -challenge after liver chemistry  stoppi[INVESTIGATOR_428157]. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8898].4. Appendix 4: Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including [COMPANY_004]2838232/RTV or an y concomitant 
medicines;
HIV susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from m ultiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to i nitiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled i n the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collectio n of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 6 ml blood or 2 ml sa liva sample will be taken for Deox yribonucleic acid 
(DNA) extraction. A sample is collected at the baseline visit, after the subject has 
been randomized and provided informed consent for genetic research. Instructions 
for collection and shippi[INVESTIGATOR_428158]. The DNA from the blood/saliva sample may  undergo quality  control 
analyses to confirm the integrity of the sample. If there are concerns regarding the 
quality  of the sample, then the sample may  be destroy ed. The blood/saliva sample 
is taken on a single occasion unless a duplicate sample is required due to an 
inability  to utilize the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study .   This number can be traced or linked back to  2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541446] by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_541447] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to parti cipate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood/saliva being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws f rom the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the a ppropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed dur ing the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn c onsent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the in vestigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample  2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541448]’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientif ic journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_428159] t are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance an d scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8899].5. Appendix 5: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considere d related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events me eting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt t o be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected o r diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack of effi cacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SAE.
Thesigns and sy mptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of efficacy " or 
"failure of expected pharmacological action" also constitutes an AE or SAE. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
79Events N OTmeeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_428240] e subject’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appen dectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
c.Results in death
d.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
e.Requires hospi[INVESTIGATOR_428160]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
80f.Results in disability/incapacity
NOTE:
The term disability  means a substa ntial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental t rauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
g. Is a congenital anomaly/birth defect
h.Other situations:
Medical or scientific judgment should be exercised in deciding whethe r reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_428161] e of the 
other outcomes listed in the above definition.  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
i.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
Refer to Appendix 2 for the required liver chemistry  follow -up instructions 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8900].5.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascul arization
12.5.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instan ces when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investi gator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detai led b y  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
82the scale’s developer.
The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
12.5.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for ra ting 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator i s obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot b e ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is ver y important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004]. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
83The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
meas urements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
By [CONTACT_428223], the investigator is obligated to report an y grade 2 or higher 
“alteration in persona lity-behavior or in mood” or “altered mental status” adverse 
events that occur in subjects taking this drug, to [COMPANY_004] within 3 day s.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological e xaminations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopatholo gy. 
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.5.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data coll ection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE f rom a study  subject or receives updated data  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
84on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE r eceipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] via paper CRF
Facsim0ile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Me dical Monitor 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of the SAE data collection tool sent by 
[CONTACT_9338]
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] vi a PI[INVESTIGATOR_46427]
Facsimile transmission of the following PI[INVESTIGATOR_428122]:
SAE listing
Demographic listing
Study  treatment listing
In rare circ umstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of all required information sent by [CONTACT_428224].
If the PI[INVESTIGATOR_428162], the site will use the paper 
SAE form and fa x that to the Medical Monitor or protocol contact. The site will enter 
the SAE data into PI [INVESTIGATOR_428124] s ystem becomes available. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8901].6. Appendix 6: Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24hrs of learning of a subject's pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, re gardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spon
taneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as describ ed in Appendix [ADDRESS_541449] who becomes pre gnant while participating 
will discontinue study  medication andbe withdrawn from the study
This will only  be included if either of the following appl y:
Investigator will attempt to collect pregnancy  information on any  female partner of a 
male study  subje ct who becomes pregnant while participating in this study .  This 
applies only  to subjects who are randomized to receive study  medication. 
After obtaining the necessary  signed informed consent from the female partner 
directly , the investigator will record pregnancy  information on the appropriate form 
report the event and submit it to [COMPANY_004] within 24hrs of learning of the partner’s 
pregnancy
Partner will also be followed to determine the outcome of the pregnancy .  
Information on the status of the mother and child will be forwarded to [COMPANY_004]. 
Generally , follow -
up will be no longer than 6 to 8 weeks following the estimated 
delivery  date.  An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication fo r procedure. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8902].7. Appendix 7: Country  Specific Requirements
No country -specific requirements exist. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[PHONE_8903].8. Appendix 8: Division Of A IDS Table For Grading The 
Severit y Of A dult And Pediatric A dverse Events Version 1.0, 
December 2004; Clarification A ugust 2009
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
ESTIMATING SEVERITY GRADE
Clinical adverse 
event NOT identified 
elsewhere in the 
grading tableMild symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicatedModerate 
symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention not 
indicatedSevere symptoms 
causing inability to 
perform usual social 
& functional act ivities 
with intervention or 
hospi[INVESTIGATOR_428125] -
threatening symptoms 
causing inability to 
perform basic self -care 
functions OR Medical or 
operative intervention 
indicated to prevent 
permanent impairment, 
persistent disability, or 
death 
CARDIOVASCULAR
Arrhythmia
(by[CONTACT_223081])
Specify type, if
applicableNo symptoms 
AND No 
intervention 
indicatedNo symptoms AND
non-urgent 
intervention 
indicatedNon-life-threatening 
symptoms AND Non -
urgent intervention 
indicatedLife-threatening 
arrhythmia OR Urgent 
intervention indicated
Blood Pressure 
Abnormalities1 
Hypertension (with 
the lowest reading 
taken after repeat 
testing during a visit) 
≥ 18 years of age 140 to < 160 
mmHg systolic 
OR 90 to < 100 
mmHg diastolic ≥ 160 to < 180 
mmHg systolic OR 
≥ 100 to < 110 
mmHg diastolic ≥ 180 mmHg systolic 
OR ≥ 110 mmHg 
diastolic Life-threatening 
consequences in a 
participant not 
previously diagnosed
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_373] 
< 18 years of age > 120/80 mmHg ≥ 95th to < 99th 
percentile + 5 
mmHg adjusted for 
age, height, and 
gender (systolic 
and/or diastolic) ≥ 99th percentile + 5 
mmHg adjusted fo r 
age, height, and 
gender (systolic 
and/or diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_428126] (stable 
angina) OR New 
testing consistent 
with ischemia Unstable angina OR 
Acute myocardial 
infarction  2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541450] or 
with minimal activity 
orexertion (e.g., 
hypoxemia) OR 
Intervention indicated 
(e.g., oxygen) Life-threatening 
consequences OR 
Urgent intervention 
indicated (e.g., 
vasoactive medications, 
ventricular assist device, 
heart transplant) 
Hemorrhage (with 
significant acute 
blood loss) NA Symptoms AND No 
transfusion 
indicated Symptoms AND 
Transfusion of ≤ 2 
units packed RBCs 
indicated Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs (for 
children, packed RBCs 
> 10 cc/kg) indicated 
Prolonged PR 
Interval or AV B lock 
Report only one 
> 16 years of age PR interval 0.21 
to < 0.25 seconds PR interval ≥ 0.25 
seconds OR Type I 
2nd degree AV 
block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
≤ [ADDRESS_541451] degree AV 
block (PR interval 
> normal for age 
and rate) Type I 2nd degree 
AV block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
Prolonged QTc 
Interval2 0.45 to 0.47 
seconds > 0.47 to 0.50 
seconds > 0.50 seconds OR ≥ 
0.06 seco nds above 
baseline Life-threatening 
consequences (e.g., 
Torsade de pointes, 
other associated serious 
ventricular dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention 
indicated Symptoms AND 
Intervention indicated Life-threatening embolic 
event (e.g., pulmonary 
embolism, thrombus) 
DERMATOLOGIC
Alopecia (scalp only) Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visu al 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities NA NA 
Bruising Localized to one 
area Localized to more 
than one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment indicated 
(e.g., or al 
antibiotics, 
antifungals, 
antivirals) IV treatment 
indicated (e.g., IV 
antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (e.g., 
sepsis, tissue necrosis)  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
89PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperpi[INVESTIGATOR_428127] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Hypopi[INVESTIGATOR_428128] & 
function al 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Petechiae Localized to one 
area Localized to more 
than one area Generalized NA 
Pruritus3(without 
skin lesions) Itchin g causing no 
or minimal 
interference with 
usual social & 
functional 
activities Itching causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Itching causing 
inability to perform 
usual social & 
functional activities NA 
Rash 
Specify type, if 
applicable Localized rash Diffuse rash OR 
Target lesions Diffuse rash AND 
Vesicles or limited 
number of bullae or 
superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized 
bullous lesions OR 
Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Stevens-
Johnson syndrome OR 
Toxic epi[INVESTIGATOR_428129]-threatening 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non -
ketotic coma, end organ 
failure) 
Gynecomastia Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing pain with 
greater than 
minimal 
interference with 
usual social & 
functional activities Disfigu ring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social 
& functional activities NA  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
90PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperthyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
suppression 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
thyroid storm) 
Hypothyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
replacement 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
myxedema coma) 
Lipoatrophy4 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy5 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
GASTROINTESTINAL
Anorexia Loss of appetite 
without decreased 
oral intake Loss of appetite 
associated with 
decreased oral 
intake without 
significant weight 
loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
Ascites No symptoms Symptoms AND 
Intervention 
indicated (e.g., 
diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despi[INVESTIGATOR_144482]-threatening 
consequences  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
91PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Bloating or 
Distension 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cholecystitis NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (e.g., 
sepsis, perforation) 
Constipation NA Persistent 
constipation 
requiring regular 
use of dietary 
modificat ions, 
laxatives, or 
enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (e.g., 
obstruction) 
Diarrhea ≥ 1 year of 
age Transient or 
intermittent 
epi[INVESTIGATOR_428130] ≤ 
3 stools over 
baseline per 24 -
hour period Persistent epi[INVESTIGATOR_428131] 4 to 6 
stools over baseline 
per 24- hour period Increase of ≥ 7 stools 
per 24- hour period 
OR IV fluid 
replacement 
indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one 
and specify 
location Symptoms but 
able to eat usual 
diet Symptoms causing 
altered dietary 
intake with no 
intervention 
indicated Symptoms causing 
severely altered 
dietary intake with 
intervention indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other 
than iron 
supplement Endoscopic 
intervention 
indicated Transfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Mucositis or 
Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes 
or ulcerations Confluent 
pseudomembranes 
or ulcerations OR 
Mucosal bleeding 
with minor trauma Life-threatening 
consequences (e.g., 
aspi[INVESTIGATOR_1516], choking) OR 
Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
Nausea Transient (< 24 
hours) or 
intermittent AND 
No or minimal 
interference with 
oral intake Persistent nausea 
resulting in 
decreased oral 
intake for 24 to 48 
hours Persistent nausea 
resulting in minimal 
oral intake for > 48 
hours OR 
Rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pancreatitis NA Symptoms with 
hospi[INVESTIGATOR_184842]-threatening 
consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis)  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
92PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort 
with no 
intervention 
indicated Symptoms causing 
greater than 
minimal 
interfe rence with 
usual social & 
functional activities 
OR Medical 
intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (e.g., 
perforation) 
Rectal Di scharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND 
No or minimal 
interference with 
oral intake Frequent epi[INVESTIGATOR_428132] 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
MUSCULOSKELETAL
Arthralgia Joint pain causing 
no or minimal 
interference with 
usual social & 
functional 
activities Joint pain causing
greater than 
minimal 
interference with 
usual social & 
functional activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self -care 
functions 
Arthritis Stiffness o r joint 
swelling causing 
no or minimal 
interference with 
usual social & 
functional 
activities Stiffness or joint 
swelling causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions 
Myalgia 
(generalized) Muscle pain 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Muscle pain 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
inability to perform 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self -care 
functions 
Osteonecrosis NA No symptoms but 
with radiographic 
findings AND No 
operative 
intervention 
indicated Bone pain with 
radiographic findings 
OR Operative 
intervention indicated Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self-care 
functions 
Osteopenia6
≥ 30 years of age BMD t -score -2.5 
to -1 NA NA NA  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
93PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
< 30 years of age BMD z -score -2 to 
-1 NA NA NA 
Osteoporosis6
≥ 30 years of age NA BMD t -score < -2.5 Pathologic fracture 
(e.g., compression 
fracture caus ing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
< 30 years of age NA BMD z -score < -2 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threaten ing 
consequences 
NEUROLOGIC
Acute Central 
nervous system 
(CNS) Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accident (e.g., stroke 
with neurological deficit) 
Altered Mental 
Status (for 
Dementia, see 
Cognitive, 
Behavioral, or 
Attentio nal 
Disturbance below) Changes causing 
no or minimal 
interference with 
usual social & 
functional 
activities Mild lethargy or 
somnolence 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Confusion, memory 
impairment, let hargy, 
or somnolence 
causing inability to 
perform usual social 
& functional activities Delirium OR 
Obtundation OR Coma 
Ataxia Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
ataxia detected on 
examination Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self -care 
functions 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance 
(includes dementia 
and attention deficit 
disorder) 
Specify type, if 
applicable Disability causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR 
Specialized 
resources not 
indica ted Disability causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part -
time basis indicated Disability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full -
time basis indicated Disability causing 
inability to perform basic 
self-care functions OR 
Institutionalization 
indicated  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
94PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Developmental 
Delay < 18 years of 
age 
Specify type, if 
applicable Mild 
developmental 
delay, either 
motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental 
delay, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Severe 
develo pmental delay, 
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting 
Headache Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428163] (includes 
myopathy and 
neuropathy) 
Specify type, if 
applicable Minimal muscle 
weakness causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
decreased 
strength on 
examination Muscle weakness 
causing greater 
than minimal 
interfere nce with 
usual social & 
functional activities Muscle weakness 
causing inability to 
perform usual social 
& functional activities Disabling muscle 
weakness causing 
inability to perform basic 
self-care functions OR 
Respi[INVESTIGATOR_428134] (includes 
paresthesia and 
painful neuropathy) 
Specify type, if 
applicable Minimal 
paresthesia 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
sensory alteration 
on examina tion Sensory alteration 
or paresthesia 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Sensory alteration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities Disabling sensory 
alteration o r paresthesia 
causing inability to 
perform basic self -care 
functions 
Seizures New Onset 
Seizure 
≥ 18 years of age NA NA 1 to 3 seizures Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
< 18 years of age 
(includes new or pre -
existing febrile 
seizures) Seizure lasting < 
5 minutes with < 
24 hours postictal 
state Seizure lasting 5 to 
< 20 minutes with < 
24 hours postictal 
state Seizure lasting ≥ 20 
minutes OR > 24 
hours postictal stateProlonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002])  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
95PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Pre-existing Seizure NA Increased 
frequency from 
previous level of 
control without 
change in seizure 
character Change in seizure 
character either in 
duration or quality 
(e.g., severity or 
focality) Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Syncope Near syncope 
without loss of 
consciousness 
(e.g., pre-
syncope) Loss of 
consciousness with 
no intervention 
indicated Loss of 
consciousness AND 
Hospi[INVESTIGATOR_428135], PUERPERIUM, AND PERINATAL
Fetal Death or 
Stillbirth (report 
using mother’s 
participant ID) 
Report only one NA NA Fetal loss occurring 
at ≥ 20 weeks 
gestation NA 
Preterm Delivery7
(report using 
mother’s participant 
ID) Delivery at 34 to < 
37 weeks 
gestational age Delivery at 28 to < 
34 weeks 
gestational age Delivery at 24 to < 28 
weeks gestational 
age Delivery at < 24 weeks 
gestational age 
Spontaneous 
Abortion or 
Miscarriage8(report 
using mother’s 
participant ID) 
Report only one Chemical 
pregnancy Uncomplicated 
spontaneous 
abortion or 
miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
PSYCHIATR IC
Insomnia Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early Moderate difficulty 
falling asleep, 
staying asleep, or 
waking up early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric 
Disorders 
(includes anxiety, 
depression, mania, 
and 
psychosis) 
Specify disorder Symptoms with 
intervention not 
indicated OR 
Behavior causing 
no or minimal 
interference with 
usual social & 
functional 
activities Symptoms with 
intervention 
indicated OR 
Behavior causin g 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms with 
hospi[INVESTIGATOR_428164] & 
functional activities Threatens harm to self 
or others OR Acute 
psychosis OR Beh avior 
causing inability to 
perform basic self -care 
functions  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
96PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Suicidal Ideation or 
Attempt 
Report only one Preoccupi[INVESTIGATOR_428165] 1 
second or peak 
flow reduced to ≥ 
70 to < 80% OR 
Mild symptoms 
with intervention 
not indicated Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 50 to < 
70% OR Symptoms 
with intervention 
indicated OR 
Symptoms causing 
greater t han 
minimal 
interference with 
usual social & 
functional activities Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 25 to < 
50% OR Symptoms 
causing inability to 
perform usual social 
& functional activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak fl ow < 25% OR 
Life-threatening 
respi[INVESTIGATOR_428137] & 
functional 
activities OR 
Wheezing OR 
Minimal increa se 
in respi[INVESTIGATOR_428138] & 
functional activities 
OR Nasal flaring 
OR Intercostal 
retractions OR 
Pulse oximetry 90 
to < 95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional activities 
OR Pulse oximetry < 
90% Respi[INVESTIGATOR_184852] (e.g., 
Continuous positive 
airway pressure [CPAP], 
Bilevel positive airway 
pressure [BPAP], 
intubation) 
SENSORY
Hearing Loss 
≥ 12 years of age NA Hearing aid or 
intervention not 
indicated Hearing aid or 
intervention indicated Profound bilateral 
hearing loss (> 80 dB at 
2 kHz and above) OR 
Non-serviceable hearing 
(i.e., >50 dB audiogram 
and <50% speech 
discrimination) 
< 12 years of age 
(based on a 1, 2, 3, 
4, 6 and 8 kHz 
audiogram) > 20 dB hearing 
loss at ≤ 4 kHz > 20 dB hearing 
loss at > 4 kHz > 20 dB hearing loss 
at ≥ 3 kHz in one ear 
with additional 
speech language 
related services 
indicated (where 
available) OR 
Hearin g loss 
sufficient to indicate 
therapeutic 
intervention, including 
hearing aids Audiologic indication for 
cochlear implant and 
additional speech -
language related 
services indicated 
(where available)  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
97PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Tinnitus Symptoms 
causing no or 
minimal 
interference w ith 
usual social & 
functional 
activities with 
intervention not 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functio nal activities NA 
Uveitis No symptoms 
AND Detectable 
on examination Anterior uveitis with 
symptoms OR 
Medicamylasal 
intervention 
indicated Posterior or pan -
uveitis OR Operative 
intervention indicated Disabling visual loss in 
affected eye(s) 
Vertig o Vertigo causing 
no or minimal 
interference with 
usual social & 
functional 
activities Vertigo causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self -care 
functions 
Visual Changes 
(assessed from 
baseline) Visual changes 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Visual changes 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Visual changes 
causing inability to 
perform usual social 
& functional activities Disabling visual loss in 
affected eye(s) 
SYSTEMIC
Acute Allergic 
Reaction Localized urticaria 
(wheals) with no 
medic al 
intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with 
no intervention 
indicated Generalized urticaria 
OR Angioedema with 
intervention indicated 
OR Symptoms of 
mild bronchospasm Acute anaphylaxis OR 
Life-threat ening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9Mild signs and 
symptoms AND 
Therapy (i.e., 
antibody infusion) 
interruption not 
indicated Therapy (i.e., 
antibody infusion) 
interruption 
indicated AND 
Responds promptly 
to sy mptomatic 
treatment OR 
Prophylactic 
medications 
indicated for ≤ 24 
hours Prolonged severe 
signs and symptoms 
OR Recurrence of 
symptoms following 
initial improvement Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support)  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
98PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Fatigue o r Malaise 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating 
symptoms of fatigue or 
malaise causing inability 
to perform basic self -
care functions 
Fever (non-axillary 
temperatures only) 38.0 to < 38.6°C 
or 100.4 to < 
101.5°F ≥ 38.6 to < 39.3°C 
or ≥ 101.5 to < 
102.7°F ≥ 39.3 to < 40.0°C or 
≥ 102.7 to < 104.0°F ≥ 40.0°C or ≥ 104.0°F 
Pain10(not 
associated with study 
agent injections and 
not specified 
elsewhere) 
Specify location Pain causing no 
or minimal 
interference with 
usual social & 
functional 
activities Pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Pain causing inability 
to perform usual 
social & functional 
activities Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428139]11 Mild signs and 
symptoms Moderate signs and 
symptoms AND 
Intervention 
indicated (e.g., 
antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(e.g., steroids or IV 
fluids) Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Underweight12
> 5 to 19 years of 
age NA World Health 
Organization 
(WHO) BMI z- score 
< -2 to ≤ -3 WHO BMI z -score < -
3 WHO BMI z -score < -3 
with life -threatening 
consequences 
2 to 5 years of age NA WHO Weight -for-
height z -score 
< -2 to ≤ -3 WHO Weight -for-
height z -score < -3 WHO Weight -for-height 
z-score < -3 with life -
threatening 
consequences 
< 2 years of age NA WHO Weight -for-
length z -score 
< -2 to ≤ -3WHO Weight -for-
length z -score < -3 WHO Weight -for-length 
z-score < -3 with life -
threatening 
consequences 
Weight Loss 
(excludes postpartum 
weight loss) NA 5 to < 9% loss in 
body weight from 
baseline ≥ 9 to < 20%  loss in 
body weight from 
baseline ≥ 20% loss in body 
weight from baseline OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
URINARY
Urinary Tract 
Obstruction NA Signs or symptoms 
of urinary tract 
obstruction without 
hydronephrosis or 
renal dysfunctionSigns or symptoms of 
urinary tract 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing life -
threatening 
consequences  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
99PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
SITE REACTIONS TO INJECTIONS AND INFUSIONS
Injection Site Pain 
or Tenderness 
Report only one Pain or 
tendernes s 
causing no or 
minimal limitation 
of use of limb Pain or tenderness 
causing greater 
than minimal 
limitation of use of 
limb Pain or tenderness 
causing inability to 
perform usual social 
& functional activities Pain or tenderness 
causing inability to 
perform basic self -care 
function OR 
Hospi[INVESTIGATOR_428140]13 
Report only one 
> 15 years of age 2.5 to < 5 cm in 
diameter OR 6.25 
to < 25 cm2 
surface area AND 
Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities ≥ 5 to < 10 cm in 
diameter OR ≥ 25 
to < 100 cm2 
surface area OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities ≥ 10 cm in diameter 
OR ≥ 100 cm2 
surface area OR 
Ulceration OR 
Seconda ry infection 
OR Phlebitis OR 
Sterile abscess OR 
Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper ti ssue) 
≤ 15 years of age ≤ 2.5 cm in 
diameter > 2.5 cm in 
diameter with < 
50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) ≥ 50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) OR Ulceration 
OR Secondary 
infection OR Phlebitis 
OR Sterile abscess 
OR Drainage Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or 
Swelling 
Report only one 
> 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, > 15 y ears of 
age 
≤ 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
age 
Injection Site 
Pruritus Itching localized 
to the injection 
site that is 
relieved 
spontaneously or 
in < 48 hours of 
treatment Itching beyond the 
injection site that is 
not generalized OR 
Itching localized to 
the injection site 
requiring ≥ 48 
hours treatment Generalized itching 
causing inability to 
perform usual social 
& functional activities NA 
LABORATORY VALUES Chemistries
Acidosis NA pH ≥ 7.3 to < Lower 
limit of normal 
(LLN) pH < 7.3 without life -
threatening 
consequences pH < 7.3 with life -
threatening 
consequences 
Albumin, Low (g/dL; 
g/L) 3.0 to < LLN 
30 to < LLN ≥ 2.0 to < 3.0
≥ 20 to < 30 < 2.0 
< 20 NA  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
100PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Alkaline 
Phosphatase, High 1.25 to < 2.[ADDRESS_541452] 2.5 to < 5.[ADDRESS_541453] 5.0 to < 10.0 x UL N ≥ 10.[ADDRESS_541454] 
Alkalosis NA pH > ULN to ≤ 7.5 pH > 7.5 without life -
threatening 
consequences pH > 7.5 with life -
threatening 
consequences 
ALT or SGPT, High 
Report only one 1.25 to < 2.[ADDRESS_541455] 2.5 to < 5.[ADDRESS_541456] 5.0 to < 10.[ADDRESS_541457] ≥ 10.[ADDRESS_541458]
Amylase 
(Pancreatic) or 
Amylase (Total), 
High 
Report only one 1.1 to < 1.[ADDRESS_541459] 1.5 to < 3.[ADDRESS_541460] 3.0 to < 5.[ADDRESS_541461] ≥ 5.[ADDRESS_541462] or SGOT, High 
Report only one 1.25 to < 2.[ADDRESS_541463] 2.5 to < 5.[ADDRESS_541464] 5.0 to < 10.[ADDRESS_541465] ≥ 10.[ADDRESS_541466] 
Bicarbonate, Low 
(mEq/L; mmol/L ) 16.0 to < LLN 
16.0 to < LLN 11.0 to < 16.0 
11.0 to < 16.0 8.0 to < 11.0 
8.0 to < 11.0 < 8.0 
< 8.[ADDRESS_541467] 
Bilirubin14, High 
> 28 days of age NA NA > ULN > ULN with life -
threatening 
consequences (e.g., 
signs and symptoms of 
liver failure) 
≤ [ADDRESS_541468] to ≤ 1 mg/dL > 1 to ≤ 1.5 mg/dL > 1.5 to ≤ 2 mg/dL > 2 mg/dL 
Total Bilirubin, High 
> 28 days of age 1.1 to < 1.[ADDRESS_541469] 1.6 to < 2.[ADDRESS_541470] 2.6 to < 5.[ADDRESS_541471] ≥ 5.[ADDRESS_541472] 
≤ 28 days of age Total Bilirubin for 
Term and Preter m 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for Term 
and Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L ) 
≥ 7 days of age 10.6 to < 11.5 
2.65 to < 2.88 11.5 to < 12.5 
2.88 to < 3.13 12.5 to < 13.5 
3.13 to < 3.38 ≥ 13.5 
≥ 3.38 
< 7 days of age 11.5 to < 12.4 
2.88 to < 3.10 12.4 to < 12.9 
3.10 to < 3.23 12.9 to < 13.5 
3.23 to < 3.38 ≥ 13.5 
≥ 3.38 
Calcium (Ionized), 
High (mg/dL; 
mmol/L ) > ULN to < 6.0
> ULN to < 1 .5 6.0 to < 6.4 
1.5 to < 1.6 6.4 to < 7.2 
1.6 to < 1.8 ≥ 7.2 
≥ 1.8  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
101PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Calcium, Low 
(mg/dL; mmol/L ) 
≥ 7 days of age 7.8 to < 8.4 
1.95 to < 2.10 7.0 to < 7.8 
1.75 to < 1.95 6.1 to < 7.0 
1.53 to < 1.75 < 6.1 
< 1.53 
< 7 days of age 6.5 to < 7. 5 
1.63 to < 1.88 6.0 to < 6.5 
1.50 to < 1.63 5.50 to < 6.0 
1.38 to < 1.50 < 5.50 
< 1.38 
Calcium (Ionized), 
Low (mg/dL; mmol/L ) < LLN to 4.0 
< LLN to 1.0 3.6 to < 4.0 
0.9 to < 1.0 3.2 to < 3.6 
0.8 to < 0.9 < 3.2 
< 0.8 
Cardiac Troponin I, 
High NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as 
defined by [CONTACT_428225], 
High 3 to < [ADDRESS_541473] 6 to < [ADDRESS_541474] 10 to < [ADDRESS_541475] ≥ [ADDRESS_541476] > 1.[ADDRESS_541477] 
OR Increase of > 
0.3 mg/dL above 
baseline > 1.8 to < 3.[ADDRESS_541478] 
OR Increase of 1.5 to 
< 2.0 x above 
baseline ≥ 3.[ADDRESS_541479] OR 
Increase of ≥ 2.0 x 
above baseline 
Creatinine 
Clearance15or
Estimated 
glomerular filtration 
rate (eGFR), Low 
Report only one NA < 90 to 60 mL/min 
or mL/min/1.73 m2 
OR 10 to < 30% 
decrease from 
baseline < 60 to 30 mL/min or 
mL/min/1.73 m2 OR 
≥ 30 to < 50%  
decrease from 
baseline < 30 mL/min or 
mL/min/1.73 m2 OR ≥ 
50% decrease from 
baseline or dialysis 
needed 
Glucose 
(mg/dL; mmol/L ) 
Fasting, High 110 to 125 
6.11 to < 6.95 > 125 to 250 
6.95 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Nonfasting, High 116 to 160 
6.44 to < 8.89 > 160 to 2 50 
8.89 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Glucose, Low 
(mg/dL; mmol/L ) 
≥ 1 month of age 55 to 64 
3.05 to 3.55 40 to < 55 
2.22 to < 3.05 30 to < 40 
1.67 to < 2.22 < 30 
< 1.[ADDRESS_541480] to < 2.[ADDRESS_541481] without 
acidosis ≥ 2.[ADDRESS_541482] without 
acidosis Increased lactate with 
pH < 7.3 without life -
threatening 
consequences Increased lactate with 
pH < 7.3 with life -
threatening 
consequences 
Lipase, High 1.1 to < 1.[ADDRESS_541483] 1.5 to < 3.[ADDRESS_541484] 3.0 to < 5.[ADDRESS_541485] ≥ 5.[ADDRESS_541486]  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
102PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Lipid Disorders 
(mg/dL; mmol/L ) 
Cholesterol, 
Fasting, High 
≥ 18 years of age 200 to < 240 
5.18 to < 6.19 240 to < 300 
6.19 to < 7.77 ≥ 300 
≥ 7.77 NA 
< 18 years of age 170 to < 200 4.40 
to < 5.15 200 to < 300 5.15 to 
< 7.77 ≥ 300 ≥ 7.77 NA 
Low Density 
Lipoprotein (LDL),
Fasting, High 
≥ 18 years of age 130 to < 160 3.37 
to < 4.12 160 to < 190 4.12 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
> 2 to < 18 years of 
age 110 to < 130 2.85 
to < 3.34 130 to < 190 3.34 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
Triglycerides, 
Fasting, High 150 to 300 
1.71 to 3.42 >300 to 500 
>3.42 to 5.7 >500 to < 1,000 
>5.7 to 11.4 > 1,000 
> 11.4 
Magnesium16, Low 
(mEq/L; mmol/L ) 1.2 to < 1.4 
0.60 to < 0.70 0.9 to < 1.2 
0.45 to < 0.60 0.6 to < 0.9 
0.30 to < 0.45 < 0.6 
< 0.30 
Phosphate, Low 
(mg/dL; mmol/L ) 
> 14 years of age 2.0 to < LLN 
0.81 to < LLN 1.4 to < 2.0 
0.65 to < 0.81 1.0 to < 1.4 
0.32 to < 0.65 < 1.0 
< 0.32 
1 to 14 years of age 3.0 to < 3.5 
0.97 to < 1.13 2.5 to < 3.0 
0.81 to < 0.97 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
< 1 year of age 3.5 to < 4.5 
1.13 to < 1.45 2.5 to < 3.5 
0.81 to < 1.13 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
Potassium, High 
(mEq/L; mmol/L ) 5.6 to < 6.0 
5.6 to < 6.0 6.0 to < 6.5 
6.0 to < 6.5 6.5 to < 7.0 
6.5 to < 7.0 ≥ 7.0 
≥ 7.0 
Potassium, Low 
(mEq/L; mmol/L ) 3.0 to < 3.4 
3.0 to < 3.4 2.5 to < 3.0 
2.5 to < 3.0 2.0 to < 2.5 
2.0 to < 2.5 < 2.0 
< 2.0 
Sodium, High 
(mEq/L; mmol/L ) 146 to < 150 
146 to < 150 150 to < 154 
150 to < 154 154 to < 160 
154 to < 1 60 ≥ 160 
≥ 160 
Sodium, Low 
(mEq/L; mmol/L ) 130 to < 135 
130 to < 135 125 to < 130 
125 to < 135 121 to < 125 
121 to < 125 ≤ 120 
≤ 120 
Uric Acid, High 
(mg/dL; mmol/L ) 7.5 to < 10.0 
0.45 to < 0.59 10.0 to < 12.0 
0.59 to < 0.71 12.0 to < 15. 0 
0.71 to < 0.89 ≥ 15.0 
≥ 0.89  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
103PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
HEMATOLOGY
Absolute cluster of 
differentiation 4 
(CD4+) Count, Low 
(cell/mm3; cells/L ) 
> 5 years of age (not 
HIV infected) 300 to < 400 
300 to < 400 200 to < 300 
200 to < 300 100 to < 200 
100 to < 200 < 100 
< 100 
Absolute 
Lymphocyte Count, 
Low 
(cell/mm3; cells/L ) 
> 5 years of age 
(not HIV infected) 600 to < 650 
0.600 x 109to < 
0.650 x 109500 to < 600 
0.500 x 109to < 
0.600 x 109350 to < 500 
0.350 x 109to < 
0.500 x 109< 350 
< 0.350 x 109
Absolu te Neutrophil 
Count (ANC), Low 
(cells/mm3; cells/L ) 
> 7 days of age 800 to 1,000 
0.800 x 109to 
1.000 x 109600 to 799 
0.600 x 109to 0.799 
x 109400 to 599 
0.400 x 109to 0.599 
x 109< 400 
< 0.400 x 109
2 to 7 days of age 1,250 to 1,500 
1.250 x 109to 
1.500 x 1091,000 to 1,249 
1.000 x 109to 1.249 
x 109750 to 999 
0.750 x 109to 0.999 
x 109< 750 
< 0.750 x 109
≤ 1 day of age 4,000 to 5,000 
4.000 x 109to 
5.000 x 109 3,000 to 3,999 
3.000 x 109to 3.999 
x 1091,500 to 2,999 
1.500 x 109to 2.999 
x 109< 1,500 
< 1.500 x 109
Fibrinogen, 
Decreased (mg/dL; 
g/L) 100 to < 200 
1.00 to < 2.00 OR 
0.75 to < 1.[ADDRESS_541487] 75 to < 100 
0.75 to < 1.00 OR ≥ 
0.50 to < 0.[ADDRESS_541488] 50 to < 75 
0.50 to < 0.75 OR 
0.25 to < 0.[ADDRESS_541489] < 50 
< 0.50 OR < 0.[ADDRESS_541490] 
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L )18 
≥ 13 years of age 
(male only) 10.0 to 10.9 
6.19 to 6.76 9.0 to < 10.0 
5.57 to < 6.19 7.0 to < 9.0 
4.34 to < 5.57 < 7.0 
< 4.34 
≥ 13 years of age 
(female only ) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
57 days of age to < 
13 years of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
<4.03  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
104PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
36 to 56 days of age 
(male and female) 8.5 to 9.6 
5.26 to 5.99 7.0 to < 8.5 
4.32 to < 5.26 6.0 to < 7.0 
3.72 to < 4.32 < 6.0 
< 3.72 
22 to 35 days of age 
(male and female) 9.5 to 11.0 
5.88 to 6.86 8.0 to < 9.5 
4.94 to < 5.88 6.7 to < 8.0 
4.15 to < 4.94 < 6.7 
< 4.15 
8 to ≤ 21 days of age 
(male and female) 11.0 to 13.0 
6.81 to 8.10 9.0 to < 11.0 
5.57 to < 6.81 8.0 to < 9.0 
4.96 to < 5.57 < 8.0 
< 4.96 
≤ 7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to < 13.0 
6.19 to < 8.05 9.0 to < 10.0 
5.59 to < 6.19 < 9.0 
< 5.59 
INR, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541491] 1.5 to < 2.[ADDRESS_541492] 2.0 to < 3.[ADDRESS_541493] ≥ 3.[ADDRESS_541494] 
Methemoglobin (% 
hemoglobin) 5.0 to < 10.0% 10.0 to < 15.0% 15.0 to < 20.0% ≥ 20.0% 
PTT, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541495] 1.66 to < 2.[ADDRESS_541496] 2.33 to < 3.[ADDRESS_541497] ≥ 3.[ADDRESS_541498] 
Platelets, 
Decreased 
(cells/mm3; cells/L ) 100,000 to < 
124,999 100.000 
x 109to < 124.999 
x [ZIP_CODE],000 to < 100,000 
50.000 x 109to < 
100.000 x 109 25,000 to < 50,000 
25.000 x 109to < 
50.000 x 109< 25,000 < 25.000 x 109
PT, High 
(not on 
anticoagulation 
therapy 1.1 to < 1.[ADDRESS_541499] 1.25 to < 1.[ADDRESS_541500] 1.50 to < 3.[ADDRESS_541501] ≥ 3.[ADDRESS_541502] 
WBC, Decreased
(cells/mm3; cells/L ) 
> 7 days of age 2,000 to 2,499 
2.000 x 109to 
2.499 x 1091,500 to 1,999 
1.500 x 109to 1.999 
x 1091,000 to 1,499 
1.000 x 109 to 1.499 
x 109< 1,000 
< 1.000 x 109
≤ 7 days of age 5,500 to 6,999 
5.500 x 109to 
6.999 x 109 4,000 to 5,499 
4.000 x 109to 5.499 
x 1092,500 to 3,999 
2.500 x 109to 3.999 
x 109< 2,500 
< 2.500 x 109
URINALYSIS
Glycosuria ( random 
collection tested by 
[CONTACT_5230]) Trace to 1+ or 
≤ 250 mg 2+ or ˃  250 to 
≤ 500 mg > 2+ or > 500 mg NA  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
105PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hematuria (not to be 
reported based on 
dipstick findings or 
on blood believed to 
be of menstrual 
origin) 6 to < 10 RBCs 
per high power 
field ≥ 10 RBCs per high 
power field Gross, with or without 
clots OR With RBC 
casts OR Intervention 
indicated Life-threatening 
consequences 
Proteinuria (random 
collection tested by 
[CONTACT_5230]) 1+ 2+ 3+ or higher NA 
1. Blood pressure norms for children <18 years of age can be found in: Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and Adolescents. Pediatrics 2011;128;S213; originally 
published online November 14, 2011; DOI: 10.1542/peds.2009 -2107C.  
2. As per Bazett’s formula.  
3. For pruritus associated with injections or infusions, see the Site Reactions to Injections and In fusions section.  
4. Definition: A disorder characterized by [CONTACT_184941], extremities, and buttocks. 
5. Definition: A disorder characterized by [CONTACT_184942], breasts, and abdomen.  
6. Bone mineral density (BMD) t an d z scores can be found in: Kanis JA on behalf of the World Health Organization 
Scientific Group (2007). Assessment of osteoporosis at the primary health -care level. Technical Report. World 
Health Organization Collaborating Centre for Metabolic Bone Diseas es, University of Sheffield, [LOCATION_006]. 2007: Printed 
by [CONTACT_184943].  
7. Definition: A delivery of a live -born neonate occurring at ≥20 to <37 weeks gestational age. 
8. Definition: A clinically recognized pregnancy occurring at <20 weeks gestational age.  
9. Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of 
breath. 
10. For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section.
11. Definition: A disord er characterized by [CONTACT_411], arthralgia, myalgia, skin eruptions, lymphadenopathy, marked 
discomfort, and/or dyspnea.
12. WHO reference tables may be accesed by [CONTACT_184944]: 
http://www.who.int/growthref/who20 07_bmi_for_age/en/ for participants >5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤ [ADDRESS_541503] bilirubin >1.5 mg/dL in a participant <28 days of age should be graded as Grade 2, if <10% of the total 
bilirubin.  
15. Use the applicable formula (i.e., Cockroft -Gault in mL/min or Schwatrz in mL/min/1.73m2).  
16. To convert a ma gnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.  
17. Male and female sexes are defined as sex at birth. 
18. The conversion factor used to convert g/dL to mmol/L is 0.[ADDRESS_541504] be converted to g/dL using the appropriate conversion factor for the particular laboratory.   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
[ZIP_CODE].9. Appendix 9: Toxicity  Management
ANEMIA
Grade 1 (mild) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541505] be repeated with the 
following additional tests:
20.peripheral blood smear
21. indirect bilirubin (abnormal if increased >50% from baseline)
22.haptoglobin (abnormal if  25 mg/dL)
23.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will per manently  discontinue study  medication and 
be withdrawn from the trial.  Subjects should be followed up until resolution of anemia.
Grade 2 (moderate) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541506] be repeated with the 
following additional tests:
1.peripheral blood smear
2. indirect bilirubin (abnormal if increased > 50% from baseline)
3.haptoglobin (abnormal if  25 mg/dL)
4.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will permanently  discontinue study  medication and 
be withdrawn from the trial.  Consultation with a Hematologist s hould be considered.  
Subjects should be followed up until resolution of anemia.
Grade 3 (severe) or Grade 4 (potentially life threatening) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541507] be repeated with 
the follow ing additional tests:
5.peripheral blood smear
6. indirect bilirubin
7.haptoglobin
8.reticulocy te count  2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541508] should be considered.  Subjects should be followed up 
until resolution of anemia.
TOTA L BILIRUBIN ELEVA TION
Grade 1 (mild) bilirubin elevation (1.[ADDRESS_541509]) or Grade 2 (moderate 
-1.6-2.[ADDRESS_541510]):
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects may  continue study  medication.  Subjects should 
be followed up until resolution (return to baseline) of elevation.
Grade 3 (severe –2.6-5.[ADDRESS_541511]) or 4 (life- threatening -> 5.[ADDRESS_541512]) 
bilirubin elevation :
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects will permanently  discontinue study medication 
and be withdrawn from the trial.  Subjects should be followed up until resoluti on (return 
to baseline) of bilirubin elevation.
AST AND ALT ELEVA TION
See Appendix 9 .
RASH
Grade 1 rash (Localized macular rash):
Subjects with Grade [ADDRESS_541513].  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
9.Temperature > 38.5°C
10.Lym phadenopathy
11.Phary ngitis
12.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541514] should remain on the study  to be 
followed for safet y and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
108Grade 2 rash (Diffuse macular, maculopapular, or morbilliform rash OR Target
lesions):
Subjects with Grade [ADDRESS_541515].  The study  drug should b e permanentl y 
discontinued if the following signs or s ymptoms are noted at an y time:
13.Temperature > 38.5°C
14.Lym phadenopathy
15.Phary ngitis
16.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subject s with Grade [ADDRESS_541516] should remain on the study to be followed for safety and PK as 
outlined in Section 10.5.
Grade 3 rash (Diffuse macular, mac ulopapular, or morbilliform rash with vesicles 
or limited number of bullae OR Superficial ulcerations of mucous membrane 
limited to one site):
Subjects with a Grade [ADDRESS_541517] should be evaluated in the phy sician’s office immediatel y and should be seen in 
the phy sician’s office or contact[CONTACT_428226]  [ADDRESS_541518] should remain on the 
study  to be followed for safet y and PK as outlined in Section 10.5.
Grade 4 rash (Extensive or generalized bullous lesions OR Stevens -Johnson 
syndrome OR Ulceration of mucous membrane involving two or more distinct 
mucosal sites OR Toxic epi[INVESTIGATOR_194] (TEN)):
Subjects with a Grade [ADDRESS_541519] sh
ould remain on the stud y to be followed 
for safety  and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
109ALLERGIC RE ACTION
Grade 1 allergic reaction (Pruritis without rash):
Subjects with Grade 1 allergic reaction should be evalu ated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
17.Temperature > 38.5°C
18.Eosinophilia
19.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
20.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541520] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428142].  The subject should remain on the study  to be 
followed for safety and PK as outlined.
Grade 2 allergic reaction (Localized urticaria):
Subjects with Grade 2 allergic reaction should be evaluated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
21.Temperature > 38.5°C
22.Eosinophilia
23.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
24.Any indicatio n of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541521] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard 
management, i ncluding discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428143].  The subject should remain on the study  to be 
followed for safet y and PK as outlined in Section 7. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
110Grade 3 allergic reaction (Generalized urticaria or angioedema):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Grad e 4 allergic reaction (Anaphylaxis):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Revised ACTG Toxicity Grade Definitions Investigator Action
Grade 1 Pruritus without rash May continue therapy
Grade 2 Localized urticaria May continue therapy
Grade 3 Generalized urticaria
AngioedemaDiscontinu e Therapy
Grade 4 Anaphylaxis Discontinue Therapy 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
[ZIP_CODE].10. Appendix 10: Protocol A mendment Changes
12.10.1. AMENDMENT 1
Protocol Amendment 1 (26- Apr-2017) from the original protocol (09 -Nov-2016)
Where the A mendment A pplies
This amendment applies to all subjects who will participate in this study  in all countries.
List of Specific Changes: (bold indicates text added and strikethrough indicates text 
removed)
Summary  of Protocol A mendment Changes with Rationale
Amendment 1 includes minor updates to I nclusion criteria (IE) c riteria, including 
clarification on use of pre- or post -exposure prophy laxis, and removal of exclusionary  
requirements related to concomitant medications and tobacco and alcohol use during the 
study . Guidance around relevant habits is included in the L ifestyle section of the protocol 
and adjustments were made to reduce restrictions on these requirements. Modifications 
were also made to the pharmacokinetics sampling, allowing for the 12 h PK collection 
timepoint on Day  1 and 10 to be optional. Minor alterati ons were made regarding the 
order of screening procedures, including the Holter monitoring requirements. 
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. Furthermore, the serial ECG collection (up to 6h post -dose) was removed on 
Day 5. Finall y, the post -study  care guidance was updated to include an option for subjects 
to receive reimbursement for marketed ART for a limited period after completion of 
study  treatment and follow up. Minor clarifications, reformatt ing of tables, re -numbering 
of sections and correction of ty pographical errors were also made throughout this 
amendment.
List of A uthors
Rationale for change
The list of authors was updated based on internal [COMPANY_004] team personnel changes.
Revised Text
PTS, Ware, [LOCATION_006]
GCSP, Stockley  Park, [LOCATION_006]
Infectious Diseases, Clinical, Upper Providence, PA, US
Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
HIV DPU, RTP, NC, US
Virology ,HIV DPU, RTP, NC, US 2018N360917_00
[COMPANY_003]
2015N227852_02 CONFIDENTIA L
200911
112CPMS, [COMPANY_004], RTP, NC, US
HIV DPU, RTP, NC, US
Clinical Pharmacology , ViiV Healthcare, RTP, NC, US
PCPS, [COMPANY_004], Upper Providence, PA, US
PCPS, [COMPANY_004], Collegeville, PA, US 
Clinical Statistics, PAREXEL , RTP, NC, US
Infectious Diseases, Clinical, Cambridge, MA, US
Medical Monitor/SA E Contact [CONTACT_428227] t the current 
contact [CONTACT_428228] y and medical monitoring. 
Revised Text
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor/SAE 
contact 
[CONTACT_428241]
([COMPANY_003]) Safety 
Hotline [LOCATION_011], 
MA[COMPANY_003], [ADDRESS_541522] 
information MD[LOCATION_011], MA
Synopsis: Design, Treatment A rms and Duration
Rationale for change
Minor clarifications were made to this section to reflect current status of studies being 
referenced. As s ynopsis being a standalone document, cross -referenced has been 
removed. 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_02 CONFIDENTIA L
200911
113Revised Text
Fourth paragraph
The possibility  that an additional, unboo sted [COMPANY_004]2838232 monotherap y cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from ongoing Study  204953 
where unboosted [COMPANY_004]2838232 at a dose of 200 mg twice dail y (BID) is being was
assessed.
Sixth paragraph
HIV Drug Resistance: Following cessation of [COMPANY_004]2838232/cobi dosing for 10 day s, 
there will be prolonged exposure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t½ (i.e., in the “tail” of the PK profile). However, based on in vitro 
resistance passage data with [COMPANY_004]2838232 [and unlike with many  other ARV therapi[INVESTIGATOR_014]], 
there appears to be a limited likelihood of developi[INVESTIGATOR_428081]-infected subjects due to its virologic profile [[COMPANY_004] Document Number 
2013N163221_00] . 
Section [ADDRESS_541523] instance has been defined.
Revised Text
[COMPANY_004]2838232 is a novel human immunodeficiency virus ( HIV)-1 maturation inhibitor 
(MI) that is being developed for the treatment of HIV -1 infection in combination with 
other antiretrovirals (ART).
Section 2.[ADDRESS_541524] instance has been defined.
Revised Text
This ‘proof of concept (PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity , pharmacokinetics (PK), the relationship between PK and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg once daily (QD) cobicistat 
([COMPANY_004]283232/cobi), administered across a range of doses over [ADDRESS_541525] paragraph
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has demonstrated significant improvement in acquired 
immunodeficiency syndrome (AIDS)-related morbidity  and mortalit y over the last 10-
15 years.
Addition of abbreviation for RNA  in second paragraph
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [Martin, 2007a; Martin, 2007b; Martin, 2008; NORVIR, 2013]). 
BVM reached Phase II studies in HIV patients; however, onl y modest reductions in 
plasma HIV -1 ribonucleic acid (RNA) concentrations were observed in Phase IIa 
monotherap y studies [Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential) antiviral activity  [Wainburg, 2010] led to termination of BVM development. 
The average decrease from baseline to Day  14 plasma HIV -1 ribonucleic acid (RNA) 
was 0.54 and 0.70 log10 copi[INVESTIGATOR_014]/mL  for 200 mg and 300 mg twice daily  regimens (Table 
2); all subjects achieved plasma BVM concentrations above the in vitro EC90. 
Responders, classified based on 5 poly morphisms in HIV -1 gag (at positions 369, 370, 
and 371), achieved an average 1.15 log10 copi[INVESTIGATOR_014]/mL reduction in plasma HIV -1 RNA, 
while an avera ge 0.17 log10 copi[INVESTIGATOR_014]/mL  reduction was achieved for non- responders.
Section 2.2.[ADDRESS_541526] current status of studies being 
referenced.
Revised Text
To date, [COMPANY_004]2838232 has been evaluated in three completed clinical studies with or 
without ritonavir (RTV) ([COMPANY_004]2838232/r). A fourth study  (204953) is on- going as of 1st
November completed late 2016 and data analysis is ongoing . Full details of the clinical 
results can be found in the Investigator’s Brochure.
Section [IP_ADDRESS] Clinical Summary  of Safety
Rationale for change
Minor clarifications were made to this section to reflect current status of studies being 
referenced. 2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541527] hadbeen exposed to [COMPANY_004]2838232 
in 3 completed studies. One study  (204953) is completed in late 2016 and the analysis 
of results are ongoing ( [ADDRESS_541528] been 63 subjects were exposed to 
[COMPANY_004]2838232/r or placebo so far in this study). Overall, drug -related adverse events have 
been few and mild, and included headache, dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428144] .  Similarly , treatment -emergent laboratory  abnormalities have also been few 
and mostly  grade 1.  There have been no discernible patterns, thus far, in terms of AEs or 
laboratory  abnormalities.
Section [IP_ADDRESS] Study 204953 (completed); Pharmacokinetic Data
Rationale for change
Minor clarifications were made to this section to reflect current stat us of studies being 
referenced.
Change in Heading
Section [IP_ADDRESS] Study 204953 ( on-going completed ); Pharmacokinetic Data
Section 4.4.[ADDRESS_541529] instance has been defined.
Revised Text 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
116Potential Ris k of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible Drug -Drug 
Interactions (DDIs )HIV Drug Resistance to unique mechanism
Recognize HIV p atients have a higher chance of comorbidities/diseases and a 
risk of taking a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resistance
Strict adherence to protocol criteria around 
concurrent meds  
 
 2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541530] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
5 . Confirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. No current and no prior ART. (A previous course of 
pre- or post -exposure prophylaxis is allowed provided that it was completed at least 
[ADDRESS_541531] dose of study drug).
Section 5.2 Exclusion Criteria
Rationale for change
This exclusion criteria was removed and the guidance for use of concomitant medications 
was further addressed in Section 6.12, Concomitant Medications and Non -Drug 
Therapi[INVESTIGATOR_014]. The Relevant Habits section of the Exclusionary  criteria was also removed 
and addressed in Section 6.10, L ifesty le and/or Dietary  Restrictions, with the exception 
of illicit drug use. Smoking and limited alcohol use are no longer exclusionary . 
Additional clarification added to note that positive Hepatitis C result would need to be 
confirmed b y RIBA. Abbreviation used on first instance has been defined.  Additional 
minor ty pographical errors were corrected.
Revised Text
CONCOMI TANT MEDICATIONS
5.Unable to refrain from the use of prescription or non- prescription drugs, including 
vitamins, herbal and dietary  supplements (including St John’s Wort) within 7 day s 
(or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is 
longer) prior to the first dose of study medication, unless in the opi[INVESTIGATOR_428145] y. 
REL EVANT HABITS
6.History  of regular alcohol consump tion within 6 months of the study  defined as: 
An average weekl y intake of >14 drinks for males or >7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL ) of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof d istilled spi[INVESTIGATOR_2120].
7.Smoking is an exclusion criteria for this study . Urinary  cotinine levels indicative of  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
118smoking at screening.
6.Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion 
criteria.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
7 . Presence of hepatitis B surface antigen (HBsAg), positive (confirmed by 
[CONTACT_428230]- Blot Assay [RIBA]) hepatitis C antibody  test result at screening 
or within [ADDRESS_541532] dose of study  treatment.
19 . Exclusion criteria f or screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual participant in 204953200911 will be Fridericia’s 
formula. 
Section 6.[ADDRESS_541533] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Method for 
individualizing dosage:Capsules supplied in high -density 
polyethylene bottles for 
individualized dosing by [CONTACT_428231] 6.9 Treatment after the End of the Study
Rationale for change 
Additional language was included in this section to allow subjects to opt to receive 
reimbursement from [COMPANY_004] for up to 3 months for marketed antiretroviral therap y (as  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
119directed and pr escribed by  [CONTACT_5936]) based on the CDC guideline recommendations that 
patients be put on ARTs when diagnosed with HIV (test and treat guidelines). 
Revised Text
Subjects will not receive any  additional treatment from [COMPANY_004].
Subjects receiving [COMPANY_004]2838232 may opt to receive marketed antiretrovirals after 
the completion of 10 days of [COMPANY_004]2838232 dosing and study follow-up visits 
(through Day 21) eligible for sponsor company reimbursement up to a maximum of 
[ADDRESS_541534]’s medical condition, whether or not [COMPANY_004] is providing specific 
reimbursement for post-study  treatment.
Section 6.10.1 Meals and Dietary  Restrictions
Previous section number 6.12
Rationale for change
This section was updated to remove language around meal provisions (language 
consistent for an in -patient trial). As this is an out -patient trial, it will be up to trial site to 
arrange when/how meals are provided during a subject’s participation in the trial. The 
section ‘L ifestyle and/or Dietary  Restrictions’ had no content described under it. The 
sections ‘Meals and Dietary  Restrictions’ and ‘Alcohol, Caffeine and Exercise’ has b een 
moved as sub- sections under the section ‘L ifestyle and/or Dietary  Restrictions’, as the 
sub-sections are related to this section.   
Revised Text
Second Bullet
Doses will be given in the fed state (light breakfast), following overnight fasting (>10 
hours). Lunch will provided 4 hours after the dose; water will be allowed ad libitum 
throughout.
Section 6.10.2 Alcohol, Caffeine and Exercise
Previous section number 6.13
Rationale for change 
Adjustments were made to these lifesty le habits to eliminate re strictions on use of 
tobacco products, reduce restrictions on alcohol use and to allow occasional and light 
exercise during study  treatment.   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
120Revised Text
Alcohol, Caffeine , Tobacco and Exercise
Subjects should refrain from alcohol for 48 hours before scr eening and then for 48 
hours prior to admission and baseline assessments (on Day  1). Alcohol is then not 
permitted for the duration of the treatment period (through Day  10) and until the 
final follow -up visit.  
Use of tobacco products is not allowed from screening until after the final follow -up 
visit
Subjects will During  the study  alcohol consumption should be limited to the 
following:
An average weekly intake of <14 drinks for males or <7 drinks for females.  
One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 
ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
Subjects willshould abstain from strenuous exercise for 72 hours prior to each blood 
collection for clinical laboratory  tests.  Subjects may  partic ipate in light recreational 
activities during studies (e.g., watch television, read). the treatment period.
Section 6.[ADDRESS_541535] include one barrier method.  There Although 
use of oral contraceptives is permitted, tThere is no d efinitive DDI information with 
[COMPANY_004]2838232 and an interaction with oral contraceptives is possible, so other (barrier, 
inter-uterine device etc.) methods of contraception will be required.
Section 6.12 Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_428146] 6.14
Rationale for change
Adjustments were made to the concomitant medication section to clarify  that certain 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (Section 6.10), the section has been 
re-numbered. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
121Deleted Text
Subjects mu st refrain from all illicit drugs throughout the study (from Screening until 
discharge from the study).  Drug screening will occur at Screening and Day -1 for 
each treatment period.  A positive result will lead to exclusion from the remainder of 
the study .
The Principal Investigator [INVESTIGATOR_428147] y 
medications taken from the time of screening until the subject is discharged from the 
study .  Over -the-counter medications will not be permitted during the treatment 
period except a s needed to treat an AE. If medication is needed, use should be 
restricted to 4 hours after dosing if possible. 
Section 6.12.1 Permitted Medications and Non -Drug Therapi[INVESTIGATOR_428146] 6.14.1
Rationale for change
Adjustments were made to the concomitant medication section to clarify  that certain 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
Section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous Section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (Section 10), the section has been re -
numbered.
Revised Text
Addition of Second bullet
Concomitant medications (prescription and non- prescription) should be 
administered only as medically necessary during the study. Subjects must 
notify their Investigator of any current or proposed concomitant medication, 
whether prescribed or over- the-counter, because of the potential for 
interactions between such t reatments and the study medications.
Section 6.12.2 Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_428148] 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
S
ection 6.12) and ‘Alcohol, Ca ffeine and Exercise’ (previous S ection 6.13) has been 
moved under Lifest yle and/or Dietary  Restriction s’ (Section 10), the section has been re -
numbered. 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
122Previous section number 6.14.2
Revised Text
Subjects must abstain from taking prescription or non- prescription drugs (including 
vitamins and dietary  or herbal supplements), within 7 day s (or 14 day s if the drug is 
a potential enzy me inducer) or 5 half -lives (whichever is longer) prior to the first 
dose of study medication until completion of the follow -up visit, unless in the 
opi[INVESTIGATOR_2511] I nvestigator and sponsor the medication will not interfere with the
study . 
Subjects must refrain from all illicit drugs throughout the study (from 
Screening until discharge from the study).  Drug screening will occur at 
Screening and Day -[ADDRESS_541536]- dose 12- lead ECG on Day  5, 
which remains in line with the FDA’s guidance regarding day s on which to perform post -
dose (2 & 6 hours to capture near Tmax) ECGs. Modifications were also made to the 
pharmacokinetics sampling, allowing for the 12 h PK collection timepoint on Day  1 and 
10 to be optional. Visit/procedure windows were included to allow more flexibility  with 
scheduling of assessments. Also minor clarifications were made and t ypographical errors 
were corrected.
Revised Text 2018N360917_00
2015N227852_02 CONFIDENTI AL
200911
123Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/ exclusion X X
Demography including height, weight and 
BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therap y X
12-lead ECG3 X X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and hepatitis 
C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X XX14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X
AE enquiry13 X X X X X X X X X X X X X
Telephone call to IVRS1314 X X X X X X X X X X X X X X X 
 
 2018N360917_00
2015N227852_02 CONFIDENTI AL
200911
124Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within 14-[ADDRESS_541537] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 and 6, perform al l “Day 5” assessments on Day 7.
3. On Day 1, ECGs (x2)will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541538] -dose. To accommodate scheduling, 
serial ECGs collected on Days 4 and 8 may be performed 1 day.   On Day 10, ECGs (x2)will be performed pre -dose, and then 1, 1.5, 2, 3, [ADDRESS_541539] dose.  On 
Day 11, an ECG will be obtained prior to the 24 -hour PK sample. ECGs will be performed in triplicate at all timepoints.
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained o n Day [ADDRESS_541540] -morning dose, and at day 12 and Follow -up (Day 21) .
5. Only SAEs related to study participation will be collected between screening and Day 1. An AE enquiry will be made at each visit, subjects will be asked if they have 
experienced any neuropsychiatric adverse events, including psychosis or altered mental status.
6. On Days 1 -5 and 8 -10 samples for HIV -1 RNA PCR collected before morning dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart. HIV -1 RNA PCR samples will also be collected on days 12, 14 & Follow -up (Day 21).
7. Lymphocyte subsets by [CONTACT_4133] (total lymphocyte counts, perce ntage, and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determination of [COMPANY_004]2838232 will be collected on Day 1 and Day 10 at pre dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12 (optional), and 24 hours (to occur on morning of Day [ADDRESS_541541]- am dose and in the morning on Day 11) .  Pre -dose PK samples (within 15 minutes prior to dose) will be 
taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be taken on Days 12 and 14.
10. Samples (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541542] experienced any neuropsychiatric adverse events , including psychosis or altered mental status
13. A screening/regist ration call should be made to the IVRS to register the subject at screening.   An additional call will be made to document a screen failure.   A randomization 
call should be made to the IVRS system approximately one week prior to scheduled Day 1.  Note: Th e randomization call must be made in order to have study drug on site for 
Day 1. Additional calls will be made every day that the subject has a scheduled study visit to the clinic.  If a subject term inates the study prematurely a call should be made to 
theIVRS
14. Only if early termination visits occur during the treatment period.
15. Plasma samples for storage will be collected at each visit starting at Day 1, including unscheduled visits (e.g. for HIV -1 RNA levels and immunological 
parameters).  Additionally the se samples will be used when needed, such as when samples are lost or arrive at the laboratory unevaluable.
AE = Adverse event; CDC= Center for Disease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Hu man chorionic gonadotr ophin; HIV = Human 
immunodeficiency virus;  IVRS= Interactive Voice Response System; PCR = Polymerase chain reaction; PK=Pharmacokinetic. 
 
 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
125Section 7.2 Visit Windows
Rationale for Addition
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. 
New Section
Screening (baseline to pre -dose): All screening assessments should take place within 
14-[ADDRESS_541543] dose. The screening visit window may be extended to 30 
days upon discussion with the Medical Monit or (i.e.; subject has scheduling conflicts 
or any screening assessment needs to be repeated).
Days 4 and 8: Based on subject and clinic schedule, Day 4 and Day 8 serial (up to 6h 
post-
dose) ECG assessments may be conducted 1 day.  
Weekend(s): The T&E ta ble is set up for study start (Day 1) to occur on a Monday 
and Days 6 and 7 to fall on the weekend. If the weekend occurs instead on Days 5 
and 6, Day 5 assessments should be performed on Day 7. The study start (Day 1) 
may also be adjusted to allow visits with assessments to be conducted over the 
weekend based on subject and clinic schedule.  
Assessments: The following applies to timing of procedures:
-Window for assessments [ADDRESS_541544] -dose = 5 minutes 
-Window for assessments >4 and < [ADDRESS_541545] -dose =  15 minutes
-Window for assessments > [ADDRESS_541546] -dose =  30 minutes
End of Treatment visit: should be within [ADDRESS_541547] for assessment of adverse events.
Section 7.3.1 Holter Monitoring (Screening criteria)
After addition of new section before this section, the section numbers from this section 
until Sections under 7.[ADDRESS_541548] has met all other inclusion criteria. period using a Holter monitoring 
device supplied by [CONTACT_1034].
Analy sis of the Holter tapes will consider the following:
Heart rate (brad ycardia and tach ycardia) 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
126Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractions, premature 
ventricular contractions, couplets, triplets, and ventricular tach ycardias
Atrio- ventricular conduction defects
Atrial fibrillation and flut ter
Section [IP_ADDRESS] Time period and Frequency  for collecting A E and      
SAE information
Rationale for Change 
Minor clarifications made regarding Sponsor (to include [COMPANY_003]). 
Revised Text
Bullet 4
All SAEs will be recorded and reported to [COMPANY_004] Sponsor within [ADDRESS_541549] dose based on this review (e.g., the 
exposure level of [COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838232 exposure 
seen previousl y in healthy subjects), the Bay esian posterior probability  that the log10 
viral load decline from baseline is greater than a cut
-point will be calculated. If the 
Bayesian probability from Cohort 1 is less than 70% ,this wi ll provide evidenceto 
evidence to not move forward into Part B. Otherwise, the study  team will review the data 
in order to make a dose selection decision for the subsequent Part B Cohorts.  I f the 
pharmacokinetic exposures after the 100 mg [COMPANY_004]2838232/cobi dose look similar to 
those obtained with 100 mg [COMPANY_004]2838232/r in prior studies, the doses for Part B will be 
extended to both lower (20 mg, 50 mg) and higher (200 mg) [COMPANY_004]2838232 doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be summ arized 
by [CONTACT_428216] . The proportion of subjects with plasma HIV -1 RNA 
<400 and <50 copi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if the two populations ar e 
not the same.
Section 10.3 Quality  Control (Study Monitoring)
Rationale for Change
Minor clarifications made regarding Sponsor (to include [COMPANY_003]).  2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541550] the site prior to the start of the study  to review with the 
site staff the protocol, study  requirements, and their responsibilities to satisfy  regulatory , 
ethical, and [COMPANY_004] requirements.
Section 10.5 Study and Site Closure
Rationale for Change 
Minor clarifications made regarding Sponsor (to include [COMPANY_003]). 
Revised Text
First Bullet
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor or 
designee will conduct site closure activities with the investigat or or site staff, as 
appropriate, in accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
Section [ADDRESS_541551].  Phase 2 study  of cobicistat versus ritonavir each with once -
daily  atazanavir and fixed -dose emtricitabine.tenofovir df in the initial treatment of HI V 
infection.  AIDS .  2011; 25:1881 -1886.
Gallant JE, Koenig E, Andrade -Villaneuva J, Chetchotisakd P, deJesus E, Antunes F, 
Arastéh K, et al. Moy le G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, 
Scwarcberg J, Rhee MS, Cheng AK.   Cobicistat versus r itonavir as a pharmacoenhancer 
of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment -naïve HIV 
type 1-infected patients:  week [ADDRESS_541552]. Dis.  2013; 208- :32- 39.
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteel e T, Hillewaert V, et 
al.Petrovic R, Hoetelmans RMW.  Pharmacokinetics of darunavir in fixed -dose 
combination with cobicistat compared with coadministration of darunavir and ritonavir as 
single agents in health y volunteers.  J. Clin. Pharmacol.   2009; 54: 949-957.
Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, et al. Safety  and 
efficacy  study  of bevirimat (BVM) in heavil y treatment experienced HIV+ patients 
identifies the target phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Mart in DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL , et al. Safety  and 
pharmacokinetics of bevirimat (PA -457), a novel inhibitor of human immunodeficiency   2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
128virus maturation, in healthy  volunteers. Antimicrobial Agents and Chemotherapy. 
2007(b);Sep:[ADDRESS_541553] Develop ment
QD Once daily
RIBA Recombinant Immuno- Blot Assay
t1/2t½ Terminal elimination half- life 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
[ZIP_CODE].10.2. AMENDMENT 2
Protocol Amendment 2 ( 24-MAY - 2017) from the P rotocol Amendment 1 (26 -Apr- 2017)
Where the A mendment A pplies
This amendment applies to all subjects wh o will participate in this study  in all countries.
List of Specific Changes: (bold indicates text added and strikethrough indicates text 
removed)
Summary  of Protocol A mendment Changes with Rationale
Amendment [ADDRESS_541554] population to allow treatment 
experienced HIV -1 infected patients, in addition to treatment naive patients
. Patients with 
a treatment history  of a prior maturation inhibitor will still be ineligible. Slight 
modifications were made to include flexible language for enrolment into Part B to allow 
prioritization of one dose cohort or to open randomization into Part B cohorts in a parallel 
fashion. Also the upper limit of the BMI inclusion criteria was increased from 31 to 35 
kg/m2.
Minor clarifications , re-numbe ring of sections and correction of ty pographical errors 
were also made throughout this amendment.
Author (s)
Rationale for change A minor correction was made to this section.
A minor correction was made to this section.
Revised Text
                PCPS, [COMPANY_004], Collegeville Upper Providence , PA, US
Title Page
Rationale for change
The protocol title was updated to reflect the new subject population, which is no longer 
limited to treatment naive patients.
Revised Text
A Phase 2a, Multicenter, Ra ndomized, Adaptive, Open -label,  Dose Ranging Study to 
Evaluate the Antiviral Effect, Safety , Tolerability  and Pharmacokinetics of Cobicistat -
boosted [COMPANY_004]2838232 Monotherap y Over 10 Days in HI V-1 Infected Treatment- Naive
Adults 2018N360917_00
[COMPANY_003]
2015N227852_02 CONFIDENTIA L
200911
130Synopsis
Rationale
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which i s now completed). The reference to a parallel enrolment design for Part 
B was also removed to allow for prioritizing enrolment into any  one dose cohort based on 
emerging data from Part A.
Revised Text
Second paragraph
Three clinical studies of [COMPANY_004]2838232 (n=53 healthy  subjects) have been completed thus 
far. One study  (Study  204953) is on- going completed at the end of [ADDRESS_541555] received [COMPANY_004]2838232 or placebo in single or 
repeated dose designs, to a maximum single dose of 250 mg or repeated dose (for 
11days) of 200 mg QD, in combination with ritonavir (RTV).
Fifth paragraph
Study  204953 is an on-going stud y and continues the investigated the safety and PK of 
[COMPANY_004]2838232 in single and repeat -dosesexploration of safet y and PK of [COMPANY_004]2838232 as 
well as the suitability  of a new, capsule formulation. Doses of up to 250 mg 
[COMPANY_004]2838232/100 mg RTV (as sin gle doses) or 200 mg [COMPANY_004]2838232/100 mg RTV (QD 
for 11 day s) were studied. As of 26 October 2016, the study  is ongoing with a cohort of 
subjects due to receive The final cohort of the study assessed unboosted [COMPANY_004]2838232 
(200mg BID) for 11 days.The study com pleted at the end of 2016 and the data 
analysis is ongoing.
Seventh paragraph
The objective of Stud y 200911 is to understand the safet y, PK and HIV antiviral profile 
of [COMPANY_004]2838232/cobicistat ([COMPANY_004]2838232/cobi) when given to HIV -infected, treatment 
naive, otherwise health y adults. Approximately  [ADDRESS_541556] paragraph
Approximately  34 HIV -
1 infected treatment -naive subjects will be enrolled overall.
Second paragraph
This study  is a 10- day monotherapy , open -label, adaptive, dose ranging, repeat- dose 
study  and will be conducted as two parts with an interim (go/no -go) analy sis performed 
after Part A (Table 1). Part A, Cohort 1 will evaluate a safe and well -tolerated dose level 
of [COMPANY_004]2838232 that has been tested (with RTV) in prior Phase I studies and that targets 
a high inhibitory  quotient (IQ) value. Following the completion of an interim analy sis of 
those data and according to criteria defined later in the protocol, further cohorts of 8 
subjects will then be studied in Part B in a parallel design in two or more cohorts 
(depending upon the data obtained in Part A).
Table 1 Study  Design for 200911
Part A: [COMPANY_004]2838232/cobi 
Once Daily x10 days1Part B: [COMPANY_004]2838232/cobi 
Once Daily x10 days1,2
Cohort
N232 Dose
(mg)Cohort
N232 Dose 
(mg)
1 10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B , which 
are planned to run in a parallel, randomized fashion . All doses will be given with [ADDRESS_541557] to modification based upon safety, PK and antiviral activity data from Cohort 
1 (Part A). More doses/cohorts (including potential removal of cobi co -dosing) may be added (the maximum dose 
in Part B would likely not exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] was 
lower in HIV infected subjects than in healthy subjects at the same dose level).
Fourth paragraph
The possibility  that an additional, unboosted [COMPANY_004]2838232 monotherapy  cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from Study  204953 where 
unboosted [COMPANY_004]2838232 at a dose of 200 mg twice daily  (BID) was assessed and St udy 
205820, which plans to evaluate [COMPANY_004]2838232 at a dose of 500mg once daily (QD) . 2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
132Section [IP_ADDRESS] Clinical Summary  of Safety
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which i s now completed).
Revised Text
Fifth paragraph
In ongoing Study  204953, there have been a small number of CV -related events of an y 
sort: There have  been n o serious adverse drug reactions, and no clinically  significant 
drug-related abnormal findings for 12 -lead ECGs, vital signs, safet y laboratory  results 
(including cardiac troponin I ), or telemetry .  The following cardiovascular AEs were 
observed during the course of the stud y but were not considered to be caused by 
[CONTACT_23983]2838232 exposure
Section [IP_ADDRESS] Study 204953 (completed); Pharmacokinetic Data
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which i s now completed and anal ysis is ongoing ).
Revised Text
Second paragraph
In addition, it eva luated the relative bioavailability of a single fasted dose of micronized 
API [INVESTIGATOR_428149] -in-bottle for oral 
suspension with RTV and the effect of a normal fat meal on the bioavailability  of a single 
dose of [COMPANY_004]2838232 in the capsule formulation with RTV.  I t will evaluate 
[COMPANY_004]2838232 exposure after repeated doses of unboosted [COMPANY_004]2838232 in the capsule 
formulation. Noncompartmental PK anal ysis was performed using scheduled sample 
times.  ThisThe study  isanaylsis of da ta from this study is ongoing; preliminary results 
are presented.
Section 4.[ADDRESS_541558], safet y, tolerability, and PK of [COMPANY_004]2838232/cobi monotherap y over [ADDRESS_541559] received an y ART (including prior MI) prior maturation ihibitor
therap y will not be eligible for this study. To minimize the number of subjects exposed to 
suboptimal doses, an adaptive and dose ranging design is applied in this study .
Study  Design for 200911
[COMPANY_004]2838232/cobi Once Daily for 10 days1,2
Part A Part B 
Cohort 1 Dose
(mg)Interim Analysis Cohort
N(mg)
N=10 100
2 8 200
3 8 50
4 8 20
Day 1 –Day 10: Dosing
Second paragraph
Serial, intensive blood PK samples will be collected on Day  1 (up to [ADDRESS_541560] -
morning dose) and Day  10 (up to [ADDRESS_541561] -morning dose), and limited, single blood 
PK samples pre -morning doses on Day s [ADDRESS_541562] for 10 hours [overnight] prior to the morning check in on the 
intensive PK sampling day s (Day s 1 and 10).  All dosing da ys will require co -
administration of treatment with a light snack/meal per cobicistat labeling guidelines. All 
doses of study  medication will be taken with 240 mL  of water.  Subjects will be required 
to stay  in the clinic on Day s 1 and 10 until all specifi ed assessments are completed ( 8-[ADDRESS_541563] -dose). Following Day  10, subjects will be required to attend the clinic for 
follow up assessments including virological and PK blood sampling for up to 3 weeks.1 . Part A Cohort 1 safety /PK/virology  data will be evaluated at interim, prior to initiating 
other cohorts in Part B , which are planned to run in a parallel, randomized fashion .  All 
doses will be given with [ADDRESS_541564] to modification based upon safet y, PK and antiviral activ ity data 
from Cohort 1 (Part A). More doses/cohorts (including potential removal of cobicistat co -
dosing) may  be added. (The maximum dose in Cohort B will likely not exceed 200 mg 
with cobicistat unless overall plasma exposure [as AUC and Cmax] is lower in HIV
-
infected subjects than in healthy  subjects at the same dose level). 2018N360917_00
2015N227852_02 CONFIDENTIA L
[ADDRESS_541565] 34 subjects will be enrolled such that approximately  6-10 evaluable subjects 
complete a number of cohorts.  Additional subjects/cohorts may be enrolled to allow for 
evaluat ion of additional dose levels as appropriate. 
If subjects prematurel y discontinue the study, additional replacement subjects may  be 
randomisedrandomized and assigned to the same treatment cohort at the discretion of the 
Sponsor in consultation with the I nvestigator.
Section 4.3 Design/Dose Justification
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which is now completed).
Revised Text
Last paragraph
There is no a priori intention to st udy [COMPANY_004]2838232 unboosted, unless: i) following the 
preliminary  anal ysis of Part A Cohort 1, there is such pronounced antiviral activity  that it 
would seem the estimates of projected IQ are low, in which case [COMPANY_004]2838232 may be 
evaluated in a subsequent coho rt unboosted, or ii) the data from ongoing and planned 
healthy volunteer trial s,Cohort 7 in Study  204953 ( planned, [COMPANY_004]2838232 200 mg BID 
unboosted )and Study 205820 ([COMPANY_004]2838232 500mg QD unboosted )support it.
Section 4.3.3 Interim A nalysis
Rationale for ch ange
Minor clarifications were made to this section to allow for flexibility  around selecting 
dose cohorts for Part B based on emerging data from Part A.
Revised Text
An evaluation of [COMPANY_004]2838232 safet y, efficacy  and PK data will be done after Part A 
Cohor t 1,if the exposure level of [COMPANY_004]2838232 is in the range of the maximum 
[COMPANY_004]2838232 exposure seen previousl y in healthy subjects and the Bay esian probability  
from Cohort 1 is less than 70%, the study will not move forward into Part B, otherwise 
doses will be selected for evaluation in Part B. If pharmacokinetic exposure after the 100 
mg [COMPANY_004]2838232/cobi dose is in the range of values observed after 100 mg 
[COMPANY_004]2838232/r in prior studies, the doses for Part B will be extended to both lower  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
135(20mgand/or ,50 mg) and higher (200 mg) doses. The highest dose tested in Part B will 
be selected to result in exposures similar to those seen with 200 mg/r in Study  204953.
Section 4.4 .3 Overall Benefit:Risk Conclusion
Rationale for change
Minor clarifications were made to this section to provide clarification regarding Study  
204953 (which is now completed).
Revised Text
To date, [ADDRESS_541566] received [COMPANY_004]2838232 in fourthree completed 
studies. One study  (204953) is ongoing ([ADDRESS_541567] completed this study  so 
far).
Section [ADDRESS_541568] population, which is no 
longer limited to treatment naive patients. Also the upper limit of the BMI inclusion 
criteria was increased from 31 to 35 kg/m2.  2018N360917_00
2015N227852_02 CONFIDENTIA L
200911
136Revised Text
5.Confir med HI V positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. No current and no prior ART. (A previous course of pre -
or post -exposure proph ylaxis is allowed provided that it was completed at least [ADDRESS_541569] dose of study  drug).
5 .6.Antiretroviral treatment naive or ART -experienced (maturation inhibitor 
naive) . No current ART (last dose completed at least [ADDRESS_541570] dose 
of study drug). (A previous course of pre -or post -exposure proph ylaxis is allowed 
provided that it was completed at least [ADDRESS_541571] dose of study  drug ).
6 .7. Body weight 50kg (110 lbs.) for men and 45kg (99 lbs) for women and bod y 
mass index (BMI) within the range 18.5 -351.0 kg/m2(inclusive)
Section 6.2 Treatment A ssignment
Rationale for change
A minor clarification was made to this section.
Revised Text
Subjects will be assigned to treatment (active) groups in accordance with the 
randomization schedule generated by  [CONTACT_278814], prior to the start of the study , 
using validated internal software.
Section 6.4 Blinding
Rationale for change
Minor clarifications were made to this section.
Revised Text
This will be an open -label study . Treatment allocation and [COMPANY_004]2838232 dose levels in 
Part B will be determined after the analysis of Part A data. randomised (to 
[COMPANY_004]2838232 dose level). 2018N360917_00
2015N227852_01 CONFIDENTIA L
The GlaxoSmithKline group of companies 200911
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A Phase 2a, Multicenter, Randomized, Adaptive, Open -label,  
Dose Ranging Study to Evaluate the Antiviral Effect, Safet y, 
Tolerability  and Pharmacokinetics of Cobicistat -boosted 
[COMPANY_004]2838232 Monotherapy  Over 10 Day s in HIV -1 Infected 
Treatment -Naive Adults
Compound Number: [COMPANY_004]2838232
Development Phase:IIA
Effective Date: 26-APR - 2017
Protocol Amendment Number:  01
Author (s):
             PTS, Ware, [LOCATION_006]
             GCSP, Stockley  Park, [LOCATION_006]
             Infectious Diseases, Clinical, Upper Providence, PA, US
             Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
            HIV DPU, Clinical RTP, NC, US
            Virology , HIV DPU, RTP, NC, US
            CPMS, [COMPANY_004], RTP, NC, US
            HIV DPU, RTP, NC, US
            
Clinical Pharmacology , ViiV Healthcare, RTP, NC, US
            PCPS, [COMPANY_004], Upper Providence, PA, US
            PCPS, [COMPANY_004], Collegeville, PA, US
Copy right 2017 the GlaxoSmithKline group of companies.  All ri ghts reserved.  
Unauthorised cop ying or use of this information is prohibited. 2018N360917_00
[COMPANY_003]
2015N227852_01 CONFIDENTIA L
The GlaxoSmithKline group of companies 200911
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2015N227852_00 2016 -NOV-09 Original
2015N227852_01 2017 -APR -26 Amendment No. 1
Amendment 1 includes minor upd ates to Inclusion- Exclusion ( IE) criteria, including
clarification on use of pre- or post -exposure prophy laxis, and removal of exclusionary  
requirements related to concomitant medications and tobacco and alcohol use during the 
study . Guidance around releva nt habits is included in the L ifesty le section of the protocol 
and adjustments were made to reduce restrictions on theserequirements. Modifications
were also made to the pharmacokinetics sampling, allowing for the 12 h PK coll ection 
timepoint on Day  1 and 10to be optional. Minor alterations were made regarding the 
order of screening procedures, including the Holter monitoring requirements. 
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. 
Furthermore , the seri al ECG collection (up to 6h post -dose) was removed on 
Day 5.Finall y, the post -study  care guidance was updated to include an option for subjects 
to receive reimbursement for marketed ART for a limited period after completion of 
study  treatment and follow u p. Minor clarifications, reformatting of tables ,re-numbering 
of sections and correction of ty pographical errors were also 
made throughout this 
amendment . 2018N360917_00
 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_01 CONFIDENTIA L
200911
4MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor/SAE 
contact 
[CONTACT_428195] 
([COMPANY_003])Safety 
Hotline [COMPANY_003], [ADDRESS_541572] 
Collegeville, PA 
[ZIP_CODE]
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_541573]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical tr ial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_428242].   
Regulatory  Agency  Identify ing Number(s):  116,[ADDRESS_541574] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 200911 ........................................................ 9
2.INTRODUCTION .................................................................................................... 13
2.1. Study Rationale .......................................................................................... 13
2.2. Brief Background ........................................................................................ 13
2.2.1. Preclinical Summary .................................................................... 14
2.2.2. Clinical Summary of Safety and Pharmacokinetics ...................... 19
[IP_ADDRESS]. Clinical Summary of Safety ......................................... 19
[IP_ADDRESS]. Study 204953 (completed); Pharmacokinetic 
Data ........................................................................... 20
[IP_ADDRESS]. Overall Summary/Conclusions of PK data .................. 23
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 25
4.STUDY DESIGN .................................................................................................... 26
4.1. Overall Design ............................................................................................ 26
4.2. Type and Number of Subjects ..................................................................... 27
4.3. Design/Dose Justification ............................................................................ 28
4.3.1. [COMPANY_004]2838232 with Ritonavir ......................................................... 28
4.3.2. [COMPANY_004]2838232 with Cobicistat ....................................................... 29
4.3.3. Interim Analysis ........................................................................... 29
4.4. Benefit:Risk Assessment ............................................................................ 30
4.4.1. Risk Assessment ......................................................................... 31
4.4.2 .Benefit Assessment ..................................................................... 33
4.4.3. Overall Benefit:Risk Conclusion ................................................... [ADDRESS_541575] AWAL CRITERIA ............. 33
5.1. Inclusion Criteria ......................................................................................... 34
5.2. Exclusion Criteria ........................................................................................ 36
5.3. Screening/Baseline/Run -in Failures ............................................................ 38
5.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 39
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 39
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_541576] and Other Study Treatment .................................... 41
6.2. Treatment Assignment ................................................................................ 42
6.3. Planned Dose Adjustments ......................................................................... 42
6.4. Blinding ....................................................................................................... 42
6.5. Packaging and Labeling .............................................................................. 42
6.6. Preparation/Handling/Storage/Accountability .............................................. 42
6.7. Compliance with Study Treatment Administration ....................................... 43
6.8. Treatment of Study Treatment Overdose .................................................... 43
6.9. Treatment after the End of the Study .......................................................... 44
6.10. Lifestyl e and/or Dietary Restrictions ............................................................ 44
6.10.1. Meals and Dietary Restrictions .................................................... 44 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
76.10.2. Alcohol, Caffeine and Exercise .................................................... 44
6.11. Contraception ............................................................................................. 44
6.12. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 45
6.12.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 45
6.12.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 45
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 45
7.1. Time and Events Table ............................................................................... 47
7.2. Visit W indows ............................................................................................. 49
7.3. Screening and Critical Baseline Assessments ............................................ 49
7.3.1. Holter Monitoring (Screening criteria) ........................................... 49
7.4. Efficacy ....................................................................................................... 50
7.4.1. HIV-1 RNA Sampling ................................................................... 50
7.4.2. Lymphocyte Subsets by [CONTACT_46110] ..................................... 50
7.5. Safety ......................................................................................................... 50
7.5.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 50
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 51
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 51
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 51
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 52
[IP_ADDRESS]. Disease -Related Event s and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 52
[IP_ADDRESS]. Regulatory Reporting Requirements for SAE .............. 53
7.5.2. Pregnancy ................................................................................... 53
7.5.3. Physical Exams ........................................................................... 53
7.5.4. Vital Signs .................................................................................... 54
7.5.5. Electrocardiogram (EGC) ............................................................. 54
7.5.6. Clinical Safety Laboratory Assessments ...................................... 54
7.6. Pharmacokinetics ....................................................................................... 56
7.6.1. Blood Sample Collection .............................................................. 56
7.6.2. Sample Analysis .......................................................................... 56
7.7. Biomarker(s)/Pharmacodynamic Markers ................................................... 56
7.7.1. Viral Genotypi[INVESTIGATOR_103623] ............................................... 56
7.8. Genetics ..................................................................................................... 56
7.9. Value Evidence and Outcomes ................................................................... 57
8.DATA MANAGEMENT ........................................................................................... 57
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .57
9.1. Hypotheses ................................................................................................ .57
9.2. Sample Size Considerations ....................................................................... 57
9.2.1. Sample Size Assumptions ........................................................... 57
9.2.2. Sample Size Sensitivity ................................................................ 58
9.2.3. Sample Size Re- estimation or Adjustment ................................... 59
9.3. Data Analysis Considerations ..................................................................... 59
9.3.1. Analysis Populations .................................................................... 59
9.3.2. Interim Analysis ........................................................................... 59
9.4. Key Elements of Analysis Plan ................................................................... 60
9.4.1. Primary Analyses ......................................................................... 60
[IP_ADDRESS]. Safety Analyses .......................................................... 60
[IP_ADDRESS]. Efficacy Analyses ....................................................... 60 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
[IP_ADDRESS]. Pharmacokinetic Analyses .......................................... 61
9.4.2. Secondary Analyses .................................................................... 61
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic Analyses ........... 61
[IP_ADDRESS]. Viral Genotypi[INVESTIGATOR_428166] .............. 62
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 62
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 62
10.2. Regulatory and Ethical Considerati ons, Including the Informed 
Consent Process ........................................................................................ 62
10.3. Quality Control (Study Monitoring) .............................................................. 63
10.4. Quality Assurance ....................................................................................... 63
10.5. Study and Site Closure ............................................................................... 63
10.6. Records Retention ...................................................................................... 64
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 65
10.8. Review Committees .................................................................................... 65
11.REFERENCES ....................................................................................................... 66
12.APPENDICES ........................................................................................................ 68
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 68
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 71
12.3. Appendix 3: Liver Safety –Study Treatment Restart or Rechallenge 
Guidelines ................................................................................................... 74
12.4. Appendix 4: Genetic Research ................................................................... 75
12.5. Appendix 5: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 78
12.5.1. Definition of Adverse Events ........................................................ 78
12.5.2. Definition of Serious Adverse Events ........................................... 79
12.5.3. Definition of Cardiovascular Events ............................................. 81
12.5.4. Recording of AEs and SAEs ........................................................ 81
12.5.5. Evaluating AEs and SAEs ............................................................ 82
12.5.6 .Reporting of SAEs to [COMPANY_004] ........................................................... 83
12.6. Appendix 6: Collection of Pregnancy Information ........................................ 85
12.7. Appendix 7: Country Specific Requirements ............................................... 86
12.8. Appendix 8: Division O f AIDS Table For Grading The Severity Of 
Adult And Pediatric Adverse Events Version 1.0, December 2004; 
Clarification August 2009 ............................................................................ 87
12.9. Appendix 9: Toxicity Management ............................................................ 106
12.10. Appendix 10: P rotocol Amendment Changes ............................................ 111 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
91. PROTOCOL SYNOPSIS FOR STUDY 200911
Rationale
[COMPANY_004]2838232 is a novel human immunodeficiency virus (HIV -1) maturation inhibitor 
that is being developed for the treatment of HIV -1 in combination wit h other 
antiretrovirals.
Three clinical studies of [COMPANY_004]2838232 (n=53 healthy  subjects) have been completed thus 
far. One study  (Study  204953) is on -going. Healthy  subjects have received [COMPANY_004]2838232 
or placebo in single or repeated dose designs, to a maximum single dose of 250 mg or 
repeated dose (for 11 days) of 200 mg QD, in combination with ritonavir (RTV). 
Study  HMI116787 (completed November 2013) was the First Time in Human study  of 
[COMPANY_004]2838232 and assessed safet y and tolerability  of escalating doses (5 mg to 100 mg), 
food effect, and the impact of stead y-state ritonavir on [COMPANY_004]2838232 pharmacokinetics 
(PK). Following successful completion of 3- month toxicology  studies in rat and dog in 
2014, clinical studies 200912 and 200207 were initiated. These were dou ble-blind, 
placebo- controlled, single (Study  200912) and repeat -dose (Study  200207) escalation 
studies to investigate the safet y, tolerabilit y, and PK of [COMPANY_004]2838232 alone and when co -
administered with ritonavir 100 mg once dail y (QD) for 8 -11 day s. Further assessment of 
an alternative formulation was also an objective in Study  200912.
Both studies were prematurely terminated/completed in March/April 2015 because of 
concerns over cardiovascular (CV) toxicity , in particular a clinical CV serious adverse 
event (SAE) whereb y the Food and Drug Administrating (FDA) imposed a clinical hold. 
Following submission of long -term (6 -month rat, 9- month dog) chronic toxicology  data 
and follow up to the clinical SAE in November 2015, the hold was released in January  
2016 and Study  204953 was initiated.
Study  204953 is an on- going stud y and continues the single and repeat- dose exploration 
of safet y and PK of [COMPANY_004]2838232 as well as the suitability  of a new, capsule formulation. 
Doses of up to 250 mg [COMPANY_004]2838232/100 mg RTV (as si ngle doses) or 200 mg 
[COMPANY_004]2838232/100 mg RTV (QD for 11 day s) were studied. As of 26 October 2016, the 
study  is ongoing with a cohort of subjects due to receive unboosted [COMPANY_004]2838232 
(200mg BID) for [ADDRESS_541577] shown [COMPANY_004]2838232 with or withou t RTV to be well tolerated and, 
together with daily  RTV dosing (“boosting”), demonstrate a PK profile suitable for 
progression to HIV patients in this Phase IIa proof of concept 10 -day, monotherapy  study  
design.  However, potential concerns over protease r esistance necessitate a change to a 
pharmacoenhancer without antiviral effects in this study  of [COMPANY_004]2838232 monotherapy . 
Therefore, for Study  200911, cobicistat (Ty bost,150 mg QD) will be substituted for RTV.  
The objective of Stud y 200911 is to understand the safet y, PK and HIV antiviral profile 
of [COMPANY_004]2838232/cobicistat ([COMPANY_004]2838232/cobi) when given to HIV -infected, treatment 
naive, otherwise health y adults. Approximately  10 HIV -1 infected subjects will be 
enrolled into Part A. If warranted b y an interim sa fety, virology , and PK data anal ysis,  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
10approximately  8 subjects will be enrolled in each of between two and four Cohorts in Part 
B, which will be a parallel group design.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected 
patients during 10 days of 
monotherapy.Change from baseline (Day 1) in plasma HIV -1 
RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered 
as monotherapy over 10 days. Safety and tolerability parameters, including 
adverse event, concurrent medication, clinical 
laboratory, electrocardiogram (ECG) and vital 
signs assessments.
To characterize the pharmacokinetics 
of [COMPANY_004]2838232 in HIV -1 infected 
patients following [COMPANY_004]2838232/cobi 
dosing for 10 days. [COMPANY_004]2838232 PK parameters following dose 
administration, as follows:
Day 1 : area under the plasma concentration time 
curve AUC(0 -24), maximum observed 
concentration (Cmax), time to maximum 
observed concentration (tmax), concentration at 
[ADDRESS_541578] dose (C24), absorption lag time 
(tlag); 
Following last repeat administration on Day 10:  
AUC(0 -), pre -dose concentration (C0), 
concentration at end of dosing interval (C ), 
Cmax, tmax, t½, and apparent oral clearance 
(CL/F), if data permit
Secondary
 To expl ore the relationship between 
[COMPANY_004]2838232 exposure and change 
in plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 AUC(0- ), 
Cmax, C with Day 11 HIV -1 RNA change from 
baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when 
administered over 10 day s in HIV -1 
infected adults Change from baseline in CD4+ cell count to Day 
11
 To explore the relationship between 
[COMPANY_004]2838232 exposure and safety or 
immunologic parameters, if 
appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax, C with Day 11 change from 
baseline in CD4+ cell count 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
11Objectives Endpoints
 To assess the development of viral 
resistance (genotypic and 
phenotypic) over 10 days and 
correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, if 
appropriate
 To estimate [COMPANY_004]28382 32 
accumulation and to assess 
attainment of steady state following 
administration of [COMPANY_004]2838232/cobi 
for 10 days in HIV infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): Day 
10 AUC(0 -), Cmax, and C compared to Day 1 
AUC(0 -24), Cmax, and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on Days 2 
through 11 
 To examine dose proportionality of 
[COMPANY_004]2838232 pharmacokinetic 
parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days
in HIV infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and Day 10 
AUC(0 -), Cmax, and C at different dose levels 
for the assessment of dose proportionality
Note: Other exploratory objectives and endpoints will be specified in the RAP
Design, Treatment A rms and Duration
Approximately  34 HIV -1 infected treatment- naive subjects will be enrolled overall. 
This study  is a 10- day monotherapy , open -label, adaptive, dose ranging, repeat- dose 
study  and will be conducted as two parts with an interim (go/no- go) analy sis performed 
after Part A ( Table 1). Part A, Cohort 1 will evaluate a safe and well- tolerated dose level 
of [COMPANY_004]2838232 that has been tested (with RTV) in prior Phase I studies and that targets 
a high inhibitory  quotient (IQ) value. Following the co mpletion of an interim analy sis of 
those data and according to criteria defined later in the protocol, further cohorts of 8 
subjects will then be studied in Part B in a parallel design in two or more cohorts 
(depending upon the data obtained in Part A). 
The totality  of this data will provide a full dose -response of [COMPANY_004]2838232 over a wide 
dose range to explore the safet y and PK/pharmacodynamics (PD) relationship of 
[COMPANY_004]2838232 in HIV -1 infected subjects and facilitate choice of doses for Phase IIb 
studies. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
12Table 1 Study  Design for 200911
Part A: [COMPANY_004]2838232/cobi 
Once Daily x 10 days1Part B: [COMPANY_004]2838232/cobi 
Once Daily x 10 days1,2
Cohort
N232 Dose
(mg)Cohort
N232 Dose 
(mg)
1 10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B, which 
are planned to run in a parallel, randomized fashion. All doses will be given with [ADDRESS_541579] to modification based upon safety, PK and antiviral activity data from Cohort 1 (Part A). More 
doses/cohorts (including potential removal of cobi co -dosing) may be added (the maximum dose in Part B would 
not exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] was lower in HIV infected 
subjects than in healthy subjects at the same dose level).
The possibility  that an additional, unboosted [COMPANY_004]2838232 monotherap y cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from Study  204953 where 
unboosted [COMPANY_004]2838232 at a dose of 200 mg twice daily  (BID) was assessed. 
Subjects in both parts will have a screening visit within [ADDRESS_541580] dose. Maximum duration of study  participation 
will be approximately  6 weeks.
HIV Drug Resistance: Following cessation of [COMPANY_004]2838232/cobi dosing for 10 day s, 
there will be prolonged exp osure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t½ (i.e., in the “tail” of the PK profile). However, based on in vitro 
resistance passage data with [COMPANY_004]2838232 [and unlike with many  other ARV therapi[INVESTIGATOR_014]], 
there appears to be a limite d likelihood of developi[INVESTIGATOR_428081]-infected subjects due to its virologic profile. 
Analysis
The primary  objectives of this study  are to investigate the safet y, tolerability, PK and 
antiviral activity  of 10 day s repeated dose s of [COMPANY_004]2838232/cobi in HIV -1 infected 
otherwise healthy  subjects. Descriptive summaries will be provided for safety , PK, and 
HIV viral load data. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
132. INTRODUCTION
[COMPANY_004]2838232 is a novel human immunodeficiency v irus ( HIV)-1 maturation inhibitor 
(MI) that is be ing developed for the treatment of HIV- 1 infection in combination with 
other antiretrovirals (ART).
2.1. Stud y Rationale
This ‘proof of concept (PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity, pharmacokinetics (PK), the r elationship between PK and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg once dail y (QD)cobicistat 
([COMPANY_004]283232/cobi), administered across a range of doses over [ADDRESS_541581] doses for further studies in Phase IIb.
2.2. Brief Background
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has dem onstrated significant improvement in acquired 
immunodeficiency  syndrome ( AIDS)-related morbidity and mortality  over the last 10 -15 
years. Emerging multi -class drug resistant viral strains and long- term toxicities warrant 
development of new classes of antir etroviral therapi[INVESTIGATOR_428082]-
1 viral life cy cle [Wainburg , 2010]. The inhibition of maturation of HIV- [ADDRESS_541582] from viral protease RT or integrase [ Saxena , 2012; 
Qian , 2009]. HI V maturation is the final cleavage step of the capsidSp1 (transcription 
factor) pol yprotein that generates the functional capsid p24 protein. This mec hanism of 
action results in accumulation of the uncleaved p25 protein with subsequent improper 
assembly  of the HIV core, resulting in a non -infectious virion. Gel -based mechanism of 
action studies suggest that compound [COMPANY_004]2838232 acts as a maturation inhib itor. 
Western Blot anal ysis shows inhibition of capsid -Sp1 cleavage and accumulation of p25 
in the presence of [COMPANY_004]2838232.
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [ Martin, 2007a; Martin, 2007b; Martin
, 2008; NORVIR , 2013]). 
BVM reached Phase II studies in HIV patients; however, onl y mo dest reductions in 
plasma HIV -1 ribonucleic acid (RNA) concentrations were observed in Phase IIa 
monotherap y studies [ Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential) antiviral activity  [Wainburg , 2010] led to termination of BVM development. 
The average decrease from baseline to Day  14 plasma HIV -1 ribonucleic acid (RNA )was 
0.54 and 0.70 log10 copi[INVESTIGATOR_014]/mL  for 200 mg and 300 mg twice daily  regimens ( Table 
2); 
all subjects achieved plasma BVM concentrations above the in vitro EC90. Responders, 
classified based on 5 polymorphisms in HIV -1 gag (at positions 369, 370, and 371), 
achieved an average 1.15 log10 copi[INVESTIGATOR_014]/mL reduction in plasma HIV -1 RNA, while an 
average 0.17 log10 copi[INVESTIGATOR_014]/mL  reduction was achieved for non -responders. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
14Table 2 Summary  of Bevirimat A ntiviral Response and PK in a 14 -day 
Monotherapy  Study in HIV -infected A dults
BVM dosage 
regimenMean (SD) viral load 
change from 
baseline to Day 142IQ Plasma BVM 
1Cmin (g/mL)Plasma BVM 
1Cmax 
(g/mL)Plasma BVM 
1AUC(0 -) 
(g.h/mL)
200mg BID
(N=14)-0.54 (0.64) 1.70 46
(41, 51)58
(53, 64)632
(571, 699 )
300mg BID
(N=18)-0.70 (0.77) 2.67 72
(65, 80)91
(84, 99)973
(890, 1064)
1. Cmin, Cmax, and AUC reported as geometric mean (95% CI).
2. IQ=geometric mean Cmin/in vitro EC90; reported EC90=27 g/mL; all subjects achieved IQ 1.
        AUC(0 -) = Area under the concentration -time curve over the dosing interval; BVM = Bevirimat; CI = Confidence 
interval; Cmax = Maximum plasma concentration; Cmin = Minimum plasma concentration; EC90 = 50% protection 
against resistant mutant HIV infection; IQ = Inhibitory quo tient; SD = Standard deviation.
Early clinical data for BMS955176, a second generation maturation inhibitor, have been 
recentl y presented [ Nowicka -Sans , 2015]. In a 10- day monotherapy  trial in HIV - infected 
patients, plasma HIV -[ADDRESS_541583] of 
inhibiting this viral target.
Although BMS955176 is currentl y in Phase II studies in HIV -infected patients, there are 
no maturation inhibitors approved for the treatment of HIV infection .  The uncertainties 
of earl y drug development and continuing need for novel ART, especially for heavil y 
treated/experienced HIV -infected persons, support continued compound development. 
[COMPANY_004]2838232’s low nanomolar in vitro potency  against multiple HI V-1 gag 
polymorphisms and broader spectrum across multiple HIV -1 subt ypes indicates it has 
utility  in this setting.
2.2.1. Preclinical Summary
Nonclinical pharmacology
Virology
[COMPANY_004]2838232, in vitro, is an inhibitor of HIV maturation by  [CONTACT_428243] V gag structural subunit p25 to p24. [COMPANY_004]2838232 is a potent antiviral agent with a 
mean 50% maximal inhibitory  concentration (50% maximal inhibitory  concentration 
[IC50]) value of 1.6 nM (range: 0.8 to 4.3 nM) when tested in a panel of 26 HIV -1 
isolates wi th various polymorphic gag genot ypes in peripheral blood mononuclear cells 
(PBMCs), suggesting that [COMPANY_004]2838232 can inhibit a broad spectrum of HIV isolates . In 
another PBMC assay , [COMPANY_004]2838232 showed potent antiviral activity  in 59 of 60 isolates 
with IC50 values ranging from 0.22 to 5.1 nM. [COMPANY_004]2838232 also inhibited HIV- 1 strains 
containing 
the consensus Sp1 QVT region or the V370A poly morphism in MT4 cells
(IC50 = 0.73 to 0.81 nM).  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
15In an MT2 cell -based assay  utilizing recombinant viruses harboring gag and protease 
from subjects before and after a protease inhibitor (PI) based regimen, [COMPANY_004]2838232 
inhibited 12 of 15 viruses with a mean IC50 value of 1.7 nM (range = 0.4 to 3 nM). The 
remaining 3 viruses were not inhibited by  [CONTACT_23983]2838232 up to the top concentrat ions 
tested at 400 nM. There was no correlation of PI [INVESTIGATOR_428083]2838232. [COMPANY_004]2838232 resistance mutations were selected for b y serial passage of 
virus in a SupT1 cell- based assay  with increasing concentrations of [COMPANY_004]2838232. I n the 
lab strain NL4- 3 and gag/protease recombinant viruses, the resistance mutation A364V 
arose and resistance confirmed by  [CONTACT_3725]-directed mutagenesis. This resistance mutation 
maintains susceptibility  to other classes of anti -retrovirals including PIs and non-
nucleoside RT inhibitors.
[COMPANY_004]2838232 was tested in vitro in combination with two marketed PI s, atazanavir and 
darunavir. 
Using a dose -wise additivity  model, [COMPANY_004]2838232A showed additive anti -viral 
activity with both PI s.
Secondary  Pharmacology
In a seconda ry pharmacology  study , [COMPANY_004]2838232 was tested against a panel of 
receptors, ion channels and transporters and demonstrated no significant effect (IC50 of 
1M). It is important to note that the selectivity for antiviral activity  of [COMPANY_004]2828232 
compared to a ll tested off -target activities was >100 -fold, and the potential for organ 
toxicity  was characterized in the nonclinical toxicology  studies (see below).
In safet y pharmacology studies in male rats, there were no hemod ynamic changes or 
neurobehavioral effec ts following single oral doses up to 300 mg/kg. A single oral dose 
of [COMPANY_004]2838232 at 30 mg/kg or 300 mg/kg produced reversible increases in respi[INVESTIGATOR_428084] (32% and 36%, respectively ) and derived minute volume (17% and 26%, 
respectivel y) at 6hours after dosing. These doses did not produce any  effect on 
respi[INVESTIGATOR_2842], airway  resistance or bod y temperature. There were no respi[INVESTIGATOR_428085] 5 mg/kg (mean maximum plasma concentration [C max] 0.12 g/mL ; AUC 0-24
1.0g.h/mL  based on Day 1 of the 4 -week repeat dose study ). These findings were not 
considered to suggest a safet y concern in humans.
[COMPANY_004]2838232 at the maximum feasible concentration, limited by  [CONTACT_16758] , of 4.09 M 
(3.31 g/mL) caused no inhibition of human ether-a- gogo relat ed gene (hERG) tail 
current in Human Embryonic Kidney 293 cells stably  transfected with hERG cDNA, 
indicating a low probability  for interaction at the hERG channel.
In conscious telemetered male dogs (n=4), a single oral dose of [COMPANY_004]2838232 at 
60mg/kg (C max0.59g/mL; AUC 0-248.7g.h/mL based on Day 1 exposure data from 
the 4- week oral repeat dose toxicity  study ) was associated with one epi[INVESTIGATOR_428086]-sustained ventricular tachy cardia in one dog lasting ~1.2 seconds. There were no 
effects on arterial pres sures, heart rate, or electrocardiogram (ECG) interval durations. An 
investigative safet y pharmacology cardiovascular study  was conducted in telemetered 
dogs given 60 mg/kg/day for 4 weeks with serial monitoring by  [CONTACT_51541] , 
cardiac biomarkers, qua litative and quantitative electrocardiology , microscopy , and 
transmission electron microscop y (TEM) of the heart.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
16There were no changes in echocardiograph y endpoints, ECG intervals, ECG waveforms, 
arterial pressures, heart rates, serum cTpn I, N-terminal p rohormone of brain natriuretic 
peptide (NTproBNP), or in heart tissue as assessed by  [CONTACT_428198]. With routine microscopy , 
one treated dog had a single focus of degeneration/necrosis of the tunica media 
(moderate) in an extramural artery  and another treated dog ha d localised, mixed -cell 
inflammation (mild) along the epi[INVESTIGATOR_428087]. Both changes have 
been reported in normal beagles and were considered of uncertain relationship to 
treatment in the absence of changes in an y other structural or functional cardiovascular 
endpoints. The 28 -day exposures were similar to the previous 4- week toxicity  study  in 
dogs: the C maxrange at 60 mg/kg/day  in this investigative safet y pharmacology stud y was 
0.542 to 2.00 g/mL and range of AUC 0-24was 6.04 to 35.7 g.h/mL. In subsequent 
repeat -dose studies in dogs treated for up to 9 months with up to 70 mg/kg/day , no 
changes were evident in cardiac biomarkers (including cTpn I and NTproBNP), functional 
(including ECG waveform) or structural (including microscopic eval uation) 
cardiovascular endpoints at slightly higher exposures than those achieved than in 
previous studies. The end of the 9 -month study , gender averaged C maxat 70 mg/kg/day  
was 1.95 g/mL and 
AUC 0-24was 38.8 g.h/mL. These studies support an absence of 
[COMPANY_004]2838232-related functional or structural effects on the heart in preclinical testing. 
The No Observed Adverse Effect Level
(NOAEL) was established at 20 mg/kg/day  (on 
the basis of mild hepatic findings) with an associated are aunder the curve at 24 hour s 
(AUC24) of 16.2 g.hr/mL  and Cmax 0.847 g/mL.
Pharmacokinetics and product metabolism in animals
The PK of [COMPANY_004]2838232 were investigated in the mouse, rat, and dog. The oral 
bioavailability  of [COMPANY_004]2838232 was low to moderate (~6% to 40%) depending on the 
species and formulation. Plasma and blood clearance were low and the volume of 
distribution at steady
 state was high relative to total body  water. The half -life of 
[COMPANY_004]2838232 was short in the mouse and rat, but moderate in the dog. S ystemic exposure 
of [COMPANY_004] 2838232 generally increased in a less than dose-proportional manner.  In rats, 
there were no differences in sy stemic exposure between single and repeat- dose 
administration, or between males and females.  In a 7 -day study  in dogs, systemic 
exposures were ge nerally similar between males and females and after single and repeat 
dosing; however, in a 4- week stud y, systemic exposures were higher in females than in 
males in the high -dose group (60 mg/kg/day ) and higher after repeat dosing than after a 
single dose. The distribution of radioactivit y in male pi[INVESTIGATOR_428088] a single 
oral administration of [14C] [COMPANY_004]2838232 at a target dose level of 20 mg/kg showed 
radioactivity  was rapi[INVESTIGATOR_428089] y distributed throughout the body with all 
tissues, e xcept the brain and spi[INVESTIGATOR_1831]. There were no tissues that retained detectable 
levels of radioactivity  at [ADDRESS_541584] canulated rat study , 30% of the 
administered dose was excreted in the bile as an acy lglucuronide. In the same study , 
unchanged drug and metabolites were eliminated primarily  in the bile and feces, while a 
mean of <1% of the dose was eliminated in urine.
In vitro, [COMPANY_004]2838232 is highl y protein bound (>99.9%) and has low passive 
permeability . In vivo evidence suggests act ive uptake of [COMPANY_004]2838232 by  [CONTACT_428199].  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
17After single oral doses of 5, 100, or 300 mg/kg, the average liver to plasma ratio was 51, 
17, and 10, respectivel y. After 7 days of dosing at 30, 100, or 300 mg/kg/day , liver to 
blood ratios rang ed from 10 to 16.
In the 13 -week repeat dose studies in dogs given 35 mg/kg BID (70 mg/kg/day ), heart 
tissue collected at necropsy  had [COMPANY_004]2838232 concentrations 2.[ADDRESS_541585] -dose plasma concentrations, similar to the previous 4-week CV 
investigative findings.  In the 13
-week repeat dose studies in rats given 300mg/kg/day , 
heart tissue collected at necrops y had[COMPANY_004]2838232 concentrations approximately  [ADDRESS_541586] -dose plasma concentrations, similar to t he previous 7- day 
findings.  Overall [COMPANY_004]2838232 did not appear to be highl y concentrated in heart tissue 
after repeat dosing and suggests that accumulation upon chronic dosing is unlikely .
Routes of metabolism identified in liver microsomal incubations and rat, dog, and human 
hepatocy tes were N-dealky lation, oxidation, oxidative deamination, and glucuronidation, 
alone or in combination , with no human- specific metabolites detected.  N -dealk ylated 
products and glucuronidation were observed in rat plasma and t he bile. In general, in 
vitro metabolite profiles of the nonclinical species and human were qualitatively  similar, 
such that all metabolites of [14C] [COMPANY_004]2838232 observed in human hepatocyte 
incubations were observed in rat and/or dog. Minor to trace levels of potential aldehy des 
metabolites formed as a result of N- dealk ylation and oxidative deamination were 
observed in rat, dog and humans.  
[COMPANY_004]2838232 did not show evidence for glutathione adduct formation in rat or human 
liver microsomes.  Data from pooled human liver microsomes along with recombinant 
cytochrome P450 ( CYP) enzy mes suggest that in vitro the oxidative metabolism of 
[COMPANY_004]2838232 was primarily  mediated b y CYP3A4.  Preliminary  in vitro investigations 
showed [COMPANY_004]2838232 did not inhibit CYP1A2, 2C9, 2C19, 2D6, 3A4 and was not a 
metabolism -dependent inhibitor of CYP3A4. No drug interaction risk was identified for 
co-administrated substrates of UGT1A1, 1A3, 1A6, 1A9, 2B7, and 2B15, OAT1, OAT3, 
OATP1B1, OATP1B3 or OCT2 at a clinical dose of 200 mg [COMPANY_004]283 8232/ritonavir 
(predicted Cmax 0.32 µM). Extrapolation of the clinical risk (using FDA and EMA 
regulatory  guidance) did indicate a risk for [COMPANY_004]2838232 -mediated inhibition of 
UGT1A4 and of gut contributions of CYP3A4, P-gp, and BCRP at the same clinical 
exposure; however, the potential for clinicall y significant interactions via these 
mechanisms is predicted to be low (<2 fold change in AUC). [COMPANY_004]2838232 did show 
weak induction of CYP3A4 enzy me activity . However, based on the maximum predicted 
plasma concentrations and high protein binding, the potential for clinicall y significant 
drug interactions through CYP3A4 induction by  [CONTACT_23983]2838232 appears to be low.
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure); however, there have been no 
preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Toxicology
[COMPANY_004]2838232 administered by  [CONTACT_428200] 6 months duration 
resulted in no adverse treatment
-related effects in rats given up to 300 mg/kg/day  QD.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
18In dogs given up to 70 mg/kg/day  (35 mg/kg/day  BID), adverse liver effects were noted 
at this dose in the 9-m onth repeat dose study .  Though isolated, low grade changes in 
heart rate and cardiac troponin I  (cTnI) had been noted in 4 -week toxicity  studies in rats 
and dogs; however, there were no treatment -related structural or functional 
cardiovascular changes in studies of 3 months and greater duration as assessed by  
[CONTACT_422878]
y, ECG, microscop y, and cardiac biomarkers, indicating an absence of 
[COMPANY_004]2838232-related functional or structural effects on the heart in preclinical testing. 
Only  non- adverse treatment -related changes were noted in the definitive 6-month rat 
study , which included occasional salivation in animals given 300mg/kg/day  and minimal 
clinical pathology  changes without histologic correlates (transient clinical chemistry  
changes at 5mg/kg/day a nd reversible urine chemistry  changes at 300 mg/kg/day ). The 
NOAEL in this study  was considered to be 300 mg/kg/day  (mean AUC[0- t] 
21.3g.h/mL , mean Cmax 1.77 g/mL [Week 26 values for males and females 
combined]).  
As noted above, dogs given [COMPANY_004]2838232 at 70 mg/kg/day  for 9 months had minimal to 
moderate pi[INVESTIGATOR_371] (consistent with bile) with minimal to mild mixed cell infiltration 
in the liver and isolated mild increases in alanine aminotransferase (ALT) activity .  These 
findings were considered adver se, but were reversible after the 6- week off -dose period.  
The NOAEL for this dog study  was considered to be the mid -dose level of 20 mg/kg/day  
(mean AUC[0- t] 16.2 g.h/mL , mean Cmax 0.847 g/mL [Week 39 values for males and 
females combined]).
Data from g enotoxicity  assessments suggest that [COMPANY_004]2838232 does not present a 
genotoxic hazard to humans.
During discussions with the FDA regarding the resolution of the clinical hold, the 
Agency  recommended that the sporadic cardiovascular changes observed in the ea rly (1-
month) rat GL P study  at the highest dose level (300 mg/kg/day ) should be considered 
when defining the NOAEL  and establishing a safe dose of GlaxoSmithKline ([COMPANY_004]) for 
the initiation of this study  protocol.  Accordingl y, for the initial PK studies, th e reference 
dose level of 30 mg/kg/day  in the 1- month rat study  was initially  used to define the 
NOAEL and therefore the values for fold cover at maximum projected mean exposure 
and Cmax in human subjects were lower, at >2.[ADDRESS_541587] sensitive species (i.e., 20 mg/kg/day  in the 9- month dog study  
based on liver endpoints) is currentl y used for assessing fold -
cover for projected clinical 
dosing in this study .
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure and toxicity ); however, there 
have been no preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Full details of non -clinical and clinical data may  be found in the current Investigator’s 
Brochure (IB) [[COMPANY_004] Document Number 2012N151889_03]. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
192.2.2. Clinical Summary  of Safety  and Pharmacokinetics
To date, [COMPANY_004]2838232 has been evaluated in three completed clinical studies with or 
without ritonavir ( RTV )([COMPANY_004]2838232/r). A fourth study  (204953) completed late 2016
and data a nalysis is ongoing . Full details of the clinical results can be found in the 
Investigator’s Brochure.
[IP_ADDRESS]. Clinical Summary  of Safety
As of November 2016 f ifty-three subjects had been exposed to [COMPANY_004]2838232 in 3 
completed studies. One study  (204953) completed in late 2016 and the analysis of results 
are ongoing (63subjects were exposed to [COMPANY_004]2838232/r or placebo so far in this study ).  
Overall, drug -related adverse events have been few and mild, and included headache, 
dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428090] .  Similarly , treatment- emergent 
laboratory  abnormalities have also been few and mostly  grade 1.  There have been no 
discernible patterns, thus far, in terms of AEs or laboratory  abnormalities.
One subject in study 200912 discontinued treatment with RTV due to an AE.  A 47 -year-
old female who developed right upper quadrant abdominal pain, nausea and flatulence 
associated with grade 4 elevations in AL T and aspartate aminotransferase, and grade 2 
elevations in total bilirubin (BIL). She was diagno sed with a common bile duct 
obstruction due to gallstones that spontaneously  resolved. The Investigator assessed this 
AE as unrelated to study treatment.
Due to sporadic CV -related safet y signals in the early animal studies (see Section 2.2.2), 
intense CV monitoring was in place for all four studies.  
One AE occurred in HMI116787 that was initially  considered a CV AE but after further 
evaluation was considered not to be of cardiac etiology .  Two CV AEs occurred in 
[ADDRESS_541588] been a small number of CV -related events of an y 
sort: There have  been n o serious adverse drug reactions, and no clinically  significant 
drug-related abnormal findings for 12 -lead ECGs, vital signs, safet y laboratory  results 
(including cardiac troponin I ), or telemetry .  The following cardiovascular AEs were 
observed during the course of the stud y but were not considered to be caused by 
[CONTACT_23983]2838232 exposure:
In Part 1A (Cohort 1), Period 2, a subject was withdrawn due to an AE (low 
hemoglobin) prior to [COMPANY_004]2838232 exposure Day 
-2.  A replacement subject 
was brought in, but was not dosed with [COMPANY_004]2838232 or placebo because during 
the 2- day RTV run -in, on Day  -1, the replacement subject met the stoppi[INVESTIGATOR_428091], NSVT prior to 
the first dose of [COMPANY_004]2838232 or placebo.  Because the subject was excluded 
from the study  prior to the first dose of investigational drug, the NSVT was not 
considered to be a serious and unexpected advers e drug reaction that would 
qualify  for IND safety  reporting.   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
20In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject was 
discontinued prior to the first dose of stu dy drug due to a series of 
cardiovascular findings (pre -ventricular contractions on telemetry ).  None of the 
findings were abnormal or aty pi[INVESTIGATOR_2855], but the investigator determined that this 
would not be a good etiology  to have in a subject about to receive 
investigational drug.  Because the event occurred prior to first dose of 
investigational drug, the finding was not considered to be due to [COMPANY_004]2838232 
exposure.  
In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject who 
had alread y been dosed on 2 previous occasions (with either [COMPANY_004]2838232 or 
placebo) was dosed for 2 day s with RTV, and then on 05 May  2016 was dosed 
with either [COMPANY_004]2838232/r or placebo/r as scheduled. O n the following day (06 
May 2016), the subject experienced an as ymptomatic, [ADDRESS_541589] had received placebo prior to experiencing the 
NSVT, the event was not considered to be due to [COMPANY_004]2838232 exposure or a 
serious and unexpected suspected adverse reaction that would qu alify for IND 
safet y reporting.
In Part 2 (Cohort 6, 200mg/r), a 40 y ear old male enrolled in the study  with no 
significant medical history experienced an as ymptomatic ventricular triplet 
(NSVT) while asleep at 5:33am on Day  8 (of 11 day s worth of dosing) 
approximately  21 hours after receiving 200 mg [COMPANY_004]2838232/r on the previous 
day at 8.25am. This event was noted by  [CONTACT_428201]. The 
[COMPANY_004] medical monitor was not ified.  Because the subject was not s ymptomatic 
and this did not meet protocol -defined stoppi[INVESTIGATOR_3418], the study  was not 
unblinded at the time, and the subject was allowed to continue dosing. Dosing 
in the study  is now complete and no further events h ave been noted. It was the 
assessment of the site PI [INVESTIGATOR_428092] /monitoring team that a ventricular 
triplet can be seen in healthy  volunteers on continuous Holter monitoring.
Therefore neither the PI [INVESTIGATOR_428093] a serious a nd 
unexpected suspected adverse reaction.
[IP_ADDRESS]. Study  204953 (completed ); Pharmacokinetic Data
Study  [ADDRESS_541590] of a normal fat meal on the bioavailability  of a single 
dose of [COMPANY_004]2838232 in the capsule formulation with RTV.  I t will evaluate 
[COMPANY_004]2838232 exposure after repeated doses of unboosted [COMPANY_004]2838232 in the capsule 
formulation. Noncompartmental PK anal ysis was performed using scheduled sample 
times.  This study  is ongoing; preliminary  results are presented.
Pharmacokinetic anal ysis was performed on [COMPANY_004]2838232 plasma concentration -time 
data using nominal time following single doses of 50, 100, and 250 mg in combination 
with RTV in Pa rt 1A of Study  204953 ( Table 3 ).  On average, [COMPANY_004]2838232 Cmax 
values were reached [ADDRESS_541591] dose pro portionalit y was observed 
for Cmax and AUC(0- ) values with ascending single doses of [COMPANY_004]2838232 (50, 100, 
and 250 mg with 100 mg RTV).
Table 3 Summary  of Preliminary  Pharmacokinetic Parameter Values after 
Single Doses of [COMPANY_004]2838232 in Combination with 100 mg Ritonavir 
(Study  204953, Part 1A )
Dose (mg) n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)
50 8 22.7
(17%)
(17.2- 28.5)0.188
(138%)
(0-0.5)3.63
(41%)
(2.5-6.0)17.2
(43%)
(8.7-27.9)458.6
(33%)
(210.6- 662.0)
100 6 18.0
(14%)
(15.8- 22.3)0.167
(155%)
(0-0.5)6.00
(59%)
(2.5-12.0)25.2
(20%)
(17.5- 31.5)890.5
(20%)
(619.1- 1053)
250 5 17.3
(6.4%)
(15.5- 18.6)0
(-)
(0-0)5.50
(71%)
(2.0-12.0)60.7
(23%)
(40.8- 73.1)1731
(29%)
(1222- 2505)
Data are presented as mea n (CV) (minimum -maximum).
Study  204953 Part 1B was an open label, 2x2+[ADDRESS_541592] on the capsule formulation in Period 3.  
The relative bioavailability  of the micronized powder blend in 50 mg hand- filled capsules 
compared to the micronized API  [INVESTIGATOR_428167] a s 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
in a randomized crossover design in [ADDRESS_541593] two periods of Part 1B of 
Study  204953. Preliminary  geometric mean AUC(0 -) and Cmax values were 
approximately  45% and 60% higher, respectivel y, after administration in the capsule 
formulation compared to oral suspension from PiB ( Table 4). 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
22Table 4 Preliminary  Assessment of Relative Bioav ailability  of Capsule 
Formulation vs. Po wder -in-Bottle Formulation of [COMPANY_004]2838232 (Study 
204953, Part 1B)
Parameter Test Reference n Ratio of Geometric 
Least Square Means90% CI of Ratio
AUC(0 -) Capsule PiB 12 1.43 (1.194,1.702)
Cmax Capsule PiB 12 1.58 (1.312,1.900)
PiB = powder -in-bottle.
The potential food effect with the capsule formulation was assessed as 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
and with a normal fat meal in a non- randomized cr ossover design (fasted in either Period 
1 or 2, fed in Period 3).  Eleven subjects provided data for both dietary  conditions.   
Preliminary  geometric mean AUC(0 -) and Cmax values were approximately  60% 
higher after administration in the capsule formulatio
n with a normal fat meal compared to 
the fasted state ( Table 5 ).
Table [ADDRESS_541594] of a Normal Fat Meal on 
[COMPANY_004]2838232 Exposure when Administered as a Capsule 
Formu lation with Ritonavir (Study  204953, Part 1B)
Parameter n Capsule –food
Geometric meanCapsule –
fasted
Geometric 
meanRatio of geometric 
means 
(food/fasted)
AUC(0 -) (ng.h/mL) 11 2414 1539 1.57
Cmax (ng/mL) 11 76.9 47.2 1.63
Repeat dose PK parameter values in Study  204953 Part 2 were determined on Day  1 and 
Day 11 using nominal time in Part 2 of Study  204953 ( Table 6). After the Day  11 dose of 
[COMPANY_004]2838232 with RTV, exposure (Cmax, AUC[0 -]) appeared to increase
proportionally  with the increase in dose level with the PiB and capsule formulations.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
23Table 6 Summary  of Preliminary  Pharmacokinetic Parameter Values on 
Day 1 and Day  11 during Repeated Dosing of [COMPANY_004]2838232 in 
Combination with 100 mg Ritonavir (Study  204953, Part 2)
Dose 
(mg)n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)C
(ng/mL)
Study Day 1
20
(PiB)6 - 0.417
(49%)
(0-0.5)3.67
(11%)
(3.0-4.0)12.2
(47%)
(5.8-20.8)189.4
(40%)
(83.7- 284.4)6.1
(39%)
(2.5-8.9)
50
(PiB)6 - 0.167
(155%)
(0-0.5)3.00
(51%)
(2.0-6.0)18.7
(40%)
(9.0-25.9)288.7
(39%)
(138.6- 380.2)9.5
(35%)
(5.1-12.6)
100
(capsules)6 - 0.167
(155%)
(0-0.5)2.25
(23%)
(1.5-3.0)48.4
(32%)
(28.1- 69.6)664.1
(31%)
(422.5- 932.7)21.6
(33%)
(12.8- 29.3)
200
(capsules)6 - 0.083
(245%)
(0-0.5)2.50
(25%)
(2.0-3.5)79.4
(38%)
(50.8- 125)1124
(39%)
(636.7- 1794)38.9
(36%)
(21.7- 58.6)
Study Day 11
20
(PiB)6 19.2
(16%)
(15.1-
24.2)- 5.00
(32%)
(2.5-6.0)27.4
(38%)
(11.3- 40.4)474.3
(31%)
(214.3- 613.2)15.3
(30%)
(7.1-19.2)
50
(PiB)6 27.3
(52%)
(15.2-
50.4)- 3.50
(46%)
(1.5-6.0)58.0
(24%)
(40.9- 78.0)1113
(23%)
(762.6- 1459)38.8
(29%)
(24.5- 51.7)
100
(capsules)6 17.9
(18%)
(15.2-
23.7)- 4.00
(40%)
(2.5-6.0)133
(23%)
(94.7- 164)2492
(27%)
(1624- 3301)81.7
(30%)
(45.9- 113)
200
(capsules)6 -1 - 3.33
(45%)
(1.5-6.0)240
(38%)
(127-368)4389
(45%)
(2095- 7161)151
(46%)
(67.8- 250)
Data are presented as mean (CV) (minimum -maximum).
1. Concentration data were available up to 24 h after the Day 11 dose, and t½ values were not 
calculated.
[IP_ADDRESS]. Overall Summary /Conclusions of PK data
The original formulation used in the first three studies with [COMPANY_004]2838232 (HMI 116787, 
200207, and 200912) was SDD.  Data from Stud y 200912 demonstrated that a change to 
the API  [INVESTIGATOR_428168]2838232 was feasible for future clinical studies. Study  
204953 utilized micronized API [INVESTIGATOR_428096] a bottle as well as in a capsule. The capsule 
was shown to be a viable solid dosage form for subsequent studies.  A more detailed 
summary  of the da ta from Study  204953 is in Section [IP_ADDRESS]. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
24[COMPANY_004]2838232 SDD did not overall demonstrate significant escalation in exposure 
from an increase in dose from 100 mg to 200 mg in a cross -study  comparison.  The 
API [INVESTIGATOR_428097] a proportional increase in AUC and Cmax for a 2 -fold 
dose escalation from 100 mg to 200 mg.
The observed tmax of the API  [INVESTIGATOR_428098] (the API [INVESTIGATOR_428099]).
The bioavailability  of the [COMPANY_004]2838232 API  [INVESTIGATOR_428100] 30 -50% of 
the bioavailability  of SDD formulation, but there was a large observed range of 
relative intra -subject exposures (11- 150%).
Both 10 mg SDD and 20 mg API [INVESTIGATOR_428101] a 10 -fold or gre ater increase in AUC with 
steady -state RTV (100 mg QD for 10 day s) with a smaller ( ≤4-fold) increase in 
observed Cmax.  The t½ of [COMPANY_004]2838232 increased from 15-18 hours to 34-42 
hours in the presence of stead y-state RTV, regardless of formulation.
After sin gle doses of 50 to 250 mg [COMPANY_004]2838232 with RTV, increases in Cmax and 
AUC(0 -) values were broadly  proportional to the increase in dose.  On Day  11 
after repeated dail y 20 to 200 mg doses of [COMPANY_004]2838232 with RTV, increases in 
Cmax and AUC(0 -) values appeare d to be proportional to the increase in dose with 
the PiB and capsule formulations.  
The relative bioavailability  of the micronized API  [INVESTIGATOR_428102]  45% -60% higher than the bioavailability of the micronized 
API [INVESTIGATOR_428169].
Co-administration of the micronized API  [INVESTIGATOR_428104] a 
normal fat meal resulted in an approximately  60% increase in geometric mean 
Cmax and AUC(0 -) values compared to the fasted state with RTV (Study  
204953).
Variability  remains fairly constant across formulations and boosted versus 
unboosted at around 30% -40% (moderate -high).
Projections of potential future efficacious boosted [COMPANY_004]2838232 API  [INVESTIGATOR_428105] [ADDRESS_541595] 3 -fold above the derived 90% maximal 
inhibitory  concentration (IC90) target value (5 ng/mL ). Even if protein binding has 
more impact than envisaged and causes a 5 -fold in
crease in IC90 as seen in some 
preclinical virology  studies, the predicted troughs will still be significantly  higher 
than the 5 -fold shifted IC90 (25 ng/mL) at doses of 50 mg or higher with RTV. 
The average and maximum AUC/Cmax values observed at the max imum dose 
studied to date are below NOAEL values in preclinical chronic toxicology  studies 
(6-month rat, 9- month dog). 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
253. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected patients
during 10 -days of monotherapy.Maximum decline from baseline (Day 1) in 
plasma HIV -1 RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered as 
monotherapy over 10 days. Safety and tolerability parameters, 
including adverse event, con current 
medication, clinical laboratory, 
electrocardiogram (ECG) and vital signs 
assessments.
To characterize pharmacokinetics (PK) of 
[COMPANY_004]2838232 in HIV -1 infected patients 
following [COMPANY_004]2838232/cobi dosing for 10 
days [COMPANY_004]2838232 PK parameters following 
dose administration, as follows:
Day 1 :  area under the plasma 
concentration time curve AUC(0 -24), 
maximum observed concentration 
(Cmax), time to maximum observed 
concentration (tmax), concentration at [ADDRESS_541596] dose (C24), absorption lag 
time (tlag); 
Following last repeat administration on 
Day 10 :  AUC(0 -), pre -dose 
concentration (C0), concentration at end 
of dosing interval (C ), Cmax, tmax, t½, 
and apparent oral clearance (CL/F), if 
data permit
Secondary
 To explore the relationship between 
[COMPANY_004]283 8232 exposure and change in 
plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 
AUC(0 -), Cmax, C with Day 11 HIV -1 
RNA change from baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when administered over 
10 days in HIV -1 infected adults Change f rom baseline in CD4+ cell count 
to Day 11
 To explore the relationship between 
[COMPANY_004]2838232 exposure and safety or 
immunologic parameters, if appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax, C   with Day 11 change 
from baseline in CD4+ cell c ount
 To assess the development of viral 
resistance (genotypic and phenotypic) over 
10 days and correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, 
if appropriate 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
26Objectives Endpoints
 To estimate [COMPANY_004]2838232 accumulation and 
to assess attainm ent of steady state 
following administration of 
[COMPANY_004]2838232/cobi for 10 days in HIV 
infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): 
Day 10 AUC(0- ), Cmax, and C 
compared to Day 1 AUC(0- 24), Cmax, 
and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on 
Day 2 through 11 
 To examine dose proportionality of 
[COMPANY_004]2838232 PK parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days in HIV 
infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and 
Day 10 AUC(0- ), Cmax and C at 
different doses levels for the assessment 
of dose proportionality
Note: Other exploratory objectives and endpoints will be specified in the RAP
4. STUDY DESIGN
4.1. Overall Design
This is a Phase IIa, multicenter, open -label, adaptive dose ranging, study  to evaluate the 
antiviral effect, safet y, tolerability, and PK of [COMPANY_004]2838232/cobi monotherap y over [ADDRESS_541597] received an y ART (including prior MI) therap y will not be eligible for 
this study . To minimize the number of subjects exposed to suboptimal doses, an adaptive 
and dose ranging design is applied in this study .
This study  consists of a screening visit, a [ADDRESS_541598] dose 
of study  drug.  Eligible HIV -1 infected subjects will receive study  treatments for 10 day s.
Study  Design for 200911
[COMPANY_004]2838232/cobi Once Daily for 10 days1,2
Part A Part B 
Cohort 1 Dose
(mg)Interim Analysis Cohort
N(mg)
N=10 100
2 8 200
3 8 50
4 8 20 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
271. Part A Cohort 1 safety/PK/virology data will be evaluated at interim, prior to initiating other cohorts in Part B, which 
are planned to run in a parallel, randomized fashion.  All doses will be given with [ADDRESS_541599] to 
modification based upon safety, PK and antiviral activity data from Cohort 1 (Part A). More doses/cohorts 
(including potential removal of cobicistat co -dosing) may be added. (The maximum dose in Cohort B  will not  
exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax] is lower in HIV -infected 
subjects than in healthy subjects at the same dose level).
After successfull y completing screening evaluations, the first cohort will enroll 10 
subjects to receive the 100 mg [COMPANY_004]2838232/cobi dose.  Following interim anal ysis of 
Cohort 1, if warranted, Cohorts 2 -4 will each enroll 8 subjects to receive a range of 
[COMPANY_004]2838232/cobi doses.
Day 1 – Day 10: Dosing 
Subjects will report to the clinic for outpatient visits in the morning on Day s 1 through 10 
during the treatment per iod, except for the weekend (Day s 6 and 7).  Subjects will arrive 
each day  prior to administration of the morning dose for safet y and lab assessments, 
including HIV -1 RNA blood draws, as described in the Time and Events Table (Section 
7.1).  Subjects will begin receiving stud y drug in the morning of Day 1.  
Serial, intensive blood PK samples will be collected on Day  1 (up to [ADDRESS_541600] -
morning dose) and Day  10 (up to [ADDRESS_541601] -
morning dose), and limited, single blood 
PK samples pre -morning doses on Day s [ADDRESS_541602] for 10 hours [overnight] prior to the morning check in on the 
intensive PK sampling day s (Day s 1 and 10).  All dosing day s will require co-
administration of treatment with a light snack/meal per cobicistat labeling guidelines. All 
doses of study  medication will be taken with 240 mL  of water.  Subjects will be required 
to stay  in the clinic on Day s 1 and 10 until all specified assessments are completed ([ADDRESS_541603] -dose). Following Day  10, subjects will be required to attend the clinic for 
follow up assessments including virological and PK blood sampling for up to 3 weeks.
Subjects will be given morning doses on Day s 1 through 10 (except for the weekend) in 
the clinic.  Weekend morning doses (Day s 6 and 7) will be packaged and sent home for 
self-administration.  After Day  11, the subjects will return frequentl y for assessments 
including blood draws for PK and HIV viral load. A diary  card w ill be used to monitor 
dosing adherence.
Follow -up Visits:
Subjects will return to the clinic on Day s 11, 12, 14 ( 1 day ), and 21 ( 1 day ) for PK and 
measurement of HIV -1 RNA levels, viral genot ype/phenoty pe and safet y assessments as 
shown in the Time and Events Table (Section 7.1). 
4.2. Type and Number of Subjects
At least 34 subjects will be enrolled such that approximately  6
-10 evaluable subjects 
complete a number of cohorts.  Additional subjects/cohorts may  be en rolled to allow for 
evaluation of additional dose levels as appropriate.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
28If subjects prematurel y discontinue the study, additional replacement subjects may be 
randomised and assigned to the same treatment cohort at the discretion of the Sponsor in 
consult ation with the I nvestigator.
4.3. Design/Dose Justification
The fastest track to establishing antiviral potential of any  novel HIV drug is to study  a 
short course of monotherapy  in HIV infected subjects. There is precedent for this across a 
number of classes of ART drugs. 
Uncertainties over the impact of protein binding on the activity  of [COMPANY_004]2838232 and the 
inherent potency  of inhibiting the HIV maturation process as a target remain key  
objectives for the [COMPANY_004]2838232 program. This two -part adaptive design will a llow an 
early understanding of the potential of [COMPANY_004]2838232 in combination with cobicistat (and 
by [CONTACT_118414], RTV), while not exposing HIV -infected subjects to longer courses of 
what may  be suboptimal doses and possible development of resistance. 
Early clinical studies have indicated that in order to achieve reasonable IQ values likely  
to be associated with antiviral efficacy , [COMPANY_004]2838232 will need to be boosted with a 
pharmacoenhancer, such as RTV or cobicistat (in common with many  CYP3A4 
substrates). 
There is no a priori intention to study  [COMPANY_004]2838232 unboosted, unless: i) following the 
preliminary  anal ysis of Part A Cohort 1, there is such pronounced antiviral activity  that it 
would seem the estimates of projected IQ are low, in which case [COMPANY_004]2838232 may be 
evaluated in a subsequent cohort unboosted, or ii) the data from Cohort 7 in ongoing 
Study  204953 (planned, [COMPANY_004]2838232 200 mg BID unboosted) support it.
4.3.1. [COMPANY_004]2838232 with Ritonavir
In Stud y HMI116787, a single dose of 10 mg [COMPANY_004]2838232 (SDD) given after 10 day s of 
RTV 100 mg dail y dosing (to stead y state) demonstrated an increase in overall exposure 
(AUC) and Cmax by  [CONTACT_5554] 10.[ADDRESS_541604] . Studies 200912 and 200207 also indicated the utility  of RTV in 
boosting [COMPANY_004]2838232 concentrations.
These data indicate the viability  of study ing a number of [COMPANY_004]2838232+RTV regimens in 
this PoC study . Predicted exposures following different [COMPANY_004]2838232 doses with steady -
state RTV are presented in Table 
7, based on the results of linear regression anal yses of 
the preliminary  Day  11 data in Study  204953 (dose levels of 20 to 200 mg) and assuming 
no significant differences in PK (ADME) between HIV -infected subjects and healthy  
subjects.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
29Table 7 Predicted Mean Steady -State [COMPANY_004]2838232 A UC(0 -24), Cmax, and IQ, 
Follo wing Repeated Dose A dministration + RTV with Fold Cover to 
NOA EL
Dose 
(mg)Projected AUC24 
(ng.h/mL)1Fold cover to 
NOAEL Dog2Projected 
Cmax 
(ng/mL)1Fold cover to 
NOAEL Dog2IQ3
20+RTV 451 36 24 35 3.1
50+ RTV 1127 14 61 14 7.7
100+ RTV 2253 7.2 122 6.9 15
150+RTV 3380 4.8 183 4.6 23
200+RTV [ADDRESS_541605] NOAEL, 20 mg/kg/day obtained from 9 -month study in dogs ( AUC24 [ZIP_CODE] ng.h/mL and Cmax 847 
ng/mL)
3. Mean IQs derived from predicted C /IC90 (with target of 5 ng/mL).
C= Pre-dose (trough) concentration at the end of the dosing interval , IQ= inhibitory quotient.
The IQ following 20 mg to 200 mg [COMPANY_004]2838232/r QD is predicted to be >3 to >30 -fold 
above the minimal target value (5 ng/mL) which was derived from preclinical virological 
assessment as 4 × EC50. No protein binding adjustment has been made because there was 
a minimal ( ≤5 fold) shift in assays where the effect of protein was assessed. If protein 
binding has more impact than anticipated, it is possible that the target Cmin value is 
approximately  25ng/mL . In that scenario, projected IQ values at 200 mg/r QD would still 
be >5.
4.3.2. [COMPANY_004]2838232 with Cobicistat
There have been no preclinical or clinical studies with [COMPANY_004]2838232 and cobicistat to 
date; however, a review of the literature indicates that pharmacoenhancement of drugs 
that are known to have dominant CYP3A metabo lic pathway s is similar with either RTV 
or cobicistat [ Kakuda , 2009; Elion , 2011; Gallant , 2013].  Thus, the use of cobicistat as 
the CYP3A [ADDRESS_541606] of ritonavir is 
expected to produce a similar profile of [COMPANY_004]2838232 ADME (and therefore s ystemic 
exposure).  The pharmacokinetic data available after Part A Cohort 1 will confirm this 
assumption.  
4.3.3. Interim A nalysis
An evaluation of [COMPANY_004]2838232 safet y, efficacy  and PK data will be done after Part A 
Cohort 1, if the exposure level of [COMPANY_004]2838232 is in the range of the maximum 
[COMPANY_004]2838232 exposure seen previousl y in healthy subjects and the Bay esian pr obability  
from Cohort 1 is less than 70%, the study will not move forward into Part B, otherwise 
doses will be selected for evaluation in Part B. If pharmacokinetic exposure after the 100 
mg [COMPANY_004]2838232/cobi dose is in the range of values observed after 100 mg 
[COMPANY_004]2838232/r in prior studies, the doses for Part B will be extended to both lower 
(20mg, 50 mg) and higher (200 mg) doses. The highest dose tested in Part B will be 
selected to result in exposures similar to those seen with 200 mg/r in Study 204953.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
304.4. Benefit:Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
[COMPANY_004]2838232 can be found in the I nvestigator’s Brochure.   The following section 
outlines the risk assessment and mitigation strategy for this protocol :   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
314.4.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [COMPANY_004]2838232 
Cardiovascular Pre-clinical studies have shown the following findings:  elevated heart rates, a n 
isolated epi[INVESTIGATOR_43180] -sustained ventricular tachycardia and minimal to mild, 
sporadic troponin I elevations in dogs.  A subsequent investigative cardiovascular 
study in telemetered dogs treated for 4 weeks did not replicate these effects. 
Isolated microscopic cardiovascular changes were noted (focal extramural 
arteritis and localized epi[INVESTIGATOR_428106]), however these changes were 
considered of uncertain relationship to [COMPANY_004]2838232 because similar findings 
occur at low incidence in normal beagles an d there were no [COMPANY_004]2838232 -related 
functional changes by [CONTACT_428202], or changes in cTpnI and 
NTproBNP.  In addition there was no correlation between histologic changes and 
plasma exposure or heart tissue concentrations of [COMPANY_004]2838232. 
3, [ADDRESS_541607], other than a 30% incidence of 
gastrointestinal symptoms (including diarrhea). There were no significant 
cardiovascular AEs reported in published clinical studies.Subjects will be clinically monitored for any signs 
of myocardial injury (chest pain, shortness of 
breath, pain with inspi[INVESTIGATOR_1516]), elevated heart rate 
or arrhythmias. Samples for the assessment of 
troponin will be taken. Baseline EKG and Holter 
(to use for screening and for later comparisons if 
needed)
Exposures of [COMPANY_004]2838232 w ill be closely 
monitored in the clinical study so as to not 
exceed pharmacokinetic stoppi[INVESTIGATOR_3418].   
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
32Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Cobicistat (Tybost)
General The cobicistat label inc ludes the following information: 
TYBOST decreases estimated creatinine clearance due to inhibition of tubular 
secretion of creatinine without affecting actual renal glomerular function. This 
effect should be considered when interpreting changes in estimat ed creatinine 
clearance in patients initiating TYBOST
In one study investigating cobi+( atazanavir and tenofovir DF/emtricitabine) vs 
RTV+( atazanavir and tenofovir DF/emtricitabine), a higher frequency of reports 
of jaundice (6% and 3%) and ocular icterus (4% and 2%) were reported in the 
cobi group compared to the RTV group.  
Changes from baseline in total cholesterol, HDL -cholesterol, LDL -cholesterol, and 
triglycerides have been observed. The implications of these findings are 
unknown.
The vast majority of available safety data has been obtained in combination 
studies with other ART. There are no warnings of obvious cobicistat -related 
adverse events or safety concerns. Subjects will be closely monitored for any signs 
or symptoms potentially associated wi th 
cobicistat administration, in particularchanges in 
serum creatinine and liver chemistry.
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible Drug -Drug 
Interactions ( DDIs )HIV Drug Resistance to unique mechanism
Reco gnize HIV patients have a higher chance of comorbidities/diseases and a 
risk of taking a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resistance
Strict adherence to protocol criteria around 
concurrent meds  
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
334.4.2. Benefit A ssessment
This study  in HIV -1 infected but otherwise healthy  subjects is a 10 -day monotherapy  
design. It is anticipated that all subjects receiving [COMPANY_004]2838232 will experience anti -HIV 
effects whereb y their (blood) HIV viral titres are reduced, until administration stops and 
the viral load returns to baseline levels. There is no expected longer term anti- HIV 
benefit to administration of [COMPANY_004]2838232.  Participation in this study  contributes to the 
process of developi[INVESTIGATOR_428107]2838232 and other new therapi[INVESTIGATOR_428108].
4.4.3. Overall Benefit:Risk Conclusion
To date, [ADDRESS_541608] received [COMPANY_004]2838232 in three completed studies. One 
study  (204953) is ongoing ([ADDRESS_541609] completed this study  so far). 
Subjects have received single doses up to 200 mg SDD alone (studies HMI116787 and 
200912), 250 mg API [INVESTIGATOR_428109] (204953), and then in repeated dail y 
doses of up to 50 mg SDD alone (200207) for 5 day s or 200 mg in combination with 
RTV (204953) for [ADDRESS_541610] was receiving [COMPANY_004]2838232 to date (one in 200207, one in 204953). Neither is 
thought likely  to be due to [COMPANY_004]2838232.
There have been no other withdrawals due to drug -related AEs and no trends relative to 
laboratory  toxicity .  One subject was withdrawn in Part 1A of [ADDRESS_541611] been no clinically  
significant changes in troponin, heart rate, blood pressure, ECG, or telemetry monitoring.
Subjects will also be at risk for AEs from cobicistat use and will be monitored closel y for 
such events.
Given the preclinical profile and the clinical profile to date, the overall risk to HIV -1 
infected but otherwise healthy  subjects at the proposed [COMPANY_004]2838232 doses (with or 
without cobicistat) for [ADDRESS_541612] eligibility  is provided in the Investigator’s Brochure. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541613] safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
Approximately  10-12 HIV -1 infected subjects will be enrolled into Part A. If warranted 
by [CONTACT_428244] y, virology  and PK data anal ysis, approximately  8 subjects will be 
enrolled in each of Cohorts 2 -4 in Part B, which will be a parallel group design. Eligible 
patients are those who are ART -naïve and who are not currently  receiving ART therapy .
Addi tional subjects/cohorts may  be enrolled to allow for evaluation of additional dose 
levels or configurations (e.g., [COMPANY_004]2838232 alone).
If subjects prematurel y discontinue the study, additional subjects may be enrolled as 
replacement subjects and assigned to the same treatment at the discretion of the Sponsor.
5.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
AGE
1.Between [ADDRESS_541614] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Health y (other than HIV infection) male or female as determined b y the investigator 
or medicall y qualified designee based on a medical evaluation including medical 
history , phy sical exam ination, laboratory  tests and cardiac monitoring. Defined as no 
other chronic medical conditions and taking no chronic medications.
3.A subject with a clinical abnormality  or laboratory  parameter(s) which is/are not 
specificall y listed in the inclusion or ex clusion criteria, outside the reference range 
for the population being studied may  be included only  if the investigator in 
consultation with the Medical Monitor agree and document that the finding is 
unlikely  to introduce additional risk factors and will not interfere with the study  
procedures. 
4.A creatinine clearance >80 mL/min as determined by  [CONTACT_3158]- Gault equation 
[Cockcroft , 1976] CLcr (mL /min) = (140 – age) * Wt / (72 * Scr) (times 0.85 if 
female) where age is in years, weight (Wt) is in kg, and serum creatinine (Scr) is in 
units of mg/dL .
5.Confirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. No current and no prior ART. (A previous course of 
pre-or post-exposure prophy laxis is allowed provided that it was completed at least 
[ADDRESS_541615] dose of study  drug ). 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
35WEI GHT
6.Body weight 50kg (110 lbs.) for men and 45kg (99 lbs) for women and body  
mass index (BMI) within the range 18.5 -31.0 kg/m2(inclusive)
SEX
7.Male or Female
A female subject of reproductive or non -reproductive potential is eligible to 
participate if she is not pregnant (as confirmed b y a negative serum or urine human 
chorionic gonadotrophin (hCG) test at screening and prior to first dose), not 
lactating, and at least one of the following conditions applies:
Reproductive potential:
Females of reproductive potential may  only be enrolled if they are using two forms 
of complementary  contraception, which must include one barrier met hod. They  will 
be counselled on safer sex practices
There is no definitive DDI information with [COMPANY_004]2838232 and an interaction with 
oral contraceptives is possible, so other (barrier, inter- uterine device etc.) methods of 
contraception will be required.
Fertile females, who have an established, long -term lifesty le of sexual abstinence, or 
only same sex partners, require no other means of birth control.  
Non-reproductive potential:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause (refer to 
laboratory  reference ranges for confirmatory  levels).  Females on hormone 
replacement therap y (HRT) must discontinue HRT to allow confirmation of 
post-menopausal status prior to study  enrolment.
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first dose of stud y medication 
until one week after the last dose of stu dy medication.
a.Vasectom y with documentation of azoospermia.  
b. Male condom plus partner use of one of the contraceptive options below:
Contraceptive subdermal implant that meets the SOP effectiveness criteria  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
36including a <1% rate of failure per year, as sta ted in the product label
Intrauterine device or intrauterine s ystem that meets the SOP effectiveness 
criteria including a <1% rate of failure per year, as stated in the product 
label
Oral contraceptive, either combined or progestogen alone or Injectable 
progestogen 
Contraceptive vaginal ring 
Percutaneous contraceptive patches
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label.  The investigator is responsible 
for ensuring t hat subjects understand how to properly  use these methods of 
contraception.
INFORMED CONSENT
8. Capable of giving signed informed consent as described in Section 10.2, which 
includes compliance with the requirem ents and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AN D QTc INTERVAL) 
1. Alanine aminotransferase (ALT) and BIL >1.5xupper limit of normal (ULN; isolated 
BIL >1.5xUL N is acceptable if BIL is fractionated and direct BIL <35%). 
2.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones); HBV and/or 
HCV positive.
3.Subjects who have an y other chronic medical condition, including CV, respi[INVESTIGATOR_696] , 
neurologic, ps ychiatric, renal, gastrointestinal (GI), oncologic, rheumatologic, or 
dermatologic
4.Medical history  of cardiac arrhy thmias or cardiac disease or a famil y or personal 
history  of long QT s yndrome. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
37CONTRAINDICATIONS 
5.History  of sensitivity  to any  of the stud y medications, or components thereof or a 
history  of drug o r other allergy  that, in the opi[INVESTIGATOR_427175], contraindicates their participation.
REL EVANT HABITS 
6.Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion 
criteria.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
7. Presence of hepatitis B surface antigen (HBsAg), positive (confirmed b y 
Recombinant I mmuno -Blot Assay  [RIBA] ) hepatitis C antibody  test result at 
screening or within [ADDRESS_541616] dose of study treatment.
8.Screening or baseline cardiac troponin I greater than the 99% cutoff (>0.045 ng/mL 
by [CONTACT_428205] ).
9.A positive pre -study  drug/alcohol screen.  
10.Prior history  of receiving an HIV maturation inhibitor
11.Where participation in the study  would result in donation of blood or blood products 
in excess of [ADDRESS_541617] dosing day  in the current 
study : [ADDRESS_541618] (whichever is longer).
13. Exposure to more than four new chemical entities within [ADDRESS_541619] 
dosing day .
14.Treatment with radiation therap y or cy totoxic chemoth erapeutic agents within 
30days of study  drug administration or anticipated need for such treatment within 
the study .
15.Treatment with immunomodulating agents (such as sy stemic corticosteroids, 
interleukins, interferons) or an y agent with known anti -HIV acti vity (such as 
hydroxyurea or foscarnet) within 30 day s of study  drug administration.
16.An active Center for Disease Control and Prevention (CDC) Category  C disease 
except cutaneous Kaposi’s sarcoma not requiring sy stemic therapy  during the trial.
17.Treatment w ith any  vaccine within 30 day s prior to receiving study  medication.
18. Exclusion Criteria for 24- Hour Screening Holter:
Any symptomatic arrhy thmia (except isolated extra s ystoles).
Sustained cardiac arrh ythmias (such as atrial fibrillation,flutter or 
supraven tricular tach ycardia ( 10 seconds)
Non-sustained or sustained ventricular tach ycardia (defined as 3 consecutive  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
38ventricular ectopic beats).
Any conduction abnormality  including but not specific to left or complete 
bundle branch block, atrioventricular [AV] block, high grade or complete heart 
block Wolff -Parkinson- White [WPW] sy ndrome etc.).
Sinus Pauses >3 seconds.
19.Exclusion criteria for screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine-
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual participant in 200911 will be Fridericia’s formula. 
Note: A heart rate from 100 to 110 beats per minute (bpm) can be reche cked by 
[CONTACT_428206] 30 minutes to verify eligibility.
Evidence of previous m
yocardial infarction (Does not include ST segment 
changes associated with repolarization).
Any conduction abnormality  (including but not specific to left or right complete
bundle branch block, AV block [2nd degree or higher], WPW syndrome).
Sinus Pauses >3 seconds.
Any significant arrh ythmia which, in the opi[INVESTIGATOR_428152], will interfere with the safet y for the individual 
subject.
Non-sustained or sustained ventricular tach ycardia ( 3 consecutive ventricular 
ectopic beats).
5.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjects who consent to participate in the clinical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from Regulatory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure 
details, Eligibility  Criteria, and an y SAEs. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
395.4. Withdrawal/Stoppi[INVESTIGATOR_428111] a subject who fails to attend the clinic 
for a required stud y visit:
The site m ust attempt to contact [CONTACT_131993]- schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
contin ue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_541620]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a pri mary  reason of “Lost to Follow -up”. 
A subject may  withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioural or 
administrative reasons. If a subject withd raws from the study , he/she may  request 
destruction of an y samples taken, and the investigator must document this request has 
occurred in the site study records. 
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
40Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 , Section 12.2 andSection 12.3. 
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_387026].
5.4.2. QTc Stoppi [INVESTIGATOR_2121]
The same QT correction formula 
must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the subject has been enrolled.
For example, if a subje ct is eligible for the protocol based on QTcB , then QTcB 
must be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , the 
same formula must continue to be used for that sub ject for all QTc data being 
collected for data analysis .  Safety  ECGs and other non -protocol specified 
ECGs are an exception.  
The QTc should be based on single or averaged QTc values of triplicate ECGs 
obtained over a brief (e.g., 5-10 minutes) recording period.  
A subject who meets either of the bulleted criteria below will be withdrawn from the 
study : 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
41QTc >500 msec OR Uncorrected QT >600 msec
Change from baseline of QTc >60 msec
5.5. Stoppi[INVESTIGATOR_428112] A dverse Events
Any grade 3 or higher treatment -related adverse events that occ ur in ≥[ADDRESS_541621]’s last visit.
6. STUDY TREA TMENT
6.1. Investigati onal Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design. Stud y treatment may 
therefore refer to the individual study  treatm ents or the combination of those study  
treatments.
Treatment
Product name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Formulation 
description:[COMPANY_004]2838232 powder blend in a 
capsuleTablet
Dosage form: Swedish orange, unmarked 
capsules ( 50 mg), and white, 
unmarked capsules (10 mg)Orange, round, biconvex, film -coated 
tablets debossed with “GSI” on one side 
and plain faced on the other side 
providing 150 mg of cobicistat.
Unit dose strength(s)/
Dosage level(s):50 mg capsule for 200 mg, 1 00 mg, 
50 mg doses and 10 mg capsule for 
20 mg doses 150 mg for 150 mg doses
Route/
Administration/
Duration:Administered orally QD for [ADDRESS_541622] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Dosing instructions: Administer with light meal and 240 
mL of water . Administer with light meal and 240 mL 
water.
Manufacturer/
source of 
procurement:[COMPANY_004] [COMPANY_009]
Method for 
individualizing dosage:Capsules supplied in high -density 
polyethylene bottles for 
individualized dosing by [CONTACT_428245]
6.2. Treatment A ssignment
Subjects will be assigned to treatment (active) in accordance with the randomization 
schedule generated b y Clinical Statistics, prior to the start of the stud y, using validated 
internal sof tware.
6.3. Planned Dose A djustments
Following the interim analy sis of safet y, virology  and PK data from the first cohort of 
subjects in Part A, the option to adjust dose levels from those described exists. No dose 
will be administered that has an associated projected mean AUC or Cmax value higher 
than the most conservative NOAEL obtained from the chronic toxicity  studies (i.e., from 
the 9- month dog toxicity  study  described in Section 2.2.1).
6.4. Blinding
This will be an open -label study . Treatment allocation in Part B will be randomised (to 
[COMPANY_004]2838232 dose level).  
6.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.6. Preparation/Handling/Storage/A ccountabilit y
A description of the methods and materials required for capsule/tablet storage and 
dispensing will be detailed in a Study  Specific Technical Agreement/Memo or Pharmacy  
Manual, which will be accompanied b y a Quality Agreement.
No special preparation of st udy treatment is required.
Only  subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
43(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for stud y treatment accountability, reconciliation, and 
record maintenance (i.e., receipt, reconciliation and final disposition records).
Further guidance and information for final disposition of unused study  treatment 
are provided in the study reference manual (S RM). 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  
A Material Safety  Data Sheet/equivalent document describing occupational 
hazards and recommended handling precau tions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
6.7. Compliance with Study  Treatment A dministration
When subjects are dosed at the site, they  will receive study  treatment directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents.  The dose of study  
treatment and stud y subject identification will be confirmed at the time of dosing b y a 
member of the stud y site staff other than the person administering the stud y treatment.  
When subjects self- administer study  treatment(s) at home , compliance with study  
treatment(s) will be assessed through querying the subject during the sit e visits and 
documented in the source documents and case report form (CRF).  A record of the 
number of study treatment(s) dispensed to and taken by [CONTACT_428209].  Treatment start and stop 
dates, including dates for treatment delay s and/or dose reductions will also be recorded in 
the CRF.
6.8. Treatment of Study  Treatment Overdose
For this study , any  dose of [COMPANY_004]2838232 >200 mg+cobicistat within a 28 -hour time 
period will be considered a n overdose.
[COMPANY_004] does not recommend specific treatment for an overdose; however, in the event of an 
overdose, the investigator or treating ph ysician should:
Contact [CONTACT_27465]
Closely  monitor the subject for AEs/SAEs and laboratory  abno rmalities until 
[COMPANY_004]2838232 can no longer be detected s ystemically  (at least 10 day s for 
[COMPANY_004]2838232)
Obtain a plasma sample for PK anal ysis within [ADDRESS_541623] dose 
of study  treatment if requested by  [CONTACT_1689] (determined on a case-by-case 
basis) 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
44Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_428246] e clinical evaluation of the subject.
6.9. Treatment after the End of the Study
Subjects receiving [COMPANY_004]2838232 may  opt to receive marketed antiretrovirals after the 
completion of 10 day s of [COMPANY_004]2838232 dosing and stud y follow- up visits (through 
Day 21) eligible f or sponsor company  reimbursement up to a maximum of [ADDRESS_541624]’s medical condition, whether or not [COMPANY_004] is providing
reimbursement for post-study  treatment.
6.10. Lifest yle and/or Dietary  Restrictions
6.10.1. Meals and Dietary  Restrictions
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice 
from [ADDRESS_541625] dose of study  medication until after the final dose.
Doses will be given in the fed state (light breakfast), following overnight fasting 
(>10 hours). 
6.10.2. Alcohol, Caffeine and Exercise
During  the study   alcohol consumption should be limited to the fo llowing:
An average weekl y intake of <14 drinks for males or <7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL ) of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
Subjects should abst ain from strenuous exercise during the treatment period.
6.11. Contraception
Female subjects can be of childbearing or non -child bearing potential.  
Females of reproductive potential may  only be enrolled if they are using two forms of 
complementary  contraceptio n, which must include one barrier method.  Although use of 
oral contraceptives is permitted, t here is no definitive DDI information with 
[COMPANY_004]2838232 and an interaction with oral contraceptives is possible, so other (barrier, 
inter-uterine device etc.) methods of contraception will be required.
Females of reproductive potential, who have an established, long -term lifesty le of sexual 
abstinence, or onl y same sex partners, require no other means of birth control.  
Male subjects with female partners of child be aring potential must comply  with the 
following contraception requirements from the time of first dose of stud y medication 
until one week after the last dose of study medication: 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
451. Vasectom y with documentation of azoospermia. The documentation on male 
sterility can come from the site personnel’s review of subject’s medical records, 
medical examination and/or semen anal ysis, or medical history  interview.
OR
2. Male condom plus partner use of one of the contraceptive options below that 
meets the SOP effective ness criteria including a <1% rate of failure per y ear, as 
stated in the product label:
-Contraceptive subdermal implant
-Intrauterine device or intrauterine s ystem
- Combined estrogen and progestogen oral contraceptive 
-Injectable progestogen
-Contrac eptive vaginal ring 
-Percutaneous contraceptive patches 
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects unde rstand how to properl y use these methods of contraception.
6.12. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014]
6.12.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
Acetaminophen at doses of 2grams/day  or NSAIDs are permitted for use any  time 
during the stud y and thei r use documented in the CRF.  Other concomitant 
medication may  be considered on a case by  [CONTACT_428235].
Concomitant medications (prescription and non- prescription) should be administere d 
only as medically  necessary  during the study . Subjects must notify  their Investigator 
of an y current or proposed concomitant medication, whether prescribed or over -the-
counter, because of the potential for interactions between such treatments and the 
study medications.
6.12.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_014]
Subjects must refrain from all illicit drugs throughout the study  (from Screening until 
discharge from the study).  Drug screening will occur at Screening and Day -
1and at 
additional timepoints throughout the stud y.  A positive result will lead to exclusion 
from the remainder of the study .
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the s tudy design requirements, including those 
specified in the Time and Events Table (Section 7.1), are essential and required for stud y 
conduct. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541626] be noted: 
If assessments are scheduled for the same nominal time, THEN the assessments 
should occur in the following order:
1. 12 -lead ECG
2.vital signs
3.blood draws.  
Note: The timing of the asses
sments should allow the blood draw to occur at the 
exact nominal time. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
477.1. Time and Events Table
Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/exclusion X X
Demography including height, weight 
and BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therapy X
12-lead ECG3 X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and 
hepatitis C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X X14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X 
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
48Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Telephone call to IVRS13 X X X X X X X X X X X X X X X
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within [ADDRESS_541627] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 and 6, perform all “Day 5” assessments on Day 7.
3. On Day 1, ECGs will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541628] -dose. To accommodate scheduling, serial ECGs collected on 
Days 4 and 8 may be performed [ADDRESS_541629] dose.  On Day 11, an ECG will be obtained 
prior to the 24 -hour PK sample. ECGs will be performed in triplicate at all timepoints. 
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained on Day [ADDRESS_541630] -morning dose, and at day 12 and Follow -up(Day 21) .
5. Only SAEs related to study participation will be collected between screening and Day 1. An AE enquiry will be made at each visit, subjects will be asked if they have 
experience d any neuropsychiatric adverse events, including psychosis or altered mental status .
6. On Days 1 -5 and 8 -10 samples for HIV -1 RNA PCR collected before morning dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart.  HI V-1 RNA PCR samples will also be collected on days 12, 14 & Follow -up (Day 21).
7. Lymphocyte subsets by [CONTACT_4133] (total lymphocyte counts, percentage, and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determination of [COMPANY_004]2838232 will be collected on Day 1 and Day 10 at pre dose (within 15 min utes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12 (optio nal), and 24 hours (to occur on morning of Day [ADDRESS_541631]- am dose and in the morning on Day 11 ).  Pre -dose PK samples (within 15 minutes prior to dose) will be 
taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be taken on Days 12 and 14.
10. Samples (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541632] 10 hours .On Days 6 and 7, doses will be self administered bu t confirmed by [CONTACT_648] 
12. PGx sample should be collected on Day 1.
13. A screening/registration call should be ma de to the IVRS to register the subject at screening.   An additional call will be made to document a screen failure.   A rand omization 
call should be made to the IVRS system approximately one week prior to scheduled Day 1.  Note: The randomization call mus t be made in order to have study drug on site for 
Day 1. Additional calls will be made every day that the subject has a scheduled study visit to the clinic.  If a subject term inates the study prematurely a call should be made to 
the IVRS
14. Only if early term ination visits occur during the treatment period.
15. Plasma samples for storage will be collected at each visit starting at Day 1, including unscheduled visits (e.g. for HIV -1 RNA levels and immunological parameters).  
Additionally these samples will be used when needed, such as when samples are lost or arrive at the laboratory unevaluable.
AE = Adverse event; CDC= Center for Disease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Hu man chorionic gonadotrophin; HIV = Human 
immun odeficiency virus;  IVRS= Interactive Voice Response System; PCR = Polymerase chain reaction; PK=Pharmacokinetic. 
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
497.2. Visit Windows
Screening (baseline to pre -dose ): All screening assessments should take place within 
14-[ADDRESS_541633] dose. The s creening visit window may  be extended to 30 
days upon discussion with the Medical Monitor (i.e.; subject has scheduling conflicts or 
any screening assessment needs to be repeated).
Days 4 and 8: 
Based on subject andclinic schedule , Day  4 and Day  8 serial (up to 6h 
post-dose) ECG assessments may  be conducted 1 day . 
Weekend (s):The T&E table is set up for study  start (Day 1) to occur on a Monday  and 
Days 6 and 7 to fall on the weekend .If the weekend occurs instead on Day s 5 and 6, Day  
5 assessments should be performed on Day  7.The study  start (Day  1) may  also be 
adjusted to allow visits with assessments to be conducted over the weekend based on 
subject and clinic schedule. 
Assessments: The following applies to timing of procedures:
-Window for assessme nts [ADDRESS_541634] -dose = 5 minutes
-Window for assessments >4 and <
12h post -dose = 15 minutes
-Window for assessments > 12h post -dose = 30 minutes
End of Treatment visit : should be within [ADDRESS_541635] for assessment of adverse events.
7.3. Screening and Critical Baseline A ssessments
Cardiovascular medical history /risk factors (as detailed in the CRF) will be assessed at 
screening.
The following demographic parameters will be captured: y
ear of birth, sex, race, and 
ethnicity .
Medical/medication/family  history  will be assessed as related to the inclusion/exclusion 
criteria.
Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count) and obtained prior to signing of informed consent may
 be utilized for Screening or 
baseline purposes provided the procedure meets the protocol- defined criteria and has 
been performed in the timeframe of the stud y.
7.3.1. Holter Monitoring (Screening criteria)
The 24- hour Holter monitoring willbe performed during the Screening period using a 
Holter monitoring device supplied by  [CONTACT_1034]. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
50Analy sis of the Holter tapes will consider the following:
Heart rate (brad ycardia and tachy cardia)
Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractions, premature 
ventricular contractions, couplets, triplets, and ventricular tach ycardias
Atrio- ventricular conduction defects
Atrial fibrillation and flutter
7.4. Efficacy
7.4.1. HIV-1 RNA  Sampling
Plasma for quantitative HIV- 1 RNA will be collected at timepoints listed in the Time and 
Events Table in Section 7.1. To reduce sample variability , two plasma HIV -1 RNA 
samples will be collected on Day s 1, 10, and 11.
An HIV -1 RNA PCR assay  with a lower limit of detection (LLOD) of 50 copi[INVESTIGATOR_014]/mL  
(ultrasensitive assay ) will be used for post
-baseline assessments. An HIV -1 RNA PCR 
assay  with a LLOD of 400 copi[INVESTIGATOR_014]/mL  (standard a ssay) will be used for screening and 
baseline assessments and will include a re -test with and ultrasensitive assay for all 
baseline values below the LLOD. An HIV -1 RNA PCR assay  with a LLOD of 2 
copi[INVESTIGATOR_014]/mL (supersensitive assay ) may  be used for exploratory  anal ysis.
7.4.2. Lymphocyte Subsets by  [CONTACT_428236] b y flow cy tometry  at the timepoints listed in the Time and Events 
Table in Section 7.1.
Details concerning the handling, labeling and shippi[INVESTIGATOR_339181] .
7.5. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1).  Additional time points for safety tests (such as vital signs, physical exams 
and laboratory  safet y tests) may be added during the course of the stud y based on newl y 
available data to ensure appropriate safet y monitoring.
7.5.1. Adverse Ev ents (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 5 , Section 12.5 .
The investigator and their designees are responsible fo r detecting, documenting and 
reporting events that meet the definition of an AE or SAE.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
AEs and SAEs will be collected from the start of Study  Treatment until the 
follow -up contact (see Section [IP_ADDRESS]), at the timepoints specified in the Time 
and Events Table (Section 
7.1). An AE enquiry  will be made at each visit, where 
subjects will be specifically  asked if they  have experienced an y neurops ychiatric 
adverse events, including psy chosis or altered mental status  
Medical occurrences that begin prior to the start of study treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject con sents to participate in the 
study  up to and including any  follow -up contact. 
All SAEs will be recorded and reported to Sponsor within 24 hours, as indicated 
in Appendix 5 , Section 12.5 .
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE report
s to [COMPANY_004] are provided in 
Appendix 5
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferre d method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
“Have you experienced any  alteration in personality , behaviour, mood or any  
altered mental status?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subseq uent visits/contacts.  All SAEs, and non- serious AEs of special interest 
(as defined in Section 12.5) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow -
up  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
52(as defined in Section 5.4). Further information on follow -up procedures is given in 
Appendix 5 .
[IP_ADDRESS]. Cardiovascular and Death Events
For any cardiovascular events detailed in Appendix 5 (Section 12.5.3) and all deaths, 
whether or not they  are considered SAEs, specific CV and Death sections of the CRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non
-cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV informati on should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed 
within oneweek of when the death is reported.
[IP_ADDRESS]. Disease- Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease -related events (DREs) are common in subjects with HIV-1 
infection and can be serious/life threatening:
events or outcomes listed in the CDC Classification Sy stem for HIV- 1 Infections 
(see Appendix 9 ; Section 12.8)
sign, s ymptom, d iagnosis, illness, and/or clinical laboratory  abnormality  that can 
be linked to an y of these events or outcomes
Because these events are ty pi[INVESTIGATOR_1306] y associated with the disease under study, they will not 
be reported according to the standard process for expe dited reporting of SAEs to [COMPANY_004] 
(even though the event may
 meet the definition of a serious adverse event). 
These events will be recorded on the DRE page in the subject’s CRF using the HIV 
Associated Conditions eCRF. These DREs will be monitored by [CONTACT_428247].
However, if an y of the following conditions apply, then the event should be reported as 
an SAE using the standard process:
The event is, in the Investigator’s opi[INVESTIGATOR_1649], of greater intensity , frequency , or 
durati on than expected for the individual subject, 
or
The Investigator considers that there is a reasonable possibility  that the event was 
related to treatment with the investigational product.
or 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
53Death occurring for an y reason during a stud y, including death due to a disease 
related event, will alway s be reported promptly . 
If either of the above conditions is met then record the DRE on the SAE page rather than 
the HIV Associated Conditions eCRF page and report promptly to [COMPANY_004].
[IP_ADDRESS]. Regulatory  Reporting Requirement s for SA E
Prompt notification by  [CONTACT_428213]- serious AEs 
related to stud y treatment (even for non -interventional post -marketing studies) is 
essential so that legal obligations and ethical responsibilities towards th e safety of 
subjects and the safety of a product under clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for susp ected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary  or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
7.5.2. Pregnancy
Details of all pregnancies in female subjects and if indicated female partners of 
male subjects will be collected after the start of dosing and until one week post 
study
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 24hrs 
of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 7 , Section 12.6 .
7.5.3. Physical Exams
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , GI and Neurological sy stems. Height and weight will 
also be measured and recorded. 
A brief ph ysical examination will include, at a minimum assessments of the skin, 
lungs, cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to pre vious 
serious illnesses 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
547.5.4. Vital Signs
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_541636] and will 
include temperature, s ystolic and diastolic blood pressure and pulse rate 
Three readings of blood pressure and pulse rate will be taken
First reading should be rejected
Second and third readings should be averaged to give the measurement to be 
recorded in the CRF. 
7.5.5. Electrocardiogram (EGC)
Triplicate [ADDRESS_541637] be 
conducted in accordance with the SRM and Protocol Time and Events Schedule (Section 
7.1). Laboratory  requisit ion forms must be completed and samples must be clearl y 
labelled with the subject number, protocol number, site/centre number, and visit date.
Details for the preparation and shipment of samples will be provided b y the laboratory 
and are detailed in the S RM. Reference ranges for all safet y parameters will be provided 
to the site by  [CONTACT_90633].
If additional non -protocol -specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a c hange in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the CRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicat e 
and/or additional blood draws.
All study -required laboratory  assessments will be performed b y a central laboratory :
NOTE:  Local laboratory results are onl y required in the event that the central laboratory 
results are not available in time for either a treatment and/or response evaluation to be 
performed. If a local sample is required it is important that the sample for central 
analysis is obtained at the same time. Additionally  if the local laboratory  results are used 
to make either a treatment or r esponse evaluation, the results must be entered in the CRF. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
55Haematology , clinical chemistry , urinal ysis, and additional parameters to be tested are 
listed below. 
Table 8 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes with T -cell 
subsets
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Bicarbonates Alkaline phosphatise Albumin
Troponin I
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic exam ination (if blood or protein is abnormal)
Other 
Screening 
TestsHIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody )
FSH and estradiol (as needed in women of non -child bearing 
potential only )
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (as needed for women of child bearing 
potential) 2
NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after liver stoppi[INVESTIGATOR_31777] 12.[ADDRESS_541638] dose of study  treatment 
should be repeated until the values return to normal or baseline.  If such values do not 
return to normal within a period judged reasonable by  [CONTACT_093], the etiology
should be identified and the sponsor notified. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
567.6. Pharmacokinetics
7.6.1. Blood Sample Collection
Blood samples for anal ysis of [COMPANY_004]2838232 concentrations will be collected at the time 
points indicated in Time and Events Tables (Section 7.1).  
The actual date and time of each blood sample collection will be recorded.  The timing of 
PK samples may be altered and/or PK samples may  be obtained at additional time points 
to ensure thorough PK monitoring.  
Details of PK blood sample collection (including volume to be collected), processing, 
storage and shippi[INVESTIGATOR_428170] (SRM).
7.6.2. Sample A nalysis
Plasma analy sis will be performed by  [CONTACT_55412], Madison under the control of 
Bioanal ysis, Immunogenicity  and Biomarkers (BIB), PTS, GlaxoSmithKline.
Concentrations of [COMPANY_004]2838232 will be determined in plasma using the curr ently 
approved bioanaly tical methodology . 
Once the plasma has been anal yzed for [COMPANY_004]2838232 any  remaining plasma may  be 
analyzed qualitatively  for other circulating metabolites and these results would be 
reported under a separate PTS protocol.
Raw data wil l be archived at the Covance, Madison facility .
7.7. Biomarker(s)/Pharmacody namic Markers
7.7.1. Viral Genoty pi[INVESTIGATOR_428171], at the times li sted in the Time and Events Table in 
Section 7.1. Details concerning the handling, labeling and shippi[INVESTIGATOR_428116] y.
Genoty pic and phenot ypic anal yses will be carried out by  [CONTACT_428248]/PR and PR/RT formats, in which PCR amplification is used to generate HIV 
cDNA products including the Gag and the PR and RT coding regions, respectivel y. 
Phenoty pic anal yses of the GAG/PR region will include susceptibility  to [COMPANY_004]2838232 . 
Analy sis will be done on Day  1 and Day  11 samples.  In the case of rebound HIV -1 viral 
load, anal ysis will be completed on samples corresponding to time point of rebound 
occurrence. 
7.8. Genetics
Information regarding genetic research is includ ed in Appendix 4 , Section 12.4 . 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
577.9. Value Evidence and Outcomes
Not required.
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data system, 
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data 
(e.g., removing errors and inconsistencies in the data).
Adverse events and concomitant medications terms will be coded using MedDRA 
and an internal validated medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be reta ined b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  objec tives of this study  are to investigate the safet y, tolerability, and 
antiviral activity  of [COMPANY_004]2838232 administered as monotherapy  in combination with 
cobicistat in HIV -1 infected subjects, over a 10 day  treatment period. The antiviral 
activity  will be asse ssed by  [CONTACT_428237] -1 RNA max change from baseline 
during the stud y. 
9.2. Sample Size Considerations
9.2.1. Sample Size A ssumptions
The sample size for this study  is based primarily  on feasibility  to provide adequate 
precision for the estimations.
Based on data from the short term monotherapy  study  of BMS -955176 PoC (AI468002) 
study  and assuming viral load values for individual subjects follow a log -normal 
distribution, 1000 trial simulations in Fixed and Adaptive Clinical Trial Simulation 
(FACTS ) software w ere conducted from the distribution with mean of change from 
baseline viral load drop on log scale at 1.0 to 1.5 copi[INVESTIGATOR_428117]=0.4 and sample sizes=10 
for Part A.  Using Bay esian calculation with non -informative priors for the mean and 
weakl y informative p riors for the error parameters, Normal (0, 100) for mean and Inverse 
Gamma (0.35, 0.0875) for error parameters, the posterior probability  to achieve a 
cutpoint 1.2 log was calculated for each simulated trial, and percentage of the trials with  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
58posterior probability  of viral load< -1.2log drop given tr ue mean) ≥70% were calculated 
and are shown below in Table 9.
Table 9 Percentage of the trials with posterior probability >=70% for Part A
True Mean Cutpoint Posterior Prob>=70%
1.0 1.2 1.4%
1.1 1.2 9%
1.2 1.2 29%
1.3 1.2 59%
1.4 1.2 83%
1.5 1.2 96%
An Emax model with functional uniform priors [ Bornkamp , 2014] was conducted using 
simulated data combining Part A and Part B with all doses. Succes s is defined as a 
posterior probability  of the highest dose to achieve a cutpoint 1.2 log reduction in viral 
load.   This was calculated for each simulated trial and the percentage of the trials with 
posterior probability  greater or equal to 70% were also calculated and are shown below 
(Table 10). The table lists different viral load drop scenarios. The last scenario assumes 
the flat drop for all doses are 0.5.  This scenario reflects the null hy pothesis of no 
treatment effect. In this scenario 0% of the trials achieve the pre -specified decision rule 
for success.
Table 10 Percentage of the trials with posterior probability  ≥70%
Cutpoint Posterior Prob ≥ Part A+ Part B 
mean VL drop for doses 
200, 100, 50, 20Part A+ Part B
1.2 70% 1.5, 1.4, 1.2, 0 99%
1.5, 1.4, 1.2, 0.5 96%
1.5, 1.4, 1.0, 0.5 93%
1.5, 1.3, 1.2, 0. 5 86%
0.5, 0.5, 0.5, 0.5 0%
9.2.2. Sample Size Sensitivity
Similar simulations in FACTS were conducted from the distribution with mean of change 
from baseline viral load drop on log scale at 1.5 copi[INVESTIGATOR_428117]=0.4 or 0.6 and sample 
sizes of 6- 8 or 10 for Part A.  Using Bay esian calculation, t he posterior probability  to 
achieve a cutpoint 1.2 log (in Table 11) was calculated for each simulated trial, and 
percentage of the trials with posterior probability  greater than o r equal to 70% was 
calculated and are shown below. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
59Table 11 Percentage of the trials with posterior probability  ≥70% for Part A
True 
MeanCutpoint Posterior 
Prob ≥Std for log10 
VLN=6 N=8 N=10
1.5 1.2 70% 0.4 90% 94% 96%
0.6 75% 81% 84%
9.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation will be performed.
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Intent to Treat Exposed Population (ITT)
The ITT-Exposed Population is defined as all subjects who meet study  criteria and are 
enrolled into the study  with documented evidence of having received at least [ADDRESS_541639]- baseline HIV -1 RNA measurement. This will be the 
primary  population for the final efficacy  anal ysis for all active treatment groups.
Per Protocol Population (PP)
The Per Protocol Population is defined as all subjects who meet study  criteria and are 
enrolled into the study  with documented evidence of having received all doses and all 
post-baseline HIV -[ADDRESS_541640] dose based on this review (e.g.,the exposure level of 
[COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838232 exposure seen previously  in 
healthy  subjec ts),the Bayesian posterior probability  that the log10 viral load decline from 
baseline is greater than a cut- point will be calculated. If the Bay esian probability  from 
Cohort 1 is less than 70% ,this will provide evidence to not move forward into Part B. 
Otherwise, the stud y team will review the data in order to make a dose selection decision 
for the subsequent Part B Cohorts.  I f the pharmacokinetic exposures after the 100 mg 
[COMPANY_004]2838232/cobi dose look similar to those obtained with 100 mg [COMPANY_004]2838232/r in  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
60prior studies, the doses for Part B will be extended to both lower (20 mg, 50 mg) and 
higher (200 mg) [COMPANY_004]2838232 doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be summarized 
by [CONTACT_428216] . The proportion of subj ects with plasma HIV- 1 RNA 
<400 and <50 copi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if the two populations are 
not the same. 
9.4. Key Elements of A nalysis Plan
9.4.1. Primary  Analyses
The final analy sis will be performed after the completion of the study  and final datasets 
authorization. Data will be listed and summarized according to GlaxoSmithKline 
reporting standards, where applicable. Listings will be sorted b y subject, period, day, and 
time, noting treatment; summaries will be presented by  [CONTACT_3148], day , and time. Unless 
stated otherwise, descriptive summaries will include n, mean, standard deviation (SD), 
coefficient of variation (%CV), median, minimum, and maximum, geometric mean with 
associated 95% confidence interval (CI), and %CVb for continuous variables, whereas n 
and percent will be used as summary  statistics for categorical variables. Baseline or pre -
dose assessment is the last available assessment prior to time of the firs t dose unless it is 
specified otherwise. If there are multiple assessments collected on the same scheduled 
time, the average of these assessments will be used. For tabulated safet y summaries, only 
the scheduled assessments will be included in the summary t ables. Version 9.1 or higher 
of the SAS sy stem will be used to anal yze the data as well as to generate tables, figures, 
and listings. Complete details will be documented in the Reporting and Analy sis Plan 
(RAP).
[IP_ADDRESS]. Safety  Analyses
Safety  data will be presente d in tabular format and summarized descriptively  according to 
[COMPANY_004]’s Integrated Data Standards Library  standards and data will be in CDISC format. 
No formal statistical analysis of the safet y data will be conducted. 
[IP_ADDRESS]. Efficacy  Analyses
Both the PP and ITT Populations will be used for all efficacy  analy ses if there are 
dropouts.  Plasma HIV -[ADDRESS_541641] , and assessment day  and 
summarized by  [CONTACT_428218].
Plots of mean and median plasma HIV -1 RNA actual and change from baseline data will 
be generated b y treatment and assessment day.
Plasma HIV -1 RNA change f rom baseline to the on- treatment nadir (maximum 
change) will be calculated for each subject and summarized by  [CONTACT_3148]. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541642] of lower doses on potential deve lopment of resistance. A dose -response 
curve will be fit to the data from Parts A & B using functional uniform priors.  
[IP_ADDRESS]. Pharmacokinetic A nalyses
Pharmacokinetic anal ysis will be the responsibility of the Clinical Pharmacokinetics 
Modeling and Simulation Department, GlaxoSmithKline. Plasma [COMPANY_004]2838232 
concentration -time data will be anal yzed by [CONTACT_105] -compartmental methods with 
WinNonlin Version 6.1 or higher. Calculations will be based on the actual sampling 
times recorded during the study. From the plasma concentration -time data, the following 
pharmacokinetic parameters will be determined, as data permit:
Plasma [COMPANY_004]2838232 Pharmacokinetic Parameters to be Estimated:
Study Day Parameters
1 AUC(0 -24), Cmax, tmax, tlag, C24
10 AUC(0 -), Cmax, tmax, t½, C0, C , CL/F, R_AUC, R_Cmax, R_C 
Results based on samples collected from a subject with emesis within 4 hours of the dose 
will not be considered as evaluable.
All PK data will be stored in the R&D archives, GlaxoSmithKline.
Statistical analy ses of the pharmacok inetic parameter data will be the responsibility  of 
Clinical Statistics, GlaxoSmithKline. Details of the statistical anal yses will be provided in 
the RAP. An outline is provided below:
Pharmacokinetic data will be presented in graphical and tabular form an d will be 
summarized descriptively. Plasma [COMPANY_004]2838232 PK parameters, with the exception of 
tmax and tlag, will be log- transformed prior to analy sis.
Dose proportionality  of plasma [COMPANY_004]2838232 PK parameters from Day  1 [AUC(0 -24) 
and Cmax] and Day  10 [AUC( 0-τ) and Cmax] will be assessed using a power model if 
multiple dose levels are assessed. The power model will be fitted by  [CONTACT_428219] (REML ) using SAS Proc Mixed. A fixed effects power model will be used. 
The mean slope will be estimate d from the power model with the corresponding 90% CI. 
The accumulation ratio (R) and stead y
-state assessments will be performed, if quality  of 
the data permits. Comparisons of Day  10 with Day  1 PK for each dose will be used for 
the accumulation ratio (R) e valuation. Pre- dose concentrations between Day s 7-10 will be 
used for stead y-state assessment. 
9.4.2. Secondary  Analyses
[IP_ADDRESS]. Pharmacokinetic/Pharmacody namic A nalyses
Relationships between various PK parameters (e.g., AUC, Cmax, Cτ, etc.) and PD 
measures (e.g., log10 reduction from baseline in plasma HIV -1 RNA on Day  11 or safet y  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
62parameters) will be explored using various models including Emax. The relationship 
between dose and PD measures will also be explored. Details of the PK/PD exploratory  
analyses will be provided in the RAP.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_428118]/phenot ypic data will be listed and descriptive summaries will be 
provided. Details of the analy ses will be provided in the clinical virology  report.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedur es, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
63Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is be ing deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors or designee will contact [CONTACT_428249], study  requirements, and their 
responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the CRF will 
serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Si te Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor 
or 
designee will conduct site closure activities with the investigator or site staff, as 
appropriate, in accordance with applicable regulations including GCP, and [COMPANY_004] 
Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
64If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notif ication to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical instit utions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicabl e regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investi gator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy , some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these repro ductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention tim e 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8893].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will b e provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full su mmary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication wil l be in accordance with [COMPANY_004] Policy .
10.8. Review  Committees
The Safet y Review Team (SRT) is a [COMPANY_004] cross -functional team reviewing all available 
safet y data related to the project, including in -stream data from this study , in an ongoing 
manner. The SRT is an inte rnal [COMPANY_004] requirement put in place to ensure holistic 
evaluation of the safet y profile of an investigational product with systematic, periodic and 
documented reviews of available safety  data, with the appropriate communication and 
escalation of new findings that have the potential to impact patient safet y 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8894]. REFERENCES
Bloch M, Bodsworth N, Fidler M, Workman C, Balach A, By [CONTACT_428221] H, et al. Efficacy , 
safet y and pharmacokinetics of MPC -4326 (bevirimat dimeglumine) 200mg BID and 
300mg BID monotherapy  administered for 14 day s in subjects with HIV -1 infection. 
ICAAC . 2009; Abstract H - 1230.
Bornkamp B, Practical considerations for using functional uniform prior distributions for 
dose-response estimation in clinical trials. Biometrical Journal 56 (2014) 6, 947 -962
Cockcroft DW, Gault MH. Prediction of creatinine clearance form serum creatinine. 
Nephron. 1976;16:31-41.
Dang Z, Huang L, Chen C. HI V
-1 maturation inhibitors:  An update. Drugs of the Future. 
2009;34 (10):797 -802.
Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC , et al .  Phase 2 study  of 
cobicistat versus ritonavir each with once -daily  atazanavir and fixed -dose 
emtricitabine.tenofovir df in the initial treatment of HIV infection.  AIDS .  2011; 
25:1881
-1886.
Food and Drug Administration (FDA). Guidance fo r industry : Estimating the maximum 
safe starting dose in initial clinical trials for therapeutics in adult healthy  subjects. CDER, 
Rockville, MD; 2005. UCM078932.
Food and Drug Administration (FDA). Guidance for Industry : Human Immunodeficiency  
Virus -1 Inf ection: Developi[INVESTIGATOR_184804]. CDER, Rockville, 
MD; 2015. UCM355128.
Gallant JE, Koenig E, Andrade -Villaneuva J, Chetchotisakd P, deJesus E, Antunes F,
Arastéh K, et al.  Cobicistat versus ritonavir as a pharmacoenhancer of atazana vir plus 
emtricitabine/tenofovir disoproxil fumarate in treatment -naïve HIV t ype 1-infected 
patients:  week [ADDRESS_541643]. Dis.  2013; 208 -:32- 39.
GlaxoSmithKline Document Number 2012N151889_03 Compound [COMPANY_004]2838232. 
Investigator’s Brochure.  Effective November 2016.
GlaxoSmithKline Non-Clinical Research report. Document Number 2013N163221_00.
Hatcher RA, Trussel J, Nelson AL , Cates W, Stewart F, Kowal D, editors. Contraceptive 
Technology . 19th ed. [LOCATION_001]:Ardent Media; 2007. 
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteele T, Hillewaert V, et 
al.  Pharmacokinetics of darunavir in fixed -dose combination with cobicistat compared 
with coadministration of darunavir and ritonavir as single agents in healthy volunteers.  J. 
Clin. Pharmacol.  2009; 54:949-957. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
67Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, et al. Safet y and 
efficacy  study  of bevirimat (BVM) in heavil y treatment experienced HIV+ patients 
identifies the target phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Mahmood I . Prediction of human drug clearance from animal data. Application of the 
rule of exponent and fu corrected intercept method (FCIM). J Pharm Sci. 
2006;95:1810-21. 
Martin D, Galbraith H, Ellis C, Schettler J and Doto J. Minimal effect of rito navir (RTV) 
on the pharmacokinetics of bevirimat in healthy  volunteers [abstract]. IAS Conference on 
HIV Pathogenesis, Treatment and Prevention. 2007; Abstract no. WEPEB015:Poster 
discussion.
Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple -dose pharmacokinetics and 
safet y of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin 
Pharmacokinet. 2007(a);46(7):589-98.
Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, et al. Safety  and 
pharmacokinetics of bevirimat (PA- 457), a novel inhibitor of human immunodeficiency  
virus maturation, in healthy  volunteers. Antimicrobial Agents and Chemotherapy. 
2007(b);Sep:3063 -6.
Martin DE, Galbraith H, Schettier J, Ellis C, Doto J. Pharmacokinetic properties and 
tolerability  of bev irimat and atazanavir in healthy volunteers:  An open -label, parallel -
group stud y. Clinical Therapeutics. 2008;30(10):1794 -1805.
NORVI R (ritonavir) Product I nformation. January , 2013.
Nowicka -Sans B, Protack T, L in Z, Li Z, Zhang S, Meanwell N, et al. BMS -955176: 
Characterization of a second- generation HIV -1 maturation inhibitor. 8th IAS Conference 
on HIV Pathogenesis, Treatment and Prevention, July  19-22, 2015, Vancouver, Canada.
Qian K, Morris -Natschke SL , Lee KH. HIV entry  inhibitors and their potential in HIV 
therap y. Medicinal Research Reviews. 2009;29(2):369
-93.
Saxena SK, Gupta A, Bhagy ashree K, Saxena R, Arora N, Banerjee AK, et al. Targeti ng 
strategies for human immunodeficiency  virus: A combinatorial approach. Min Rev Med 
Chem. 2012;12(3):236- 54.
TYBOST (cobicistat) Product Information. 2012
Wainburg MA, Albert J. Can the further clinical development of bevirimat be justified?. 
AIDS. 2010;24:773 -4. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8895]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
g/mL Microgram per millilitre
ABC Abacavir
AE Adverse Event
AIDS Acquired immunodeficiency  syndrome
ALT Alanine aminotransferase
API [INVESTIGATOR_428120] y
AST Aspartate aminotransferase
AUC Area under the plasma concentration time curve
AUC(0 -) Area under the concentration- time curve from time zero 
(pre-dose) extrapolated to infinite time
AUC(0 -) Area under the concentration- time curve over the dosing 
interval 
AUC(0 -24) Area under the concentration- time curve from zero (pre -
dose) to 24 h
AUC(0 -48) Area under the concentration- time curve from zero (pre -
dose) to 48 h
AUC(0 -t) Area under the concentration- time curve from zero (pre -
dose) to time of last quantifiable concentration
BCRP Breast cancer resistance protein
BID Twice dail y
Bpm beats per minute
BVM Bevirimat
BIL Bilirubin
C Pre-dose (trough) concentration at the end of the dosing 
interval
C24 24hour trough concentration
CDC Center for Disease Control and Prevention
CI Confidence interval
CL/F Oral Clearance
Cmax Maximum plasma concentration
Cmin Minimum plasma concentration
CPK Creatine Phosphokinase
CRF Case report form
cTnI Cardiac troponin I
CV Coefficient of variation
CVb Between -subject variability
CYP Cytochrome P450
DDI Drug Drug Interaction
DNA Deox yribo nucleic acid
EC50 50% protection against resistant mutant HI V infection  2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541644] time in Human Study
g Gram
GI Gastrointestinal
[COMPANY_004] GlaxoSmi thKline
h Hour(s)
HBsAg Hepatitis B surface antigen
hcG Human chorionic gonadotrophin
HDPE High densit y pol yethylene
hERG Human Ether -a-gogo Related Gene
HIV Human Immunodeficiency  Virus
IC50/90 50% or 90% maximal inhibitory  concentration
IEC Inter national Ethics Committee
IQ Inhibitory  quotient
IRB Institutional Review Board
ISR Injection site reaction
IV Intravenous
IVRS Interactive voice response sy stem
kg Kilogram
L Litre
LLOD Lower limit of detection
MC Melanocortin
MedDRA Medical Dic tionary  for Regulatory  Activities
mg/mL Milligram per millilitre
MI Maturation inhibitor
mL Milliliter
mRNA messenger Ribonucleic Acid
ND Not done
ng/mL Nanogram per millilitre 
nm Nanometer
NO Not observed
NOAEL No Observed Adverse Effect Level
NTproBNP N-terminal prohormone of brain natriuretic peptide
NSVT Non-sustained ventricular tachy cardia
OAT Organic anion transporter
OATP Organic anion transporting pol ypeptide
OCT Organic cation transporter
PBL Peripheral Blood Ly mphocy tes
PBMC Peripheral Blood Mononuclear Cells
PD Pharmacod ynamics
[COMPANY_003] Pharmaceutical Product Development
P-gp P-glycoprotein
PHIV Pseudo- HIV 2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541645] quantifiable concentration
tmax Time of occurrence of Cmax
U Units
UGT Uridine 5' -diphospho- glucuronos yltransferase
Vz/F Mean apparent oral volume of distribution
WPW Wolff -Parkinson -White
Trademark Information
Trademarks of the GlaxoSmithKline 
group of com paniesTrademarks not owned by [CONTACT_428222], [COMPANY_002] HIV kit
Chiron RIBA 
Inform
Monogram
Phoenix WinNonlin 
SAS
Tybost (cobicistat) 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8896].2. Appendix 2: Liver Safety  Required A ctions and Follow up 
Assessmen ts
Phase II liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drug s/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Phase II liver chemistry stoppi[INVESTIGATOR_420682] – Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN p ersists for 4 weeks
Bilirubin1, 2 ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2 ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3 ALT   3xULN associated with s ymptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or ret urn to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with study 
treatment unless allowed per protocol and [COMPANY_004] 
Medical Governance approval is granted 
If restart/rechallenge not allowed per protocol 
or not granted, permanently di scontinue study 
treatment and may continue subject in the study Viral hepatitis serology4
Blood sample for phar macokinetic (PK) 
analysis, obtained within 24hrs after 
last dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Recor d the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
72for any protocol specified follow up assessments 
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within 
24hours
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (inclu de ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72hours 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineform including acetaminophen, herbal 
remedies, other over the counter
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct high-
performance liquid chromatography
assay (quantifies potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week 
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If s erum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy ’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen a nd Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK sample may not be require d for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last d ose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi [INVESTIGATOR_131971].   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
73Phase II liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms belie ved to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_541646] safety. 
Subject can continue study treatment  
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 w eeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmac okinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8897].3. Appendix 3: Liver Safety  –Stud y Treatment Restart or 
Rechallenge Guidelines
Study  treatment restart or re -challenge afte r liver chemistry  stoppi[INVESTIGATOR_387026]. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8898].4. Appendix 4: Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including [COMPANY_004]2838232/RTV or an y concomitant 
medicines;
HIV susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limit ed to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
descri ption of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research .
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 6 ml blood or 2 ml saliva sample will be taken for Deox yribonucleic acid 
(DNA) extraction. A sample is collected at the baseline visit, after the subject has 
been randomized and p rovided informed consent for genetic research. Instructions 
for collection and shippi[INVESTIGATOR_428121]. The DNA from the blood/saliva sample may  undergo quality  control 
analyses to confirm the integrit y of the sample. If there are concerns regarding the 
quality  of the sample, then the sample may  be destroy ed. The blood/saliva sample 
is taken on a single occasion unless a duplicate sample is required due to an 
inability  to utilize the original sample.  
The genet ic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study.   This number can be traced or linked back to  2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541647] by  [CONTACT_132018]. Coded samples do not carry  personal 
ident ifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_541648] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other resea rchers) will only  use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can re quest their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood/saliva being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the ge netic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for ge netic research or requests sample destruction for any  
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be anal yzed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determ ined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample  2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541649]’s Genetic Data
[COMPANY_004] may  summarize the genetic re search results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does n ot inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information ge nerated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8899].5. Appendix 5: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investig ation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, ra diological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre- existing condition incl uding either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self-
harming intent.  This should be reported regardless of sequelae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae r esulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SAE.
The signs and symptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of e fficacy " or 
"failure of expected pharmacological action" also constitutes an AE or SAE. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
79Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admissi on to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then i t cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
c.Results in death
d.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might ha ve caused death, if it were more severe.
e.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline i s not considered an AE. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
80f.Results in disability/incapacity
NOTE:
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
g.Is a congenital anomaly/bir th defect
h.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_428172].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, i ntensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
i.Is associated with liver injury andimpaired liver functio n defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained , the value is to be 
recorded on the SAE form.
Refer to Appendix 2 for the required liver chemistry  follow -up instructions 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8900].5.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators wi ll be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient isch emic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.5.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_428173]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject numbe r, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detailed b y  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
82the scale’s developer.
The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inapprop riate.
12.5.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE t hat is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -define d 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey  that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases , concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed pro ducts, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004]. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
83The investi gator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
By [CONTACT_428250], the investigator is obligated to report any  grade 2 or higher 
“alteration in personality -behavior or in mood” or “altered mental status” adverse 
events that occur in subjects taking this drug, to [COMPANY_004] within 3 day s.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology . 
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designat ed 
reporting time frames.
12.5.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to pr event the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
84on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can repo rt this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] via paper CRF
Facsim0il e transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of the SAE data collectio n tool sent by  
[CONTACT_9338]
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] via PI[INVESTIGATOR_46427]
Facsimile transmission of the following PI[INVESTIGATOR_428122]:
SAE listing
Demographic listing
Study  treatment listing
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of all required information sent by [CONTACT_428224].
If the PI[INVESTIGATOR_428162], the site will use the paper 
SAE form and fax that to the Medical Monitor or protocol contact. The site will enter 
the SAE data into PI [INVESTIGATOR_428124] s ystem becomes available. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8901].6. Appendix 6: Collectio n of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24hrs of learning of a subject's pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  preg nancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_541650] who becomes pregnant while participating 
will discontinue study  medication andbe withdrawn from the study
This will only  be included if either of the following appl y:
Investigator will attempt to collect pregnancy  information on any  female partner of a 
male study  subject who becomes pregnant while participating in this study .  This 
applies only  to subjects who are randomized to receive study  medication. 
After obtaining the necessary  signed informed consent from the female partner 
directly , the investigator will record pregnancy  information on the appropriate form 
report the event and submit it to [COMPANY_004] within 24hrs of learning of the partner’s 
pregnancy
Partner will also be f ollowed to determine the outcome of the pregnancy .  
Information on the status of the mother and child will be forwarded to [COMPANY_004]. 
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date.  An y termination of the pregnan cy will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8902].7. Appendix 7: Country  Specific Requirements
No country -specific requirements exist. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[PHONE_8903].8. Appendix 8: Division Of A IDS Table For Grading The 
Severit y Of Adult And Pediatric A dverse Events Version 1.0, 
December 2004; Clarification A ugust 2009
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
ESTIMATING SEVERITY GRADE
Clinical adverse 
event NOT identified 
elsewher e in the 
grading tableMild symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicatedModerate 
symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with int ervention not 
indicatedSevere symptoms 
causing inability to 
perform usual social 
& functional activities 
with intervention or 
hospi[INVESTIGATOR_428125] -
threatening symptoms 
causing inability to 
perform basic self -care 
functions OR Medical or 
operative intervention 
indicated to prevent 
permanent impairment, 
persistent disability, or 
death 
CARDIOVASCULAR
Arrhythmia
(by[CONTACT_223081])
Specify type, if
applicableNo symptoms 
AND No 
intervention 
indicatedNo symptoms AND
non-urgent 
intervention 
indicatedNon-life-threatening 
symptoms AND Non -
urgent intervention 
indicatedLife-threatening 
arrhythmia OR Urgent 
intervention indicated
Blood Pressure 
Abnormalities1 
Hypertension (with 
the lowest reading 
taken after repeat 
testing during a visit) 
≥ 18 years of age 140 to < 160 
mmHg systolic 
OR 90 to < 100 
mmHg diastolic ≥ 160 to < 180 
mmHg systolic OR 
≥ 100 to < 110 
mmHg diastolic ≥ 180 mmHg systolic 
OR ≥ 110 mmHg 
diastolic Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_373] 
< 18 years of age > 120/80 mmHg ≥ 95th to < 99th 
percentile + 5 
mmHg adjusted for 
age, height, and 
gender (systolic 
and/or diastolic) ≥ 99th percentile + 5
mmHg adjusted for 
age, height, and 
gender (systolic 
and/or diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_428174] (stabl e 
angina) OR New 
testing consistent 
with ischemia Unstable angina OR 
Acute myocardial 
infarction  2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541651] or 
with mi nimal activity 
or exertion (e.g., 
hypoxemia) OR 
Intervention indicated 
(e.g., oxygen) Life-threatening 
consequences OR 
Urgent intervention 
indicated (e.g., 
vasoactive medications, 
ventricular assist device, 
heart transplant) 
Hemorrhage (with 
significant acute 
blood loss) NA Symptoms AND No 
transfusion 
indicated Symptoms AND 
Transfusion of ≤ 2 
units packed RBCs 
indicated Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs (for 
children, packed RBCs 
> 10 cc/kg) indicated 
Prolonged PR
Interval or AV Block 
Report only one 
> 16 years of age PR interval 0.21 
to < 0.25 seconds PR interval ≥ 0.25 
seconds OR Type I 
2nd degree AV 
block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
≤ [ADDRESS_541652] degree AV 
block (PR interval 
> normal for age 
and rate) Type I 2nd degree 
AV block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
Prolonged QTc 
Interval2 0.45 to 0.47 
seconds > 0.47 to 0.50 
seconds > 0.50 secon ds OR ≥ 
0.06 seconds above 
baseline Life-threatening 
consequences (e.g., 
Torsade de pointes, 
other associated serious 
ventricular dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention 
indicated Symptoms AND 
Intervention indicated Life-threatening embolic 
event (e.g., pulmonary 
embolism, thrombus) 
DERMATOLOGIC
Alopecia (scalp only) Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activitiesObvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities NA NA 
Bruising Localized to one 
area Localized to more 
than one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment in dicated 
(e.g., oral 
antibiotics, 
antifungals, 
antivirals) IV treatment 
indicated (e.g., IV 
antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (e.g., 
sepsis, tissue necrosis)  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
89PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperpi[INVESTIGATOR_428128] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Hypopi[INVESTIGATOR_428128] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Petechiae Localized to one 
area Localized to more 
than one area Generalized NA 
Pruritus3(without 
skinlesions) Itching causing no 
or minimal 
interference with 
usual social & 
functional 
activities Itching causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Itching causing 
inability to perform 
usual social & 
functional act ivities NA 
Rash 
Specify type, if 
applicable Localized rash Diffuse rash OR 
Target lesions Diffuse rash AND 
Vesicles or limited 
number of bullae or 
superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized 
bullous lesio ns OR 
Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Stevens-
Johnson syndrome OR 
Toxic epi[INVESTIGATOR_428175]-threatening 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non -
ketotic coma, end organ 
failure) 
Gynecomastia Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing pain with 
greater than 
minimal 
interference with 
usual social & 
functional activities Disfiguring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social 
& functional activities NA  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
90PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperthyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with
usual social & 
functional activities 
OR Thyroid 
suppression 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
thyroid storm) 
Hypothyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
replacement 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
function al activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
myxedema coma) 
Lipoatrophy4 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy5 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minima l 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
GASTROINTESTINAL
Anorexia Loss of appetite 
without d ecreased 
oral intake Loss of appetite 
associated with 
decreased oral 
intake without 
significant weight 
loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
Ascites No symptoms Symptoms AND 
Intervention 
indicated (e.g., 
diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despi[INVESTIGATOR_144482]-threatening 
consequences  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
91PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Bloating or 
Distension 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cholecystitis NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (e.g., 
sepsis, perforation) 
Constipation NA Persistent 
constipation 
requiring regular 
use of dietary 
modifications, 
laxatives, or 
enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (e.g., 
obstruction) 
Diarrhea ≥ 1 year of 
age Transient or 
intermittent 
epi[INVESTIGATOR_428130] ≤ 
3 stools over 
baseline per 24 -
hour period Persistent epi[INVESTIGATOR_428131] 4 to 6 
stools over baseline 
per 24- hour period Increase of ≥ 7 stools 
per 24- hour period 
OR IV fluid 
replacement 
indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one 
and specify 
location Symptoms but 
able to eat usual 
diet Symptoms causing 
altered dietary 
intake with no 
intervention 
indicated Symptoms causing 
severely altered 
dietary intake with 
interventio n indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other 
than iron 
supplement Endoscopic 
intervention 
indicated Transfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Mucositis or 
Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes 
or ulcerations Confluent 
pseudomembranes 
or ulcerations OR 
Mucosal bleeding 
with minor trauma Life-threatening 
consequences (e.g., 
aspi[INVESTIGATOR_1516], choking) OR 
Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
Nausea Transient (< 24 
hours) or 
intermittent AND 
No or minimal 
interference with 
oral intake Persistent nausea 
resulting in 
decreased oral 
intake for 24 to 48 
hours Persistent nausea 
resulti ng in minimal 
oral intake for > 48 
hours OR 
Rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pancreatitis NA Symptoms with 
hospi[INVESTIGATOR_184842]-threatening 
consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis)  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
92PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort 
with no 
intervention 
indicated Symptoms causing 
greater tha n 
minimal 
interference with 
usual social & 
functional activities 
OR Medical 
intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (e.g., 
perforation) 
Rectal Discharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND 
No or minimal 
interference with 
oral intake Frequent epi[INVESTIGATOR_428132] 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
MUSCULOSKELETAL
Arthralgia Joint pain causing 
no or minimal 
interference with 
usual social & 
functional 
activities Joint pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self -care 
functions 
Arthr itis Stiffness or joint 
swelling causing 
no or minimal 
interference with 
usual social & 
functional 
activities Stiffness or joint 
swelling causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling cau sing 
inability to perform 
usual social & 
functional activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions 
Myalgia 
(generalized) Muscle pain 
causing no or 
minimal 
interference with 
usual social & 
functio nal 
activities Muscle pain 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
inability to perform 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self -care 
functions 
Osteonecrosis NA No symptoms but 
with radiographic 
findings AND No 
operative 
intervention 
indicated Bone pain with 
radiographic findings 
OR Operative 
intervention indicated Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self -care 
functions 
Osteopenia6
≥ 30 years of age BMD t -score -2.5 
to -1 NA NA NA  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
93PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
< 30 years of age BMD z -score -2 to 
-1 NA NA NA 
Osteoporosis6
≥ 30 years of age NA BMD t -score < -2.5 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
< 30 years of age NA BMD z -score < -2 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
caus ing life -threatening 
consequences 
NEUROLOGIC
Acute Central 
nervous system 
(CNS) Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accident (e.g., stroke 
with neurological deficit) 
Altered Mental 
Status (for 
Dementia, see 
Cognitive, 
Behavi oral, or 
Attentional 
Disturbance below) Changes causing 
no or minimal 
interference with 
usual social & 
functional 
activities Mild lethargy or 
somnolence 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Confusion, memor y 
impairment, lethargy, 
or somnolence 
causing inability to 
perform usual social 
& functional activities Delirium OR 
Obtundation OR Coma 
Ataxia Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
ataxia detected on 
examination Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self- care 
functions 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance 
(includes dementia 
and attention deficit 
disorder) 
Specify type, if 
applicable Disability causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR 
Specialized 
resources not 
indicated Disability causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part -
time basis indicated Disability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full-
time basis indicated Disability causing 
inability to perform basic 
self-care functions OR 
Institutionalization 
indicated  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
94PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Developmental 
Delay < 18 years of 
age 
Specify type, if 
applicable Mild 
developmental 
delay, either 
motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental 
delay, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Severe 
developmental delay, 
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting 
Headache Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inabi lity to perform 
usual social & 
functional activities Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428163] (i ncludes 
myopathy and 
neuropathy) 
Specify type, if 
applicable Minimal muscle 
weakness causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
decreased 
strength on 
examination Muscle weakness 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle weakness 
causing inability to 
perform usual social 
& functional activities Disabling muscle 
weakness causing 
inability to perform basic 
self-care functions OR 
Respi[INVESTIGATOR_428176] (includes 
paresthesia and 
painful neuropathy) 
Specify type, if 
applicable Minimal 
paresthesia 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
sensory alte ration 
on examination Sensory alteration 
or paresthesia 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Sensory alteration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities Disabling sen sory 
alteration or paresthesia 
causing inability to 
perform basic self -care 
functions 
Seizures New Onset 
Seizure 
≥ 18 years of age NA NA 1 to 3 seizures Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
< 18 years of age 
(includes new or pre -
existing febrile 
seizures) Seizure lasting < 
5 minutes with < 
24 hours postictal 
state Seizure lasting 5 to 
< 20 minutes with < 
24 hours postictal 
state Seizure lasting ≥ 20 
minutes OR > 24 
hours postictal state Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002])  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
95PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Pre-existing Seizure NA Increased 
frequency from 
previous level of 
control without 
change in seizure 
character Change i n seizure 
character either in 
duration or quality 
(e.g., severity or 
focality) Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Syncope Near syncope 
without loss of 
consciousness 
(e.g., pr e-
syncope) Loss of 
consciousness with 
no intervention 
indicated Loss of 
consciousness AND 
Hospi[INVESTIGATOR_428135], PUERPERIUM, AND PERINATAL
Fetal Death or 
Stillbirth (report 
using mother’s 
participant ID) 
Report only o ne NA NA Fetal loss occurring 
at ≥ 20 weeks 
gestation NA 
Preterm Delivery7
(report using 
mother’s participant 
ID) Delivery at 34 to < 
37 weeks 
gestational age Delivery at 28 to < 
34 weeks 
gestational age Delivery at 24 to < 28 
weeks gestational 
age Delivery at < 24 weeks 
gestational age 
Spontaneous 
Abortion or 
Miscarriage8(report 
using mother’s 
participant ID) 
Report only one Chemical 
pregnancy Uncomplicated 
spontaneous 
abortion or 
miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
PSYC HIATRIC
Insomnia Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early Moderate difficulty 
falling asleep, 
staying asleep, or 
waking up early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric 
Disorders 
(includes anxiety, 
depression, mania, 
and 
psychosis) 
Specify disorder Symptoms with 
intervention not 
indicated OR 
Behavior causing 
no or minimal 
interference with 
usual social & 
functional 
activities Symptoms with 
intervention 
indicated OR 
Behavior c ausing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms with 
hospi[INVESTIGATOR_428164] & 
functional activities Threatens harm to self 
or others OR Acute 
psychosis O R Behavior 
causing inability to 
perform basic self -care 
functions  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
96PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Suicidal Ideation or 
Attempt 
Report only one Preoccupi[INVESTIGATOR_428165] 1 
second or peak 
flow reduced to ≥ 
70 to < 80% OR 
Mild symptoms 
with intervention 
not indicated Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 50 to < 
70% OR Symptoms 
with intervention 
indicated OR 
Symptoms causing 
greater t han 
minimal 
interference with 
usual social & 
functional activities Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 25 to < 
50% OR Symptoms 
causing inability to 
perform usual social 
& functional activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak fl ow < 25% OR 
Life-threatening 
respi[INVESTIGATOR_428137] & 
functional 
activities OR 
Wheezing OR 
Minimal increa se 
in respi[INVESTIGATOR_428138] & 
functional activities 
OR Nasal flaring 
OR Intercostal 
retractions OR 
Pulse oximetry 90 
to < 95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional activities 
OR Pulse oximetry < 
90% Respi[INVESTIGATOR_184852] (e.g., 
Continuous positive 
airway pressure [CPAP], 
Bilevel positive airway 
pressure [BPAP], 
intubation) 
SENSORY
Hearing Loss 
≥ 12 years of age NA Hearing aid or 
intervention not 
indicated Hearing aid or 
intervention indicated Profound bilateral 
hearing loss (> 80 dB at 
2 kHz and above) OR 
Non-serviceable hearing 
(i.e., >50 dB audiogram 
and <50% speech 
discrimination) 
< 12 years of age 
(based on a 1, 2, 3, 
4, 6 and 8 kHz 
audiogram) > 20 dB hearing 
loss at ≤ 4 kHz > 20 dB hearing 
loss at > 4 kHz > 20 dB hearing loss 
at ≥ 3 kHz in one ear 
with additional 
speech language 
related services 
indicated (where 
available) OR 
Hearin g loss 
sufficient to indicate 
therapeutic 
intervention, including 
hearing aids Audiologic indication for 
cochlear implant and 
additional speech -
language related 
services indicated 
(where available)  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
97PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Tinnitus Symptoms 
causing no or 
minimal 
interference w ith 
usual social & 
functional 
activities with 
intervention not 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functio nal activities NA 
Uveitis No symptoms 
AND Detectable 
on examination Anterior uveitis with 
symptoms OR 
Medicamylasal 
intervention 
indicated Posterior or pan -
uveitis OR Operative 
intervention indicated Disabling visual loss in 
affected eye(s) 
Vertig o Vertigo causing 
no or minimal 
interference with 
usual social & 
functional 
activities Vertigo causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self -care 
functions 
Visual Changes 
(assessed from 
baseline) Visual changes 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Visual changes 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Visual changes 
causing inability to 
perform usual social 
& functional activities Disabling visual loss in 
affected eye(s) 
SYSTEMIC
Acute Allergic 
Reaction Localized urticaria 
(wheals) with no 
medic al 
intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with 
no intervention 
indicated Generalized urticaria 
OR Angioedema with 
intervention indicated 
OR Symptoms of 
mild bronchospasm Acute anaphylaxis OR 
Life-threat ening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9Mild signs and 
symptoms AND 
Therapy (i.e., 
antibody infusion) 
interruption not 
indicated Therapy (i.e., 
antibody infusion) 
interruption 
indicated AND 
Responds promptly 
to sy mptomatic 
treatment OR 
Prophylactic 
medications 
indicated for ≤ 24 
hours Prolonged severe 
signs and symptoms 
OR Recurrence of 
symptoms following 
initial improvement Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support)  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
98PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Fatigue o r Malaise 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating 
symptoms of fatigue or 
malaise causing inability 
to perform basic self -
care functions 
Fever (non-axillary 
temperatures only) 38.0 to < 38.6°C 
or 100.4 to < 
101.5°F ≥ 38.6 to < 39.3°C 
or ≥ 101.5 to < 
102.7°F ≥ 39.3 to < 40.0°C or 
≥ 102.7 to < 104.0°F ≥ 40.0°C or ≥ 104.0°F 
Pain10(not 
associated with study 
agent injections and 
not specified 
elsewhere) 
Specify location Pain causing no 
or minimal 
interference with 
usual social & 
functional 
activities Pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Pain causing inability 
to perform usual 
social & functional 
activities Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428139]11 Mild signs and 
symptoms Moderate signs and 
symptoms AND 
Intervention 
indicated (e.g., 
antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(e.g., steroids or IV 
fluids) Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Underweight12
> 5 to 19 years of 
age NA World Health 
Organization 
(WHO) BMI z- score 
< -2 to ≤ -3 WHO BMI z -score < -
3 WHO BMI z -score < -3 
with life -threatening 
consequences 
2 to 5 years of age NA WHO Weight -for-
height z -score 
< -2 to ≤ -3 WHO Weight -for-
height z -score < -3 WHO Weight -for-height 
z-score < -3 with life -
threatening 
consequences 
< 2 years of age NA WHO Weight -for-
length z -score 
< -2 to ≤ -3WHO Weight -for-
length z -score < -3 WHO Weight -for-length 
z-score < -3 with life -
threatening 
consequences 
Weight Loss 
(excludes postpartum 
weight loss) NA 5 to < 9% loss in 
body weight from 
baseline ≥ 9 to < 20%  loss in 
body weight from 
baseline ≥ 20% loss in body 
weight from baseline OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
URINARY
Urinary Tract 
Obstruction NA Signs or symptoms 
of urinary tract 
obstruction without 
hydronephrosis or 
renal dysfunctionSigns or symptoms of 
urinary tract 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing life -
threatening 
consequences  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
99PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
SITE REACTIONS TO INJECTIONS AND INFUSIONS
Injection Site Pain 
or Tenderness 
Report only one Pain or 
tendernes s 
causing no or 
minimal limitation 
of use of limb Pain or tenderness 
causing greater 
than minimal 
limitation of use of 
limb Pain or tenderness 
causing inability to 
perform usual social 
& functional activities Pain or tenderness 
causing inability to 
perform basic self -care 
function OR 
Hospi[INVESTIGATOR_428140]13 
Report only one 
> 15 years of age 2.5 to < 5 cm in 
diameter OR 6.25 
to < 25 cm2 
surface area AND 
Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities ≥ 5 to < 10 cm in 
diameter OR ≥ 25 
to < 100 cm2 
surface area OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities ≥ 10 cm in diameter 
OR ≥ 100 cm2 
surface area OR 
Ulceration OR 
Seconda ry infection 
OR Phlebitis OR 
Sterile abscess OR 
Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper ti ssue) 
≤ 15 years of age ≤ 2.5 cm in 
diameter > 2.5 cm in 
diameter with < 
50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) ≥ 50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) OR Ulceration 
OR Secondary 
infection OR Phlebitis 
OR Sterile abscess 
OR Drainage Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or 
Swelling 
Report only one 
> 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, > 15 y ears of 
age 
≤ 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
age 
Injection Site 
Pruritus Itching localized 
to the injection 
site that is 
relieved 
spontaneously or 
in < 48 hours of 
treatment Itching beyond the 
injection site that is 
not generalized OR 
Itching localized to 
the injection site 
requiring ≥ 48 
hours treatment Generalized itching 
causing inability to 
perform usual social 
& functional activities NA 
LABORATORY VALUES Chemistries
Acidosis NA pH ≥ 7.3 to < Lower 
limit of normal 
(LLN) pH < 7.3 without life -
threatening 
consequences pH < 7.3 with life -
threatening 
consequences 
Albumin, Low (g/dL; 
g/L) 3.0 to < LLN 
30 to < LLN ≥ 2.0 to < 3.0
≥ 20 to < 30 < 2.0 
< 20 NA  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
100PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Alkaline 
Phosphatase, High 1.25 to < 2.[ADDRESS_541653] 2.5 to < 5.[ADDRESS_541654] 5.0 to < 10.0 x UL N ≥ 10.[ADDRESS_541655] 
Alkalosis NA pH > ULN to ≤ 7.5 pH > 7.5 without life -
threatening 
consequences pH > 7.5 with life -
threatening 
consequences 
ALT or SGPT, High 
Report only one 1.25 to < 2.[ADDRESS_541656] 2.5 to < 5.[ADDRESS_541657] 5.0 to < 10.[ADDRESS_541658] ≥ 10.[ADDRESS_541659]
Amylase 
(Pancreatic) or 
Amylase (Total), 
High 
Report only one 1.1 to < 1.[ADDRESS_541660] 1.5 to < 3.[ADDRESS_541661] 3.0 to < 5.[ADDRESS_541662] ≥ 5.[ADDRESS_541663] or SGOT, High 
Report only one 1.25 to < 2.[ADDRESS_541664] 2.5 to < 5.[ADDRESS_541665] 5.0 to < 10.[ADDRESS_541666] ≥ 10.[ADDRESS_541667] 
Bicarbonate, Low 
(mEq/L; mmol/L ) 16.0 to < LLN 
16.0 to < LLN 11.0 to < 16.0 
11.0 to < 16.0 8.0 to < 11.0 
8.0 to < 11.0 < 8.0 
< 8.[ADDRESS_541668] 
Bilirubin14, High 
> 28 days of age NA NA > ULN > ULN with life -
threatening 
consequences (e.g., 
signs and symptoms of 
liver failure) 
≤ [ADDRESS_541669] to ≤ 1 mg/dL > 1 to ≤ 1.5 mg/dL > 1.5 to ≤ 2 mg/dL > 2 mg/dL 
Total Bilirubin, High 
> 28 days of age 1.1 to < 1.[ADDRESS_541670] 1.6 to < 2.[ADDRESS_541671] 2.6 to < 5.[ADDRESS_541672] ≥ 5.[ADDRESS_541673] 
≤ 28 days of age Total Bilirubin for 
Term and Preter m 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for Term 
and Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L ) 
≥ 7 days of age 10.6 to < 11.5 
2.65 to < 2.88 11.5 to < 12.5 
2.88 to < 3.13 12.5 to < 13.5 
3.13 to < 3.38 ≥ 13.5 
≥ 3.38 
< 7 days of age 11.5 to < 12.4 
2.88 to < 3.10 12.4 to < 12.9 
3.10 to < 3.23 12.9 to < 13.5 
3.23 to < 3.38 ≥ 13.5 
≥ 3.38 
Calcium (Ionized), 
High (mg/dL; 
mmol/L ) > ULN to < 6.0
> ULN to < 1 .5 6.0 to < 6.4 
1.5 to < 1.6 6.4 to < 7.2 
1.6 to < 1.8 ≥ 7.2 
≥ 1.8  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
101PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Calcium, Low 
(mg/dL; mmol/L ) 
≥ 7 days of age 7.8 to < 8.4 
1.95 to < 2.10 7.0 to < 7.8 
1.75 to < 1.95 6.1 to < 7.0 
1.53 to < 1.75 < 6.1 
< 1.53 
< 7 days of age 6.5 to < 7. 5 
1.63 to < 1.88 6.0 to < 6.5 
1.50 to < 1.63 5.50 to < 6.0 
1.38 to < 1.50 < 5.50 
< 1.38 
Calcium (Ionized), 
Low (mg/dL; mmol/L ) < LLN to 4.0 
< LLN to 1.0 3.6 to < 4.0 
0.9 to < 1.0 3.2 to < 3.6 
0.8 to < 0.9 < 3.2 
< 0.8 
Cardiac Troponin I, 
High NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as 
defined by [CONTACT_428225], 
High 3 to < [ADDRESS_541674] 6 to < [ADDRESS_541675] 10 to < [ADDRESS_541676] ≥ [ADDRESS_541677] > 1.[ADDRESS_541678] 
OR Increase of > 
0.3 mg/dL above 
baseline > 1.8 to < 3.[ADDRESS_541679] 
OR Increase of 1.5 to 
< 2.0 x above 
baseline ≥ 3.[ADDRESS_541680] OR 
Increase of ≥ 2.0 x 
above baseline 
Creatinine 
Clearance15or
Estimated 
glomerular filtration 
rate (eGFR), Low 
Report only one NA < 90 to 60 mL/min 
or mL/min/1.73 m2 
OR 10 to < 30% 
decrease from 
baseline < 60 to 30 mL/min or 
mL/min/1.73 m2 OR 
≥ 30 to < 50%  
decrease from 
baseline < 30 mL/min or 
mL/min/1.73 m2 OR ≥ 
50% decrease from 
baseline or dialysis 
needed 
Glucose 
(mg/dL; mmol/L ) 
Fasting, High 110 to 125 
6.11 to < 6.95 > 125 to 250 
6.95 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Nonfasting, High 116 to 160 
6.44 to < 8.89 > 160 to 2 50 
8.89 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Glucose, Low 
(mg/dL; mmol/L ) 
≥ 1 month of age 55 to 64 
3.05 to 3.55 40 to < 55 
2.22 to < 3.05 30 to < 40 
1.67 to < 2.22 < 30 
< 1.[ADDRESS_541681] to < 2.[ADDRESS_541682] without 
acidosis ≥ 2.[ADDRESS_541683] without 
acidosis Increased lactate with 
pH < 7.3 without life -
threatening 
consequences Increased lactate with 
pH < 7.3 with life -
threatening 
consequences 
Lipase, High 1.1 to < 1.[ADDRESS_541684] 1.5 to < 3.[ADDRESS_541685] 3.0 to < 5.[ADDRESS_541686] ≥ 5.[ADDRESS_541687]  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
102PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Lipid Disorders 
(mg/dL; mmol/L ) 
Cholesterol, 
Fasting, High 
≥ 18 years of age 200 to < 240 
5.18 to < 6.19 240 to < 300 
6.19 to < 7.77 ≥ 300 
≥ 7.77 NA 
< 18 years of age 170 to < 200 4.40 
to < 5.15 200 to < 300 5.15 to 
< 7.77 ≥ 300 ≥ 7.77 NA 
Low Density 
Lipoprotein (LDL),
Fasting, High 
≥ 18 years of age 130 to < 160 3.37 
to < 4.12 160 to < 190 4.12 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
> 2 to < 18 years of 
age 110 to < 130 2.85 
to < 3.34 130 to < 190 3.34 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
Triglycerides, 
Fasting, High 150 to 300 
1.71 to 3.42 >300 to 500 
>3.42 to 5.7 >500 to < 1,000 
>5.7 to 11.4 > 1,000 
> 11.4 
Magnesium16, Low 
(mEq/L; mmol/L ) 1.2 to < 1.4 
0.60 to < 0.70 0.9 to < 1.2 
0.45 to < 0.60 0.6 to < 0.9 
0.30 to < 0.45 < 0.6 
< 0.30 
Phosphate, Low 
(mg/dL; mmol/L ) 
> 14 years of age 2.0 to < LLN 
0.81 to < LLN 1.4 to < 2.0 
0.65 to < 0.81 1.0 to < 1.4 
0.32 to < 0.65 < 1.0 
< 0.32 
1 to 14 years of age 3.0 to < 3.5 
0.97 to < 1.13 2.5 to < 3.0 
0.81 to < 0.97 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
< 1 year of age 3.5 to < 4.5 
1.13 to < 1.45 2.5 to < 3.5 
0.81 to < 1.13 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
Potassium, High 
(mEq/L; mmol/L ) 5.6 to < 6.0 
5.6 to < 6.0 6.0 to < 6.5 
6.0 to < 6.5 6.5 to < 7.0 
6.5 to < 7.0 ≥ 7.0 
≥ 7.0 
Potassium, Low 
(mEq/L; mmol/L ) 3.0 to < 3.4 
3.0 to < 3.4 2.5 to < 3.0 
2.5 to < 3.0 2.0 to < 2.5 
2.0 to < 2.5 < 2.0 
< 2.0 
Sodium, High 
(mEq/L; mmol/L ) 146 to < 150 
146 to < 150 150 to < 154 
150 to < 154 154 to < 160 
154 to < 1 60 ≥ 160 
≥ 160 
Sodium, Low 
(mEq/L; mmol/L ) 130 to < 135 
130 to < 135 125 to < 130 
125 to < 135 121 to < 125 
121 to < 125 ≤ 120 
≤ 120 
Uric Acid, High 
(mg/dL; mmol/L ) 7.5 to < 10.0 
0.45 to < 0.59 10.0 to < 12.0 
0.59 to < 0.71 12.0 to < 15. 0 
0.71 to < 0.89 ≥ 15.0 
≥ 0.89  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
103PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
HEMATOLOGY
Absolute cluster of 
differentiation 4 
(CD4+) Count, Low 
(cell/mm3; cells/L ) 
> 5 years of age (not 
HIV infected) 300 to < 400 
300 to < 400 200 to < 300 
200 to < 300 100 to < 200 
100 to < 200 < 100 
< 100 
Absolute 
Lymphocyte Count, 
Low 
(cell/mm3; cells/L ) 
> 5 years of age 
(not HIV infected) 600 to < 650 
0.600 x 109to < 
0.650 x 109500 to < 600 
0.500 x 109to < 
0.600 x 109350 to < 500 
0.350 x 109to < 
0.500 x 109< 350 
< 0.350 x 109
Absolu te Neutrophil 
Count (ANC), Low 
(cells/mm3; cells/L ) 
> 7 days of age 800 to 1,000 
0.800 x 109to 
1.000 x 109600 to 799 
0.600 x 109to 0.799 
x 109400 to 599 
0.400 x 109to 0.599 
x 109< 400 
< 0.400 x 109
2 to 7 days of age 1,250 to 1,500 
1.250 x 109to 
1.500 x 1091,000 to 1,249 
1.000 x 109to 1.249 
x 109750 to 999 
0.750 x 109to 0.999 
x 109< 750 
< 0.750 x 109
≤ 1 day of age 4,000 to 5,000 
4.000 x 109to 
5.000 x 109 3,000 to 3,999 
3.000 x 109to 3.999 
x 1091,500 to 2,999 
1.500 x 109to 2.999 
x 109< 1,500 
< 1.500 x 109
Fibrinogen, 
Decreased (mg/dL; 
g/L) 100 to < 200 
1.00 to < 2.00 OR 
0.75 to < 1.[ADDRESS_541688] 75 to < 100 
0.75 to < 1.00 OR ≥ 
0.50 to < 0.[ADDRESS_541689] 50 to < 75 
0.50 to < 0.75 OR 
0.25 to < 0.[ADDRESS_541690] < 50 
< 0.50 OR < 0.[ADDRESS_541691] 
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L )18 
≥ 13 years of age 
(male only) 10.0 to 10.9 
6.19 to 6.76 9.0 to < 10.0 
5.57 to < 6.19 7.0 to < 9.0 
4.34 to < 5.57 < 7.0 
< 4.34 
≥ 13 years of age 
(female only ) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
57 days of age to < 
13 years of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
<4.03  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
104PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
36 to 56 days of age 
(male and female) 8.5 to 9.6 
5.26 to 5.99 7.0 to < 8.5 
4.32 to < 5.26 6.0 to < 7.0 
3.72 to < 4.32 < 6.0 
< 3.72 
22 to 35 days of age 
(male and female) 9.5 to 11.0 
5.88 to 6.86 8.0 to < 9.5 
4.94 to < 5.88 6.7 to < 8.0 
4.15 to < 4.94 < 6.7 
< 4.15 
8 to ≤ 21 days of age 
(male and female) 11.0 to 13.0 
6.81 to 8.10 9.0 to < 11.0 
5.57 to < 6.81 8.0 to < 9.0 
4.96 to < 5.57 < 8.0 
< 4.96 
≤ 7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to < 13.0 
6.19 to < 8.05 9.0 to < 10.0 
5.59 to < 6.19 < 9.0 
< 5.59 
INR, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541692] 1.5 to < 2.[ADDRESS_541693] 2.0 to < 3.[ADDRESS_541694] ≥ 3.[ADDRESS_541695] 
Methemoglobin (% 
hemoglobin) 5.0 to < 10.0% 10.0 to < 15.0% 15.0 to < 20.0% ≥ 20.0% 
PTT, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541696] 1.66 to < 2.[ADDRESS_541697] 2.33 to < 3.[ADDRESS_541698] ≥ 3.[ADDRESS_541699] 
Platelets, 
Decreased 
(cells/mm3; cells/L ) 100,000 to < 
124,999 100.000 
x 109to < 124.999 
x [ZIP_CODE],000 to < 100,000 
50.000 x 109to < 
100.000 x 109 25,000 to < 50,000 
25.000 x 109to < 
50.000 x 109< 25,000 < 25.000 x 109
PT, High 
(not on 
anticoagulation 
therapy 1.1 to < 1.[ADDRESS_541700] 1.25 to < 1.[ADDRESS_541701] 1.50 to < 3.[ADDRESS_541702] ≥ 3.[ADDRESS_541703] 
WBC, Decreased
(cells/mm3; cells/L ) 
> 7 days of age 2,000 to 2,499 
2.000 x 109to 
2.499 x 1091,500 to 1,999 
1.500 x 109to 1.999 
x 1091,000 to 1,499 
1.000 x 109 to 1.499 
x 109< 1,000 
< 1.000 x 109
≤ 7 days of age 5,500 to 6,999 
5.500 x 109to 
6.999 x 109 4,000 to 5,499 
4.000 x 109to 5.499 
x 1092,500 to 3,999 
2.500 x 109to 3.999 
x 109< 2,500 
< 2.500 x 109
URINALYSIS
Glycosuria ( random 
collection tested by 
[CONTACT_5230]) Trace to 1+ or 
≤ 250 mg 2+ or ˃  250 to 
≤ 500 mg > 2+ or > 500 mg NA  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
105PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hematuria (not to be 
reported based on 
dipstick findings or 
on blood believed to 
be of menstrual 
origin) 6 to < 10 RBCs 
per high power 
field ≥ 10 RBCs per high 
power field Gross, with or without 
clots OR With RBC 
casts OR Intervention 
indicated Life-threatening 
consequences 
Proteinuria (random 
collection tested by 
[CONTACT_5230]) 1+ 2+ 3+ or higher NA 
1. Blood pressure norms for children <18 years of age can be found in: Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and Adolescents. Pediatrics 2011;128;S213; originally 
published online November 14, 2011; DOI: 10.1542/peds.2009 -2107C.  
2. As per Bazett’s formula.  
3. For pruritus associated with injections or infusions, see the Site Reactions to Injections and In fusions section.  
4. Definition: A disorder characterized by [CONTACT_184941], extremities, and buttocks. 
5. Definition: A disorder characterized by [CONTACT_184942], breasts, and abdomen.  
6. Bone mineral density (BMD) t an d z scores can be found in: Kanis JA on behalf of the World Health Organization 
Scientific Group (2007). Assessment of osteoporosis at the primary health -care level. Technical Report. World 
Health Organization Collaborating Centre for Metabolic Bone Diseas es, University of Sheffield, [LOCATION_006]. 2007: Printed 
by [CONTACT_184943].  
7. Definition: A delivery of a live -born neonate occurring at ≥20 to <37 weeks gestational age. 
8. Definition: A clinically recognized pregnancy occurring at <20 weeks gestational age.  
9. Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of 
breath. 
10. For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section.
11. Definition: A disord er characterized by [CONTACT_411], arthralgia, myalgia, skin eruptions, lymphadenopathy, marked 
discomfort, and/or dyspnea.
12. WHO reference tables may be accesed by [CONTACT_184944]: 
http://www.who.int/growthref/who20 07_bmi_for_age/en/ for participants >5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤ [ADDRESS_541704] bilirubin >1.5 mg/dL in a participant <28 days of age should be graded as Grade 2, if <10% of the total 
bilirubin.  
15. Use the applicable formula (i.e., Cockroft -Gault in mL/min or Schwatrz in mL/min/1.73m2).  
16. To convert a ma gnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.  
17. Male and female sexes are defined as sex at birth. 
18. The conversion factor used to convert g/dL to mmol/L is 0.[ADDRESS_541705] be converted to g/dL using the appropriate conversion factor for the particular laboratory.   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
[ZIP_CODE].9. Appendix 9: Toxicity  Management
ANEMIA
Grade 1 (mild) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541706] be repeated with the 
following additional tests:
3.peripheral blood smear
4. indirect bilirubin (abnormal if increased >50% from baseline)
5.haptoglobin (abnormal if  25 mg/dL)
6.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will per manently  discontinue study  medication and 
be withdrawn from the trial.  Subjects should be followed up until resolution of anemia.
Grade 2 (moderate) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541707] be repeated with the 
following additional tests:
7.peripheral blood smear
8. indirect bilirubin (abnormal if increased > 50% from baseline)
9.haptoglobin (abnormal if  25 mg/dL)
10.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will permanently  discontinue study  medication and 
be withdrawn from the trial.  Consultation with a Hematologist s hould be considered.  
Subjects should be followed up until resolution of anemia.
Grade 3 (severe) or Grade 4 (potentially life threatening) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541708] be repeated with 
the follow ing additional tests:
11.peripheral blood smear
12. indirect bilirubin
13.haptoglobin
14.reticulocy te count  2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541709] should be considered.  Subjects should be followed up 
until resolution of anemia.
TOTA L BILIRUBIN ELEVA TION
Grade 1 (mild) bilirubin elevation (1.[ADDRESS_541710]) or Grade 2 (moderate 
-1.6-2.[ADDRESS_541711]):
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects may  continue study  medication.  Subjects should 
be followed up until resolution (return to baseline) of elevation.
Grade 3 (severe –2.6-5.[ADDRESS_541712]) or 4 (life- threatening -> 5.[ADDRESS_541713]) 
bilirubin elevation :
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects will permanently  discontinue study medication 
and be withdrawn from the trial.  Subjects should be followed up until resoluti on (return 
to baseline) of bilirubin elevation.
AST AND ALT ELEVA TION
See Appendix 9 .
RASH
Grade 1 rash (Localized macular rash):
Subjects with Grade [ADDRESS_541714].  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
15.Temperature > 38.5°C
16.Lym phadenopathy
17.Phary ngitis
18.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541715] should remain on the study  to be 
followed for safet y and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
108Grade 2 rash (Diffuse macular, maculopapular, or morbilliform rash OR Target
lesions):
Subjects with Grade [ADDRESS_541716].  The study  drug should b e permanentl y 
discontinued if the following signs or s ymptoms are noted at an y time:
19.Temperature > 38.5°C
20.Lym phadenopathy
21.Phary ngitis
22.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subject s with Grade [ADDRESS_541717] should remain on the study to be followed for safety and PK as 
outlined in Section 10.5.
Grade 3 rash (Diffuse macular, mac ulopapular, or morbilliform rash with vesicles 
or limited number of bullae OR Superficial ulcerations of mucous membrane 
limited to one site):
Subjects with a Grade [ADDRESS_541718] should be evaluated in the phy sician’s office immediatel y and should be seen in 
the phy sician’s office or contact[CONTACT_428226]  [ADDRESS_541719] should remain on the 
study  to be followed for safet y and PK as outlined in Section 10.5.
Grade 4 rash (Extensive or generalized bullous lesions OR Stevens -Johnson 
syndrome OR Ulceration of mucous membrane involving two or more distinct 
mucosal sites OR Toxic epi[INVESTIGATOR_194] (TEN)):
Subjects with a Grade [ADDRESS_541720] sh
ould remain on the stud y to be followed 
for safety  and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
109ALLERGIC RE ACTION
Grade 1 allergic reaction (Pruritis without rash):
Subjects with Grade 1 allergic reaction should be evalu ated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
23.Temperature > 38.5°C
24.Eosinophilia
25.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
26.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541721] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428142].  The subject should remain on the study  to be 
followed for safety and PK as outlined.
Grade 2 allergic reaction (Localized urticaria):
Subjects with Grade 2 allergic reaction should be evaluated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
27.Temperature > 38.5°C
28.Eosinophilia
29.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
30.Any indicatio n of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541722] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard 
management, i ncluding discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428143].  The subject should remain on the study  to be 
followed for safet y and PK as outlined in Section 7. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
110Grade 3 allergic reaction (Generalized urticaria or angioedema):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Grad e 4 allergic reaction (Anaphylaxis):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Revised ACTG Toxicity Grade Definitions Investigator Action
Grade 1 Pruritus without rash May continue therapy
Grade 2 Localized urticaria May continue therapy
Grade 3 Generalized urticaria
AngioedemaDiscontinu e Therapy
Grade 4 Anaphylaxis Discontinue Therapy 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
[ZIP_CODE].10. Appendix 10: Protocol A mendment Changes
Protocol Amendment 1 ( 26-Apr-2017 ) from the original protocol (09 -Nov-2016)
Where the A mendment A pplies
This amendment applies to all subjects who will participate in this study  in all countries.
List of Specific Changes :(bold indicates text added and strikethrough indicates text 
removed)
Summary  of Protocol A mendment Changes with Rationale
Amendment 1 includes minor updates to Inclusion criteria (IE) criteria, inc luding 
clarification on use of pre- or post -exposure prophy laxis, and removal of exclusionary  
requirements related to concomitant medications and tobacco and alcohol use during the 
study . Guidance around relevant habits is included in the L ifesty le section of the protocol 
and adjustments were made to reduce restrictions on these requirements. Modifications 
were also made to the pharmacokinetics sampling, allowing for the 12 h PK collection 
timepoint on Day  1 and 10 to be optional. Minor alterations were mad e regarding the 
order of screening procedures, including the Holter monitoring requirements. 
Visit/procedure windows were included to allow more flexibility  with scheduling of 
assessments. Furthermore, the serial ECG collection (up to 6h post -dose) was rem oved on 
Day 5. Finall y, the post -study  care guidance was updated to include an option for subjects 
to receive reimbursement for marketed ART for a limited period after completion of 
study  treatment and follow up. Minor clarifications, reformatting of table s, re-numbering 
of sections and correction of typographical errors were also made throughout this 
amendment.
List of Authors
Rationale for change
The list of authors was updated based on internal [COMPANY_004] team personnel changes.
Revised Text
PTS, Ware, [LOCATION_006]
GCSP, Stockley  Park, [LOCATION_006]
Infectious Diseases, Clinical, Upper Providence, PA, US
Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
HIV DPU, RTP, NC, US
Virology , HIV DPU, RT P, NC, US
CPMS, [COMPANY_004], RTP, NC, US 2018N360917_00
[COMPANY_003]
2015N227852_01 CONFIDENTIA L
200911
112HIV DPU, RTP, NC, US
Clinical Pharmacology , ViiV Healthcare, RTP, NC, US
PCPS, [COMPANY_004], Upper Providence, PA, US
PCPS, [COMPANY_004], Collegeville, PA, US 
Clinical Statistics, PAREXEL , RTP, NC, US
Infectious Diseases, Clinical, Cambridge, MA, US
Medical Monitor/SA E Contact [CONTACT_428251] t 
contact [CONTACT_428228] y and medical monitoring. 
Revised Text
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor/SAE 
contact 
[CONTACT_428241]
([COMPANY_003])Safety 
Hotline [LOCATION_011], 
MA[COMPANY_003], [ADDRESS_541723] 
information  MD[LOCATION_011], MA
Synopsis : Design, Treatment A rms and Duration
Rationale for change
Minor clarifications were made to this section to reflect current status of studies being 
referenced. As synopsis being a standalone document, cross -referenced has been 
removed. 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_01 CONFIDENTIA L
200911
113Revised Text
Fourth paragraph
The possibility  that an additional, unboosted [COMPANY_004]2838 232 monotherap y cohort will be 
assessed in Part B is dependent on anal ysis of the PK data from ongoing Study  204953 
where unboosted [COMPANY_004]2838232 at a dose of 200 mg twice dail y (BID) is being was
assessed.
Sixth paragraph
HIV Drug Resistance: Following cessa tion of [COMPANY_004]2838232/cobi dosing for 10 days, 
there will be prolonged exposure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t½ (i.e., in the “tail” of the PK profile). However, based on in vitro 
resistance passage data with [COMPANY_004]2838232 [ and unlike with many other ARV therapi[INVESTIGATOR_014]], 
there appears to be a limited likelihood of developi[INVESTIGATOR_428081]-infected subjects due to its virologic profile [[COMPANY_004] Document Number 
2013N163221_00] . 
Section [ADDRESS_541724] instance has been defined.
Revised Text
[COMPANY_004]2838232 is a novel human immunodeficiency virus ( HIV)-1 maturation inhibitor 
(MI) that is being developed for the treatment of HIV -1 infection in combination with 
other antire trovirals (ART).
Section 2.[ADDRESS_541725] instance has been defined.
Revised Text
This ‘proof of concept (PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity , pharmacokinetics (PK), the relationship between PK and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg once daily (QD) cobicistat 
([COMPANY_004]283232/cobi), administered across a range of doses over [ADDRESS_541726] paragraph
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has demonstrated significant improvement in acquired 
immunodeficiency syndrome (AIDS)-related morbidity  and mortalit y over the last 10-
15 years.
Addition of abbreviation for RNA  in second paragraph
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [Martin, 2007a; Martin, 2007b; Martin, 2008; NORVIR, 201 3]). 
BVM reached Phase II studies in HIV patients; however, onl y modest reductions in 
plasma HIV -1 ribonucleic acid (RNA) concentrations were observed in Phase IIa 
monotherap y studies [Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential ) antiviral activity  [Wainburg, 2010] led to termination of BVM development. 
The average decrease from baseline to Day  14 plasma HIV -1 ribonucleic acid (RNA) 
was 0.54 and 0.70 log10 copi[INVESTIGATOR_014]/mL  for 200 mg and 300 mg twice daily  regimens (Table 
2); all subjec ts achieved plasma BVM concentrations above the in vitro EC90. 
Responders, classified based on 5 poly morphisms in HIV -1 gag (at positions 369, 370, 
and 371), achieved an average 1.15 log10 copi[INVESTIGATOR_014]/mL reduction in plasma HIV -1 RNA, 
while an average 0.17 log1 0 copi[INVESTIGATOR_014]/mL  reduction was achieved for non- responders.
Section 2.2.[ADDRESS_541727] current status of studies being 
referenced.
Revised Text
Todate, [COMPANY_004]2838232 has been evaluated in three completed clinical studies with or 
without ritonavir (RTV )([COMPANY_004]2838232/r). A fourth study  (204953) is on- going as of 1st
November completed late 2016 and data analysis is ongoing . Full details of the clinical 
results can be found in the Investigator’s Brochure.
Section [IP_ADDRESS] Clinical Summary  of Safety
Rationale for change
Minor clarifications were made to this section to reflect current status of studies being 
referenced. 2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541728] hadbeen exposed to [COMPANY_004]2838232 
in 3 completed studies. One study  (204953) is completed in late 2016 and the analysis 
of results are ongoing ( [ADDRESS_541729] been 63subjects were exposed to 
[COMPANY_004]2838232/r or placebo so far in th is study). Overall, drug -related adverse events have 
been few and mild, and included headache, dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428144] .  Similarly , treatment -emergent laboratory  abnormalities have also been few 
and mostly  grade 1.  There h ave been no discernible patterns, thus far, in terms of AEs or 
laboratory  abnormalities.
Section [IP_ADDRESS] Study 204953 (completed); Pharmacokinetic Data
Rationale for change
Minor clarifications were made to this section to reflect current status of studie s being 
referenced.
Change in Heading
Section [IP_ADDRESS] Study 204953 ( on-going completed ); Pharmacokinetic Data
Section 4.4.[ADDRESS_541730] instance has been defined.
Revised Text 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
116Potential Risk of Clinica l 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible Drug -Drug 
Interactions (DDIs )HIV Drug Resistance to unique mechanism
Recognize HIV patients have a higher chance of comorbidities/diseases and a 
risk of taking a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resistance
Strict adherence to protocol criteria around 
concurrent meds  
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541731] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
5 . C onfirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening. No current and no prior ART. 
(A previous course of 
pre- or post -exposure prophylaxis is allowed provided that it was completed at least 
[ADDRESS_541732] dose of study drug).
Section 5.2 Exclusion Criteria
Rationale for change
This exclusion criteria was removed and the guidance for use of concomitant medications 
was f urther addressed in Section 6.12, Concomitant Medications and Non -Drug 
Thera pi[INVESTIGATOR_014]. The Relevant Habits section of the Exclusionary  criteria was also remov ed and 
addressed in Section 6.10 , Lifesty le and/or Dietary Restrictions, with the exception of 
illicit drug use. Smoking and limited alcohol use are no longer exclusionary. Additi onal 
clarification added to note that positive Hepatitis C result would need to be confirmed b y 
RIBA. Abbreviation used on first instance has been defined.  Additional minor 
typographical errors were corrected.
Revised Text
CONCOMI TANT MEDICATIONS
5.Unable to refrain from the use of prescription or non -prescription drugs, including 
vitamins, herbal and dietary  supplements (including St John’s Wort) within 7 day s 
(or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is 
longer) prior to the first dose of study  medication, unless in the opi[INVESTIGATOR_428145] y. 
REL EVANT HABITS
6.History  of regular alcohol consumption within 6 months of the study  defined as: 
An average weekl y intake of >14 drinks for males or >7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL ) of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distil led spi[INVESTIGATOR_2120].
7.Smoking is an exclusion criteria for this study . Urinary  cotinine levels indicative of  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
118smoking at screening.
6.Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion 
criteria.
DIAGNOSTIC ASSESSMENTS AND OTHER CR ITERIA
7 . Presence of hepatitis B surface antigen (HBsAg), positive (confirmed by 
[CONTACT_428230]
-Blot Assay [RIBA] ) hepatitis C antibody  test result at screening 
or within [ADDRESS_541733] dose of study  treatment.
19 . Exclusion criteria for sc reening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual partici pant in 204953200911 will be Fridericia’s 
formula. 
Section 6.[ADDRESS_541734] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat, cobi) tablet
Method for 
individualizing dosage:Capsules supplied in high -density 
polyethylene bottles for 
individualized dosing by [CONTACT_428231] 6.9 Treatment after the End of the Study
Rationale for change
Additional language was included in this section to allow subjects to opt to receive 
reimbursement from [COMPANY_004] for up to 3 months for market edantiretroviral therapy  (as  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
119directed and prescri bedby [CONTACT_5936]) based on the CDC guideline recommend ations that 
patients be put on ARTs when diagnosed with HIV (test andtreat guideline s). 
Revised Text
Subjects will not receive any  additional treatment from [COMPANY_004].
Subjects receiving [COMPANY_004]2838232 may opt to receive marketed antiretrovirals after 
the completion of 10 days of [COMPANY_004]2838232 dosing and study follow- up visits (through 
Day 21) eligible for sponsor company reimbursement up to a maximum of [ADDRESS_541735]’s medical condition, whether or not [COMPANY_004] is providing specific
reimbursement for post-study  treatment.
Section 6.10.1 Meals and Dietary  Restrictions
Previous section number 6.12
Rationale for change
This section was updated to remove language around meal provisions (language 
consistent for an in-patient trial). As this is an out- patient trial, it will be up to trial site to 
arrange when/how meals are provided during a subject’s participation in the trial. The 
section ‘L ifestyle and/or Dietary  Restrictions’ had no content described under it. The 
sections ‘Meals and Dietary  Restrictions’ and ‘Alcohol, Caffeine and Exercise’ has been 
moved as sub- sections under the section ‘L ifestyle and/or Dietary  Restrictions’, as the 
sub-sections are related to this section.  
Revised Text
Second Bullet
Doses will be given in the fed state (light breakfast), following overnight fasting (>10 
hours). Lunch will provided 4 hours after the dose; water will be allowed ad libitum 
throughout.
Section 6.10.2 Alcohol, Caffeine and Exercise
Previous section number 6.13
Rationale for change
Adjustments were made to these lifesty le habits to eliminate restric tions on use of 
tobacco products, reduce restrictions on alcohol use and to allow occasional and light 
exercise during study  treatment.  2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
120Revised Text
Alcohol, Caffeine , Tobacco and Exercise
Subjects should refrain from alcohol for 48 hours before screenin g and then for 48 
hours prior to admission and baseline assessments (on Day  1). Alcohol is then not 
permitted for the duration of the treatment period (through Day  10) and until the final 
follow -up visit.  
Use of tobacco products is not allowed from scree ning until after the final follow -up 
visit
Subjects will During  the study  alcohol consumption should be limited to the 
following:
An average weekly intake of <14 drinks for males or <7 drinks for females.  
One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 
ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
Subjects willshould abstain from strenuous exercise for 72 hours prior to each blood 
collection for clinical laboratory  tests.  Subjects may  participate in light recreational 
activities during studies (e.g., watch television, read). the treatment period.
Section 6.[ADDRESS_541736] include one barrier method.  There Although 
use of oral contraceptives is permitted, tThere is no defini tive DDI information with 
[COMPANY_004]2838232 and an interaction with oral contraceptives is possible, so other (barrier, 
inter-uterine device etc.) methods of contraception will be required.
Section 6.12 Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_428177] 6.14
Rationale for change
Adjustments were made to the concomitant medication section to clarify  that certain 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘ Meals and Dietary  Restrictions’ (previous 
section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (Section 6.10), the section has been 
re-numbered. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
121Deleted Text
Subjects must refrain from all illicit drugs throughout the study  (from Screening until 
discharge from the study).  Drug screening will occur at Screening and Day -1 for 
each treatment period.  A positive result will lead to exclusion from the remainder of 
the study .
The Principal Investigator [INVESTIGATOR_428178] .  Over -the-counter medications will not be permitted during the treatment 
period except as nee ded to treat an AE. If medication is needed, use should be 
restricted to 4 hours after dosing if possible. 
Section 6.12 .1 Permitted Medications and Non -Drug Therapi[INVESTIGATOR_428146] 6.14.1
Rationale for change
Adjustments were made to the conco mitant medication section to clarify  that certain 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
section 6.12) and ‘Alcohol, Caf feine and Exercise’ (previous section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (Section 10), the section has been re -
numbered.
Revised Text
Addition of Second bullet
Concomitant medications (prescription and non- prescription) shoul d be 
administered only as medically necessary during the study. Subjects must 
notify their Investigator of any current or proposed concomitant medication, 
whether prescribed or over- the-counter, because of the potential for 
interactions between such treatments and the study medications.
Section 6.12 .2 Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_428179] 
(medicall y necessary) medications were allowed and that all medication use should be 
discussed with the investigator. As section on ‘Meals and Dietary  Restrictions’ (previous 
section 6.12) and ‘Alcohol, Caffeine and Exercise’ (previous section 6.13) has been 
moved under Lifest yle and/or Dietary  Restrictions’ (S ection 10), the section has been re -
numbered. 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
122Previous section number 6.14.2
Revised Text
Subjects must abstain from taking prescription or non- prescription drugs (including 
vitamins and dietary  or herbal supplements), within 7 day s (or 14 day s if the drug is 
a potential enzy me inducer) or 5 half -lives (whichever is longer) prior to the first 
dose of study medication until completion of the follow -up visit, unless in the 
opi[INVESTIGATOR_2511] I nvestigator and sponsor the medication will not interfere with the 
study. 
Subjects must refrain from all illicit drugs throughout the study (from 
Screening until discharge from the study).  Drug screening will occur at 
Screening and Day -[ADDRESS_541737] -dose 12- lead EC G on Day  5, 
which remains in line with the FDA’s guidance regarding day s on which to perform post -
dose (2 & 6 hours to capture near Tmax) EC Gs.Modifications were also made to the 
pharmacokinetics sampling, allowing for the 12 h PK collection timepoint on Day  1 and 
10 to be optional. Visit/procedure windows were included to allow more flexi bility  with 
scheduling of assessments. Also minor clarifications were made and t ypographical errors 
were corrected.
Revised Text 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
123Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/exclusi on X X
Demography including height, weight and 
BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therapy X
12-lead ECG3 X X X X X X X X X X
Holter (24 hr) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and hepatitis 
C antibody testingX
Serum or uri ne -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X XX14
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X
AE enquiry13 X X X X X X X X X X X X X
Telephone call to IVRS1314 X X X X X X X X X X X X X X X 
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
124Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Plasma for storage15 X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within 14-[ADDRESS_541738] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 and 6, perform all “Day 5” assessments on Day 7.
3. On Day 1, ECGs (x2)will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541739] -dose. To accommodate scheduling, 
serial ECGs collected on Days 4 and 8 may be performed 1 day.   On Day 10, ECGs (x2)will be performed pre -dose, and then 1, 1.5, 2, 3, [ADDRESS_541740] dose.  On 
Day 11, an ECG will be obtained prior to the 24 -hour PK sample. ECGs will be performed in triplicate at all timepoints.
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained on Day [ADDRESS_541741] -morning dose, and at day 12 and Follow -up (Day 21) .
5. Only SAEs related to study participation will be collected between screeni ng and Day 1. An AE enquiry will be made at each visit, subjects will be asked if they have 
experienced any neuropsychiatric adverse events, including psychosis or altered mental status .
6. On Days 1 -5 and 8 -10 samples for HIV -1 RNA PCR collected before morni ng dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart. HIV -1 RNA PCR samples will also be collected on days 12, 14 & Follow -up (Day 21).
7. Lymphocyte subsets by [CONTACT_4133] (total lymphocyte counts, percentage, and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determination of [COMPANY_004]2838232 will be collected on Day 1 and Day 10 at pre dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12 (optional), and 24 hours (to occur on morning of Day [ADDRESS_541742]- am dose and in the morning on Day 11) .  Pre -dose PK samples (within 15 minutes prior to dose) will b e 
taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be taken on Days 12 and 14.
10. Samples (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541743] experienced any neuropsychiatric adverse events , including psychosis or altered mental status
13. A screening/registration call should be made to the IVRS to register the subject at screening.   An additional call will be made to document a screen failure.   A randomization 
call should be made to the IVRS system approximately one week prior to scheduled Day 1.  Note: The rando mization call must be made in order to have study drug on site for 
Day 1. Additional calls will be made every day that the subject has a scheduled study visit to the clinic.  If a subject term inates the study prematurely a call should be made to 
the IVRS
14. Only if early termination visits occur during the treatment period.
15. Plasma samples for storage will be collected at each visit starting at Day 1, including unscheduled visits (e.g. for HIV -1 RNA levels and immunological 
parameters).  Additionally these samp les will be used when needed, such as when samples are lost or arrive at the laboratory unevaluable.
AE = Adverse event; CDC= Center for Disease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Hu man chorionic gonadotrophin; HIV = Human 
immunodeficiency virus;  IVRS= Interactive Voice Response System; PCR = Polymerase chain reaction; PK=Pharmacokinetic. 
 
 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
125Section 7.2 Visit Windows
Rationale for Addition
Visit/procedure windows were included to allow more flexibility  with sche duling of 
assessments. 
New Section
Screening (baseline to pre -dose): All screening assessments should take place within 
14-[ADDRESS_541744] dose. The screening visit window may be extended to 30 
days upon discussion with the Medical Monitor (i.e .; subject has scheduling conflicts 
or any screening assessment needs to be repeated).
Days 4 and 8: Based on subject and clinic schedule, Day 4 and Day 8 serial (up to 6h 
post-
dose) ECG assessments may be conducted 1 day.  
Weekend(s): The T&E table is set up for study start (Day 1) to occur on a Monday 
and Days 6 and 7 to fall on the weekend. If the weekend occurs instead on Days 5 
and 6, Day 5 assessments should be performed on Day 7. The study start (Day 1) 
may also be adjusted to allow visits with as sessments to be conducted over the 
weekend based on subject and clinic schedule.  
Assessments: The following applies to timing of procedures:
-Window for assessments [ADDRESS_541745] -dose = 5 minutes 
-Window for assessments >4 and < [ADDRESS_541746] -dose = 
15 minut es
-Window for assessments > [ADDRESS_541747] -dose =  30 minutes
End of Treatment visit: should be within [ADDRESS_541748] for assessment of adverse events.
Section 7.3.1 Holter Monitoring (Screening criteria)
After addition of new section before this section, the section numbers from this section 
until Sections under 7.[ADDRESS_541749] has met all other inclusion criteria. period using a Holter monitoring 
device supplied by [CONTACT_1034].
Analy sis of the Holter tapes will consider the following:
Heart rate (brad ycardia and tach ycardia) 2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
126Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractions, premature 
ventricular contractions, couplets, triplets, and ventricular tach ycardias
Atrio- ventricular conduction defects
Atrial fibrillation and flutter
Section [IP_ADDRESS] Time period and Frequency  for collecting A E and      
SAE information
Rationale for Change
Minor clarifications made regarding Sponsor (to include [COMPANY_003]). 
Revised Text
Bullet 4
All SAEs will be recorded and reported to [COMPANY_004] Sponsor within [ADDRESS_541750] dose based on this review (e.g., the 
exposure level of [COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838 232 exposure 
seen previousl y in healthy subjects), the Bay esian posterior probability  that the log10 
viral load decline from baseline is greater than a cut
-point will be calculated. If the 
Bayesian probability from Cohort 1 is less than 70% ,this will provide evidenceto
evidence to not move forward into Part B. Otherwise, the study  team will review the data 
in order to make a dose selection decision for the subsequent Part B Cohorts.  I f the 
pharmacokinetic exposures after the 100 mg [COMPANY_004]2838232/cobi dose lo ok similar to those 
obtained with 100 mg [COMPANY_004]2838232/r in prior studies, the doses for Part B will be 
extended to both lower (20 mg, 50 mg) and higher (200 mg) [COMPANY_004]2838232 doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be summarized 
by [CONTACT_428216] . The proportion of subjects with plasma HIV -1 RNA 
<400 and <50 copi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if the two populations are 
not the same.
Section 10.3 Quality  Control (Study Monitoring)
Rationale for Change
Minor clarifications made regarding Sponsor (to include [COMPANY_003]).  2018N360917_00
2015N227852_01 CONFIDENTIA L
[ADDRESS_541751] the site prior to the start of the study  to review with the 
site staff the protocol, study  requirements, and their responsibilities to satisfy  regulatory , 
ethical, and [COMPANY_004] requirements.
Section 10.5 Study and Site Closure
Ratio nale for Change
Minor clarifications made regarding Sponsor (to include [COMPANY_003]). 
Revised Text
First Bullet
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor or 
designee will conduct site closure activities with the investigator or site staff, as 
appropriate, in accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
Section [ADDRESS_541752].  Phase 2 study  of cobicistat versus ritonavir each with once -
daily  atazanavir and fixed -dose emtricitabine.tenofovir df in the initial treatment of HIV 
infec tion.  AIDS .  2011; 25:1881 -1886.
Gallant JE, Koenig E, Andrade -Villaneuva J, Chetchotisakd P, deJesus E, Antunes F, 
Arastéh K, et al. Moy le G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, 
Scwarcberg J, Rhee MS, Cheng AK.   Cobicistat versus ritonavir as a pharmacoenhancer 
of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment -naïve HIV 
type 1-infected patients:  week [ADDRESS_541753]. Dis.   2013; 208- :32-39.
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteele T, Hi llewaert V, et 
al.Petrovic R, Hoetelmans RMW.  Pharmacokinetics of darunavir in fixed -dose 
combination with cobicistat compared with coadministration of darunavir and ritonavir as 
single agents in health y volunteers.  J. Clin. Pharmacol.   2009; 54:949-957.
Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, 
et al. Safety  and 
efficacy  study  of bevirimat (BVM) in heavil y treatment experienced HIV+ patients 
identifies the target phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL , et al. Safety  and 
pharmacokinetics of bevirimat (PA -457), a novel inhibitor of human immunodeficiency   2018N360917_00
2015N227852_01 CONFIDENTIA L
200911
128virus maturation, in healthy  volunteers. Antimicrobial Agents and Chemotherapy. 
2007(b);Sep:[ADDRESS_541754] Development
QD Once daily
RIBA Recombinant Immuno- Blot Assay
t1/2t½ Terminal elimination half- life 2018N360917_00
2015N227852_00 CONFIDENTIA L
GlaxoSmithKline group of companies 200911
1TITLE PA GE
Division:   Worldwide Development
Information Type: 
Clinical Protocol
Title: A Phase 2a, Multicenter, Randomized, Adaptive ,Open -label ,  
Dose Ranging Stud y to Evaluate the 
Antiviral Effect, Safet y, 
Tolerability  and Pharmacokinetics of Cobicistat -boosted 
[COMPANY_004]2838232 Monotherapy  Over 10 D ays in HIV -1 Infected 
Treatment -Naive Adults
Compound Number: [COMPANY_004]2838232
Development Phase IIA
Effective Date: 09-NOV -2016
Author(s):
Clinical Pharmacology , ViiV Healthcare, RTP, NC, US
PCPS, [COMPANY_004], Collegeville, P A, US 
HIV DPU, RTP, NC, US
Clinical Statistics, PAREXEL , RTP, NC, US
Clinical Statistics, [COMPANY_004], Upper Providence, PA, US
Infectious Diseases, Clinical, Cambridge, MA, US
PCPS, [COMPANY_004], Upper Providence, PA, US
Virology , HIV DPU, RTP, NC, US
GCSP, Stockley  Park, [LOCATION_006]
PTS, Ware, [LOCATION_006]
CPMS, [COMPANY_004], RTP, NC, US
Copy right 2
016the GlaxoSmithKline group of companie s.  All rights reserved.  
Unauthoris edcopying or use of this information is prohibited. 2018N360917_00
[COMPANY_003]
 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_00 CONFIDENTIA L
200911
3MEDICA L MONITOR /SPONSOR INFORM ATION PA GE
Medic al Monitor /SAE Contact [CONTACT_7171]:
Role Name [CONTACT_428261] -hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor MD[LOCATION_011], MA
Secondary
Medical 
Monitor MDGlaxoSmithKline
[ADDRESS_541755]  
information 
MD[LOCATION_011], MA
Sponsor Legal Registered Address:
GlaxoSmithKline Research & Development Limited
[ADDRESS_541756]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_131980].    
Regulatory  Agency  Identify ing Number(s): 116,094 2018N360917_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N227852_00 CONFIDENTIA L
200911
4INVESTIGA TOR PROTOCOL A GREEMENT PA GE
I confirm agreement to conduct the study  in compliance with the protocol.
I acknowledge that I am responsible for overall study  conduct. I agree to 
personall y conduct or supervise the described study.
I agree to ensure that all associates, colleagues and employ ees assisting in the 
conduct of the stud y are informed about their obligations. Mechanisms are in 
place to ensure that site staff receive sthe appropriate information throughout the 
study .
Investigator Name:  ______________________________
Investigator Signature [CONTACT_1782] 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
5TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 200911 ........................................................ 8
2.INTRODUCTION .................................................................................................... 12
2.1. Study R ationale ................................................................
.......................... 12
2.2. Brief Background ........................................................................................ 12
2.2.1. Preclinical Summary .................................................................... 13
2.2.2. Clinical Summary of Safety and Pharmacokinetics ...................... 18
[IP_ADDRESS]. Clinical Summary of Safety ......................................... 18
[IP_ADDRESS]. Study 204953 (on -going); Pharmacokinetic 
Data ........................................................................... 19
[IP_ADDRESS]. Overall Summary/Conclusions of PK data .................. 22
3.OBJECTIVE(S) AND END POINT( S)...................................................................... 24
4.STUDY DESIGN .................................................................................................... 25
4.1. Overall Design ............................................................................................ 25
4.2. Type and Number of Subjects ..................................................................... 27
4.3. Design/Dose Justification ............................................................................ 27
4.3.1. [COMPANY_004]2838232 with Ritonavir ......................................................... 27
4.3.2. [COMPANY_004]2838232 with Cobicistat ....................................................... 28
4.3.3. Interim Analysis ........................................................................... 28
4.4. Benefit:Risk Assessment ............................................................................ 29
4.4.1. Risk Assessment ......................................................................... 30
4.4.2. Benefit Assessment ..................................................................... 32
4.4.3. Overall Benefit:Risk Conclusion ................................................... [ADDRESS_541757] AWAL CRITERIA ............. 32
5.1. Inclusion Criteria ......................................................................................... 33
5.2. Exclusion Criteria ........................................................................................ 35
5.3. Screening/Baseline/Run -in Failures ............................................................ 38
5.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 38
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 38
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_541758] and Other Study Treatment .................................... 40
6.2. Treatment Assignment ................................................................................ 41
6.3. Planned Dose Adjustments ......................................................................... 41
6.4. Blinding ....................................................................................................... 41
6.5. Packaging and Labeling .............................................................................. 41
6.6. Preparation/Handling/Storage/Accountability .............................................. 41
6.7. Compliance with Study Treatment Administration ....................................... 42
6.8. Treatment of Study Treatment Overdose .................................................... 42
6.9. Treatment after the End of the Study .......................................................... 43
6.10. Lifestyle and/or Dietary Restrictions ............................................................ 43 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
66.11. Contraception ............................................................................................. 43
6.12. Meals and Dietary Restrictions ................................................................... 44
6.13. Caffeine, Tobacco and Exercise ................................................................ .44
6.14. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 44
6.14.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 44
6.14.2. Prohibi ted Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 44
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 45
7.1. Time and Events Table ............................................................................... 46
7.2. Screening and Critical Baseline Assessments ............................................ 48
7.2.1. Holter Monitoring (Screening criteria) ........................................... 48
7.3. Efficacy ....................................................................................................... 48
7.3.1. HIV-1 RNA Sampling ................................................................... 48
7.3.2. Lymphocyte Subsets by [CONTACT_46110] ..................................... 49
7.4. Safety ......................................................................................................... 49
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 49
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 49
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 50
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 50
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 50
[IP_ADDRESS]. Disease -Related Events and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 50
[IP_ADDRESS]. Regulatory Reporting Requirements for SAE .............. 51
7.4.2. Pregnancy ................................................................................... 52
7.4.3. Physical Exa ms........................................................................... 52
7.4.4. Vital Signs .................................................................................... 52
7.4.5. Electrocardiogram (EGC) ............................................................. 52
7.4.6. Clinical Safety Laboratory Assessments ...................................... 52
7.5. Pharmacokinetics ....................................................................................... 54
7.5.1. Blood Sample Collection .............................................................. 54
7.5.2. Sample Analysis .......................................................................... 54
7.6. Biomarker(s)/Pharmacodynamic Markers ................................................... 54
7.6.1. Viral Genotypi[INVESTIGATOR_428180] ............................................... 54
7.7. Genetics ..................................................................................................... 55
7.8. Value Evidence and Outcomes ................................................................... 55
8.DATA MANAGEMENT ........................................................................................... 55
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .55
9.1. Hypotheses ................................................................................................ .55
9.2. Sample Size Considerations ....................................................................... 56
9.2.1. Sample Size Assumptions ........................................................... 56
9.2.2. Sample Size Sensitivity ................................................................ 57
9.2.3. Sample Size Re- estimation or Adjustment ................................... 57
9.3. Data Analysis Considerations ..................................................................... 57
9.3.1. Analysis Populations .................................................................... 57
9.3.2. Interim Analysis ........................................................................... 58
9.4. Key Elements of Analysis Plan ................................................................... 58
9.4.1. Primary Analyses ......................................................................... 58
[IP_ADDRESS]. Safety Analyses .......................................................... 59
[IP_ADDRESS]. Efficacy Analyses ....................................................... 59 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
[IP_ADDRESS]. Pharmacokinetic Analyses .......................................... 59
9.4.2. Secondary Analyses .................................................................... 60
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic Analyses ........... 60
[IP_ADDRESS]. Viral Genotypi[INVESTIGATOR_428181] .............. 60
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 60
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 60
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 60
10.3. Quality Control (Study Monitoring) .............................................................. 61
10.4. Quality Assurance ....................................................................................... 62
10.5. Study and Site Closure ............................................................................... 62
10.6. Records Retention ...................................................................................... 62
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 63
10.8. Review Committees .................................................................................... 63
11.REFERENCES ....................................................................................................... 64
12.APPENDICES ........................................................................................................ 66
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 66
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 69
12.3. Appendix 3: Liver Safety –Study Treatment Restart or Rechallenge 
Guidelines ................................................................................................... 72
12.4. Appendix 4: Genetic Research ................................................................... 73
12.5. Appendix 5: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 76
12.5.1. Definition of Adverse Events ........................................................ 76
12.5.2. Definition of Se rious Adverse Events ........................................... 77
12.5.3. Definition of Cardiovascular Events ............................................. 79
12.5.4. Recording of AEs and SAEs ........................................................ 79
12.5.5. Evaluating AEs and SAEs ............................................................ 80
12.5.6. Reporting of SAEs to [COMPANY_004] ........................................................... 81
12.6. Appendix 6: Collection of Pregnancy Information ........................................ 83
12.7. Appendix 7: Country Specific Requirements ............................................... 84
12.8. Appendix 8: Division Of AIDS Table For Grading The Severity Of 
Adult And Pediatric Adverse Events Version 1.0, December 2004; 
Clarification August 2009 ............................................................................ 85
12.9. Appendix 9: Toxicity Management ............................................................ 104 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
81. PROTOCOL SYNOPSIS FOR STUDY 200911
Rationale
[COMPANY_004]2838232 is a novel human immunodeficiency virus ( HIV-1) maturation inhibitor 
that is being developed for the treatment of HIV -1 in combination with other 
antiretrovirals.
Three clinical studies of [COMPANY_004]2838232 ( n=53 healthy  subjects) have been completed thus 
far. One study  (Study 204953) is on -going. H ealthy  subjects have received [COMPANY_004]2838232 
or placebo in single or repeated dose designs, to a maximum single dose of 250 mg or 
repeated dose (for 11days) of 200 mg QD, in combination with ritonavir (RTV) . 
Study  HMI116787 (completed November 2013) was the First Time in Human study  of 
[COMPANY_004]2838232 and assessed safet y and tolerability  of escalating doses (5 mg to 100 mg), 
food effect ,and the impact of stead y
-state riton aviron [COMPANY_004]2838232 pharmacokinetics
(PK) . Following successful completion of 3-month toxicology  studies in rat and dog in 
2014, clinical studies 200912 and 200207 were initiated .These were 
double -blind, 
placebo- controlled, single ( Study 200912) and repeat -dose ( Study 200207) escalation 
studies to investigate the safet y, tolerabilit y,and PK of [COMPANY_004]2838232 alone and when co -
administered with ritonavir 100mgonce daily (QD) for 8 -11 day s. Further assessment of 
an alternative formulation was also an objective in Study 200912.
Both studies were prematurely  terminated/ completed in March/April 2015 because of 
concerns over cardiovascular (CV) toxicity , in particular a clinical CV 
serious adverse 
event ( SAE )whereb ytheFood and Drug Administrating (FDA )imposed a clinical hold. 
Following submission of long-term (6 -month rat, 9 -month dog) chronic toxicology  data 
and follow up to the clinical SAE in November 2015, the hold was released in January  
2016 and 
Study 204953 was initiated.
Study  204953 is an on -going stud yand continues the single and repeat -dose exploration 
of safet y and PK of [COMPANY_004]2838232 as well as the suitability  of a new, capsule formulation. 
Doses of up to 250 mg [COMPANY_004]2838232/100 mg RTV (as single dose s) or 200mg
[COMPANY_004]2838232/100 mg RTV (QD for 11 day s) we re studied. As of 26 October 2016, the 
study  is ongoing with a cohort of subjects 
due to receive unboosted [COMPANY_004]2838232 
(200mg BID) for 11days.
These studies have shown [COMPANY_004]2838232 with or without RTV to be well tolerated and , 
together with daily  RTV dosing (“boosting”), demonstrate a PK profile suitable for 
progression to HIV patients in this Phase IIa proof of concept 10- day, monotherapy  study  
design. However, potential concerns over protease resistance necessitate a change to a 
pharmacoenhancer without an tiviral effects in this study  of[COMPANY_004]2838232 monotherapy . 
Therefore ,for Study 200911 ,cobicistat ( Tybost,150 mg QD ) will be substituted for RTV.  
The objective of Study 200911 is to understand the safet y, PK and HIV antiviral profile 
of [COMPANY_004]2838232/ cobicis
tat([COMPANY_004]2838232/ cobi) when given to HIV- infected , treatment 
naive ,otherwise health y adults. Approximately  10HIV-1 infected subjects will be 
enrolled into Part A. If warranted by [CONTACT_428252], virology ,and PK data anal ysis,  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
9approximately  8 subjects will be enrolled in each of between two and four Cohorts in Part 
B, which will be a parallel group design.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232 /cobi in HIV -1 infected 
patients during 10 days o f 
monotherapy.Change from baseline (Day 1) in plasma HIV -1 
RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered 
as monotherapy over 10 days. Safety and tolerability parameters, including 
adverse event, concurrent medication, clinic al 
laboratory, electrocardiogram (ECG) and vital 
signs assessments.
To characterize the pharmacokinetics 
of [COMPANY_004]2838232 in HIV -1 infected 
patients following [COMPANY_004]2838232/cobi 
dosing for 10 days. [COMPANY_004]2838232 PK parameters following dose 
administration, as follows:
Day 1 : area under the plasma concentration time 
curve AUC(0 -24), maximum observed 
concentration (Cmax), time to maximum 
observed concentration (tmax), concentration at 
[ADDRESS_541759] dose (C24), absorption lag time 
(tlag); 
Following last repeat admin istration on Day 10:  
AUC(0 -), pre -dose concentration (C0), 
concentration at end of dosing interval (C ), 
Cmax, tmax, t½, and apparent oral clearance 
(CL/F), if data permit
Secondary
 To explore the relationship between 
[COMPANY_004]2838232 exposure and change 
in plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 AUC(0- ), 
Cmax, C with Day 11 HIV -1 RNA change from 
baseline
 To assess the immunologic effect of 
[COMPANY_004]2838232/cobi when 
administered over 10 days in HIV -1 
infected adults Change from baseline in CD4+ cell co unt to Day 
11
 To explore the relationship between 
[COMPANY_004]2838232 exposure and safety or 
immunologic parameters, if 
appropriate. [COMPANY_004]2838232 PK parameters on Day 10: 
AUC(0 -), Cmax , Cwith Day 11 change from 
baseline in CD4 + cell count 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
10Objectives Endpoints
 To assess the develop ment of viral 
resistance (genotypic and 
phenotypic) over 10 days and 
correlate with viral response, if 
appropriate. Emergence of drug resistance mutations, if 
appropriate
 To estimate [COMPANY_004]2838232 
accumulation and to assess 
attainment of steady state follow ing 
administration of [COMPANY_004]2838232/cobi
for 10 days in HIV infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): Day 
10 AUC(0 -), Cmax, and C compared to Day 1 
AUC(0 -24), Cmax, and C24, respectively
 Steady State:
pre-morning dose concent rations (C0) on Days 2 
through 11
 To examine dose proportionality of 
[COMPANY_004]2838232 pharmacokinetic 
parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days
in HIV infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and Day 10 
AUC(0 -), Cmax, and C at differen t dose levels 
for the assessment of dose proportionality
Note: Other exploratory objectives and endpoints will be specified in the RAP
Design, Treatment A rms and Duration
Approximately  34 HIV -1 infected treatment -naive subjects will be enrolled overall. 
This study  is a 10- day monotherapy , open -label, adaptive ,dose ranging, repeat -dose 
study  and will be conducted as two parts with an interim ( go/no -go) analy sis performed 
after Part A (Table 1 ).Part A, Cohort 1 will evaluate a safe and well -tolerated dose level
of [COMPANY_004]2838232 that has been tested (with RTV) in prior Phase I studies andthattargets 
a high inhibitory  quotient ( IQ)value .Following the completion of an interim analy sis of 
those data andaccording to criteria defined later in the protocol, further cohorts of 8 
subjects will then be studied in Part B in a parallel design in two or more cohorts 
(depending upon the data obtained in Part A). 
The totality  of this data will provide a full dose -response of G SK2838232 over a wide 
dose range to explore the safet y and PK/ pharmacody namics ( PD)relationship of 
[COMPANY_004]2838232 in HIV -1 infected subjects and facilitate choice of doses for Phase IIb
studies . 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
11Table 1 Study  Design for 200 911
Part A: [COMPANY_004]2838232/cobi
Once Daily x10days1Part B: [COMPANY_004]2838232/cobi
Once Daily x 10 days1,2
Cohort
N232 Dose
(mg)Cohort
N232 Dose 
(mg)
1 10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluated at inte rim, prior to initiating other cohorts in Part B, which 
areplanned to run in a parallel, randomized fashion. All dose swill be given with [ADDRESS_541760] to modification based upon safety, PK and antiviral activity data from Cohort 1 ( Part A). More 
doses/cohorts (including potential removal of cobi co-dosing )may be added (t he maximum dose in Part Bwould 
not exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax ] was lower in HIV infected 
subjects than in healthy subjects at the same dose level).
The possibility  that an additional, unboosted [COMPANY_004]2838232 monotherap y cohort will be 
assessed in Part B is dep endent on anal ysis of the PK data from ongoing Study  204953 
where unboosted [COMPANY_004]2838232 at a dose of 200 mg twice dail y (BID) is being assessed. 
Subjects in both parts will have a screening visit within [ADDRESS_541761] dose. Maximum duration of study  parti cipation 
will be approximately  6weeks.
HIV Drug Resistance: 
Following cessation of [COMPANY_004]2838232/cobi dosing for 10 day s,
there will be prolonged exposure to waning plasma concentrations of [COMPANY_004]2838232, 
because of the long t ½(i.e.,in the “tail” of the PK profile). However, b ased on in vitro 
resistance passage data with [COMPANY_004]2838232 [and unlike with many  other ARV therapi[INVESTIGATOR_014] ],
there appears to be a limited likelihood of developi[INVESTIGATOR_428182] m utations in 
HIV-infected subjects due to its virologic profile [[COMPANY_004] Document Number 
2013N163221_00]. 
Analysis
The primary  objectives of this study  are to investigate the safet y, tolerability, PK and 
antiviral activity  of 10 day s repeated doses of [COMPANY_004]2838232/cobi in HIV -1 infected 
otherwise healthy  subjects. Descriptive summaries will be provided for safety , PK,and 
HIV viral load data. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
122. INTRODUCTION
[COMPANY_004]2838232 is a novel HIV -1maturation inhibitor (MI) that is being developed for the 
treatment of HIV -1 infection in combination with other antiretrovirals (ART) .
2.1. Stud y Rationale
This ‘proof of concept ( PoC)’ open -label study  is being conducted to characterize the 
acute antiviral activity , pharmacokinetics (PK) , the relationship between PK 
and antiviral 
activity , and safet y of [COMPANY_004]2838232 given with 150 mg QD cobicistat
([COMPANY_004]283232/ cobi),administered across a range of doses over [ADDRESS_541762] doses for further studies in Phase IIb.
2.2. Brief Background
Combination antiviral therap y with inhibitors of HIV protease, integrase, entry  and 
reverse transcriptase (RT) has demonstrated s ignificant improvement in AIDS -related 
morbidity  and mortality  over the last 10 -15 years. Emerging multi -class drug resistant 
viral strains and 
long-term toxicities warrant development of new classes of antiretroviral 
therapi[INVESTIGATOR_428183] t he HIV -1 viral life cy cle [Wainburg ,2010 ].The 
inhibition of maturation of HIV -[ADDRESS_541763] from 
viral protease RT or integrase [ Saxena , 2012; Qian , 2009]. HI V maturation is the final 
cleavage step of the capsidSp1 (transcription factor) polyprotein that generates the 
functional capsid p24 protein. This mechanism of action results in accumulation of the 
uncleaved p25 protein with subsequent improper assembly  of the HIV core, resulting in a 
non-infectious virion. Gel - based mechanism of action studies suggest that compound 
[COMPANY_004]2838232 acts as a maturation inhibitor. Western Blot anal ysis shows inhibition of 
capsid- Sp1 cleavage and accumulation of p25 in the presence of [COMPANY_004]2838232.
Prior validation of this target was demonstrated with the HIV maturation inhibitor known 
as bevirimat (BVM; [Martin, 2007a ; Martin, 2007b; Martin, 2008; NORVIR , 2013] ).
BVM reached Phase II studies in HIV patients
; however, onl y modest reductions in 
plasma HIV -1 ribonucleic acid (RNA )concentrations were observed in Phase IIa 
monotherap y studies [ Mahmood, 2006; Martin, 2007] and a pattern of pol ymorphic 
(differential) antiviral activity  [Wainburg , 2010] led to termination of BVM development. 
The average decrease from baseline to Day  14 plasma HIV -1 RNA was 0.54 and 0.70 
log10 copi[INVESTIGATOR_014]/mL for 200 mg and 300 mg twice daily  regimens ( Table 
2); all subjects 
achieved plasma BVM concentrations above the in vitro EC90. Responders, classified 
based on 5 pol ymorphisms in HI V-1 gag (at positions 369, 370, and 371), achieved an 
average 1.15 log10 copi[INVESTIGATOR_014]/mL  reduction in plasma HIV -1 RNA ,while an average 0.17 
log10 copi[INVESTIGATOR_014]/mL reduction was achieved for non- responders. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
13Table 2 Summary  of Bevirimat A ntiviral Response and PK in a 14 -day 
Monotherapy  Study  in HIV -infected A dults
BVM dosage 
regimenMean (SD) viral load 
change from 
baseline to Day 142IQ Plasma BVM 
1Cmin (g/mL)Plasma BVM 
1Cmax 
(g/mL)Plasma BVM 
1AUC(0 -) 
(g.h/mL)
200mg BID
(N=14)-0.54 (0.64) 1.70 46
(41, 51)58
(53, 64)632
(571, 699)
300mg BID
(N=18)-0.70 (0.77) 2.67 72
(65, 80)91
(84, 99)973
(890, 1064)
1. Cmin, Cmax, and AUC reported as geometric mean (95% CI) .
2. IQ=geometric mean Cmin/in vitro EC90; reported EC90=27 g/mL; all subjects achieved IQ 1.
        AUC(0 -) = Area under the concentration -time curve over the dosing interval; BVM = Bev irimat; CI = Confidence 
interval; Cmax = Maximum plasma concentration; Cmin = Minimum plasma concentration; EC90 = 50% protection 
against resistant mutant HIV infection; IQ = Inhibitory quotient; SD = Standard deviation.
Early clinical data for BMS955176, a second generation maturation inhibitor, have been 
recentl y presented [ Nowicka -Sans , 2015]. In a 10- day monotherapy  trial in HIV -infected 
patients, plasma HIV -[ADDRESS_541764] of 
inhibiting this viral target.
Although BMS955176 is currentl y in Phase II studies in HIV -infected patients, there are 
no maturation inhibitors approved for the treatment of HIV infection.  The uncertainties 
of earl y drug development and continuing need for novel ART , especially  for heavil y 
treated/experienced HIV -infected persons, support continued compound development. 
[COMPANY_004]2838232’s low nanomolar in vitro potency  against multiple HI V-1 gag 
polymorphisms and broader spectrum across multiple HIV -1 subt ypes indicates it has 
utility  in this setting.
2.2.1. Preclinical Summary
Nonclinical pharmacology
Virology
[COMPANY_004]2838232, in vitro, is an inhibitor of HIV maturation by  [CONTACT_428197] p25 to p24. [COMPANY_004]2838232 is a potent antivir al agent with a 
mean 50% maximal inhibitory  concentration ( 50% maximal inhibitory  concentration 
[IC50]) value of 1.6 nM (range: 0.8 to 4.3 nM) when tested in a panel of 26 HIV - 1 
isolates with various polymorphic gag genot ypes in peripheral blood mononuclea r cells 
(PBMCs), suggesting that [COMPANY_004]2838232 can inhibit a broad spectrum of HIV isolates . In 
another PBMC assay , [COMPANY_004]2838232 showed potent antiviral activity  in 59 of 60 isolates 
with IC50 values ranging from 0.22 to 5.1 nM. [COMPANY_004]2838232 also inhibited HIV-1 strains 
containing the consensus Sp1 QVT region or the V370A poly morphism in MT4 cells
(IC50 = 0.73 to 0.81 nM).  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
14In anMT2 cell -based assay  utilizing recombinant viruses harboring gag and protease 
from subjects before and after a protease inhibitor (PI)based regimen, [COMPANY_004]2838232 
inhibited 12 of 15 viruses with a mean IC50 value of 1.7 nM (range = 0.4 to 3 nM). The 
remaining 3 viruses were not inhibited by  [CONTACT_23983]2838232 up to the top concentrations 
tested at 400 nM. There was no correlation of PI[INVESTIGATOR_428083]2838232. [COMPANY_004]2838232 resistance mutations were selected for b y serial passage of 
virus in a SupT1 cell
-based assay  with increasing concentrations of [COMPANY_004]2838232. I n the 
lab strain NL4- 3 and gag/protease recombinant viruses, the resist ance mutation A364V 
arose and resistance confirmed by  [CONTACT_3725]-directed mutagenesis. This resistance mutation 
maintains susceptibility  to other classes of anti -retrovirals including PIs and non-
nucleoside RTinhibitors.
[COMPANY_004]2838232 was tested in vitro in combination with two marketed PIs, atazanavir and 
darunavir. Using a dose -wise additivity  model, [COMPANY_004]2838232A showed additive anti -viral 
activity  with both PIs.
Secondary  Pharmacology
In a secondary  pharmacology  study , [COMPANY_004]2838232 was tested against a panel of 
receptors, ion channels and transporters and demonstrated no significant effect (IC50 of 
1M). It is important to note that the selectivity for antiviral activity  of [COMPANY_004]2828232 
compared to all tested off-target activit ies wa s >100 -fold, and the potential for organ 
toxicity  was characterized in the nonclinical toxicology  studies (see below).
In safet y pharmacology studies in male rats, there were no hemod ynamic changes or 
neurobehavioral effects following single oral doses up to 300 mg/kg. A single oral dose 
of [COMPANY_004]2838232 at 30 mg/kg or 300 mg/kg produced reversible increases in respi[INVESTIGATOR_428084] (32
%and 36%, respectively ) and derived minute volume (17% and 26%, 
respectivel y) at 6hours after dosing. These doses did not produce any  effect on 
respi[INVESTIGATOR_13521] y rate, airway  resistance or bod y temperature. There were no respi[INVESTIGATOR_428085] 5 mg/kg (mean maximum plasma concentration [C max] 0.12 g/mL ; AUC 0-24
1.0g.h/mL  based on Day  1 of the 4-week repeat dose study ). These findings were not 
considered to suggest a safet y concern in humans.
[COMPANY_004]2838232 at the maximum feasible concentration, limited by  [CONTACT_16758] , of 4.09 M 
(3.31 g/mL) caused no inhibition of human ether -a-gogo related gene ( hERG )tail 
current in Human Embryonic Kidney 293 cells sta bly transfected with hERG cDNA, 
indicating a low probability  for interaction at the hERG channel.
In conscious telemetered male dogs (n=4), a single oral dose of [COMPANY_004]2838232 at 
60mg/kg (C max0.59g/mL; AUC 0-248.7g.h/mL based on Day 1 exposure data from
the 4- week oral repeat dose toxicity  study ) was associated with one epi[INVESTIGATOR_428086]-sustained ventricular tachy cardia in one dog lasting ~1.2 seconds. There were no 
effects on arterial pressures, heart rate ,or electrocardiogram (ECG )interval durations. A n 
investigative safet y pharmacology cardiovascular study  was conducted in telemetered 
dogs given 60mg/kg/day for 4 weeks with serial monitoring by  [CONTACT_51541] , 
cardiac biomarkers, qualitative and quantitative electrocardiology , microscopy ,and 
transm ission electron microscop y (TEM) of the heart.  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
15There were no changes in echocardiograph y endpoints, ECG intervals, ECG waveforms, 
arterial pressures, heart rates, serum cTpn I, N-terminal prohormone of brain natriuretic 
peptide ( NTproBNP ), or in heart tiss ue as assessed by  [CONTACT_428198]. With routine microscopy , 
one treated dog had a single focus of degeneration/necrosis of the tunica media 
(moderate) in a nextramural artery  and another treated dog had localised, mixed -cell 
inflammation (mild) along the epi[INVESTIGATOR_428087]. Both changes have 
been reported in normal beagles and were considered of uncertain relationship to 
treatment in the absence of changes in an y other structural or functional cardiovascular 
endpoints. The 28 -day exposures were similar t o the previous 4 -week toxicity  study  in 
dogs: the C maxrange at 60 mg/kg/day  in this investigative safet y pharmacology stud y was 
0.542 to 2.00 g/mL and range of AUC 0-24was 6.04 to 35.7 g.h/mL. In subsequent 
repeat -dose studies in dogs treated for up to 9 month s with up to 70 mg/kg/day , no 
changes were evident in cardiac biomarkers (including cTpn I and NTproBNP) ,functional 
(including ECG waveform) or structural (including microscopic evaluation) 
cardiovascular endpoints at slightly higher exposures than those achieved than in 
previous studies. The end of the 9-month study , gender averaged C maxat 70 mg/kg/day  
was 1.95g/mL and 
AUC 0-24was 38.8g.h/mL. These studies support an absence of 
[COMPANY_004]2838232 -related functional or structural effects on the heart in preclinical testing.
The No Observed Adverse Effect Level (NOAEL ) was established at 20 mg/kg/day  (on 
the basis of mild hepatic findings) with an associated are under the curve at 24 hours 
(AUC24 )of 16.2 g.hr/mL  and Cmax 0.847 g/mL.
Pharmacokinetics and product metabolism in animals
The PK 
of [COMPANY_004]2838232 were investigated in the mouse, rat, and dog. The oral 
bioavailability  of [COMPANY_004]2838232 was low to moderate (~6% to 40%) depending on the 
species and formulation. Plasma and blood clearance were low and the volume of 
distribution at steady state was high relative to total body  water. The half -life of 
[COMPANY_004]2838232 was short in the mouse and rat, but moderate in the dog. S ystemic exposure 
of [COMPANY_004]2838232 generally increased in a less than dose- proportional manner.   In rats, 
there were no differences in sy stemic exposure between single and repeat -dose 
administration, or between males and females.  In a 7 -day study  in dogs, systemic 
exposures were generally similar between males and females and after single and repea t 
dosing ; however, in a 4- week stud y, systemic exposures were higher in females than in 
males in the high-dose group (60 mg/kg/day ) and higher after repeat dosing than after a 
single dose. The distribution of radioactivit y in male pi[INVESTIGATOR_428088] a single 
oral administration of [14C] [COMPANY_004]2838232 at a target dose level of 20mg/kg showed 
radioactivity  was rapi[INVESTIGATOR_428089] y distributed throughout the body with all 
tissues, except the brain and spi[INVESTIGATOR_1831]. There were no tissues that retained detectable 
levels of radioactivity  at 28days post dose. In a bile duct canulated rat study ,30% of the 
administered dose was excreted in the bile as an acylglucuronide. In the same study , 
unchanged drug and metabolites were eliminated primarily  in the bi le and feces, while a 
mean of <1% of the dose was eliminated in urine.
In vitro, [COMPANY_004]2838232 is highl y protein bound (>99.9%) and has low passive 
permeability . Invivo e vidence suggests active uptake of [COMPANY_004]2838232 by  [CONTACT_428199].  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
16After si ngle oral doses of 5, 100, or 300 mg/kg, the average liver to plasma ratio was 51, 
17,and 10, respectivel y. After 7 days of dosing at 30, 100 ,or 300 mg/kg/day , liver to 
blood ratios ranged from 10 to 16.
In the 13 -
week repeat dose studies in dogs given 35 mg/kg BID (70 mg/kg/day ), heart 
tissue collected at necropsy  had [COMPANY_004]2838232 concentrations 2.[ADDRESS_541765] -dose plasma concentrations, similar to the previous 4 -week CV 
investigative findings.  In the 13- week repeat dose studi es in rats given 300 mg/kg/day , 
heart tissue collected at necrops y had[COMPANY_004]2838232 concentrations approximately  3times 
higher than the [ADDRESS_541766] -dose plasma concentrations, similar to the previous 7- day 
findings.  Overall [COMPANY_004]2838232 did not appear to be highl y concentrated in heart tissue 
after repeat dosing and suggests that accumulation upon chronic dosing is unlikely .
Routes of metabolism identified in liver microsomal incubations and rat, dog ,and human 
hepatocy tes were N
-dealky lation, oxidation, oxi dative deamination, and glucuronidation, 
alone or in combination , with no human- specific metabolites detected.  N -dealk ylated 
products and glucuronidation were observed in rat plasma and the bile. In general, in 
vitro metabolite profiles of the nonclinical species and human were qualitatively  similar, 
such that all metabolites of [14C] [COMPANY_004]2838232 observed in human hepatocyte 
incubations were observed in rat and/or dog. Minor to trace levels of potential aldeh ydes 
metabolites formed as a result of N- dealk ylation and oxidative deamination were 
observed in rat, dog and humans.  
[COMPANY_004]2838232 did not show evidence for glutathione adduct formation in rat or human 
liver microsomes.  Data from pooled human liver microsomes along with recombinant 
cytochrome P450 ( CYP )enzy mes suggest that in vitro the oxidative metabolism of 
[COMPANY_004]2838232 was primarily  mediated b y CYP3A4.  Preliminary  in vitro investigations 
showed [COMPANY_004]2838232 did not inhibit CYP1A2, 2C9, 2C19, 2D6, 3A4 and was not a 
metabolism -dependent inhibitor of CYP3A 4. No drug interaction risk was identified for 
co-administrated substrates of UGT1A1, 1A3, 1A6, 1A9, 2B7, and 2B15, OAT1, OAT3, 
OATP1B1, OATP1B3 or OCT2 at a clinical dose of 200 mg [COMPANY_004]2838232/ritonavir 
(predicted Cmax 0.32 µM). Extrapolation of the clinic al risk (using FDA and EMA 
regulatory  guidance) did indicate a risk for [COMPANY_004]2838232 -mediated inhibition of 
UGT1A4 and of gut contributions of CYP3A4, P-gp, and BCRP at the same clinical 
exposure; however, the potential for clinicall y significant interaction s via these 
mechanisms is predicted to be low (<2 fold change in AUC). [COMPANY_004]2838232 did show 
weak induction of CYP3A4 enzy me activity . However, based on the maximum predicted 
plasma concentrations and high protein binding, the potential for clinicall y signif icant 
drug interactions through CYP3A4 induction by  [CONTACT_23983]2838232 appears to be low.
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure) ; however, t here have been no 
preclinical studies conducted with [COMPANY_004]2838232 and cobicistat to date.  
Toxicology
[COMPANY_004]2838232 administered by  [CONTACT_428200] 6month s duration
resulted in no adverse treatment- related effects in rats given up to 300 mg/kg/day  QD.  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
17In dogs given up to 70 mg/kg/day  (35 mg/kg/day  BID) ,adverse liver effects were noted 
at this dose in the 9 -month repeat dose study .  Though isolated, low grade changes in 
heart rate and cardiac troponin I  (cTnI )had been noted in 4
-week toxicity  studies in rats 
and dogs ; however, there were no treatment- related structural or functional 
cardiovascular changes in studies of 3 months and greater duration as assessed by  
[CONTACT_186658], ECG, microscop y, and cardiac biomarkers , indicating an absence of 
[COMPANY_004]2838232- related functional or structural effects on the heart in preclinical testing . 
Only non- adverse treatment -related changes were noted in the definitive 6-month rat 
study ,whichincluded occasional salivation in animals given 300mg/kg/day  and minimal 
clinical pathology  changes without histologic correlates (transient clinical chemistry  
changes at 5mg/kg/day and reversible urine chemistry  changes at 300 mg/kg/day ).The 
NOAEL i n this study  was considered to be 300 mg/kg/day  (mean AUC[0-t ] 
21.3g.h/mL , mean Cmax 1.77 g/mL [Week 26 values for males and females 
combined ]).  
As noted above, dogs given [COMPANY_004]2838232 at 70 mg/kg/day  for 9 months had minimal to 
moderate pi[INVESTIGATOR_371] (c onsistent with bile) with minimal to mild mixed cell infiltration 
in the liver and isolated mild increases in alanine aminotransferase (ALT) activity .  These 
findings were considered adverse, but were reversible after the 6
-week off -dose period.  
The NOAEL for this dog study  was considered to be the mid -dose level of 20 mg/kg/day  
(mean AUC [0-t] 16.2g.h/mL , mean Cmax 0.847 g/mL [Week 39 values for males and 
females combined] ).
Data from genotoxicity  assessments suggest that [COMPANY_004]2838232 does not present a 
genotoxic hazard to humans.
During discussions with the FDA regarding the resolution of the clinical hold, the 
Agency  recommended that the sporadic cardiovascular changes observed in the earl y (1-
month) rat GL P study  at the highest dose level (300 mg/kg/day ) should be considered 
when defining the NOAEL  and establishing a safe dose of Gl axoSmithKline ( [COMPANY_004] )for 
the initiation of this study  protocol.  Accordingl y, for the initial PK studies, the reference
dose level of 30 mg/kg/day  in the 1- month rat study  was initially  used to define the 
NOAEL and therefore the values for fold cover at maximum projected mean exposure 
and Cmax in human subjects were lower, at >2.[ADDRESS_541767] sensitive species (i.e., 20 mg/kg/day  in the 9- month dog study  
based on liver endpoints) is currentl y used for assessing fold
-cover for projected clinical 
dosing in this study .
The inclusion of cobicistat as a CYP3A4 inhibitor pharmacoenhancer in this Phase IIa 
study  in place of ritonavir is unlikely  to produce a significantl y different profile of 
[COMPANY_004]2838232 ADME (and therefore s ystemic exposure and toxicity ); however, t here 
have been no preclinical studies conducted with [COMPANY_004]28 [ZIP_CODE] and cobicistat to date.  
Full details of non -clinical and clinical data may  be found in the current Investigator’s 
Brochure (IB) [[COMPANY_004] Document Number 2012N151889_03]. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
182.2.2. Clinical Summary of Safety  and Pharma cokinetics
To date, [COMPANY_004]2838232 has been evaluated in three completed clinical studies with or 
without RTV ([COMPANY_004]2838232/r). A fourth study  (204953) is on -going as of 1stNovember 
2016. F ull details of the clinical results can be found in the I nvestigator ’s Brochure .
[IP_ADDRESS]. Clinical Summary  of Safety
Fifty -
three subjects have been exposed to [COMPANY_004]2838232 in 3 completed studies. One 
study  (204953) is ongoing ([ADDRESS_541768] been exposed to [COMPANY_004]2838232/r or placebo 
so far) .  Overall, drug-related adverse events have bee n few and mild, and included 
headache, dizziness, fatigue, nausea, and palpi[INVESTIGATOR_428090] .  Similarly , treatment-
emergent laboratory  abnormalities have also been few and mostl y grade 1.  There have 
been no discernible patterns, thus far, in terms of AEs or laboratory  abnormalities.
One subject in study  200912 discontinued treatment with RTV due to an AE.  A 47- year-
old female who developed right upper quadrant abdominal pain, nausea and flatulence 
associated with grade 4 elevations in AL T and aspartat e aminotransferase, and grade 2 
elevations in total bilirubin (BIL). She was diagnosed with a common bile duct 
obstruction due to gallstones that spontaneously  resolved. The Investigator assessed this 
AE as unrelated to study treatment.
Due to sporadic CV -related safet y signals in the early animal studies (see Section 2.2.2), 
intense CV monitoring was in place for all four studies.  
One AE occurred in HMI116787 that was initially  considered a CV AE but after fu rther 
evaluation was considered not to be of cardiac etiology .  Two CV AEs occurred in 
[ADDRESS_541769] been a small number of CV -related events of an y 
sort: There have been no serious adverse drug reactions, and no clinically  significant 
drug-related abnormal findings for 12 -lead ECGs, vital signs, safet y laboratory  results 
(including cardiac troponin I ), or telemetry .  The following cardiovascular AEs were 
observed during the course of the stud y but were not considered to be caused by 
[CONTACT_23983]2838232 exposure:
In Part 1A (Cohort 1), Period 2, a subject was withdrawn due to an AE (low 
hemoglobin) prior to [COMPANY_004]2838232 exposure Day 
-2.  A replacement subject 
was brought in, but was not dosed with [COMPANY_004]2838232 or placebo because during 
the 2- day RTV run -in, on Day  -1, the replacement subject met the stoppi[INVESTIGATOR_428091], NSVT prior to 
the first dose of [COMPANY_004]2838232 or placebo.  Because the subject was excluded 
from the study  prior to the first dose of inve stigational drug, the NSVT was not 
considered to be a serious and unexpected adverse drug reaction that would 
qualify  for IND safety  reporting.   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
19In Part 1A (Cohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs . 200 mg [COMPANY_004]2838232/r), one subject was 
discontinued prior to the first dose of study  drug due to a series of 
cardiovascular findings (pre -ventricular contractions on telemetry ).  None of the 
findings were abnormal or atypi[INVESTIGATOR_2855], but the investigator determined that this 
would not be a good etiology  to have in a subject about to receive 
investigational drug.  Because the event occurred prior to first dose of 
investigational drug, the finding was not considered to be due to [COMPANY_004]2838232 
exposure.  
In Part 1A (C ohort 1), Period 3 (Period “3A” for the purpose of differentiating 
between 100 mg [COMPANY_004]2838232/r vs. 200 mg [COMPANY_004]2838232/r), one subject who 
had alread y been dosed on 2 previous occasions (with either [COMPANY_004]2838232 or 
placebo) was dosed for 2 day s with RTV, and t hen on 05 May  2016 was dosed 
with either [COMPANY_004]2838232/r or placebo/r as scheduled. On the following day (06 
May 2016), the subject experienced an as ymptomatic, [ADDRESS_541770] had received placebo prior to experiencing the 
NSVT, the event was not considered to be due to [COMPANY_004]28 [ZIP_CODE] exposure or a 
serious and unexpected suspected adverse reaction that would qualify  for IND 
safet y reporting.
In Part 2 (Cohort 6, 200mg/r), a 40 y ear old male enrolled in the study  with no 
significant medical history experienced an as ymptomatic ventr icular triplet 
(NSVT) while asleep at 5:33am on Day  8 (of 11 day s worth of dosing) 
approximately  21hours after receiving 200 mg [COMPANY_004]2838232/r on the previous 
day at 8.25am. This event was noted by  [CONTACT_428253] h ave no associated clinical sy mptoms or complaints. The 
[COMPANY_004] medical monitor was notified.   
Because the subject was not s ymptomatic 
and this did not meet protocol -defined stoppi[INVESTIGATOR_3418], the study  was not 
unblinded at the time, and the subjec t was allow ed to continue dosing .Dosing 
in the study  is now complete and no further events have been noted. It was the 
assessment of the site PI [INVESTIGATOR_428092] /monitoring team that a ventricular 
triplet can be seen in he althy  volunteers on continuous H olter mo nitoring.
Therefore neither the PI [INVESTIGATOR_428093] a serious and 
unexpected suspected adverse reaction .
[IP_ADDRESS]. Study  204953 (on-going); Pharmacokinetic Data
Study  [ADDRESS_541771] of a normal fat meal on the bioavailability  of a single 
dose of [COMPANY_004]2838232 in the capsule formulation with RTV.  I t will evaluate 
[COMPANY_004]2838232 exposure after repeated doses of unboosted [COMPANY_004]2838232 in the capsule 
formulation. Noncompartmental PK anal ysis was performed using scheduled sample 
times.  This study  is ongoing; preliminary  results are presented.
Pharmacokinetic anal ysis was performed on [COMPANY_004]2838232 plasma concentration -time 
data using nomina l time following single doses of 50, 100, and 250 mg in combination 
with RTV in Part 1A of Study  204953 ( Table 3 ).  On average, [COMPANY_004]2838232 Cmax 
values were reached [ADDRESS_541772] dose proportionalit y was observed 
for Cmax and AUC(0- ) values with ascending single doses of [COMPANY_004]2838232 (50, 100, 
and 250 mg with 100 mg RTV).
Table 3 Summar y of Preliminary  Pharmacokinetic Parameter Values after 
Single Doses of [COMPANY_004]2838232 in Combination with 100 mg Ritonavir 
(Study  204953, Part 1A )
Dose (mg) n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)
50 8 22.7
(17%)
(17.2- 28.5)0.188
(138%)
(0-0.5)3.63
(41%)
(2.5-6.0)17.2
(43%)
(8.7-27.9)458.6
(33%)
(210.6- 662.0)
100 6 18.0
(14%)
(15.8- 22.3)0.167
(155%)
(0-0.5)6.00
(59%)
(2.5-12.0)25.2
(20%)
(17.5- 31.5)890.5
(20%)
(619.1- 1053)
250 5 17.3
(6.4%)
(15.5- 18.6)0
(-)
(0-0)5.50
(71%)
(2.0-12.0)60.7
(23%)
(40.8- 73.1)1731
(29%)
(1222- 2505)
Data are presented as mean (CV) (minimum -maximum).
Study  204953 Part 1B was an open label, 2x2+[ADDRESS_541773] on the capsule formulation in Period 3.  
The relative bioavailability  of the micronized powder blend in 50 mg hand- filled capsules 
compared to the micronized API  [INVESTIGATOR_428184] 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
in a randomized crossover design in [ADDRESS_541774] two periods of Pa rt 1B of 
Study  204953. P reliminary  geometric mean AUC(0 -) and Cmax values were 
approximately  45% and 60% higher , respectivel y,after administration in the capsule 
formulation compared to oral suspension from PiB ( Table 
4). 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
21Table 4 Preliminary  Assessment of Relative Bioavailability  of Capsule 
Formulation vs. Po wder -in-Bottle Formulation of [COMPANY_004]2838232 (Study 
204953, Part 1B)
Parameter Test Reference n Ratio of Geometric 
Least Square Means90% CIof Ratio
AUC(0 -) Capsule PiB 12 1.43 (1.194 ,1.70 2)
Cmax Capsule PiB 12 1.58 (1.312,1.900)
PiB = powder -in-bottle.
The potential food effect with the capsule formulation was assessed as 100 mg 
[COMPANY_004]2838232 single doses with 100 mg RTV after two pre- doses (48 h) in the fasted state 
and with a normal fat meal in a non-randomized crossover design (fasted in either Period 
1 or 2, fed in Period 3).  Eleven subjects provided data for both dietary  conditions.   
Preliminary  geometric mean AUC(0 -) and Cmax v alues were a pproximately  60%
higher after administration in the capsule formulation with a normal fat meal compared to 
the fasted state (Table 
5).
Table 5 Preliminary  Assessment of the Effec t of a Normal Fat Meal on 
[COMPANY_004]2838232 Exposure when Administered as a Capsule 
Formulation with Ritonavir (Study  204953, Part 1B)
Parameter n Capsule –food
Geometric meanCapsule –
fasted
Geometric 
meanRatio of geometric 
means 
(food/fasted)
AUC(0 -) (ng.h /mL) 11 2414 1539 1.57
Cmax (ng/mL) 11 76.9 47.2 1.63
Repeat dose PK parameter values in Study  204953 Part 2 were determined on Day  1 and 
Day 11 using nominal time in Part 2 of Study  204953 ( Table 6). After the Day  11dose of 
[COMPANY_004]2838232 with RTV, exposure (Cmax, AUC[0 -]) appeared to increase 
proportionally  with the increase in dose level with the PiB and capsule formulations.  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
22Table 6 Summary  of Preliminary  Pharmacokinetic Parameter Values on 
Day 1 and Day  11 during Repeated Dosing of [COMPANY_004]2838232 in 
Combination with 100 mg Ritonavir (Study  204953, Part 2)
Dose 
(mg)n t½ 
(h)tlag 
(h)tmax 
(h)Cmax 
(ng/mL)AUC(0 -) 
(ng.h/mL)C
(ng/mL)
Study Day 1
20
(PiB)6 - 0.417
(49%)
(0-0.5)3.67
(11%)
(3.0-4.0)12.2
(47%)
(5.8-20.8)189.4
(40%)
(83.7- 284.4)6.1
(39%)
(2.5-8.9)
50
(PiB)6 - 0.167
(155%)
(0-0.5)3.00
(51%)
(2.0-6.0)18.7
(40%)
(9.0-25.9)288.7
(39%)
(138.6- 380.2)9.5
(35%)
(5.1-12.6)
100
(capsules)6 - 0.167
(155%)
(0-0.5)2.25
(23%)
(1.5-3.0)48.4
(32%)
(28.1- 69.6)664.1
(31%)
(422.5- 932.7)21.6
(33%)
(12.8- 29.3)
200
(capsules)6 - 0.083
(245%)
(0-0.5)2.50
(25%)
(2.0-3.5)79.4
(38%)
(50.8- 125)1124
(39%)
(636.7- 1794)38.9
(36%)
(21.7- 58.6)
Study Day 11
20
(PiB)6 19.2
(16%)
(15.1-
24.2)- 5.00
(32%)
(2.5-6.0)27.4
(38%)
(11.3- 40.4)474.3
(31%)
(214.3- 613.2)15.3
(30%)
(7.1-19.2)
50
(PiB)6 27.3
(52%)
(15.2-
50.4)- 3.50
(46%)
(1.5-6.0)58.0
(24%)
(40.9- 78.0)1113
(23%)
(762.6- 1459)38.8
(29%)
(24.5- 51.7)
100
(capsules)6 17.9
(18%)
(15.2-
23.7)- 4.00
(40%)
(2.5-6.0)133
(23%)
(94.7- 164)2492
(27%)
(1624- 3301)81.7
(30%)
(45.9- 113)
200
(capsules)6 -1 - 3.33
(45%)
(1.5-6.0)240
(38%)
(127-368)4389
(45%)
(2095- 7161)151
(46%)
(67.8- 250)
Data are presented as mean (CV) (minimum -maximum).
1. Concentration data were available up to 24 h after the Day 11 dose, and t½ values were not 
calculated.
[IP_ADDRESS]. Overall Summary /Conclusions of PK data
The original formulation used in the first three studies with [COMPANY_004]2838232 (HMI 116787, 
200207, and 200912) was SDD.  Data from Stud y 200912 demonstrated that a change to 
the API  [INVESTIGATOR_428095]2838232 was feasible for future clinical studies. Study  
204953 utilized micronized API [INVESTIGATOR_428096] a bottle as well as in a capsule. The capsule 
was shown to be a v iable solid dosage form for subsequent studies.  A more detailed 
summary  of the data fro m Study  204953 is in S ection [IP_ADDRESS]. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
23[COMPANY_004]2838232 SDD did not overall demonstrate significant escalation in exposure 
from an increase in dose from 100 mg to 200 mg in a cross -study  comparison.  The 
API [INVESTIGATOR_428097] a proportional increase in AUC and Cmax for a 2 -fold 
dose escalation from 100 mg to 200 mg.
The observed tmax of the API  [INVESTIGATOR_428098] (the API [INVESTIGATOR_428099]).
The bioavailability  of the [COMPANY_004]2838232 API  [INVESTIGATOR_428100] 30 -50% of 
the bioavailability  of SDD formulation, but there was a large observed range of 
relative intra -subject exposures (11- 150%).
Both 10 mg SDD and 20 mg API [INVESTIGATOR_428101] a 10 -fold or greater increase in AUC with 
steady -state RTV (100 mg QD for 10 day s) with a smaller ( ≤4-fold) increase in 
observed Cmax.  The t½ of [COMPANY_004]2838232 increased from 15-18 hours to 34-42 
hours in the presence of stead y-state RTV, regardless of formulation.
After single doses of 50 to 250 mg [COMPANY_004]2838232 with RTV, increases in Cmax and 
AUC(0 -) values were broadly  proportional to the increase in dose.  On Day  11 
after repeated dail y 20 to 200 mg doses of [COMPANY_004]2838232 with RTV, increases in 
Cmax and AUC(0 -) values appeared to be proportional to the increase in dose with 
the PiB and capsule formulations.  
The relative bioavailability  of the micronized API  [INVESTIGATOR_428102]  45% -60% higher than the bioavailability of the micronized 
API [INVESTIGATOR_428103].
Co-administration of the micronized API  [INVESTIGATOR_428104] a 
normal fat meal resulted in an approximately  60% increase in geometric mean 
Cmax and AUC(0 -) values compared to the fasted state with RTV (Study  
204953).
Variability  remains fairly constant across formulations and boosted versus 
unboosted at around 30% -40% (moderate -high).
Projections of potential futu re efficacious boosted [COMPANY_004]2838232 API  [INVESTIGATOR_428105] [ADDRESS_541775] 3 -fold above the derived 90% maximal 
inhibitory  concentration (IC90) target value (5
ng/mL). Even if protein binding has 
more impact than envisaged and causes a 5 -fold increase in IC90 as seen in some 
preclinical virology  studies, the predicted troughs will still be significantly  higher 
than the 5 -fold shifted IC90 (25 ng/mL) at doses of 50 m g or higher with RTV. 
The average and maximum AUC/Cmax values observed at the maximum dose 
studied to date are below NOAEL values in preclinical chronic toxicology  studies 
(6-month rat, 9- month dog). 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
243. OBJECTIVE(S) AND ENDPOINT(S)
Objectives Endpoints
Primary
To evaluate antiviral activity of 
[COMPANY_004]2838232/cobi in HIV -1 infected patients 
during 10 -days of monotherapy.Maximum decline from baseline (Day 1) in 
plasma HIV -1 RNA 
To assess safety and tolerability of 
[COMPANY_004]2838232/cobi when administered as 
monother apy over 10 days. Safety and tolerability parameters, 
including adverse event, concurrent 
medication, clinical laboratory, 
electrocardiogram (ECG) and vital signs 
assessments.
To characterize pharmacokinetics (PK) of 
[COMPANY_004]2838232 in HIV -1 infected patients 
following [COMPANY_004]2838232/cobi dosing for 10 
days [COMPANY_004]2838232 PK parameters following 
dose administration, as follows:
Day 1 :  area under the plasma 
concentration time curve AUC(0 -24), 
maximum observed concentration 
(Cmax), time to maximum observed 
concentratio n (tmax), concentration at [ADDRESS_541776] dose (C24), absorption lag 
time (tlag); 
Following last repeat administration on 
Day 10 :  AUC(0 -), pre -dose 
concentration (C0), concentration at end 
of dosing interval (C ), Cmax, tmax, t½, 
and apparent oral clear ance (CL/F), if 
data permit
Secondary
 To explore the relationship between 
[COMPANY_004]2838232 exposure and change in 
plasma HIV -1 RNA [COMPANY_004]2838232 PK parameters Day 10 
AUC(0 -), Cmax, C with Day 11 HIV -1 
RNA change from baseline
 To assess the immunologic effect o f 
[COMPANY_004]2838232/cobi when administered over 
10 days in HIV -1 infected adults Change from baseline in CD4+ cell count 
to Day 11
 To explore the relationship between 
[COMPANY_004]2838232 exposure and safety or 
immunologic parameters, if appropriate. [COMPANY_004]2838232 PK paramet ers on Day 10: 
AUC(0 -), Cmax , Cwith Day 11 change 
from baseline in CD4 + cell count
 To assess the development of viral 
resistance (genotypic and phenotypic) over 
10 days and correlate with viral response, if  Emergence of drug resistance mu tations, 
if appropriate 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
25Objectives Endpoints
appropriate.
 To estimate [COMPANY_004]2838232 accumulation and 
to assess attainment of steady state 
following administration of 
[COMPANY_004]2838232/cob i for 10 days in HIV 
infected subjects. Accumulation:
[COMPANY_004]2838232 PK accumulation ratios (R): 
Day 10 AUC(0- ), Cm ax, and C 
compared to Day 1 AUC(0- 24), Cmax, 
and C24, respectively
 Steady State:
pre-morning dose concentrations (C0) on 
Day 2 through 11 
 To examine dose proportionality of 
[COMPANY_004]2838232 PK parameters following 
[COMPANY_004]2838232/cobi dosing for 10 days in HIV 
infected subjects. Day 1 AUC(0 -24), Cmax, and C24, and 
Day 10 AUC(0- ), Cmax and C   at 
different doses levels for the assessment 
of dose proportionality
Note: Other exploratory objectives and endpoints will be specified in the RAP
4. STUDY DESIGN
4.1. Overall Des ign
This is a P hase IIa, multicenter, open -label, adaptive dose ranging, stud y to evaluate the 
antiviral effect, safet y, tolerability, and PK of [COMPANY_004]2838232/cobi monotherap y over [ADDRESS_541777] received any ART (including prior MI )therapy  will not be eligible for 
this study .To minimize the number of subjects exposed to suboptimal doses, an adaptive 
and dose ranging design is applied in this study .
This study  consists of a screening visit, a [ADDRESS_541778] dose 
of study  drug.  Eligible HIV -1 infected subjects will receive study  treatments for 10 day s. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
26Study  Design for 200911
[COMPANY_004]2838232/cobi Once Daily for 10 days1,2
Part A Part B
Cohort 1 Dose
(mg)Interim Analysis Cohort
N(mg)
N=10 100
2 8 200
3 8 50
4 8 20
1. Part A Cohort 1 safety/PK/virology data will be evaluate d at interim, prior toinitiat ing other cohorts in Part B , which 
areplanned to run in a parallel, randomized fashion.   All doses will be given with [ADDRESS_541779] to 
modification based upon safety, PK and antiviral activity data from Cohort 1 (Part A) . More doses/cohorts 
(including potential removal of cobicistat co-dosing) may be added. ( The maximum dose in Cohort B willnot  
exceed 200 mg with cobicistat unless overall plasma exposure [as AUC and Cmax ]islower in HIV -infected 
subjects than in healthy subjects at the same dose level).
After successfull y completing screening evaluations, the first cohort will enroll 10 
subjects to receive the100mg [COMPANY_004]2838232/cobi dose.  Following interim anal ysis of 
Cohort 1, if warranted, Cohorts 2 -
4 will each enroll 8 subjects to receive a range of 
[COMPANY_004]2838232/cobi doses
.
Day 1 – Day 10: Dosing 
Subjects will report to the clinic fo r outpatient visits in the morning on Day s 1through 10 
during the treatment period , except for the weekend ( Days 6 and 7 ).  Subjects will arrive 
each day  prior to administration of the morning dose for safet y and lab assessments, 
including HIV -1 RNA blood draws, as described in the Time and Events Table (Section 
7.1).  Subjects will begin receiving stud y drug in the morning of Day 1.  
Serial ,
intensive blood PK samples will be collected on Day  1 (up to [ADDRESS_541780]-
morning dose) and Day  10 (up to [ADDRESS_541781] -morning dose), and limited , single blood 
PKsamples pre -morning dose son Day s 3through 9, except for the weekend. Subjects 
will be required to fast for 10 hours [overnight] 
prior to the morning check in on the 
intensive PK sampling day s (Day s 1 and 10).  All dosing days will require co -
administration of treatment with a light snack/meal per cobicistat labeling guidelines. All 
doses of study  medication will be taken with 240 mL  of water.  Subjects will be required 
to stay  in the clinic on Day s 1 and 10 until all specified assessments are completed ([ADDRESS_541782] -dose) .Following Day  10, subjects will be required to attend the clinic for 
follow up assessments including virological and PK blood sa mpling for up to 3 weeks.
Subjects will be given morning doses on Day s 1through 10 (except for the weekend) in 
the clinic.  Weekend morning doses (Day s 6 and 7) will be packaged and sent home for 
self-administ ration. After Day  11, the subjects will return frequentl y for assessments 
including blood draws for PK and HIV viral load. A diary  card will be used to monitor 
dosing adherence. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
27Follow -up Visits:
Subjects will return to the clinic on Day s 11, 12, 14 ( 1 day ),and 21 ( 1 day ) for PK and 
measurement of HIV -1 RNA l evels, viral genot ype/phenoty pe and safet y assessments as 
shown in the Time and Events Table ( Section 7.1). 
4.2. Type and Number of Subjects
At least 34 subjects will be enrolled such that approximately  6
-10 evaluable subjects 
complete a number of cohorts.  Additional subjects/cohorts may
 be enrolled to allow for 
evaluation of additional dose levels as appropriate . 
If subjects prematurel y discontinue the study, additional replacement subjects may  be 
randomised and a ssigned to the same treatment cohort at the discretion of the Sponsor in 
consultation with the Investigator.
4.3. Design/Dose Justification
The fastest track to establishing antiviral potential of any  novel HIV drug is to study  a 
short course of monotherapy  in HIV infected subjects. There is precedent for this across a 
number of classes of ART drugs. 
Uncertainties over the impact of protein binding on the activity  of [COMPANY_004]2838232 and the 
inherent potency  of inhibiting the HIV maturation process as a target remain key 
objectives for the [COMPANY_004]2838232 program. This two -part adaptive design will allow an 
early understanding of the potential of [COMPANY_004]2838232 in combination with cobicistat (and 
by [CONTACT_118414], RTV) , while not exposing HIV -infected subjects to longer courses of 
what may  be suboptimal doses and possible development of resistance. 
Early clinical studies have indicated that in order to achieve reasonable IQ values likely  
to be associated with antiviral efficacy , [COMPANY_004]2838232 will need to be boosted with a 
pharmaco enhancer ,such as RTV or cobicistat (in common with many  CYP3A4 
substrates). 
There is no a priori intention to study  [COMPANY_004]2838232 unboosted, unless :i) following the 
preliminary  anal ysis of Part A Cohort 1, there is such pronounced antiviral activity  that i t 
would seem the estimates of projected IQ are low, in which case [COMPANY_004]2838232 may  be 
evaluated in a subsequent c ohort unboosted, or ii) the data from Cohort 7 in ongoing 
Study 204953 (planned, [COMPANY_004]2838232 200 mg BID unboosted) support it.
4.3.1. [COMPANY_004]2838232 with Rit onavir
In Study HMI116787, a single dose of 10 mg [COMPANY_004]2838232 (SDD) given after 10 day s of 
RTV 100 mg dail y dosing (to stead y state) demonstrated an increase in overall exposure 
(AUC) and Cmax by  [CONTACT_5554] 10.[ADDRESS_541783] .Studies 200912 and 200207 also indicated the utility  of RTV in 
boos ting [COMPANY_004]2838232 concentrations. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
28These data indicate the viability  of study ing a number of [COMPANY_004]2838232+RTV regimens in 
this PoC study . Predicted exposures following different [COMPANY_004]2838232 doses with steady -
state RTV are presented in Table 7, based on the results of linear regression anal yses of
the preliminary  Day  11 data in Study 204953 (dose levels of 20 to 200 mg) and assuming 
no significant differences in PK (ADME) between HIV
-infected subjects and healthy  
subjects .
Table 7 Predicted Mean Steady -State [COMPANY_004]2838232 A UC(0-24), Cmax ,and IQ, 
Follo wing Repeated Dose A dministration + RTV with Fold Cover to
NOA EL
Dose 
(mg)Projected AUC24 
(ng.h/mL)1Fold cover to 
NOAEL Dog2Projected 
Cmax 
(ng/mL)1Fold cover to 
NOAEL Dog2IQ3
20+RTV 451 36 24 35 3.1
50+ RTV 1127 14 61 14 7.7
100+ RTV 2253 7.2 122 6.9 15
150+RTV 3380 4.8 183 4.6 23
200+RTV [ADDRESS_541784] NOAEL, 20 mg/kg/day obtained from 9 -month study in dogs ( AUC24 [ZIP_CODE] ng.h/mL and Cmax 847 
ng/mL)
3. Mean IQs derived from predicted C /IC90 (with target of 5 ng/mL).
C= Pre-dose (trough) concentration at the end of the dosing interval ,IQ= inhibitory quotient.
The IQ following 20 mg to 200 mg [COMPANY_004]2838232/r QD is predicted to be >3 to >30 -fold 
above the minimal target value (5 ng/mL) which was derived from preclinical virological 
assessment as 4 ×EC50. No protein binding adjustment has been made because there was 
a minimal ( ≤5 fold) shift in assays where the effect of protein was assessed. If protein 
binding has more impact than anticipated, it is possible that the target Cmin value is 
approximately  25ng/mL . In that scenario, projected IQ values at 200 mg/r QD would still 
be >5.
4.3.2. [COMPANY_004]2838232 with Cobicistat
There have been no preclinical or clinical studies with [COMPANY_004]2838232 and cobicistat to 
date; however, a review of the literature indicates that pharmacoenhancement of drugs 
that are known to have dominant CYP3A metabolic pathway s is similar with either RTV 
or cobicistat [Kakuda , 2009; Elion , 2011; Gallant , 2013].  Thus, t he useof cobicistat as 
theCYP 3A4 inhibitor pharmacoenhancer in this Phase IIa study  in place of ritonavir is 
expected to produce a similar profile of [COMPANY_004]2838232 ADME (and therefore s ystemic 
exposure) .  The pharmacokinetic data available after Part A Cohort 1 will confirm this 
assumption.  
4.3.3. Interim A nalysis
An evaluation of [COMPANY_004]2838232 safet y, efficacy  and PKdata will be done after Part A 
Cohort 1
, if the exposure level of [COMPANY_004]2838232 is in the range of the maximum 
[COMPANY_004]2838232 exposure seen previousl y in health y subjects and the Bay esian probability   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
29from Cohort 1 is less than 70%, the study  will not move forward into Part B, otherwise 
doses will be selected for evaluation in Part B. If pharmacokinetic exposure after the 100
mg [COMPANY_004]2838232/cobi dose is in the rang e of values observed after 100mg 
[COMPANY_004]2838232/r in prior studies, the doses for Part B will be extended to both lower 
(20 mg, 50 mg) and higher (200 mg) doses. The highest dose tested in Part B will be 
selected to result in exposures similar to those seen w ith 200 mg/r in Study 204953.
4.4. Benefit: Risk Assessment
Summaries of findings from both clinical and non- clinical studies conducted with 
[COMPANY_004]2838232 can be found in the Investigator’s Brochure.   The following section 
outlines the risk assessment and mitigat ion strategy  for this protocol:   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
304.4.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [COMPANY_004]2838232 
Cardiovascular Pre-clinical studies have shown the following find ings:  elevated heart rates, an 
isolated epi[INVESTIGATOR_43180] -sustained ventricular tachycardia and minimal to mild, 
sporadic troponin I elevations in dogs .  A subsequent investigative cardiovascular 
study in telemetered dogs treated for 4 weeks did not replicat e these effects. 
Isolated microscopic cardiovascular changes were noted (focal extramural 
arteritis and localized epi[INVESTIGATOR_428106]), however these changes were 
considered of uncertain relationship to [COMPANY_004]2838232 because similar findings 
occur at low incidence in normal beagles and there were no [COMPANY_004]2838232 -related 
functional changes by [CONTACT_428202], or changes in cTpnI and 
NTproBNP.  In addition there was no correlation between histologic changes and 
plasma exposure or heart tissue co ncentrations of [COMPANY_004]2838232. 
3, [ADDRESS_541785], other than a 30% incidence of 
gastrointestinal symptoms (including diarrhea). There were no significant 
cardiovascular AEs reported in published clinical studies.Subjects will be clinically monitored for a ny signs 
of myocardial injury (chest pain, shortness of 
breath, pain with inspi[INVESTIGATOR_1516]), elevated heart rate 
or arrhythmias. Samples for the assessment of 
troponin will be taken. Baseline EKG and Holter 
(to use for screening and for later comparisons if 
needed)
Exposures of [COMPANY_004]2838232 will be closely 
monitored in the clinical study so as to not 
exceed pharmacokinetic stoppi[INVESTIGATOR_3418] .   
 
 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
31Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Cobicistat (Tybo st)
General The cobicistat label includes the following information: 
TYBOST decreases estimated creatinine clearance due to inhibition of tubular 
secretion of creatinine without affecting actual renal glomerular function. This 
effect should be considered when i nterpreting changes in estimated creatinine 
clearance in patients initiating TYBOST
In one study investigating cobi+( atazanavir and tenofovir DF/emtricitabine) vs 
RTV+( atazanavir and tenofovir DF/emtricitabine), a higher frequency of reports 
of jaundice (6% and 3%) and ocular icterus (4% and 2%) were reported in the 
cobi group compared to the RTV group.  
Changes from baseline in total cholesterol, HDL -cholesterol, LDL -cholesterol, and 
triglycerides have been observed. The implications of these findings a re 
unknown.
The vast majority of available safety data has been obtained in combination 
studies with other ART. There are no warnings of obvious cobicistat -related 
adverse events or safety concerns. Subjects will be closely monitored for any signs 
or symp toms potentially associated with 
cobicistat administration , in particularchanges in 
serum creatinine and liver chemistry.
HIV-1 Infection/Patient population
HIV Resistance
Propensity for co -meds and 
possible DDIsHIV Drug Resistance to unique mechanism
Recognize HIV patients have a higher chance of comorbid ities/diseases and a 
risk of tak ing a medicine or product contraindicated in the studyClosely monitor HIV viral load and genotypic 
resistance
Strict adherence to protocol criteria around 
concurrent m eds  
 
 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
324.4.2. Benefit A ssessment
This study  in HIV -1 infected but otherwise healthy  subjects is a 10 -day monotherapy
design. It is anticipated that all subjects receiving [COMPANY_004]2838232 will experience anti -HIV 
effects whereb y their (blood ) HIV viral titres are redu ced, until administration stops and 
the viral load returns to baseline levels. T here is no expected longer term anti -HIV 
benefit to administration of [COMPANY_004]2838232. Participation in this study  contribute s to the 
process of developi[INVESTIGATOR_428107]2838232 and other new therapi[INVESTIGATOR_428185].
4.4.3. Overall Benefit:Risk Conclusion
To date, [ADDRESS_541786] received [COMPANY_004]2838232 in three completed studies. One 
study  (204953) is ongoing ([ADDRESS_541787] completed this study so far ). 
Subjects have received single doses up to 200 mg SDD alone (studies HMI116787 and 
200912), 250 mg API [INVESTIGATOR_428109] (204953), and then in repeated dail y 
doses of up to 50 mg SDD alone (200207) for 5 day sor 200mg in combination with 
RTV (204953) for [ADDRESS_541788] was receiving [COMPANY_004]2838232 to date 
(one in 200207, one in 204953). Neither is 
thought likely  to be due to [COMPANY_004]2838232.
There have been no other withdrawals due to drug-related AEs and no trends relative to 
laboratory  toxicity .  One subject was withdrawn in Part 1A of [ADDRESS_541789] been no clinically  
significant changes in troponin, heart rate, blood pressure ,ECG ,or telemetry  monitoring.
Subjects will also be at risk for AEs from cobicistat use and will be monitored closel y for 
such events.
Given the preclinical profil
e and the clinical profile to date, the overall risk to HIV-1 
infected but otherwise healthy  subjects at th e proposed [COMPANY_004]2838232 doses (with or 
without cobicistat ) for [ADDRESS_541790] eligibility  is provided in the Investigator ’
s Brochure. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541791] safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
Approximately  10-12 HIV -1 infected subjects will be enrolled into Part A. If warranted 
by [CONTACT_428252], virology  and PK data anal ysis, approximately  8 subjects will be 
enrolled in each of Cohorts 2 -4in Part B ,which will be a parallel group design. Eligible 
patients are those who are ART -naïve and who are not currently  receiving ART therap y.
Additional subjects/cohorts may  be enrolled to allow for evaluation of additional dose
levels or configurations ( e.g., [COMPANY_004]2838232 alone) .
If subjects prematurel y discontinue the study, additional subjects may be enrolled as
replacement subjects and assign ed to the same treatment at the discretion of the Sponsor.
5.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
AGE
1.Between [ADDRESS_541792] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Health y (other than HIV infection) male or female as determined b y the investigator 
or medicall y qualified designee based on a medical evaluation including medical 
history , phy sical examination, laboratory  tests and cardiac monitoring. Defined as no 
other chronic medical conditions and taking no chronic medications.
3.A subject with a clinical abnormality  or laboratory  parameter(s) which is/are not 
specificall y listed in the inclusion or exclusion criteria, outside the reference range 
for the population being studied may  be included only  if the investigator in 
consultation with the Medical Monitor agree and document that the finding is 
unlikely  to introduce additional risk factors and w ill not interfere with the study  
procedures. 
4.A creatinine clearance >80 mL/min as determined by  [CONTACT_3158]- Gault equation 
[Cockcroft , 1976] CLcr (mL /min) = (140 – age) * Wt / (72 * Scr) (times 0.85 if 
female) where age is in years, weight (Wt) is in kg, and serum creatinine (Scr) is in 
units of mg/dL .
5.Confirmed HIV positive; CD4+ cell count ≥350 cells/mm3 and plasma HIV -1 RNA 
≥5000 copi[INVESTIGATOR_014]/mL  at Screening.
6.No current and no prior ART . 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
34WEI GHT
7.Body weight 50 kg (110 lbs.) for men and 45kg (99 lbs) for women and body  
mass index (BMI) within the range 18.5 -31.0 kg/m2(inclusive)
SEX
8.Male or Female
A female subject of reproductive or non- reproductive potentia lis eligible to 
participate if she is not pregnant (a s confirmed by  a negative serum or urine human 
chorionic gonadotrophin (hCG) test at screening and prior to first dose ), not 
lactating, and at least one of the following conditions applies:
Reproductive potential:
Females of reproductive potential may  only be enrolled if they  are using two forms 
of complementary  contraception, which must include one barrier method. They  will 
be counselled on safer sex practices
There is no definitive DDI information with [COMPANY_004]2838232 and an interaction with 
oral contraceptive s is possible, so other ( barrier, inter -uterine device etc .) methods of 
contraception will be required.
Fertile females, who have an established, long -term lifesty le of sexual abstinence, or 
only same sex partners, require no other means of birth control. 
Non-reproductive potential:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophore ctom y
Postmenopausal defined as 12 months of spontaneous amenorrhea in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause (refer to 
laboratory  reference ranges for confirmat ory levels).  Females on hormone 
replacement therap y (HRT) must discontinue HRT to allow confirmation of 
post-menopausal status prior to study  enrolment.
Male subjects with female partners of child bearing potential must comply  with the 
following contracep tion requirements from the time of first dose of stud y medication 
until one week after the last dose of study  medication.
a.Vasectom y with documentation of azoospermia.  
b. Male condom plus partner use of one of the contraceptive options below:
Contraceptive subdermal implant that meets the SOP effectiveness criteria  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
35including a <1% rate of failure per year, as stated in the product label
Intrauterine device or intrauterine s ystem that meets the SOP effectiveness 
criteria including a <1% rate of failure per year, as stated in the product 
label
Oral contraceptive, either combined or progestogen alone or Injectable 
progestogen 
Contraceptive vaginal ring 
Percutaneous contraceptive patches
These allowed methods of contraception are only  effective when used consis tently , 
correctly  and in accordance with the product label.  The investigator is responsible 
for ensuring that subjects understand how to properly  use these methods of 
contraception.
INFORMED CONSENT
9. Capable of giving signed informed consent as describe d in Section 10.2, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this stud y if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1.Alanine aminotransferase ( ALT) and BIL >1.5x upper limit of normal ( ULN ; isolated 
BIL >1.5xUL N is acceptable if BIL is fractionated and direct BIL <35%). 
2.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones) ;HBV and
/or
HCV positive .
3.Subjects who have an y other chronic medical condit ion, including CV, respi[INVESTIGATOR_696] , 
neurologic, ps ychiatric, renal, gastrointestinal (GI), oncologic, rheumatologic, or 
dermatologic
4.Medical history  of cardiac arrhy thmias or cardiac disease or a famil y or personal 
history  of long QT s yndrome. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
36CONCOMI TANT MEDICATIONS
5. Unable to refrain from the use of prescription or non- prescription drugs, including 
vitamins, herbal and dietary  supplements (including St John’s Wort) within 7 day s 
(or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whiche ver is 
longer) prior to the first dose of study  medication, unless in the opi[INVESTIGATOR_428145] y. 
REL EVANT HABITS
6.History  of regular alcohol consumption within 6 months of the study  defined as: 
An average weekl y intake of >14 drinks for males or >7 drinks for females.  One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 mL )of 80 proof distilled spi[INVESTIGATOR_2120].
7.Smoking is an exclusion criteria for this study . Urinary  cotinine levels indicative of 
smoking 
at screening .
8. Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion 
criteria.
CONTRAINDICAT IONS 
9.History  of sensitivity  to any  of the stud y medications, or components thereof or a 
history  of drug or other allergy  that, in the opi[INVESTIGATOR_427175], contraindicates their participation.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
10.Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody  test 
result at screening or within [ADDRESS_541793] dose of study  treatment. 
11.Screening or baseline cardiac troponin I greater than the 99% cutoff (> 0.045 ng/mL 
by[CONTACT_428205] ).
12.A positive pre -study  drug/alcohol screen.  
13.Prior history  of receiving an HIV maturation inhibitor
14.Where participation in the study
 would result in donation of blood or blood products 
in excess of [ADDRESS_541794] dosing day  in the current 
study : [ADDRESS_541795] (whichever is longer).
16. Exposure to more than four new chemical entities within [ADDRESS_541796] 
dosing day . 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8904].Treatment with radiation therap y or cy totoxic chemotherapeutic agents within 
30days of study  drug administration or anticipated need for such treatment within 
the study .
18.Treatment with immunomodulating agents (such as sy stemic corticosteroids, 
interleukins, interferons) or an y agent with known anti -HIV activity  (such as 
hydroxyurea or foscarnet) within 30 day s of study drug administration.
19.An active Center for Disease Control and Prevention (CDC) Category  C disease 
except cutaneous Kaposi’s sarcoma not requiring sy stemic therapy  during the trial.
20.Treatment with an y vaccine within 30 days prior to receiving stud y medicat ion.
21. Exclusion Criteria for 24- Hour Screening Holter:
Any symptomatic arrhy thmia (except isolated extra s ystoles).
Sustained cardiac arrh ythmias (such as atrial fibrillation,flutter or
supraventricular tach ycardia ( 10 seconds )
Non-sustained or sustained v entricular tach ycardia (defined as 3 consecutive 
ventricular ectopic beats).
Any conduction abnormality  including but not specific to left or complete 
bundle branch block, atrioventricular [AV] block, high grade or complete heart 
block Wolff -Parkinson- White [WPW ]syndrome etc.).
Sinus Pauses >3 seconds.
22.Exclusion criteria for screening ECG (a single repeat is allowed for eligibility  
determination):
Males Females
Heart rate <45 and >100 bpm <50 and >100 bpm
PR Interval <120 and >220 msec
QRS duration <70 and >120 msec
*QTc interval >450 msec
*The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machine -
read or manuall y over -read. The specific formula used to determine eligibility  and 
discontinuation for an individual participant in 204953 will be Fridericia’s formula. 
Note: A heart rate from 100 to 110 beats per minute ( bpm)can be rechecked by 
[CONTACT_428206] 30 minutes to verify eligibility.
Evidence of previous myocardial infarction (Does not include ST segment 
changes associated with repolarization).
Any conduction abnormality  (including but not specific to left or right complete 
bundle branch block, AV block [2nd degree or higher], WPW sy ndrome).
Sinus Pauses >3 seconds. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
38Any significant arrh ythmia which, in the opi[INVESTIGATOR_428152], will interfere with the safet y for the individual 
subject. 
Non-sustained or sustained ventricular tach ycardia ( 3 consec utive ventricular 
ectopic beats).
5.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjects who consent to participate in the clinical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from Regulatory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure 
details, El igibility  Criteria, and an y SAEs.
5.4. Withdrawal/Stoppi[INVESTIGATOR_428111] a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993] -schedule the missed v isit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_541797]’s last 
known mailing address or local equivalent methods). These conta ct attempts 
should be documented in the subject’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
A subject may  withdraw fro m study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioural or 
administrative reasons. If a subject withdraws from the study , he/she may  request 
destruction of an y samp les taken, and the investigator must document this request has 
occurred in the site study records. 
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the FDA 
premarketing cl inical liver safety  guidance).  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
39http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 , Section 12.2 and Section 12.3.
[IP_ADDRESS]. Study Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_387026].
5.4.2. QTc 
Stoppi[INVESTIGATOR_2121]
The same QT correction formula must be used for eac h individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the subject has been enrolled.
For example, if a subject is eligible for the protocol based on QTcB , then QTcB 
must b e used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis .  Safet y ECGs and other non- protocol specified 
ECGs are an exception.   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
40The QTc should be based on single or averaged QTc values of triplicate ECGs 
obtained over a brief (e.g., 5- 10 minute s) recording period.  
A subject who meets either of the bulleted criteria below will be withdrawn from the 
study :
QTc >500 msec OR Uncorrected QT >600 msec
Change from baseline of QTc >60 msec
5.5. Stoppi[INVESTIGATOR_428112] A dverse Events
Any grade 3 or higher treatment -related adverse events that occur in ≥[ADDRESS_541798]’s last visit.
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design. Stu dy treatment may  
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Treatment
Product name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat , cobi ) tablet
Formulation 
description:[COMPANY_004]2838232 powder blend in a 
capsuleTablet
Dosage form: Swedish orange, unmarked 
capsules (50 mg), and white, 
unmarked capsules (10 mg)Orange, round, biconvex, film -coated 
tablets debossed with “GSI” on one side 
and plain faced on the other side 
providing 150 mg of cobicistat.
Unit dose strength(s)/
Dosage level(s):[ADDRESS_541799] name: [CONTACT_23983]2838232 
Capsule (API)Tybost 
(cobicistat , cobi ) tablet
Route/
Administration/
Duration:Administered orally QD for 10 days Administer orally, QD for 10 days
Dosing i nstructions: Administer with light meal and 240 
mL of water . Administer with light meal and 240 mL 
water.
Manufacturer/
source of 
procurement:[COMPANY_004] [COMPANY_009]
Method for 
individualizing dosage:Capsules supplied in high-density 
polyethylene bottles for 
individualized dosing by [CONTACT_428254]
6.2. Treatment A ssignment
Subjects will be assigned to treatment (active) in accordance with the randomization 
schedule generated b y Clinical Statistic s, prior to the start of the stud y, using validated 
internal software.
6.3. Planned Dose A djustments
Following the interim analy sis of safet y, virology  and PK data from the first cohort of 
subjects in Part A, the option to adjust dose levels from those describe d exists. No dose 
will be administered that has an associated projected mean AUC or Cmax value higher 
than the most conservative NOAEL obtained from the chronic toxicity  studies (i .e.,from 
the 9
-month dog toxicity  study  described in Section 2.2.1).
6.4. Blinding
This will be an open
-label study . Treatment allocation in Part B will be randomised (to 
[COMPANY_004]2838232 dose level ). 
6.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable reg ulatory  
requirements.
6.6. Preparation/Handling/Storage/A ccountability
A description of the methods and materials required for capsule/tablet storage and 
dispensing will be detailed in a Study  Specific Technical Agreement/Memo or Pharmacy  
Manual ,which will be accompanied by  a Quality  Agreement .
No special preparation of study  treatment is required. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
42Only  subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must b e stored in a secure environmentally  controlled and monitored 
(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of th e medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e. , receipt, reconciliation and final disposition records).
Further guidance and information for final disposition of unus ed study  treatment 
are provided in the study  reference manual ( SRM ).
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  
A Material Safety Data Sheet/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
6.7. Compliance with Study  Treatment A dministration
When subjects are dosed at the site, they  will receive study  treatment directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents.  The dose of study  
treatment a nd study  subject identification will be confirmed at the time of dosing b y a 
member of the stud y site staff other than the person administering the stud y treatment.  
When subjects self- administer study  treatment(s) at home , compliance with study  
treatment (s) will be assessed through query ing the subject during the site visits and 
documented in the source documents and case report form ( CRF ).  A record of the 
number of study treatment(s) dispensed to and taken by [CONTACT_428255].  Treatment start and stop 
dates, including dates for treatment delay s and/or dose reductions will also be recorded in 
the CRF.
6.8. Treatment of Study  Treatment Overdose
For this study , any  dose of [COMPANY_004]2838232 >200 mg+cobicistat within a 28-hour time 
period will be considered an overdose.
[COMPANY_004] does not recommend specific treatment for an overdose
;however, in the event of an 
overdose ,the investigator or treating ph ysician should:
Contact [CONTACT_373733]
Closely  monitor the subject for AEs/SAEs and laboratory  abnormalities until 
[COMPANY_004] 2838232 can no longer be detected s ystemically  (at least 10days for 
[COMPANY_004]2838232) 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
43Obtain a plasma sample for PK anal ysis within [ADDRESS_541800] dose 
of study treatment if requested by  [CONTACT_1689] (determined on a case -by-case 
basis)
Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_941] i
nvestigator 
in consultation with the Medical Monitor based on the clinical evaluation of the subject.
6.9. Treatment after the End of the Study
Subjects will not receive any  additional treatment from [COMPANY_004] .
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, whether or not [COMPANY_004] is providing specific 
post-study  treatment.
6.10. Lifest yle 
and/or Dietary  Restrictions
6.11. Contraception
Female subjects can be of childbearing or non -child bearing potential .  
Females of reproductive potential may  only be enrolled if they are using two forms of 
complementary  contraception, which must include one barrier method.  There is no 
definitive DDI information with [COMPANY_004]2838232 and an interaction with oral con traceptives 
is possible, so other 
(barrier, inter -uterine device etc .) methods of contraception will be 
required.
Females of reproductive potential, who have an established, long -term lifesty le of sexual 
abstinence, or onl y same sex partners, require no ot her means of birth control.  
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first dose of stud y medication 
until one week after the last dose of study medication:
1.Vasectom y with documentation of azoospermia. The documentation on male 
sterility  can come from the site personnel’s review of subject’s medical records, 
medical examination and/or semen anal ysis, or medical history  interview.
OR
2. Male condom plus partner use of one of the contraceptive options below that 
meets the SOP effectiveness criteria including a <1% rate of failure per year, as 
stated in the product label:
-Contraceptive subdermal implant
-Intrauterine device or intrauterine s ystem
- Combined estrogen and progestogen oral contraceptive 
-Injectable progestogen
-Contraceptive vaginal ring  2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541801] label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception .
6.12. Meals and Dietary  Restrictions
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice 
from [ADDRESS_541802] dose of study medication until after the final dose.
Doses will be given in the fedstate (light breakfast) , following overnight fasting 
(>10 hours). Lunch will provided 4 hours after the dose; water will be allowed ad 
libitum throughout.
6.13. Caffeine, Tobacco and Exercise
Subjects should refrain from alcohol for 48 hours before screening and then for 48 
hours prior to admission and baseline assessments (on Day  1). Alcohol is then not 
permitted for the duration of the treatment perio d (through Day  10) and until the 
final follow -up visit.  
Use of tobacco products is not allowed from screening until after the final follow -up 
visit
Subjects will abstain from strenuous exercise for 72 hours prior to each blood 
collection for clinical lab oratory  tests.  Subjects may  participate in light recreational 
activities during studies (e.g., watch television, read).
6.14. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014]
Subjects must refrain from all illicit drugs throughout the study  (from Screening until 
discharge from the study).  Drug screening will occur at Screening and Day -1 for 
each treatment period.  A positive result will lead to exclusion from the remainder of 
the study .
The Principal Investigator [INVESTIGATOR_428147] y 
medications taken from the time of screening until the subject is discharged from the 
study .  Over -the-counter medications will not be permitted during the treatment 
period except as needed to treat an AE.If medication is needed, use should be 
restricted to 4 hours after dosing if possible .  
6.14.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
Acetaminophen at doses of  2grams/day  or NSAIDs are permitted for use any  time 
during the stud yand their use documented in the CRF .  Other concomitant 
medication may  be con sidered on a case by
 [CONTACT_428235].
6.14.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_014]
Subjects must abstain from taking prescription or non
-prescription drugs (including 
vitamins and dietary or herbal supplements), within 7 day s (or 14 day s if the drug is  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
45a potential enzy me inducer) or 5 half -lives (whichever is longer) prior to the first 
dose of study medication until completion of the follow -up visit, unless in the 
opi[INVESTIGATOR_2511] I nvestigat or and sponsor the medication will not interfere with the 
study . 
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, includ ing those 
specified in the Time and Events Table (Section 7.1), are essential and required for stud y 
conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Secti
on 7.1. I n 
overview, subjects will be screened, begin dosing and then continue assessments through 
and for up to [ADDRESS_541803] be noted: 
If assessments are scheduled for the same nominal time, THEN the assessments 
should occur in the following order:
1.
12-lead ECG
2.vital signs
3.blood draws.  
Note: The timing of the assessments should allow the blood dr
aw to occur at the 
exact nominal time. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
467.1. Time and Events Table
Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
Informed Consent X
Review inclusion/exclusion X X
Demography including height, weight 
and BMIX
Brief physical X
Medical/medication/
drug/alcohol historyX X
CDC Classification X X X X
Prior antiretroviral therapy X
12-lead ECG3 X X X X X X X X X
Holter (24 h r) X
Vital signs4 X X X X X X X X X
Drug screen X X X X X
Hepatitis B Surface antigen and 
hepatitis C antibody testingX
Serum or urine -hCG (WoCBP only) X X X
Clinical lab tests (inc troponin) X X X X X X X X X X X X X X
Fasting lipid panel X X
AE assessment5 X X X X X X X X X X X X X X
Con Medication Review X X X X X X X X X X X X X X
HIV-1 RNA PCR6 X X X X X X X X X X X X X X
Lymphocyte subsets7 X X X
Plasma for genotype/phenotype8 X X X X X X X
HIV-associated conditions assessment X X X X X X X X X X X X X X
PK blood sample9 X X X X X X X X X X X X
Plasma samples10 X X X
Dosing11 X X X X X X X X X X
PGx12 X 
 
 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
47Day: Screen1 Random 1 2 3 4 5 627 8 9 10 11 12 141 211 
(FU)ET
AE enquiry13 X X X X X X X X X X X X X
Telephone call to IVRS14 X X X X X X X X X X X X X X X
Outpatient visit X X X X X X X X X X X X
1. Screening will occur within [ADDRESS_541804] dose of study drug.
2. Table is set up for the weekend during dosing to occur on Days 6 and 7.  If the weekend occurs on Days 5 and 6, perform all “Day 5” assessments on Day 7.
3. On Day 1, ECGs (x2) will be performed pre -dose , and then 1, 1.5, 2, 3, [ADDRESS_541805]- dose. On Day 10, ECGs (x2) will be 
performed pre -dose, an d then 1, 1.5, 2, 3, [ADDRESS_541806] dose.  On Day 11, an ECG will be obtained prior to the 24 -hour PK sample.
4. BP, RR, HR and temperature will be obtained at Screening (x1) and Day 1 pre -dose (x2).  BP and HR will be obtained on Day [ADDRESS_541807] -morning dose, and at Follow -up.
5. Only SAEs related to study participation will be collected between screening and Day 1.
6. On Days 1 -5 and 8 -10 samp les for HIV -1 RNA PCR collected before morning dose.  On Days 1, 10 and 11 two samples for HIV -1 RNA PCR will be collected 5 -30 minutes 
apart.  
7. Lymphocyte subsets by [CONTACT_4133] (total lymphocyte counts, percentage, and absolute CD4+and CD8+counts).
8. Blood samples for phenotype and genotype will be collected at pre -dose on Days 1, 4, 5 and 8 in the morning on Day 11 and at follow -up. 
9. Serial plasma samples (2 mL) for determination of [COMPANY_004]2838232 will be collected on Day 1 and Day 10 at pre dose (within 15 minutes prior to dose) and 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12, and [ADDRESS_541808] -am dose.  Pre -dose PK samples (within 15 minutes prior to dose) will be taken on the mornings of Days 3, 4, 5, 8 and 9 and a single sample will be 
taken on Days 12 and 14.
10. Sample s (2 x 0.5mL) of plasma for assessment of immunological markers at screen, baseline (pre -dose) and day [ADDRESS_541809] experienced any neuropsychiatric adverse events, including psychosis or altered mental status  
14. A screening/registration call should be made to the IVRS to register the subject at screening.   An additional call will be m ade to document a screen failure.   A randomization 
call should be made to the IVRS system approximately one week prior to scheduled Day 1.  Note: The randomization call must be made in order to have study drug on site for 
Day 1. Additional calls will be made ev ery day that the subject has a scheduled study visit to the clinic.  If a subject terminates the study prematurely a call sho uld be made to 
the IVRS
15. Only if early termination visits occur during the treatment period.
AE = Adverse event; CDC= Center for Di sease Control and Prevention; ECG = Electrocardiogram; ET = Early termination; hCG = Human chorionic gonadotrophin; HIV = Human 
immunodeficiency virus;  IVRS= Interactive Voice Response System ; PCR = Polymerase chain reaction ; PK=Pharmacokinetic. 
 
 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
487.2. Screeni ng and Critical Baseline A ssessments
Cardiovascular medical history /risk factors ( as detailed in the CRF) will be assessed at 
screening .
The following demographic parameters will be captured: year of birth, sex, race ,and 
ethnicity .
Medical/medication/ family history  will be assessed as related to the inclusion/exclusion 
criteria .
Procedures conducted as part of the subject’s routine clinical management (e.g.,blood
count )and obtained prior to signing of informed consent may  be utilized for Screening or 
baseline purposes provided the procedure meets the protocol -defined criteria and has 
been performed in the timeframe of the stud y.
7.2.1. Holter Monitoring (Screening criteria)
The 24-hour Holter monitoring should only  be performed at Screening after the subject 
hasmet all other inclusion criteria.
Analy sis of the Holter tapes will consider the following:
Heart rate (brad y and tachy cardia)
Normal and aberrant beats
Number of supraventricular contractions, premature atrial contractions, premature 
ventricular contract
ions, couplets, triplets, and ventricular tachy cardias
Atrio- ventricular conduction defects
Atrial fibrillation and flutter .
7.3. Efficacy
7.3.1. HIV-1 RNA  Sampling
Plasma for quantitative HIV- 1 RNA will be collected at timepoints listed in the Time and
Events Table i n Section 7.1. To reduce sample variability , two plasma HIV -1 RNA
samples will be collected on Day s 1, 10
,and 11.
An HIV -1 RNA PCR assay  with a lower limit of detection (LLOD) of 50 copi[INVESTIGATOR_014]/mL
(ultrasensitive assay ) will be used for post- baseline assessments. An HIV -1 RNA PCR
assay  with a LLOD of 400 copi[INVESTIGATOR_014]/mL  (standard assay ) will be used for screening and
baseline assessments and will include a re -test with and ultrasensitive assay for all
baseline values below the LLOD. An HIV -1 RNA PCR assay with a LLOD of 2 
copi[INVESTIGATOR_014]/mL (supersensitive assay ) may  be used for exploratory analysis. 2018N360917_00
2015N227852_00 CONFIDENTIAL  
  [ADDRESS_541810] for the analysis of 
lymphocyte subsets by [CONTACT_428256] 7.1. 
Details concerning the handling, labeling and shippi[INVESTIGATOR_339181]. 
7.4. Safety 
Planned time points for all safety assessments  are listed in the Time and Events Table 
(Section 7.1).  Additional time points for safety tests (such as vital signs, physical exams 
and laboratory safety tests) may be added during the course of the study based on newly 
available data to ensure appropriate safety monitoring. 
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) 
The definitions of an AE or SAE can be found in Appendix 5, Section 12.5. 
The investigator and their designees are responsible fo r detecting, documenting and 
reporting events that meet the definition of an AE or SAE.  
[IP_ADDRESS]. Time period and Frequency for collecting AE and SAE information 
• AEs and SAEs will be collected from the start of Study Treatment until the 
follow-up contact (see Section [IP_ADDRESS]), at the timepoints specif ied in the Time 
and Events Table (Section 7.1). An AE enquiry will be made at each visit, where 
subjects will be specifically asked if th ey have experienced any neuropsychiatric 
adverse events, including psychosis  or altered ment al status   
• Medical occurrences that begin prior to  the start of study treatment but after 
obtaining informed consent may be reco rded on the Medical History/Current 
Medical Conditions section of the CRF. 
• Any SAEs assessed as related to stud y participation (e.g., protocol-mandated 
procedures, invasive tests, or change in existing ther apy) or related to a [COMPANY_004] 
product will be recorded from  the time a subject consents  to participate in the 
study up to and including any follow-up contact.  
• All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in Appendix 5, Section 12.5. 
• Investigators are not obligated to active ly seek AEs or SAEs in former study 
subjects. However, if the investigator learns of any SAE, including a death, at any time after a subject has been discharged from the study, and he/she considers the 
event reasonably related to the study treatment or study participation, the 
investigator must promptly notify [COMPANY_004].  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
50NOTE: The method of recording ,evaluatin g and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 5
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when det ecting AEs and/or SAEs. Open- ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
“Have you experienced any  alteration in personality , behaviour, mood or any  
altered mental status?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non- serious AEs of special interest 
(as defined in Section 12.5) will be f ollowed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow -
up 
(as defined in Section 5.4). Further information on follow -up procedure s is given in 
Appendix 5 .
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in Appendix 5 (Section 12.5.3) and all deaths, 
whether or not they  are considered SAEs, specific CV and Death sections of the CRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non
-cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed 
within oneweek of when the death is reported.
[IP_ADDRESS]. Disease- Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease -related events (DREs) are common in subjects with HIV-1 
infection and can be serious/life threatening: 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
51events or outcomes listed in the CDC Classification Sy stem for HIV- 1 Infections 
(see Appendix 9; Section 12.8)
sign, s ymptom, diagnosis, illness, and/or clinical laboratory  abnormality  that can 
be linked to an y of these events or outcomes
Because these events are ty pi[INVESTIGATOR_1306] y associate d with the disease under study , they  will not 
be reported according to the standard process for expedited reporting of SAEs to [COMPANY_004] 
(even though the event may
 meet the definition of a serious adverse event). 
These events will be recorded on the DRE page in the subject’s CRF using the HIV 
Associated Conditions eCRF. These DREs will be monitored by [CONTACT_428212].
However, if an y of the following conditions apply, then the event should be reported as 
an SAE using the stand ard process:
The event is, in the Investigator’s opi[INVESTIGATOR_1649], of greater intensity , frequency , or 
duration than expected for the individual subject, 
or
The Investigator considers that there is a reasonable possibility  that the event was 
related to treatment w ith the investigational product.
or
Death occurring for an y reason during a stud y, including death due to a disease 
related event, will alway s be reported promptly . 
If either of the above conditions is met then record the DRE on the SAE page rather than 
the HIV Associated Conditions eCRF page and report promptly to [COMPANY_004].
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA E
Prompt notification by [CONTACT_428213]- serious AEs 
related to stud y treatment ( even for non- interventional post-marketing studies) is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and the safet
y of a product under clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Ind ependent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary . 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
52An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements .
7.4.2. Pregnancy
Details of all pregnancies in female subjects and if indicated female partners of 
male subjects will be collected after the start of dosing and until one week post 
study
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 
24hrs
of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 7, Section 12.6 .
7.4.3. Physical Exams
A complete ph ysical examination will include , at a min imum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_13521] y
, GI and Neurological sy stems. Height and weight will 
also be measured and recorded.
A brief ph ysical examination will include, at a minimum assessments of the skin ,
lungs, cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses
7.4.4. Vital Signs
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_541811] and will 
include 
temperature, sy stolic and dias tolic blood pressure and pulse rate
Three readings of blood pressure and pulse rate will be taken
First reading should be rejected
Second and third readings should be averaged to give the measurement to be 
recorded in the CRF. 
7.4.5. Electrocardiogram (EGC)
Triplicate 12-lead ECGs will be obtained at each timepoint during the study  using 
an ECG machine that automatically  calculates the heart rate and measures PR,
QRS, QT, and QTc intervals.  Refer to Section 5.4.[ADDRESS_541812] be 
conducted in accordance with the SRM and Protocol Time an d Events Schedule (Section 
7.1). Laboratory  requisition forms must be completed and samples must be clearl y 
labelled with the subject number, protocol number, site/centre number, and visit date.
Details for th
e preparation and shipment of samples will be provided b y the laboratory 
and are detailed in the SRM .Reference ranges for all safet y parameters will be provided 
to the site by  [CONTACT_90633]. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
53If additional non -protocol -specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded i n the CRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
All study -required laboratory  assessments will be performed b y a central laboratory :
NOTE: Local laboratory results are only  required in the event that the central laboratory  
results are not available in time for either a treatment and/or response evaluation to be 
performed. If a local sample is required it is important that the sample for central 
analysis is obtained at the same time. Additionally  if the local laboratory  results are used 
to make either a treatment or response evaluation, the results
must be entered in theCRF.
Haematology , clinical chemistry , urinal ysis,and additional parame ters to be tested are 
listed below.
Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes with T -cell 
subsets
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Bicarbonates Alkaline phosphatise Albumin
Troponin I
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsHIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody )
FSH and estradiol (as needed in women of non -child bearing 
potential onl y)
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (as needed for women of child bearing 
potential) 2 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
54NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_428186] -Up 
Assessments after liver stoppi[INVESTIGATOR_31777] 12.[ADDRESS_541813] dos e of study  treatment 
should be repeated until the values return to normal or baseline.  If such values do not 
return to normal within a period judged reasonable by  [CONTACT_093], the etiology
should be iden tified and the sponsor notified
.
7.5. Pharmacokinetics
7.5.1. Blood Sample Collection
Blood samples for anal ysis of [COMPANY_004]2838232 concentrations will be collected at the time 
points indicated in Time and Events Tables (Section 7.1).  
The actual date and time of each blood sample collection will be recorded.  The timing of 
PK samples may  be altered and/or PK samples may  be obtained at additional time points 
to ensure thorough PK monitoring.  
Details of PK blood sample collection (including volume to be collected), processi ng, 
storage and shippi[INVESTIGATOR_428114] (SRM).
7.5.2. Sample A nalysis
Plasma analy sis will be performed by  [CONTACT_55412], Madison under the control of 
Bioanal ysis, Immunogenicity  and Biomarkers (BIB), PTS, GlaxoSmithKline.
Concen
trations of [COMPANY_004]2838232 will be determined in plasma using the currentl y 
approved bioanaly tical methodology . 
Once the plasma has been anal yzed for [COMPANY_004]2838232 any  remaining plasma may  be 
analyzed qualitatively  for other circulating metabolites and these res ults would be 
reported under a separate PTS protocol.
Raw data will be archived at the Covance, Madison facility .
7.6. Biomarker(s)/Pharmacody namic Markers
7.6.1. Viral Genoty pi[INVESTIGATOR_428187], at the times listed in the Time and Events Table in 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
55Section 7.1. Details concerning the handling, labeling and shippi[INVESTIGATOR_428188].
Genoty pic and phenot ypic anal yses will be carried out by  [CONTACT_428257]/PR and PR/RT formats, in which PCR amplification is used to generate HIV 
cDNA products including the Gag and the PR and RT coding regions, respectivel y. 
Phenotypic anal yses of the GAG/PR region will include susceptibility  to [COMPANY_004]2838232 . 
Analy sis will be done on Day  1 and Day  11 samples.  In the case of rebound HIV -1 viral 
load, anal ysis will be completed on samples corresponding to time point of rebound 
occu rrence. 
7.7. Genetics
Information regarding genetic research is included in Appendix 4 , Section 12.4 .
7.8. Value Evidence and Outcomes
Not required.
8. DATA MAN
AGEMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem , 
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data 
(e.g., removing errors and inconsistencies in the data).
Adverse events and concomitant medications terms will be coded using MedDRA 
and an internal validated medication dictionary ,[COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATIST ICAL CONSIDERA TIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  objectives of this study  are to investigate the safet y, tolerability, and 
antiviral activity of [COMPANY_004]2838232 administered as monotherapy  in combination with 
cobicistat in HIV-1 infected subjects , over a 10 day  treatment period. The antiviral 
activity  will be assessed by [CONTACT_428237] -1 RNA 
max change from baseline 
during the stud y.  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
569.2. Sample Size Considerations
9.2.1. Sample Size A ssumptions
The sample size for this study  is based primarily  on feasibility  to provide adequate 
precision for the estimations.
Based on data from the short term monotherap y study  of BMS -955176 PoC (AI468002) 
study  and assuming viral load values for individual subjects follow a log -normal 
distribution, 1000 trial simulations in Fixed and Adaptive Clinical Trial Simulation 
(FACTS ) software were conducted from the distribution with mean of change from 
baseline viral load drop on log scale at 1.0 to 1.5 copi[INVESTIGATOR_428117]=0.4 and sample sizes=10 
for Part A.  Using Bayesian calculation with non- informative priors for the mean and 
weakl y informative priors for the error parameters ,Normal (0, 100) for mean and Inverse 
Gamma (0.35, 0.0875) for error parameters, the posterior probability  to achieve a 
cutpoint 1.2 log was calculated for eac h simulated trial, and percentage of the trials with 
posterior probability of viral load< -1.2log drop given true mean) ≥70% were calculated 
and are shown below in Table 8.
Table 8 Percentage of the trials with posterior probability >=70% for Part A
True Mean Cutpoint Posterior Prob>=70%
1.0 1.2 1.4%
1.1 1.2 9%
1.2 1.2 29%
1.3 1.2 59%
1.4 1.2 83%
1.5 1.2 96%
An Emax model with functional uniform priors [ Bornkamp , 2014] was conducted using 
simulated data combining Part A and Part B with all doses. Success is defi ned as a
posterior probability  of the highest dose to achieve a cutpoint 1.2 log reduction in viral 
load.   This was calculated for each simulated trial andthe percentage of the trials with 
posterior probability  greater or equal to 70% were also calculate d and are shown below 
(Table 9). The table lists different viral load drop scenarios. The last scenario assumes the 
flat drop for all doses are 0.5 .  This scenario reflects the null hypothesis of no treatment 
effec t.   In this scenario 0% of the trials achieve the pre -specified decision rule for 
success.   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
57Table 9 Percentage of the trials with posterior probability  ≥70%
Cutpoint Posterior Prob ≥ Part A+ Part B 
mean VL drop for doses 
200, 100, 50, 20Part A+ Part B
1.2 70% 1.5, 1.4, 1.2, 0 99%
1.5, 1.4, 1.2, 0.5 96%
1.5, 1.4, 1.0, 0.5 93%
1.5, 1.3, 1.2, 0.5 86%
0.5, 0.5, 0.5, 0.5 0%
9.2.2. Sample Size Sensitivity
Similar simulations in FACT Swere conducted from the distribution with mean of change 
from baseline viral load drop on log scale at 1.5 c opi[INVESTIGATOR_428117]=0.4 or 0.6 and sample 
sizes of 6- 8 or 10 for Part A .  Using Bay esian calculation , the posterior probability  to 
achieve a cutpoint 1.2 log (in Table 10) was calculated for each simulated trial, and 
percentage of 
the trials with posterior probability  greater than or equal to 70% was 
calculated a nd are shown below .
Table 10 Percentage of the trials with posterior probability  ≥70% for Part A
True 
MeanCutpoint Posterior
Prob ≥Std for log10 
VLN=6 N=8 N=10
1.5 1.2 70% 0.4 90% 94% 96%
0.6 75% 81% 84%
9.2.3. Sample Size Re -estimation or Adjustment
No sample size re -estimation will be performed.
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Intent to Treat Exposed Population (ITT)
The ITT- Exposed Population is defined as all subjects who meet study  criteria and are 
enrolle d into the study  with documented evidence of having received at least [ADDRESS_541814]- baseline HIV -1 RNA measurement. This will be the 
primary  population for the final efficacy  anal ysis for all active treatment groups.
Per Protoco l Population (PP)
The Per Protocol Population is defined as all subjects who meet study  criteria and are 
enrolled into the study  with documented evidence of having received all doses and all 
post-baseline HIV -[ADDRESS_541815] dose ( e.g. the exposure level of 
[COMPANY_004]2838232 is in the range of the maximum [COMPANY_004]2838232 exposure seen previously  in 
healthy  subjects), the Bayesian posterior pr obability  that the log10 viral load decline from 
baseline is greater than a cut-point will be calculated. I f the Bay esian probability  from 
Cohort 1 
is less than 70% this will provide evidence tonot move forward into Part B. 
Otherwise , the stud y team will r eview the data in order to make a dose selection decision 
for the subsequent Part B Cohorts . If the pharmacokinetic exposures after the 100 mg 
[COMPANY_004]2838232/cobi dose look similar to those obtained with 100 mg [COMPANY_004]2838232/r in 
prior studies, the doses for Par
t B will be extended to both lower (20 mg, 50 mg) and 
higher (200 mg) doses.
Maximum change and change from baseline in plasma HIV- 1 RNA will be summarized 
by [CONTACT_428258] . The proportion of subjects with plasma HIV -1 RNA < 
400 and < 50 c opi[INVESTIGATOR_014]/mL will be summarized by  [CONTACT_428217] . The 
analyses will be done for both PP and I TT exposed population if two populations are not 
the same.
9.4. Key Elements of A nalysis Plan
9.4.1. Primary  Analyses
The final analy sis will be performed after th e completion of the study  and final datasets
authorization. Data will be listed and summarized according to GlaxoSmithKline 
reporting standards, where applicable. Listings will be sorted b y subject, period, day, and 
time, noting treatment; summaries will b e presented by  [CONTACT_3148], day , and time. Unless 
stated otherwise, descriptive summaries will include n, mean, standard deviation (SD), 
coefficient of variation (%CV), median, minimum, and maximum, geometric mean with 
associated 95% confidence interval (CI) , and %CVb for continuous variables, whereas n 
and percent will be used as summary  statistics for categorical variables . Baseline or pre-
dose assessment is the last available assessment prior to time of the first dose unless it is 
specified otherwise. If there are multiple assessments collected on the same scheduled 
time, the average of these assessments will be used. For tabulated safet y summaries, only 
the scheduled assessments will be included in the summary tables. Version 9.1 or higher 
of the SAS sy stem will be used to anal yze the data as well as to generate tables, figures,  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
59and listings. Complete details will be documented in the Reporting and Analy sis Plan 
(RAP).
[IP_ADDRESS]. Safety  Analyses
Safety  data will be presented in tabular format and summarized descriptiv ely according to
[COMPANY_004]’s Integrated Data Standards Library  standards and data will be in CDISC format. 
No formal statistical analy sis of the safet y data will be conducted. 
[IP_ADDRESS]. Efficacy  Analyses
Both the PP and ITT Populations will be used for all efficacy  analy ses if there are 
dropouts.  Plasma HIV -[ADDRESS_541816], and assessment day  and 
summarized by  [CONTACT_428259].
Plots of mean and median plasma HIV -1 RNA actual and change from baseline data will 
be generated b y treatment and assessment day.
Plasma HIV -1 RNA change from baseline to the on- treatment nadir (maxim um 
change) will be calculated for each subject and summarized by [CONTACT_3148] .
Together, the data from Parts A and B will investigate the complete dose -response curve 
and the impact of lower doses on potential development of resistance . A dose -response 
curve will be fit to the data from Parts A & B using functional uniform priors .  
[IP_ADDRESS]. Pharmacokinetic A nalyses
Pharmacokinetic anal ysis will be the responsibility of the Clinical Pharmacokinetics
Modeling and Simulation Department, Gl axoSmithKline. Plasma [COMPANY_004]2838232
concentration -time data will be anal yzed by [CONTACT_105] -compartmental methods with
WinNonlin Version 6.1 or higher. Calculations will be based on the actual sampling
times recorded during the study
. From the plasma concentration- time data, the following
pharmacokinetic parameters will be determined, as data permit:
Plasma [COMPANY_004]2838232 Pharmacokinetic Parameters to be Estimated:
Study Day Parameters
1 AUC(0 -24), Cmax, tmax, tlag, C24
10 AUC(0 -), Cmax, tmax, t½, C0, C , CL/F, R_AUC, R_Cmax, R_C 
Results based on samples collected from a subject with emesis within 4 hours of the dose 
will not be considered as evaluable.
All PK data will be stored in the R&D archives, GlaxoSmithKline. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
60Statistical analy ses of the pharmacokinetic parameter data will be the responsibility  of
Clinical Statistics , GlaxoSmithKline. Details of the statistical anal yses will be provided in 
the RA P. An outline is provided below:
Pharmacokinetic data will be presented in graphical and tabular form and will be 
summarized descriptively. Plasma GS K2838232 PK parameters , with the exception of 
tmax and tlag, will be log -transformed prior to analy sis.
Dose proportionality  of plasma [COMPANY_004]2838232 PK parameters from Day  1 [AUC(0 - 24)
andCmax] and Day  10 [AUC(0- τ)andCmax] will be assessed using a power model if 
multiple dose levels are assessed . The power model will be fitted by  [CONTACT_428219] (REML )using SAS Proc Mixed. A fixed effects power model will be used. 
The mean slope will be estimated from the power model with the corresponding 90% CI.
The accumulation ratio (R) and stead y-state assessments will be performed, if quality  of 
the data permits. Comparisons of Day  10 with Day  1 PK for each dose will be used for 
the ac cumulation ratio (R) evaluation. Pre- dose concentration sbetween Day s 7-10 will be 
used for stead y-state assessment. 
9.4.2. Secondary  Analyses
[IP_ADDRESS]. Pharmacokinetic/Pharmacody namic A nalyses
Relationships between various PK parameters ( e.g., AUC, Cmax, Cτ ,etc.) and PD 
measures (e.g., l og10 reduction from baseline in plasma HIV -1 RNA on Day  11 or safet y 
parameters) will be explored using various models including Emax . The relationship 
between dose and PD measures will also be explored. Details ofthe PK/PD exploratory  
analyses will be provided in the RAP.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_428189]/phenot ypic data will be listed and descriptive summaries will be
provided. Details of the analy ses will be provided in the clinical vi rology report.
10. STUDY GOVERNANCE CONSIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
61The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with ICH Good C linical Practice (GCP) , 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority
, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after a pproval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of t he optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accorda nce with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which theCRF will 
serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
62The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after comp letion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accorda nce with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating P rocedures.
[COMPANY_004] reserves the right to temporaril y suspend o r prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance . For multicenter studies, this can occur a t one or more 
or at all sites.  
If [COMPANY_004] determines such action is needed , [COMPANY_004] will discuss the reasons for taking 
such action 
with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safety reasons, [COMPANY_004] will
promptly  inform all investigators, head sof the medical institution s(where 
applicable) and /or institution(s) conducting the study . [COMPANY_004] w ill also promptly  
inform the relevant regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (whe re applicable) must inform the IRB/IECpromptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must mainta in all site study  records (except for 
those required b y local regulations to be maintained elsewhere ), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory inspection) and must be available for review  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
63in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a f ormat other than hard copy  (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and m eet accessibility  and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making t hese reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, a s dictated by  
[CONTACT_65406], [COMPANY_004] 
standards/procedures
, and/or institutional requirements. 
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off -site facility  ortransfer of 
ownership of the records in the event the investigator is no longer associated with
the site.
10.7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and P ublication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant r eports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the su mmary  results with the study  subjects, as 
appropriate.
The procedures and timing for public disclosure of the results summary and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
10.8. Review  Committees
The Safet y Review Tea m (SRT) is a [COMPANY_004] cross -functional team reviewing all available 
safet y data related to the project, including in -stream data from this study , in an ongoing 
manner. The SRT is an internal [COMPANY_004] requirement put in place to ensure holistic 
evaluation of the safe ty profile of an investigational product with sy stematic, periodic and 
documented reviews of available safety  data, with the appropriate communication and 
escalation of new findings that have the potential to impact patient safet y 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8905]. REFERENCES
Bloch M, Bodsw orth N, Fidler M, Workman C, Balach A, By [CONTACT_428221] H, et al. Efficacy , 
safet y and pharmacokinetics of MPC -4326 (bevirimat dimeglumine) 200mg BID and 
300mg BID monotherapy  administered for 14 day s in subjects with HIV -1 infection. 
ICAAC . 2009; Abstract H - 1230.
Bornkamp B, Practical considerations for using functional uniform prior distributions for 
dose-response estimation in clinical trials. Biometrical Journal 56 (2014) 6, 947 -962
Cockcroft DW, Gault MH. Prediction of creatinine clearance form serum creatinin e. 
Nephron. 1976;16:31-41.
Dang Z, Huang L, Chen C. HI V
-1 maturation inhibitors:  An update. Drugs of the Future. 
2009;34 (10):[ADDRESS_541817].  Phase 2 study  of cobicistat versus ritonavir each with once -
daily  atazanavir and fixed -dose emtricitabine.tenofovir df in the initial treatment of HIV 
infection.  AIDS .  2011; 25:1881 -1886.
Food and Drug Administration (FDA). Guidance for industry : Estimating the maximum 
safe starting dose in initial clinical trials for therapeutics in adult healthy  subjects. CDER, 
Rockville, MD; 2005. UCM078932.
Food and Drug Administration (FDA). Guidance for Industry : Human Immunodeficiency  
Virus -1 Infection: Developi[INVESTIGATOR_428119]. CDER, Rockville, 
MD; 2015. UCM355128.
Gallant JE, Koenig E, Andrade -Villaneuva J, Chetchotisakd P, deJesus E, Antunes F, 
Arastéh K, Mo yle G, Rizzardini G, Fehr J, L iu Y, Zhong L, Callebaut C, Scwarcberg J, 
Rhee MS, Cheng AK.  Cobicistat v ersus ritonavir as a pharmacoenhancer of atazanavir 
plus emtricitabine/tenofovir disoproxil fumarate in treatment- naïve HIV t ype 1 -infected 
patients:  week [ADDRESS_541818]. Dis.  2013; 208 -:32- 39.
GlaxoSmithKline Document Number 2012N151889_03 Compound [COMPANY_004]2838232. 
Investigator’s Brochure.  Effective November 2016.
GlaxoSmithKline Non-Clinical Research report. Document Number 2013N163221_00.
Hatcher RA, Trussel J, Nelson AL , Cates W, Stewart F, Kowal D, editors. Contraceptive 
Technology . 19th ed. [LOCATION_001]:Ardent Media; 2007. 
Kakuda TN, Opsomer M, Timmers M, I terbeke K, Van De Casteele T, Hillewaert V, 
Petrovic R, Hoetelmans RMW.  Pharmacokinetics of darunavir in fixed -dose 
combination with cobicistat compared with coadministration of darunavir and rit onavir as 
single agents in health y volunteers.  
J. Clin. Pharmacol.   2009; 54:949-957. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
65Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, et al. Safety  and efficacy  study  
of bevirimat (BVM) in heavily  treatment experienced HIV+ patients identifies t he target 
phase 3 study  profile. ICAAC. 2008; Abstract: H891. 
Mahmood I . Prediction of human drug clearance from animal data. Application of the 
rule of exponent and fu corrected intercept method (FCIM). J Pharm Sci. 
2006;95:1810-21. 
Martin D, Galbraith H, Ellis C, Schettler J and Doto J. Minimal effect of ritonavir (RTV) 
on the pharmacokinetics of bevirimat in healthy  volunteers [abstract]. IAS Conference on 
HIV Pathogenesis, Treatment and Prevention. 2007; Abstract no. WEPEB015:Poster 
discussion.
Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple -dose pharmacokinetics and 
safet y of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin 
Pharmacokinet. 2007(a);46(7):589-98.
Martin DE, Blum R, Wilton J, Doto J, Galbraith H, et a l. Safet y and pharmacokinetics of 
bevirimat (PA -457), a novel inhibitor of human immunodeficiency  virus maturation, in 
healthy  volunteers. Antimicrobial Agents and Chemotherapy. 2007(b);Sep:3063-6.
Martin DE, Galbraith H, Schettier J, Ellis C, Doto J. Phar macokinetic properties and 
tolerability  of bevirimat and atazanavir in healthy volunteers:  An open -label, parallel -
group stud y. Clinical Therapeutics. 2008;30(10):1794 -1805.
NORVI R (ritonavir) Product I nformation. January , 2013.
Nowicka -Sans B, Protack T, Lin Z, Li Z, Zhang S, Meanwell N, et al. BMS -955176: 
Characterization of a second- generation HIV -1 maturation inhibitor. 8th IAS Conference 
on HIV Pathogenesis, Treatment and Prevention, July  19-22, 2015, Vancouver, Canada.
Qian K, Morris -Natschke SL , Lee KH. HIV entry  inhibitors and their potential in HIV 
therap y. Medicinal Research Reviews. 2009;29(2):369
-93.
Saxena SK, Gupta A, Bhagy ashree K, Saxena R, Arora N, Banerjee AK, et al. Targeti ng 
strategies for human immunodeficiency  virus: A combinatorial ap proach. Min Rev Med 
Chem. 2012;12(3):236- 54.
TYBOST (cobicistat) Product I nformation. 2012
Wainburg MA, Albert J. Can the further clinical development of bevirimat be justified?. 
AIDS. 2010;24:773 -4. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8906]. APPENDICES
12.1. Appendix 1 :Abbreviations and Trademarks
Abbrev iations
g/mL Microgram per millilitre
ABC Abacavir
AE Adverse Event
AIDS Auto immunodeficiency  syndrome
ALT Alanine aminotransferase
API [INVESTIGATOR_428120] y
AST Aspartate aminotransferase
AUC Area under the plasma concentration time curve
AUC (0-) Area under the concentration- time curve from time zero 
(pre-dose) extrapolated to infinite time
AUC (0-) Area under the concentration- time curve over the dosing 
interval 
AUC (0-24) Area under the concentratio n-time curve from zero (pre -
dose) to 24 h
AUC (0-48) Area under the concentration -time curve from zero (pre -
dose) to 48 h
AUC (0-t) Area under the concentration- time curve from zero (pre -
dose) to time of last quantifiable concentration
BCRP Breast cancer resistance protein
Bpm beats per minute
BVM Bevirimat
BIL Bilirubin
C Pre-dose (trough) concentration at the end of the dosing 
interval
C24 24hour trough concentration
CDC Center for Disease Control and Prevention
CI Confidence interval
CL/F Oral Clearance
Cmax Maximum plasma concentration
Cmin Minimum plasma concentration
CPK Creatine Phosphokinase
CRF Case report form
cTnI Cardiac troponin I
CV Coefficient of variation
CVb Between -subject variability
CYP Cytochrome P450
DDI
DNA Deox yribonucleic acid
EC50 50% protection against resistant mutant HI V infection 
ECG Electrocardiogram 2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541819] time in Human Study
g Gram
GI Gastrointestinal
[COMPANY_004] Glax oSmithKline
h Hour(s)
HBsAg Hepatitis B surface antigen
hcG Human chorionic gonadotrophin
HDPE High densit y pol yethylene
hERG Human Ether -a-gogo Related Gene
HIV Human Immunodeficiency  Virus
IC50/90 50% or 90% maximal inhibitory  concentration
IEC International Ethics Committee
IQ Inhibitory  quotient
IRB Institutional Review Board
ISR Injection site reaction
IV Intravenous
IVRS Interactive voice response sy stem
kg Kilogram
L Litre
LLOD Lower limit of detection
MC Melanocortin
MedDRA Medical Dictionary  for Regulatory  Activities
mg/mL Milligram per millilitre
MI Maturation inhibitor
mL Milliliter
mRNA messenger Ribonucleic Acid
ND Not done
ng/mL Nanogram per millilitre 
nm Nanometer
NO Not observed
NOAEL No Observed Adverse Effect Lev el
NTproBNP N-terminal prohormone of brain natriuretic peptide
NSVT Non-sustained ventricular tachy cardia
OAT Organic anion transporter
OATP Organic anion transporting pol ypeptide
OCT Organic cation transporter
PBL Peripheral Blood Ly mphocy tes
PBMC Peripheral Blood Mononuclear Cells
PD Pharmacod ynamics
P-gp P-glycoprotein
PHIV Pseudo- HIV
PiB Powder -in-bottle
PK Pharmacokinetic 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
68PoC Proof of Concept
PI [INVESTIGATOR_428190]
t1/[ADDRESS_541820] quantifiable concentration
tmax Time of occurrence of Cmax
U Units
UGT Uridine 5' -diphospho- glucuronos yltransferase
Vz/F Mean apparent oral volume of distribution
WPW Wolff -Parkinson -White
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_428222], [COMPANY_002] HIV kit
Chiron RIBA 
Inform
Monogram
Phoenix WinNonlin 
SAS
Tybost (cobicistat) 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8907].2. Appendix 2: Liver Safety  Required A ctions and Follow up 
Assessments
Phase II liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Phase II liver che mistry stoppi[INVESTIGATOR_420682] – Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2 ALT  3xULN andbilirubin 2xULN (>35% direct bi lirubin)
INR2 ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3 ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an 
SAE data collecti on tool if the event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with study 
treatment unless allowed per protocol and [COMPANY_004] 
Medical Governance approval is granted 
If restart/rechallenge not allowed per protocol 
or not granted, permanently discontinue study 
treatment and may continue subject in the study Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtained within 24hrs after 
last dose5
Serum creatine phos phokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivi ty, on the AE report form
Record use of concomitant medications 
on the concomitant medications report  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
70for any protocol spec ified follow up assessments 
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within 
24hours
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up asses sments within  24-
72hours 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineform including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct high-
performance liquid chromato graphy
assay (quantifies potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week 
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatmen t for that subject if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury . 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirr hosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or ten derness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  E pstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Reco rd the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the las t dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
71Phase II liver chemistry increased monitoring criteria with cont inued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekl y for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_541821] safety. 
Subject can continue study treatment  
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubi n) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8908].3. Appendix 3: Liver Safety  –Stud y Treatment Restart or 
Rechallenge Guidelines
Study  treatment restart or re -challenge after liver chemistry  stoppi[INVESTIGATOR_428191] y is not allowed. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8909].4. Appendix 4 :Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including [COMPANY_004]2838232/RTV or an y concomit ant 
medicines;
HIVsusceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed usin g data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.   
A 6 ml blood or 2 ml saliva sample will be taken for Deox yribonucleic acid 
(DNA) extraction. A sample is collected at the baseline visit, after the subject has 
been randomized and provided informed consent for genetic research. Instructions 
for collection and shippi [INVESTIGATOR_428192]. The DNA from the blood/saliva sample may  undergo quality  control 
analyses to confirm the integrity of the sample. If there are concerns regarding the 
quality  of the sample, then the sample ma y be destroyed. The blood/saliva sample 
is taken on a single occasion unless a duplicate sample is required due to an 
inability  to utilize the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study .   This number can be traced or linked back to  2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541822] by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_541823] 
completes the study ,or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood/saliva being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic researc h withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must c omplete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may beanalyzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time o f withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destroy ed. No forms are required to 
complete this process as it will be completed as part of the consent and sample  2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541824]’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately andmay publish the result s in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genotypin g results that are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the si gnificance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8910].5. Appendix 5: Definition of and Procedures for Recording, 
Evaluating, F ollow -Up and Reporting of A dverse Events
12.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product .
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baselin e, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an A E or SAE.
The signs and symptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of efficacy " or 
"failure of expected pharmacological action" also constitutes an AE or SA E.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_941]  2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541825]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., end oscopy , appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_428193] s/symptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
c.Results in death
d.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
e.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_3094]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
78f.Results in disability/incapacity
NOTE:
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
andaccidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
g. Is a congenital anomaly/birth defect
h.Other situations:
Medical or scientific judgment should be exercised in de ciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood d yscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
i.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
Refer to Appendix 2 for the required liver chemistry  follow -up instructions 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8911].5.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AE s and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embo lism
Revascularization
12.5.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical pro cedures detailed b y  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
80the scale’s developer.
The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
12.5.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The i nvestigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relation ship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator mustdocument in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  Howev er, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004]. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
81The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amen ding the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supp lemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
By [CONTACT_428223], the investigator is obligated to report an y grade 2 or higher 
“alterati on in personality -behavior or in mood” or “altered mental status” adverse 
events that occur in subjects taking this drug, to [COMPANY_004] within 3 day s.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histop athological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.5.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electro nic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page wit hin 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm system) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report o f a new SAE from a study  subject or receives updated data  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
82on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Conta cts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE reporting to [COMPANY_004] via paper CRF
Facsim 0ile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of the SAE data collection tool sent by 
[CONTACT_9338]
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE report ing to [COMPANY_004] via PI[INVESTIGATOR_46427]
Facsimile transmission of the following PI[INVESTIGATOR_428122]:
SAE listing
Demographic listing
Study  treatment listing
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of all required information sent by [CONTACT_428224].
If the PI[INVESTIGATOR_428162], the site will use the paper 
SAE form and fax that to the Medical Monitor or protocol contact. The site will enter 
the SAE data into PI [INVESTIGATOR_428124] s ystem becomes available. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8912].6. Appendix 6: Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24hrs of learning of a subject's pregnancy .
Subject will be followed to determine the outcome of the pregna ncy. The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE o r 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to G SK 
as de scribed in Appendix [ADDRESS_541826] wh o becomes pregnant while participating 
will discontinue study  medication andbe withdrawn from the study
This will only  be included if either of the following appl y:
Investigator will attempt to collect pregnancy  information on any  female partner of a 
male study  subject who becomes pregnant while participating in this study .  This 
applies only  to subjects who are randomized to receive study  medication. 
After obtaining the necessary  signed informed consent from the female partner 
directly , the investigator will record pregnancy information on the appropriate form 
report the event and submit it to [COMPANY_004] within 24hrs of learning of the partner’s 
pregnancy
Partner will also be followed to determine the outcome of the pregnancy .  
Information on the status of the mother and child will be forwarded to [COMPANY_004]. 
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date.  An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8913].7. Appendix 7:Country  Specific Requirements
No country -specific requirements exist. 2018N360917_00
2015N227852_00 CONFIDENTIA L
[PHONE_8901].8. Appendix 8:Division Of A IDS Table For Grading The 
Severit y Of A dult And Pediatric A dverse Events Version 1.0, 
December 2004; Clarification A ugust 2 009
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
ESTIMATING SEVERITY GRADE
Clinical adverse 
event NOT identified 
elsewhere in the 
grading tableMild symptoms 
causing no or 
minimal 
interference with 
usual so cial & 
functional 
activities with 
intervention not 
indicatedModerate 
symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention not 
indicatedSevere symptoms 
causing inability to 
perform usual social 
& functional activities 
with intervention or 
hospi[INVESTIGATOR_428125] -
threatening symptoms 
causing inability to 
perform basic self -care 
functions OR Medical or 
operative intervention 
indicated to prevent 
permanent impairment, 
persistent disa bility, or 
death 
CARDIOVASCULAR
Arrhythmia
(by[CONTACT_223081])
Specify type, if
applicableNo symptoms 
AND No 
intervention 
indicatedNo symptoms AND
non-urgent 
intervention 
indicatedNon-life-threatening 
symptoms AND Non -
urgent intervention
indicatedLife-threatening 
arrhythmia OR Urgent 
intervention indicated
Blood Pressure 
Abnormalities1 
Hypertension (with 
the lowest reading 
taken after repeat 
testing during a visit) 
≥ 18 years of age 140 to < 160 
mmHg systolic 
OR 90 to < 100 
mmHg diastolic ≥ 160 to < 180 
mmHg systolic OR 
≥ 100 to < 110 
mmHg diastolic ≥ 180 mmHg systolic 
OR ≥ 110 mmHg 
diastolic Life-threatening 
consequences in a 
participant not 
previously diagnosed
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_373] 
< 18 years of age > 120/80 mmHg ≥ 95th to < 99th 
percentile + 5 
mmHg adjusted for 
age, height, and 
gender (systolic 
and/or diastolic) ≥ 99th percentile + 5 
mmHg adjusted fo r 
age, height, and 
gender (systolic 
and/or diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_428126] (stable 
angina) OR New 
testing consistent 
with ischemia Unstable angina OR 
Acute myocardial 
infarction  2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541827] or 
with minimal activity 
orexertion (e.g., 
hypoxemia) OR 
Intervention indicated 
(e.g., oxygen) Life-threatening 
consequences OR 
Urgent intervention 
indicated (e.g., 
vasoactive medications, 
ventricular assist device, 
heart transplant) 
Hemorrhage (with 
significant acute 
blood loss) NA Symptoms AND No 
transfusion 
indicated Symptoms AND 
Transfusion of ≤ 2 
units packed RBCs 
indicated Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs (for 
children, packed RBCs 
> 10 cc/kg) indicated 
Prolonged PR 
Interval or AV B lock 
Report only one 
> 16 years of age PR interval 0.21 
to < 0.25 seconds PR interval ≥ 0.25 
seconds OR Type I 
2nd degree AV 
block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
≤ [ADDRESS_541828] degree AV 
block (PR interval 
> normal for age 
and rate) Type I 2nd degree 
AV block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
Prolonged QTc 
Interval2 0.45 to 0.47 
seconds > 0.47 to 0.50 
seconds > 0.50 seconds OR ≥ 
0.06 seco nds above 
baseline Life-threatening 
consequences (e.g., 
Torsade de pointes, 
other associated serious 
ventricular dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention 
indicated Symptoms AND 
Intervention indicated Life-threatening embolic 
event (e.g., pulmonary 
embolism, thrombus) 
DERMATOLOGIC
Alopecia (scalp only) Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visu al 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities NA NA 
Bruising Localized to one 
area Localized to more 
than one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment indicated 
(e.g., or al 
antibiotics, 
antifungals, 
antivirals) IV treatment 
indicated (e.g., IV 
antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (e.g., 
sepsis, tissue necrosis)  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
87PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperpi[INVESTIGATOR_428127] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Hypopi[INVESTIGATOR_428128] & 
function al 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Petechiae Localized to one 
area Localized to more 
than one area Generalized NA 
Pruritus3(without 
skin lesions) Itchin g causing no 
or minimal 
interference with 
usual social & 
functional 
activities Itching causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Itching causing 
inability to perform 
usual social & 
functional activities NA 
Rash 
Specify type, if 
applicable Localized rash Diffuse rash OR 
Target lesions Diffuse rash AND 
Vesicles or limited 
number of bullae or 
superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized 
bullous lesions OR 
Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Stevens-
Johnson syndrome OR 
Toxic epi[INVESTIGATOR_428129]-threatening 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non -
ketotic coma, end organ 
failure) 
Gynecomastia Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing pain with 
greater than 
minimal 
interference with 
usual social & 
functional activities Disfigu ring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social 
& functional activities NA  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
88PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperthyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
suppression 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
thyroid storm) 
Hypothyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
replacement 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
myxedema coma) 
Lipoatrophy4 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy5 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
GASTROINTESTINAL
Anorexia Loss of appetite 
without decreased 
oral intake Loss of appetite 
associated with 
decreased oral 
intake without 
significant weight 
loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
Ascites No symptoms Symptoms AND 
Intervention 
indicated (e.g., 
diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despi[INVESTIGATOR_144482]-threatening 
consequences  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
89PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Bloating or 
Distension 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cholecystitis NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (e.g., 
sepsis, perforation) 
Constipation NA Persistent 
constipation 
requiring regular 
use of dietary 
modificat ions, 
laxatives, or 
enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (e.g., 
obstruction) 
Diarrhea ≥ 1 year of 
age Transient or 
intermittent 
epi[INVESTIGATOR_428130] ≤ 
3 stools over 
baseline per 24 -
hour period Persistent epi[INVESTIGATOR_428131] 4 to 6 
stools over baseline 
per 24- hour period Increase of ≥7 stools 
per 24- hour period 
OR IV fluid 
replacement 
indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one 
and specify 
location Symptoms but 
able to eat usual 
diet Symptoms causing 
altered dietary 
intake with no 
intervention 
indicated Symptoms causing 
severely altered 
dietary intake with 
intervention indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other 
than iron 
supplement Endoscopic 
intervention 
indicated Transfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Mucositis or 
Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes 
or ulcerations Confluent 
pseudomembranes 
or ulce rations OR 
Mucosal bleeding 
with minor trauma Life-threatening 
consequences (e.g., 
aspi[INVESTIGATOR_1516], choking) OR 
Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
Nausea Transient (< 24 
hours) or 
intermittent AND 
No or minimal 
interference with 
oral intake Persistent nausea 
resulting in 
decreased oral 
intake for 24 to 48 
hours Persistent nausea 
resulting in minimal 
oral intake for > 48 
hours OR 
Rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pancreati tis NA Symptoms with 
hospi[INVESTIGATOR_184842]-threatening 
consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis)  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
90PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort 
with no 
intervention 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Medical 
intervention 
indicated Symptoms causing 
inability to perform 
usual social &
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (e.g., 
perforation) 
Rectal Discharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND 
No or minimal 
interfe rence with 
oral intake Frequent epi[INVESTIGATOR_428132] 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
MUSCULOSKELETAL
Arthralgia Joint pain causing 
no or minimal 
interference with 
usual social & 
functional 
activities Joint pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self -care 
functions 
Arthritis Stiffness or joint 
swelling causing 
no or minimal 
interference with 
usual social & 
functional 
activities Stiffness or joint 
swelling causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions 
Myalgia 
(generalized) Muscle pain 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Muscle pain 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
inability to perfor m 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self -care 
functions 
Osteonecrosis NA No symptoms but 
with radiographic 
findings AND No 
operative 
intervention 
indicated Bone pain with 
radiographic findin gs 
OR Operative 
intervention indicated Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self -care 
functions 
Osteopenia6
≥ 30 years of age BMD t -score -2.5 
to -1 NA NA NA  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
91PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
< 30 years of age BMD z -score -2 to 
-1 NA NA NA 
Osteoporosis6
≥ 30 years of age NA BMD t -score < -2.5 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
< 30 years of age NA BMD z -score < -2 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
NEUROLOGIC
Acute Central 
nervous system 
(CNS) Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accide nt (e.g., stroke 
with neurological deficit) 
Altered Mental 
Status (for 
Dementia, see 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance below) Changes causing 
no or minimal 
interference with 
usual social & 
functional 
activities Mild lethargy or 
somnolen ce 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Confusion, memory 
impairment, lethargy, 
or somnolence 
causing inability to 
perform usual social 
& functional activities Delirium OR 
Obtundation OR Coma 
Ataxia Sympt oms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
ataxia detected on 
examination Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self -care 
functions 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance 
(includes dementia 
and attention deficit 
disorder) 
Specify type, if 
applicable Disability causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR 
Specialized 
resources not 
indicated Disability causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part -
time basis indicated Disability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full-
time basis indicated Disability causing 
inability to perform basic 
self-care functions OR 
Institutionalization 
indicated  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
92PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Developmental 
Delay < 18 years of 
age 
Specify type, if 
applicable Mild 
developmental 
delay, either 
motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental 
delay, either motor
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Severe 
developmental delay, 
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting 
Headache Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms cau sing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428133] (includes 
myopathy and 
neuropathy) 
Specify type, if 
applicable Minimal muscle 
weakness causing 
no or minimal 
interference with 
usual social & 
functional
activities OR No 
symptoms with 
decreased 
strength on 
examination Muscle weakness 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle weakness 
causing inability to 
perform usual social 
& functional activities Disab ling muscle 
weakness causing 
inability to perform basic 
self-care functions OR 
Respi[INVESTIGATOR_428134] (includes 
paresthesia and 
painful neuropathy) 
Specify type, if 
applicable Minimal 
paresthesia 
causi ng no or 
minimal 
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
sensory alteration 
on examination Sensory alteration 
or paresthesia 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Sensory al teration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self -care 
functions 
Seizures New Onset 
Seizure 
≥ 18 years of age NA NA 1 to 3 seizures Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
< 18 years of age 
(includes new or pre -
existing febrile 
seizures) Seizure lasting < 
5 minutes w ith < 
24 hours postictal 
state Seizure lasting 5 to 
< 20 minutes with < 
24 hours postictal 
state Seizure lasting ≥ 20 
minutes OR > 24 
hours postictal state Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002])  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
93PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Pre-existing Seizure NA Increased 
frequency from 
previous level of 
control without 
change in seizure 
character Change in seizure 
character either in 
duration or quality 
(e.g., severity or 
focality) Prolonged and repetitive 
seizures (e .g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Syncope Near syncope 
without loss of 
consciousness 
(e.g., pre-
syncope) Loss of 
consciousness with 
no intervention 
indicated Loss of 
consciousness AND 
Hospi[INVESTIGATOR_428135], PUERPERIUM, AND PERINATAL
Fetal Death or 
Stillbirth (report 
using mother’s 
participant ID) 
Report only one NA NA Fetal loss occurring 
at ≥ 20 weeks 
gestation NA 
Preterm Delivery7
(report using 
mother’s participant 
ID) Delivery at 34 to < 
37 weeks 
gestational age Delivery at 28 to < 
34 weeks 
gestational age Delivery at 24 to < 28 
weeks gestational 
age Delivery at < 24 weeks 
gestational age 
Spontaneous 
Abortion or 
Miscarriage8(report 
using mother’s 
participant ID) 
Report only one Chemical 
pregnancy Uncomplicated 
spontaneous 
abortion or 
miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
PSYCHIATRIC
Insomnia Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early Moderate difficul ty 
falling asleep, 
staying asleep, or 
waking up early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric 
Disorders 
(includes anxiety, 
depression, mania, 
and 
psychosis) 
Specify disorder Symptoms with 
intervention no t 
indicated OR 
Behavior causing 
no or minimal 
interference with 
usual social & 
functional 
activities Symptoms with 
intervention 
indicated OR 
Behavior causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms with 
hospit alization 
indicated OR 
Behavior causing 
inability to perform 
usual social & 
functional activities Threatens harm to self 
or others OR Acute 
psychosis OR Behavior 
causing inability to 
perform basic self -care 
functions  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
94PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Suicidal Ideation or 
Attempt 
Report only one Preoccupi[INVESTIGATOR_428136] 1 
second or peak 
flow reduced to ≥ 
70 to < 80% OR 
Mild symptoms 
with intervention 
not indicated Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 50 to < 
70% OR Symptoms 
with intervention 
indicated OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 25 to < 
50% OR Symptoms 
causing inability to 
perform usual social 
& functional activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow < 25% OR 
Life-threatening 
respi[INVESTIGATOR_428137] & 
functional 
activities OR 
Wheezing OR 
Minimal increase 
in respi[INVESTIGATOR_428138] & 
functional activities 
OR Nasal flaring 
OR Intercostal 
retraction s OR 
Pulse oximetry 90 
to < 95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional activities 
OR Pulse oximetry < 
90% Respi[INVESTIGATOR_184852] (e.g., 
Continuous positive 
airway pressure [CPAP], 
Bilevel positive airway 
pressure [BPAP], 
intubation) 
SENSORY
Hearing Loss 
≥ 12 years of age NA Hearing aid or 
intervention not 
indicated Hearing aid or 
intervention indicated Profound bilateral 
hearing loss (> 80 dB at 
2 kHz and above) OR 
Non-serviceable hear ing 
(i.e., >50 dB audiogram 
and <50% speech 
discrimination) 
< 12 years of age 
(based on a 1, 2, 3, 
4, 6 and 8 kHz 
audiogram) > 20 dB hearing 
loss at ≤ 4 kHz > 20 dB hearing 
loss at > 4 kHz > 20 dB hearing loss 
at ≥ 3 kHz in one ear 
with additional 
speech language 
related services 
indicated (where 
available) OR 
Hearing loss 
sufficient to indicate 
therapeutic 
intervention, including 
hearing aids Audiologic indication for 
cochlear implant and 
additional speech -
language related 
services indicated 
(where available)  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
95PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Tinnitus Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Uveitis No symptoms 
AND Detectable 
on examination Anterior uveitis with 
symptoms OR 
Medicamylasal 
intervention 
indicated Posterior or pan -
uveitis OR Operative 
interv ention indicated Disabling visual loss in 
affected eye(s) 
Vertigo Vertigo causing 
no or minimal 
interference with 
usual social & 
functional 
activities Vertigo causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self -care 
functions 
Visual Changes 
(assessed from 
baseline) Visual changes 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Visual changes 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Visual changes 
causing inability to 
perform usual social 
& functional activities Disabling visual loss in 
affected eye(s) 
SYSTEMIC
Acute Allergic 
Reaction Localized urticaria 
(wheals) with no 
medical 
intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with 
no intervention 
indicated Generalized urticaria 
OR Angioedema with 
intervention indicated
OR Symptoms of 
mild bronchospasm Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference wit h 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9Mild signs and 
symptoms AND 
Therapy (i.e., 
antibody infusion) 
interruption not 
indicated Therapy (i.e., 
antibody infusion) 
interruption 
indicated AND 
Responds promptly 
to symptomatic 
treatment OR 
Prophylactic 
medications 
indicated for ≤ 24 
hours Prolonged severe 
signs and symptoms 
OR Recurrence of 
symptoms following 
initial improvement Life-threatening 
conse quences (e.g., 
requiring pressor or 
ventilator support)  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
96PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Fatigue or Malaise 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating 
symptoms of fatigue or 
malaise causing inability 
to perform basic self -
care functions 
Fever (non-axillary 
temperatures only) 38.0 to < 38.6°C 
or 100.4 to < 
101.5°F ≥ 38.6 to < 39.3°C 
or ≥ 101.5 to < 
102.7°F ≥ 39.3 to < 40.0°C or 
≥ 102.7 to < 104.0°F ≥ 40.0°C or ≥ 104.0°F 
Pain10(not 
associated with study 
agent injections and 
not specified 
elsewhere) 
Specify location Pain causing no 
or minimal 
interference with 
usual social & 
functional 
activities Pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Pain causing inability 
to perform usual 
social & functional 
activities Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428139]11 Mild signs and 
symptoms Moderate signs and 
symptoms AND 
Intervention 
indicated (e.g., 
antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(e.g., steroids or IV 
fluids) Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Underweight12
> 5 to 19 years of 
age NA World Health 
Organization 
(WHO) BMI z- score 
< -2 to ≤ -3 WHO BMI z -score < -
3 WHO BMI z -score < -3 
with life- threatening 
consequences 
2 to 5 years of age NA WHO Weight -for-
height z -score 
< -2 to ≤ -3 WHO Weight -for-
height z -score < -3 WHO Weight -for-height 
z-score < -3 with life -
threatening 
consequences 
< 2 years of age NA WHO Weight -for-
lengt h z-score 
< -2 to ≤ -3 WHO Weight -for-
length z -score < -3 WHO Weight -for-length 
z-score < -3 with life -
threatening 
consequences 
Weight Loss 
(excludes postpartum 
weight loss) NA 5 to < 9% loss in 
body weight from 
baseline ≥ 9 to < 20%  loss in 
body w eight from 
baseline ≥ 20% loss in body 
weight from baseline OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
URINARY
Urinary Tract 
Obstruction NA Signs or symptoms 
of urinary tract 
obstruction without 
hydronephros is or 
renal dysfunction Signs or symptoms of 
urinary tract 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing life -
threatening 
consequences  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
97PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
SITE REACTIONS TO INJECTIONS AND INFUSIONS
Injection Site Pain 
or Tenderness 
Report only one Pain or 
tenderness 
causing no or 
minimal limitation 
of use of limb Pain or tenderness 
causing greater 
than minimal 
limitation of use of 
limb Pain or tenderness 
causing inability to 
perform usual social 
& functional activities Pain or tenderness 
causing inability to 
perform basic self -care 
function OR 
Hospi[INVESTIGATOR_428140]13 
Report only one 
> 15 years of age 2.5 to < 5 cm in 
diameter OR 6.25 
to < 25 cm2 
surface area AND 
Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities ≥ 5 to < 10 cm in 
diameter OR ≥ 25 
to < 100 cm2 
surface area OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities ≥ 10 cm in diameter 
OR ≥ 100 cm2 
surface area OR 
Ulceration OR 
Secondary infection 
OR Phlebitis OR
Sterile abscess OR 
Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
≤ 15 years of age ≤2.5 cm in 
diameter > 2.5 cm in 
diameter with < 
50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) ≥ 50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) OR Ulceration 
OR Secondary 
infection OR Phlebitis 
OR Sterile abscess 
OR Drainage Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or 
Swelling 
Report only one 
> 15 years of age Same as for 
Injecti on Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, > 15 years of 
age 
≤ 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
age 
Injection Site 
Pruritus Itching localized 
to the injection 
site that is 
relieved 
spontaneously or 
in < 48 hours of 
treatment Itching beyond the 
injection site that is 
not generalized OR 
Itching localized to 
the injection s ite 
requiring ≥ 48 
hours treatment Generalized itching 
causing inability to 
perform usual social 
& functional activities NA 
LABORATORY VALUES Chemistries
Acidosis NA pH ≥ 7.3 to < Lower 
limit of normal 
(LLN) pH < 7.3 without life -
threatening 
conseq uences pH < 7.3 with life -
threatening 
consequences 
Albumin, Low (g/dL; 
g/L) 3.0 to < LLN 
30 to < LLN ≥ 2.0 to < 3.0
≥ 20 to < 30 < 2.0 
< 20 NA  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
98PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Alkaline 
Phosphatase, High 1.25 to < 2.[ADDRESS_541829] 2.5 to < 5.[ADDRESS_541830] 5.0 to < 10.[ADDRESS_541831] ≥ 10.0 x UL N 
Alkalosis NA pH > ULN to ≤ 7.5 pH > 7.5 without life -
threatening 
consequences pH > 7.5 with life -
threatening 
consequences 
ALT or SGPT, High 
Report only one 1.25 to < 2.[ADDRESS_541832] 2.5 to < 5.[ADDRESS_541833] 5.0 to < 10.[ADDRESS_541834] ≥ 10.[ADDRESS_541835] 
Amylase 
(Pancreatic) or 
Amylase (Total), 
High 
Report only one 1.1 to < 1.[ADDRESS_541836] 1.5 to < 3.[ADDRESS_541837] 3.0 to < 5.[ADDRESS_541838] ≥ 5.[ADDRESS_541839] or SGOT, High 
Report only one 1.25 to < 2.[ADDRESS_541840] 2.5 to < 5.[ADDRESS_541841] 5.0 to < 10.[ADDRESS_541842] ≥ 10.[ADDRESS_541843] 
Bicarbonate, Low
(mEq/L; mmol/L ) 16.0 to < LLN 
16.0 to < LLN 11.0 to < 16.0 
11.0 to < 16.0 8.0 to < 11.0 
8.0 to < 11.0 < 8.0 
< 8.[ADDRESS_541844] 
Bilirubin14, High 
> 28 days of age NA NA > ULN > ULN with life -
threatening 
consequences (e.g., 
signs and sympt oms of 
liver failure) 
≤ [ADDRESS_541845] to ≤ 1 mg/dL > 1 to ≤ 1.5 mg/dL > 1.5 to ≤ 2 mg/dL > 2 mg/dL 
Total Bilirubin, High 
> 28 days of age 1.1 to < 1.[ADDRESS_541846] 1.6 to < 2.[ADDRESS_541847] 2.6 to < 5.[ADDRESS_541848] ≥ 5.[ADDRESS_541849] 
≤ 28 days of age Total Bilirubin for 
Term and Preter m 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for Term 
and Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L ) 
≥ 7 days of age 10.6 to < 11.5 
2.65 to < 2.88 11.5 to < 12.5 
2.88 to < 3.13 12.5 to < 13.5 
3.13 to < 3.38 ≥ 13.5 
≥ 3.38 
< 7 days of age 11.5 to < 12.4 
2.88 to < 3.10 12.4 to < 12.9 
3.10 to < 3.23 12.9 to < 13.5 
3.23 to < 3.38 ≥ 13.5 
≥ 3.38 
Calcium (Ionized), 
High (mg/dL; 
mmol/L ) > ULN to < 6.0
> ULN to < 1 .5 6.0 to < 6.4 
1.5 to < 1.6 6.4 to < 7.2 
1.6 to < 1.8 ≥ 7.2 
≥ 1.8  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
99PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Calcium, Low 
(mg/dL; mmol/L ) 
≥ 7 days of age 7.8 to < 8.4 
1.95 to < 2.10 7.0 to < 7.8 
1.75 to < 1.95 6.1 to < 7.0 
1.53 to < 1.75 < 6.1 
< 1.53 
< 7 days of age 6.5 to < 7. 5 
1.63 to < 1.88 6.0 to < 6.5 
1.50 to < 1.63 5.50 to < 6.0 
1.38 to < 1.50 < 5.50 
< 1.38 
Calcium (Ionized), 
Low (mg/dL; mmol/L ) < LLN to 4.0 
< LLN to 1.0 3.6 to < 4.0 
0.9 to < 1.0 3.2 to < 3.6 
0.8 to < 0.9 < 3.2 
< 0.8 
Cardiac Troponin I, 
High NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as 
defined by [CONTACT_428225], 
High 3 to < [ADDRESS_541850] 6 to < [ADDRESS_541851] 10 to < [ADDRESS_541852] ≥ [ADDRESS_541853] > 1.[ADDRESS_541854] 
OR Increase of > 
0.3 mg/dL above 
baseline > 1.8 to < 3.[ADDRESS_541855] 
OR Increase of 1.5 to 
< 2.0 x above 
baseline ≥ 3.[ADDRESS_541856] OR 
Increase of ≥ 2.0 x 
above baseline 
Creatinine 
Clearance15or
Estimated 
glomerular filtration 
rate (eGFR), Low 
Report only one NA < 90 to 60 mL/min 
or mL/min/1.73 m2 
OR 10 to < 30% 
decrease from 
baseline < 60 to 30 mL/min or 
mL/min/1.73 m2 OR 
≥ 30 to < 50%  
decrease from 
baseline < 30 mL/min or 
mL/min/1.73 m2 OR ≥ 
50% decrease from 
baseline or dialysis 
needed 
Glucose 
(mg/dL; mmol/L ) 
Fasting, High 110 to 125 
6.11 to < 6.95 > 125 to 250 
6.95 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Nonfasting, High 116 to 160 
6.44 to < 8.89 > 160 to 2 50 
8.89 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Glucose, Low 
(mg/dL; mmol/L ) 
≥ 1 month of age 55 to 64 
3.05 to 3.55 40 to < 55 
2.22 to < 3.05 30 to < 40 
1.67 to < 2.22 < 30 
< 1.[ADDRESS_541857] to < 2.[ADDRESS_541858] without 
acidosis ≥ 2.[ADDRESS_541859] without 
acidosis Increased lactate with 
pH < 7.3 without life -
threatening 
consequences Increased lactate with 
pH < 7.3 with life -
threatening 
consequences 
Lipase, High 1.1 to < 1.[ADDRESS_541860] 1.5 to < 3.[ADDRESS_541861] 3.0 to < 5.[ADDRESS_541862] ≥ 5.[ADDRESS_541863]  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
100PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Lipid Disorders 
(mg/dL; mmol/L ) 
Cholesterol, 
Fasting, High 
≥ 18 years of age 200 to < 240 
5.18 to < 6.19 240 to < 300 
6.19 to < 7.77 ≥ 300 
≥ 7.77 NA 
< 18 years of age 170 to < 200 4.40 
to < 5.15 200 to < 300 5.15 to 
< 7.77 ≥ 300 ≥ 7.77 NA 
Low Density 
Lipoprotein (LDL),
Fasting, High 
≥ 18 years of age 130 to < 160 3.37 
to < 4.12 160 to < 190 4.12 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
> 2 to < 18 years of 
age 110 to < 130 2.85 
to < 3.34 130 to < 190 3.34 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
Triglycerides, 
Fasting, High 150 to 300 
1.71 to 3.42 >300 to 500 
>3.42 to 5.7 >500 to < 1,000 
>5.7 to 11.4 > 1,000 
> 11.4 
Magnesium16, Low 
(mEq/L; mmol/L ) 1.2 to < 1.4 
0.60 to < 0.70 0.9 to < 1.2 
0.45 to < 0.60 0.6 to < 0.9 
0.30 to < 0.45 < 0.6 
< 0.30 
Phosphate, Low 
(mg/dL; mmol/L ) 
> 14 years of age 2.0 to < LLN 
0.81 to < LLN 1.4 to < 2.0 
0.65 to < 0.81 1.0 to < 1.4 
0.32 to < 0.65 < 1.0 
< 0.32 
1 to 14 years of age 3.0 to < 3.5 
0.97 to < 1.13 2.5 to < 3.0 
0.81 to < 0.97 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
< 1 year of age 3.5 to < 4.5 
1.13 to < 1.45 2.5 to < 3.5 
0.81 to < 1.13 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
Potassium, High 
(mEq/L; mmol/L ) 5.6 to < 6.0 
5.6 to < 6.0 6.0 to < 6.5 
6.0 to < 6.5 6.5 to < 7.0 
6.5 to < 7.0 ≥ 7.0 
≥ 7.0 
Potassium, Low 
(mEq/L; mmol/L ) 3.0 to < 3.4 
3.0 to < 3.4 2.5 to < 3.0 
2.5 to < 3.0 2.0 to < 2.5 
2.0 to < 2.5 < 2.0 
< 2.0 
Sodium, High 
(mEq/L; mmol/L ) 146 to < 150 
146 to < 150 150 to < 154 
150 to < 154 154 to < 160 
154 to < 1 60 ≥ 160 
≥ 160 
Sodium, Low 
(mEq/L; mmol/L ) 130 to < 135 
130 to < 135 125 to < 130 
125 to < 135 121 to < 125 
121 to < 125 ≤ 120 
≤ 120 
Uric Acid, High 
(mg/dL; mmol/L ) 7.5 to < 10.0 
0.45 to < 0.59 10.0 to < 12.0 
0.59 to < 0.71 12.0 to < 15. 0 
0.71 to < 0.89 ≥ 15.0 
≥ 0.89  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
101PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
HEMATOLOGY
Absolute cluster of 
differentiation 4 
(CD4+) Count, Low 
(cell/mm3; cells/L ) 
> 5 years of age (not 
HIV infected) 300 to < 400 
300 to < 400 200 to < 300 
200 to < 300 100 to < 200 
100 to < 200 < 100 
< 100 
Absolute 
Lymphocyte Count, 
Low 
(cell/mm3; cells/L ) 
> 5 years of age 
(not HIV infected) 600 to < 650 
0.600 x 109to < 
0.650 x 109500 to < 600 
0.500 x 109to < 
0.600 x 109350 to < 500 
0.350 x 109to < 
0.500 x 109< 350 
< 0.350 x 109
Absolu te Neutrophil 
Count (ANC), Low 
(cells/mm3; cells/L ) 
> 7 days of age 800 to 1,000 
0.800 x 109to 
1.000 x 109600 to 799 
0.600 x 109to 0.799 
x 109400 to 599 
0.400 x 109to 0.599 
x 109< 400 
< 0.400 x 109
2 to 7 days of age 1,250 to 1,500 
1.250 x 109to 
1.500 x 1091,000 to 1,249 
1.000 x 109to 1.249 
x 109750 to 999 
0.750 x 109to 0.999 
x 109< 750 
< 0.750 x 109
≤ 1 day of age 4,000 to 5,000 
4.000 x 109to 
5.000 x 109 3,000 to 3,999 
3.000 x 109to 3.999 
x 1091,500 to 2,999 
1.500 x 109to 2.999 
x 109< 1,500 
< 1.500 x 109
Fibrinogen, 
Decreased (mg/dL; 
g/L) 100 to < 200 
1.00 to < 2.00 OR 
0.75 to < 1.[ADDRESS_541864] 75 to < 100 
0.75 to < 1.00 OR ≥ 
0.50 to < 0.[ADDRESS_541865] 50 to < 75 
0.50 to < 0.75 OR 
0.25 to < 0.[ADDRESS_541866] < 50 
< 0.50 OR < 0.[ADDRESS_541867] 
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L )18 
≥ 13 years of age 
(male only) 10.0 to 10.9 
6.19 to 6.76 9.0 to < 10.0 
5.57 to < 6.19 7.0 to < 9.0 
4.34 to < 5.57 < 7.0 
< 4.34 
≥ 13 years of age 
(female only ) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
57 days of age to < 
13 years of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
<4.03  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
102PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
36 to 56 days of age 
(male and female) 8.5 to 9.6 
5.26 to 5.99 7.0 to < 8.5 
4.32 to < 5.26 6.0 to < 7.0 
3.72 to < 4.32 < 6.0 
< 3.72 
22 to 35 days of age 
(male and female) 9.5 to 11.0 
5.88 to 6.86 8.0 to < 9.5 
4.94 to < 5.88 6.7 to < 8.0 
4.15 to < 4.94 < 6.7 
< 4.15 
8 to ≤ 21 days of age 
(male and female) 11.0 to 13.0 
6.81 to 8.10 9.0 to < 11.0 
5.57 to < 6.81 8.0 to < 9.0 
4.96 to < 5.57 < 8.0 
< 4.96 
≤ 7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to < 13.0 
6.19 to < 8.05 9.0 to < 10.0 
5.59 to < 6.19 < 9.0 
< 5.59 
INR, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541868] 1.5 to < 2.[ADDRESS_541869] 2.0 to < 3.[ADDRESS_541870] ≥ 3.[ADDRESS_541871] 
Methemoglobin (% 
hemoglobin) 5.0 to < 10.0% 10.0 to < 15.0% 15.0 to < 20.0% ≥ 20.0% 
PTT, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_541872] 1.66 to < 2.[ADDRESS_541873] 2.33 to < 3.[ADDRESS_541874] ≥ 3.[ADDRESS_541875] 
Platelets, 
Decreased 
(cells/mm3; cells/L ) 100,000 to < 
124,999 100.000 
x 109to < 124.999 
x [ZIP_CODE],000 to < 100,000 
50.000 x 109to < 
100.000 x 109 25,000 to < 50,000 
25.000 x 109to < 
50.000 x 109< 25,000 < 25.000 x 109
PT, High 
(not on 
anticoagulation 
therapy 1.1 to < 1.[ADDRESS_541876] 1.25 to < 1.[ADDRESS_541877] 1.50 to < 3.[ADDRESS_541878] ≥ 3.[ADDRESS_541879] 
WBC, Decreased
(cells/mm3; cells/L ) 
> 7 days of age 2,000 to 2,499 
2.000 x 109to 
2.499 x 1091,500 to 1,999 
1.500 x 109to 1.999 
x 1091,000 to 1,499 
1.000 x 109 to 1.499 
x 109< 1,000 
< 1.000 x 109
≤ 7 days of age 5,500 to 6,999 
5.500 x 109to 
6.999 x 109 4,000 to 5,499 
4.000 x 109to 5.499 
x 1092,500 to 3,999 
2.500 x 109to 3.999 
x 109< 2,500 
< 2.500 x 109
URINALYSIS
Glycosuria ( random 
collection tested by 
[CONTACT_5230]) Trace to 1+ or 
≤ 250 mg 2+ or ˃  250 to 
≤ 500 mg > 2+ or > 500 mg NA  2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
103PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hematuria (not to be 
reported based on 
dipstick findings or 
on blood believed to 
be of menstrual 
origin) 6 to < 10 RBCs 
per high power 
field ≥ 10 RBCs per high 
power field Gross, with or without 
clots OR With RBC 
casts OR Intervention 
indicated Life-threatening 
consequences 
Proteinuria (random 
collection tested by 
[CONTACT_5230]) 1+ 2+ 3+ or higher NA 
1. Blood pressure norms for children <18 years of age can be found in: Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and Adolescents. Pediatrics 2011;128;S213; originally 
published online November 14, 2011; DOI: 10.1542/peds.2009 -2107C.  
2. As per Bazett’s formula.  
3. For pruritus associated with injections or infusions, see the Site Reactions to Injections and In fusions section.  
4. Definition: A disorder characterized by [CONTACT_184941], extremities, and buttocks. 
5. Definition: A disorder characterized by [CONTACT_184942], breasts, and abdomen.  
6. Bone mineral density (BMD) t an d z scores can be found in: Kanis JA on behalf of the World Health Organization 
Scientific Group (2007). Assessment of osteoporosis at the primary health -care level. Technical Report. World 
Health Organization Collaborating Centre for Metabolic Bone Diseas es, University of Sheffield, [LOCATION_006]. 2007: Printed 
by [CONTACT_184943].  
7. Definition: A delivery of a live -born neonate occurring at ≥20 to <37 weeks gestational age. 
8. Definition: A clinically recognized pregnancy occurring at <20 weeks gestational age.  
9. Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of 
breath. 
10. For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section.
11. Definition: A disord er characterized by [CONTACT_411], arthralgia, myalgia, skin eruptions, lymphadenopathy, marked 
discomfort, and/or dyspnea.
12. WHO reference tables may be accesed by [CONTACT_184944]: 
http://www.who.int/growthref/who20 07_bmi_for_age/en/ for participants >5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤ [ADDRESS_541880] bilirubin >1.5 mg/dL in a participant <28 days of age should be graded as Grade 2, if <10% of the total 
bilirubin.  
15. Use the applicable formula (i.e., Cockroft -Gault in mL/min or Schwatrz in mL/min/1.73m2).  
16. To convert a ma gnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.  
17. Male and female sexes are defined as sex at birth. 
18. The conversion factor used to convert g/dL to mmol/L is 0.[ADDRESS_541881] be converted to g/dL using the appropriate conversion factor for the particular laboratory.   2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
[ZIP_CODE].9. Appendix 9: Toxicity  Management
ANEMIA
Grade 1 (mild) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541882] be repeated with the 
following additional tests:
3.peripheral blood smear
4. indirect bilirubin (abnormal if increased >50% from baseline)
5.haptoglobin (abnormal if  25 mg/dL)
6.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will per manently  discontinue study  medication and 
be withdrawn from the trial.  Subjects should be followed up until resolution of anemia.
Grade 2 (moderate) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541883] be repeated with the 
following additional tests:
7.peripheral blood smear
8. indirect bilirubin (abnormal if increased > 50% from baseline)
9.haptoglobin (abnormal if  25 mg/dL)
10.reticulocy te count (abnormal if  4%) 
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will permanently  discontinue study  medication and 
be withdrawn from the trial.  Consultation with a Hematologist s hould be considered.  
Subjects should be followed up until resolution of anemia.
Grade 3 (severe) or Grade 4 (potentially life threatening) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_541884] be repeated with 
the follow ing additional tests:
11.peripheral blood smear
12. indirect bilirubin
13.haptoglobin
14.reticulocy te count  2018N360917_00
2015N227852_00 CONFIDENTIA L
[ADDRESS_541885] should be considered.  Subjects should be followed up 
until resolution of anemia.
TOTA L BILIRUBIN ELEVA TION
Grade 1 (mild) bilirubin elevation (1.[ADDRESS_541886]) or Grade 2 (moderate 
-1.6-2.[ADDRESS_541887]):
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects may  continue study  medication.  Subjects should 
be followed up until resolution (return to baseline) of elevation.
Grade 3 (severe –2.6-5.[ADDRESS_541888]) or 4 (life- threatening -> 5.[ADDRESS_541889]) 
bilirubin elevation :
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects will permanently  discontinue study medication 
and be withdrawn from the trial.  Subjects should be followed up until resoluti on (return 
to baseline) of bilirubin elevation.
AST AND ALT ELEVA TION
See Appendix 9.
RASH
Grade 1 rash (Localized macular rash):
Subjects with Grade [ADDRESS_541890].  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
15.Temperature > 38.5°C
16.Lym phadenopathy
17.Phary ngitis
18.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541891] should remain on the study  to be 
followed for safet y and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
106Grade 2 rash (Diffuse macular, maculopapular, or morbilliform rash OR Target
lesions):
Subjects with Grade [ADDRESS_541892].  The study  drug should b e permanentl y 
discontinued if the following signs or s ymptoms are noted at an y time:
19.Temperature > 38.5°C
20.Lym phadenopathy
21.Phary ngitis
22.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subject s with Grade [ADDRESS_541893] should remain on the study to be followed for safety and PK as 
outlined in Section 10.5.
Grade 3 rash (Diffuse macular, mac ulopapular, or morbilliform rash with vesicles 
or limited number of bullae OR Superficial ulcerations of mucous membrane 
limited to one site):
Subjects with a Grade [ADDRESS_541894] should be evaluated in the phy sician’s office immediatel y and should be seen in 
the phy sician’s office or contact[CONTACT_428226]  [ADDRESS_541895] should remain on the 
study  to be followed for safet y and PK as outlined in Section 10.5.
Grade 4 rash (Extensive or generalized bullous lesions OR Stevens -Johnson 
syndrome OR Ulceration of mucous membrane involving two or more distinct 
mucosal sites OR Toxic epi[INVESTIGATOR_194] (TEN)):
Subjects with a Grade [ADDRESS_541896] should remain on the stud y to be followed 
for safety  and PK as outlined in Section 10.5. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
107ALLERGIC RE ACTION
Grade 1 allergic reaction (Pru ritis without rash):
Subjects with Grade 1 allergic reaction should be evalu ated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
23.Temperature > 38.5°C
24.Eosinophilia
25.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
26.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541897] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428142].  The subject should remain on the study  to be 
followe d for safety and PK as outlined.
Grade 2 allergic reaction (Localized urticaria):
Subjects with Grade 2 allergic reaction should be evaluated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
27.Temperature > 38.5°C
28.Eosinophilia
29.Respi[INVESTIGATOR_428141], lary ngospasm, or 
angioedema
30.Any indicatio n of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_541898] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard 
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_428194].  The subject should remain on the study  to be 
followed for safet y and PK as outlined in Section 7. 2018N360917_00
2015N227852_00 CONFIDENTIA L
200911
108Grade 3 allergic reaction (Generalized urticaria or angioedem a):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be und ertaken.
Grade 4 allergic reaction (Anaphylaxis):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adver se event and standard management should be undertaken.
Revised ACTG Toxicity Grade Definitions Investigator Action
Grade 1 Pruritus without rash May continue therapy
Grade 2 Localized urticaria May continue therapy
Grade 3 Generalized urticaria
Angioede maDiscontinue Therapy
Grade 4 Anaphylaxis Discontinue Therapy 2018N360917_00